10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________________________________________

 FORM 10-Q

_______________________________________________

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: October 2, 2021

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission file number 001-36353

_______________________________________________

Perrigo Company plc

(Exact name of registrant as specified in its charter)

_______________________________________________

Ireland	Not Applicable
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74

+353 1 7094000

(Address, including zip code, and telephone number, including

area code, of registrant’s principal executive offices)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary shares	PRGO	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐	Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.							☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 ☐  Yes  ☒ No

As of November 5, 2021, there were 133,773,881 ordinary shares outstanding.

PERRIGO COMPANY PLC

FORM 10-Q

INDEX

		PAGE NUMBER
Cautionary Note Regarding Forward-Looking Statements		1
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Condensed Consolidated Statements of Operations		2
Condensed Consolidated Statements of Comprehensive Income		3
Condensed Consolidated Balance Sheets		4
Condensed Consolidated Statements of Shareholders' Equity		5
Condensed Consolidated Statements of Cash Flows		7
Notes to the Condensed Consolidated Financial Statements
1	Summary of Significant Accounting Policies	8
2	Revenue Recognition	9
3	Acquisitions and Divestitures	11
4	Goodwill and Intangible Assets	14
5	Inventories	15
6	Fair Value Measurements	15
7	Investments	17
8	Discontinued Operations	17
9	Assets Held for Sale	20
10	Derivative Instruments and Hedging Activities	21
11	Leases	28
12	Indebtedness	30
13	Earnings per Share and Shareholders' Equity	32
14	Accumulated Other Comprehensive Income (Loss)	32
15	Income Taxes	33
16	Contingencies	37
17	Restructuring Charges	51
18	Segment Information	52
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		52
Item 3. Quantitative and Qualitative Disclosures About Market Risk		73
Item 4. Controls and Procedures		73
PART II. OTHER INFORMATION
Item 1. Legal Proceedings		74
Item 1A. Risk Factors		74
Item 6. Exhibits		75
Signatures		76

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this report are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this report, including certain statements contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” "forecast," “predict,” “potential” or the negative of those terms or other comparable terminology.

The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including: the effect of the novel coronavirus (COVID-19) pandemic and the associated supply chain impacts on the Company’s business; general economic, credit, and market conditions; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company’s appeal of the draft and final Notices of Proposed Assessment (“NOPAs”) issued by the U.S. Internal Revenue Service and the impact that an adverse result in any such proceedings would have on operating results, cash flows, and liquidity; pending and potential third-party claims and litigation, including litigation relating to the Company’s restatement of previously-filed financial information and litigation relating to uncertain tax positions, including the NOPAs; potential impacts of ongoing or future government investigations and regulatory initiatives; potential costs and reputational impact of product recalls or sales halts; the impact of tax reform legislation and healthcare policy; the timing, amount and cost of any share repurchases; fluctuations in currency exchange rates and interest rates; the Company’s ability to achieve the benefits expected from the sale of its Rx business and the risk that potential costs or liabilities incurred or retained in connection with the transaction may exceed the Company’s estimates or adversely affect the Company’s business or operations; the consummation and success of the proposed acquisition of HRA and the ability to achieve the expected benefits thereof, including the risk that the parties fail to obtain the required regulatory approvals or to fulfill the other conditions to closing on the expected timeframe or at all, the occurrence of any other event, change or circumstance that could delay the transaction or result in the termination of the securities sale agreement or the risks that the Company’s synergy estimates are inaccurate or that the Company faces higher than anticipated integration or other costs in connection with the proposed acquisition; the consummation and success of other announced acquisitions or dispositions, and the Company’s ability to realize the desired benefits thereof; and the Company’s ability to execute and achieve the desired benefits of announced cost-reduction efforts and strategic and other initiatives. An adverse result with respect to the Company’s appeal of any material outstanding tax assessments or pending litigation, including securities or drug pricing matters, could ultimately require the use of corporate assets to pay such assessments, damages from third-party claims, and related interest and/or penalties, and any such use of corporate assets would limit the assets available for other corporate purposes. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2020, this report under “Risk Factors” and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this report are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

TRADEMARKS, TRADE NAMES AND SERVICE MARKS

This report contains trademarks, trade names and service marks that are the property of Perrigo Company plc, as well as, for informational purposes, trademarks, trade names, and service marks that are the property of other organizations. Solely for convenience, certain trademarks, trade names, and service marks referred to in this report appear without the ®, ™ and SM symbols, but those references are not intended to indicate that we or the applicable owner, as the case may be, will not assert, to the fullest extent under applicable law, our or their rights to such trademarks, trade names, and service marks.

1

Perrigo Company plc - Item 1

PART I.     FINANCIAL INFORMATION

ITEM 1.        FINANCIAL STATEMENTS (UNAUDITED)

PERRIGO COMPANY PLC

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share amounts)

(unaudited)

 

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Net sales	$	1,042.7	$	1,003.0	$	3,033.8	$	3,035.0
Cost of sales	706.3		633.3		1,980.0		1,924.5
Gross profit	336.4		369.7		1,053.8		1,110.5
Operating expenses
Distribution	23.3		22.5		69.0		62.4
Research and development	27.6		30.4		91.7		88.7
Selling	129.7		130.1		405.0		389.0
Administration	130.6		111.3		368.1		345.2
Impairment charges	3.5		—		162.1		—
Restructuring	1.0		0.8		11.8		1.5
Other operating expense (income)	(417.6)		(3.9)		(417.6)		(3.9)
Total operating expenses	(101.9)		291.2		690.1		882.9
Operating income	438.3		78.5		363.7		227.6
Change in financial assets	—		(22.2)		—		(25.9)
Interest expense, net	30.9		33.3		94.5		94.3
Other (income) expense, net	18.5		(1.0)		20.4		17.9
Loss on extinguishment of debt	—		20.0		—		20.0
Income (loss) from continuing operations before income taxes	388.9		48.4		248.8		121.3
Income tax expense (benefit)	442.8		22.0		411.8		24.9
Income (loss) from continuing operations	(53.9)		26.4		(163.0)		96.4
Income (loss) from discontinued operations, net of tax	(5.0)		(181.0)		84.5		(84.0)
Net income (loss)	$	(58.9)	$	(154.6)	$	(78.5)	$	12.4
Earnings (loss) per share
Basic
Continuing operations	$	(0.40)	$	0.19	$	(1.22)	$	0.71
Discontinued operations	(0.04)		(1.32)		0.63		(0.62)
Basic earnings per share	$	(0.44)	$	(1.13)	$	(0.59)	$	0.09
Diluted
Continuing operations	$	(0.40)	$	0.19	$	(1.22)	$	0.70
Discontinued operations	(0.04)		(1.31)		0.63		(0.61)
Diluted earnings per share	$	(0.44)	$	(1.12)	$	(0.59)	$	0.09
Weighted-average shares outstanding
Basic	133.8		136.5		133.5		136.3
Diluted	133.8		137.6		133.5		137.5

See accompanying Notes to the Condensed Consolidated Financial Statements.

2

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in millions)

(unaudited)

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Net income (loss)	$	(58.9)	$	(154.6)	$	(78.5)	$	12.4
Other comprehensive income (loss):
Foreign currency translation adjustments	(228.3)		86.5		(307.5)		81.0
Change in fair value of derivative financial instruments, net of tax	(23.8)		(2.3)		(31.1)		(12.4)
Change in post-retirement and pension liability, net of tax	(0.8)		(1.2)		(2.2)		(4.3)
Other comprehensive income (loss), net of tax	(252.9)		83.0		(340.8)		64.3
Comprehensive income (loss)	$	(311.8)	$	(71.6)	$	(419.3)	$	76.7

See accompanying Notes to the Condensed Consolidated Financial Statements.

3

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except per share amounts)

(unaudited)

	October 2, 2021		December 31, 2020
Assets
Cash and cash equivalents	$	2,078.1	$	631.5
Accounts receivable, net of allowance for credit losses of $7.6 and $6.5, respectively	686.2		593.5
Inventories	1,092.5		1,059.4
Prepaid expenses and other current assets	355.7		182.2
Current assets held for sale	13.4		666.9
Total current assets	4,225.9		3,133.5
Property, plant and equipment, net	842.8		864.6
Operating lease assets	170.6		154.7
Goodwill and indefinite-lived intangible assets	3,036.9		3,102.7
Definite-lived intangible assets, net	2,226.2		2,481.5
Deferred income taxes	40.2		40.6
Non-current assets held for sale	—		1,364.0
Other non-current assets	373.3		346.8
Total non-current assets	6,690.0		8,354.9
Total assets	$	10,915.9	$	11,488.4
Liabilities and Shareholders’ Equity
Accounts payable	$	405.6	$	451.6
Payroll and related taxes	106.6		152.9
Accrued customer programs	140.1		128.5
Other accrued liabilities	339.9		183.1
Accrued income taxes	353.0		9.0
Current indebtedness	629.4		37.3
Current liabilities held for sale	29.2		419.6
Total current liabilities	2,003.8		1,382.0
Long-term debt, less current portion	2,920.9		3,527.6
Deferred income taxes	243.0		276.2
Non-current liabilities held for sale	—		108.3
Other non-current liabilities	565.8		539.2
Total non-current liabilities	3,729.7		4,451.3
Total liabilities	5,733.5		5,833.3
Commitments and contingencies - Refer to Note 16
Shareholders’ equity
Controlling interests:
Preferred shares, $0.0001 par value per share, 10 shares authorized	—		—
Ordinary shares, €0.001 par value per share, 10,000 shares authorized	7,064.8		7,118.2
Accumulated other comprehensive income	54.2		395.0
Retained earnings (accumulated deficit)	(1,936.6)		(1,858.1)
Total shareholders’ equity	5,182.4		5,655.1
Total liabilities and shareholders' equity	$	10,915.9	$	11,488.4
Supplemental Disclosures of Balance Sheet Information
Preferred shares, issued and outstanding	—		—
Ordinary shares, issued and outstanding	133.7		133.1

See accompanying Notes to the Condensed Consolidated Financial Statements.

4

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in millions, except per share amounts)

(unaudited)

	Ordinary Shares Issued			Accumulated Other Comprehensive Income		Retained Earnings (Accumulated Deficit)		Total
	Shares	Amount
Balance at December 31, 2019	136.1	$	7,359.9	$	139.4	$	(1,695.5)	$	5,803.8
Net income	—	—		—		106.4		106.4
Other comprehensive loss	—	—		(103.5)		—		(103.5)
Restricted stock plan	0.3	—		—		—		—
Compensation for stock options	—	0.8		—		—		0.8
Compensation for restricted stock	—	15.4		—		—		15.4
Cash dividends, $0.23 per share	—	(30.9)		—		—		(30.9)
Shares withheld for payment of employees' withholding tax liability	(0.1)	(5.6)		—		—		(5.6)
Balance at March 28, 2020	136.3	$	7,339.6	$	35.9	$	(1,589.1)	$	5,786.4
Net income	—	—		—		60.6		60.6
Other comprehensive income	—	—		84.8		—		84.8
Restricted stock plan	0.3	—		—		—		—
Compensation for stock options	—	0.4		—		—		0.4
Compensation for restricted stock	—	13.1		—		—		13.1
Cash dividends, $0.23 per share	—	(31.0)		—		—		(31.0)
Shares withheld for payment of employees' withholding tax liability	(0.1)	(3.9)		—		—		(3.9)
Balance at June 27, 2020	136.5	$	7,318.2	$	120.7	$	(1,528.5)	$	5,910.4
Net loss	—	—		—		(154.6)		(154.6)
Other comprehensive income	—	—		83.0		—		83.0
Compensation for stock options	—	0.4		—		—		0.4
Compensation for restricted stock	—	13.8		—		—		13.8
Cash dividends, $0.23 per share	—	(31.1)		—		—		(31.1)
Shares withheld for payment of employees' withholding tax liability	—	(0.5)		—		—		(0.5)
Minority share purchase	—	(1.1)		—		—		(1.1)
Balance at September 26, 2020	136.5	$	7,299.7	$	203.7	$	(1,683.1)	$	5,820.3

5

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (CONTINUED)

(in millions, except per share amounts)

(unaudited)

	Ordinary Shares Issued			Accumulated Other Comprehensive Income		Retained Earnings (Accumulated Deficit)		Total
	Shares	Amount
Balance at December 31, 2020	133.1	$	7,118.2	$	395.0	$	(1,858.1)	$	5,655.1
Net income	—	—		—		38.1		38.1
Other comprehensive loss	—	—		(118.3)		—		(118.3)
Restricted stock plan	0.6	—		—		—		—
Compensation for stock options	—	0.4		—		—		0.4
Compensation for restricted stock	—	24.6		—		—		24.6
Cash dividends, $0.24 per share	—	(32.6)		—		—		(32.6)
Shares withheld for payment of employees' withholding tax liability	(0.2)	(9.3)		—		—		(9.3)
Balance at April 3, 2021	133.5	$	7,101.3	$	276.7	$	(1,820.0)	$	5,558.0
Net loss	—	—		—		(57.7)		(57.7)
Other comprehensive income	—	—		30.4		—		30.4
Restricted stock plan	0.1	—		—		—		—
Compensation for stock options	—	0.2		—		—		0.2
Compensation for restricted stock	—	13.9		—		—		13.9
Cash dividends, $0.24 per share	—	(32.5)		—		—		(32.5)
Shares withheld for payment of employees' withholding tax liability	—	(1.2)		—		—		(1.2)
Balance at July 3, 2021	133.6	$	7,081.7	$	307.1	$	(1,877.7)	$	5,511.1
Net loss	—	—		—		(58.9)		(58.9)
Other comprehensive loss	—	—		(252.9)		—		(252.9)
Restricted stock plan	0.2	—		—		—		—
Compensation for stock options	—	0.2		—		—		0.2
Compensation for restricted stock	—	18.5		—		—		18.5
Cash dividends, $0.24 per share	—	(32.7)		—		—		(32.7)
Shares withheld for payment of employees' withholding tax liability	(0.1)	(2.9)		—		—		(2.9)
Balance at October 2, 2021	133.7	$	7,064.8	$	54.2	$	(1,936.6)	$	5,182.4

See accompanying Notes to the Condensed Consolidated Financial Statements.

6

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

(unaudited)

	Nine Months Ended
	October 2, 2021		September 26, 2020
Cash Flows From (For) Operating Activities
Net income (loss)	$	(78.5)	$	12.4
Adjustments to derive cash flows:
Depreciation and amortization	238.8		284.7
Loss (Gain) on sale of business	(63.9)		18.6
Share-based compensation	50.2		43.9
Impairment charges	162.1		202.4
Change in financial assets	—		(25.9)
Loss on extinguishment of debt	—		20.0
Restructuring charges	11.8		1.9
Deferred income taxes	(24.0)		25.7
Amortization of debt premium	(2.7)		(1.7)
Other non-cash adjustments, net	9.2		(12.0)
Subtotal	303.0		570.0
Increase (decrease) in cash due to:
Accounts receivable	(182.3)		106.4
Inventories	(70.2)		(93.2)
Prepaid expenses	(1.8)		(23.8)
Accounts payable	(10.4)		15.2
Payroll and related taxes	(60.6)		(2.2)
Accrued customer programs	13.4		(35.5)
Accrued liabilities	(5.8)		(16.0)
Accrued income taxes	313.2		(9.0)
Other, net	(36.8)		13.9
Subtotal	(41.3)		(44.2)
Net cash from (for) operating activities	261.7		525.8
Cash Flows From (For) Investing Activities
Proceeds from royalty rights	2.8		3.2
Purchase of equity method investment	—		(15.0)
Acquisitions of businesses, net of cash acquired	—		(106.0)
Asset acquisitions	(70.6)		(34.1)
Additions to property, plant and equipment	(110.4)		(104.3)
Net proceeds from sale of business	1,493.1		187.8
Other investing, net	2.8		8.1
Net cash from (for) investing activities	1,317.7		(60.3)
Cash Flows From (For) Financing Activities
Issuances of long-term debt	—		743.8
Payments on long-term debt	—		(590.0)
Borrowings (repayments) of revolving credit agreements and other financing, net	(5.8)		0.1
Deferred financing fees	—		(6.7)
Premiums on early debt retirement	—		(19.0)
Cash dividends	(97.8)		(93.0)
Other financing, net	(17.1)		(14.9)
Net cash from (for) financing activities	(120.7)		20.3
Effect of exchange rate changes on cash and cash equivalents	(12.0)		9.3
Net increase (decrease) in cash and cash equivalents	1,446.7		495.1
Cash and cash equivalents of continuing operations, beginning of period	631.5		344.5
Cash and cash equivalents held for sale, beginning of period	10.0		9.8
Less cash and cash equivalents held for sale, end of period	(10.1)		(9.2)
Cash and cash equivalents of continuing operations, end of period	$	2,078.1	$	840.2

See accompanying Notes to the Condensed Consolidated Financial Statements.

7

Perrigo Company plc - Item 1

Note 1

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General Information

The Company

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

Our vision is to make lives better by bringing Quality, Affordable Self-Care Products that consumers trust everywhere they are sold. We are a leading provider of over-the-counter ("OTC") health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

On March 1, 2021, we announced a definitive agreement to sell our generic RX Pharmaceuticals business ("RX business") to Altaris Capital Partners, LLC ("Altaris"). On July 6, 2021, we completed the sale of the RX business. The financial results of our RX business, which were previously reported in our Prescription Pharmaceuticals ("RX") segment, have been classified as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented. The assets and liabilities of our RX business are reflected as assets and liabilities held for sale in the Condensed Consolidated Balance Sheets for all periods presented prior to the sale. Refer to Note 8 for additional information regarding discontinued operations. Unless otherwise noted, amounts and disclosures throughout the Notes to the unaudited Condensed Consolidated Financial Statements relate to our continuing operations.

Segment Reporting

Our reporting and operating segments are as follows:

•Consumer Self-Care Americas ("CSCA") comprises our consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the U.S., Mexico and Canada.

•Consumer Self-Care International ("CSCI") comprises our consumer self-care business primarily branded in Europe and Australia, our store brand business in the United Kingdom and parts of Europe and Asia, and our liquid licensed products business in the United Kingdom until it was disposed on June 19, 2020.

Allowance for Credit Losses

Expected credit losses on trade receivables and contract assets are measured collectively by geographic location. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and for reasonable and supportable forecasts. Historical credit loss experience provides the primary basis for estimation of expected credit losses. Adjustments to historical loss information may be made for

8

Perrigo Company plc - Item 1

Note 1

significant changes in a geographic location’s economic conditions. Receivables that do not share risk characteristics are evaluated on an individual basis. These receivables are not included in the collective evaluation.

The allowance for credit losses is a valuation account that is deducted from the instruments’ cost basis to present the net amount expected to be collected. Trade receivables and contract assets are charged off against the allowance when the balance is no longer deemed collectible.

The following table presents the allowance for credit losses activity (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Beginning balance	$	7.7	$	5.5	$	6.5	$	6.0
Provision for credit losses, net	0.1		0.6		3.7		1.1
Receivables written-off	—		(0.4)		(0.7)		(1.5)
Transfer to held for sale	—		—		(1.4)		—
Currency translation adjustment	(0.2)		0.1		(0.5)		0.2
Ending balance	$	7.6	$	5.8	$	7.6	$	5.8

NOTE 2 – REVENUE RECOGNITION

Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.

Disaggregation of Revenue

We generated net sales in the following geographic locations(1) (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
U.S.	$	657.4	$	638.7	$	1,859.0	$	1,913.4
Europe(2)	334.5		326.6		1,037.6		1,011.0
All other countries(3)	50.8		37.7		137.2		110.6
Total net sales	$	1,042.7	$	1,003.0	$	3,033.8	$	3,035.0

(1) Derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $7.6 million and $17.4 million for the three and nine months ended October 2, 2021 respectively, and $10.8 million and $22.3 million for the three and nine months ended September 26, 2020, respectively.

(3) Includes net sales generated primarily in Mexico, Australia and Canada.

9

Perrigo Company plc - Item 1

Note 2

Product Category

The following is a summary of our net sales by category (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
CSCA(1)
Upper respiratory	$	121.9	$	117.1	$	345.8	$	397.2
Digestive health	110.6		111.8		344.0		339.9
Pain and sleep-aids	108.4		102.6		292.9		325.7
Nutrition	105.3		100.3		293.3		291.5
Oral self-care	76.7		81.9		227.4		202.5
Healthy lifestyle	72.9		86.9		214.9		256.2
Skincare and personal hygiene	56.0		51.4		165.9		145.4
Vitamins, minerals, and supplements	8.1		6.3		24.3		19.1
Other CSCA(2)	34.3		5.7		48.5		14.7
Total CSCA	694.2		664.0		1,957.0		1,992.2
CSCI
Skincare and personal hygiene	88.5		83.1		307.9		275.4
Upper respiratory	58.7		62.3		144.2		191.9
Vitamins, minerals, and supplements	54.7		52.9		162.8		139.9
Pain and sleep-aids	52.1		49.0		148.4		136.0
Healthy lifestyle	42.2		40.6		140.5		124.7
Oral self-care	24.4		25.2		72.4		68.8
Digestive health	10.1		6.8		28.3		17.9
Other CSCI(3)	17.8		19.1		72.3		88.2
Total CSCI	348.5		339.0		1,076.8		1,042.8
Total net sales	$	1,042.7	$	1,003.0	$	3,033.8	$	3,035.0

(1) Includes net sales from our OTC contract manufacturing business.

(2) Consists primarily of diagnostic and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

(3) Consists primarily of our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $80.8 million and $213.7 million for the three and nine months ended October 2, 2021, respectively and $76.3 million and $190.0 million for the three and nine months ended September 26, 2020, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):

	Balance Sheet Location	October 2, 2021		December 31, 2020
Short-term contract assets	Prepaid expenses and other current assets	$	42.2	$	19.7

10

Perrigo Company plc - Item 1

Note 3

NOTE 3 – ACQUISITIONS AND DIVESTITURES

Acquisitions During the Nine Months Ended October 2, 2021

Héra SAS (“HRA Pharma”) Acquisition Agreement

On September 8, 2021, we and our wholly-owned subsidiary Habsont Unlimited Company (the "Purchaser"), entered into a Put Option Agreement to acquire certain holding companies holding all of the outstanding equity interests of HRA Pharma from funds affiliated with private equity firms Astorg and Goldman Sachs Asset Management (collectively, the "Sellers"). Pursuant to the Put Option Agreement, following completion of the works council consultation process required under French law, the selling shareholders exercised their put option right under the Put Option Agreement and, on October 20, 2021, the Company, the Purchaser and the Sellers entered into a Securities Sale Agreement in the form previously agreed by the parties (the “Purchase Agreement”). Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, the Purchaser has agreed to acquire certain holding companies holding all of the outstanding equity interests of HRA from the Sellers for cash. The transaction values HRA at approximately €1.8 billion, or approximately $2.1 billion as of the date of the Put Option Agreement, on an enterprise value basis and using a lockbox mechanism set forth in the Purchase Agreement. The proposed final transaction is expected to close in the first half of 2022, subject to the satisfaction of customary closing conditions, including regulatory approvals. We intend to pay the purchase price using a combination of cash on hand and, depending upon market conditions, either funds available under our current credit facility or funds from new debt financing. HRA Pharma is one of the fastest growing OTC companies globally, with three category-leading self-care brands in blister care (Compeed®), women’s health (ellaOne®) and scar care (Mederma®), and brings expertise in prescription-to-OTC switches. This acquisition would strengthen our presence in Europe, improve our financial profile and margins, and will complete our transformation to a consumer self-care company. Operating results are expected to be reported within both our CSCA and CSCI segments.

Acquisitions Accounted for as a Business Combination During the Year Ended December 31, 2020

Eastern European OTC Dermatological Brands Acquisition

On October 30, 2020, we acquired three Eastern European OTC dermatological brands ("Eastern European Brands"), skincare brands Emolium® and Iwostin® and hair loss treatment brand Loxon®, from Sanofi. The transaction closed for €53.3 million ($62.3 million). We capitalized $52.5 million as brand-named intangible assets and allocated the remainder of the purchase price to goodwill, inventory, customer relationships and deferred tax assets.

The addition of these market-leading OTC brands complements our already robust skincare portfolio and adds scale to our Eastern European business. The acquisition also serves as another step for Perrigo’s CSCI growth plans and provides new opportunities for self-care revenue synergy in the European markets. The operating results of the brands are reported within our CSCI segment. The acquisition of the Eastern European Brands was accounted for as a business combination and has been reported in our Consolidated Statements of Operations as of the acquisition date.

The goodwill arising from the acquisition consists largely of the assembled workforce, and the cost and revenue synergies expected from integrating the business into the CSCI segment. The goodwill was allocated to our CSCI segment, none of which is deductible for income tax purposes. The definite-lived intangible assets acquired consisted of brands and customer relationships which are being amortized over a weighted average useful life of approximately 18.8 years. Both the brands and customer relationships were valued using the multi-period excess earnings method. Significant judgment was applied in estimating the fair value of the intangible assets acquired, which involved the use of significant estimates and assumptions with respect to the timing and amounts of cash flow projections, including revenue growth rates, projected profit margins, and discount rates. The opening balance sheet is final.

Oral Care Assets of High Ridge Brands

On April 1, 2020, we acquired the oral care assets of High Ridge Brands ("Dr. Fresh") for total purchase consideration of $113.0 million, subject to customary adjustments, including a working capital settlement. After such adjustments as of December 31, 2020, total cash consideration paid was $106.2 million net of $2.0 million that we allocated as prepayment of contract consideration for transitional services to be received related to the transaction.

11

Perrigo Company plc - Item 1

Note 3

This acquisition includes the children’s oral care value brand, Firefly®, in addition to the REACH® and Dr. Fresh® brands, and a licensing portfolio. The U.S. operations, which represent a significant portion of the business, are reported in our CSCA segment and the non-U.S. operations are reported in our CSCI segment.

The following table summarizes the consideration paid for Dr. Fresh and the amounts of the assets acquired and liabilities assumed (in millions):

	Oral Care Assets of High Ridge Brands (Dr. Fresh)
Purchase price paid	$	106.2
Assets acquired:
Accounts receivable	13.1
Inventories	22.2
Prepaid expenses and other current assets	0.4
Property, plant and equipment, net	0.7
Operating lease assets	2.6
Goodwill	17.2
Distribution and license agreements and supply agreements	$	2.2
Developed product technology, formulations, and product rights	0.1
Customer relationships and distribution networks	20.6
Trademarks, trade names, and brands	43.2
Total intangible assets	$	66.1
Total assets	$	122.3
Liabilities assumed:
Accounts payable	$	6.1
Other accrued liabilities	3.8
Payroll and related taxes	0.7
Accrued customer programs	3.0
Other non-current liabilities	2.5
Total liabilities	$	16.1
Net assets acquired	$	106.2

The goodwill of $17.2 million arising from the acquisition consists largely of the anticipated growth from new product sales, sales to new customers, the assembled workforce, and the synergies expected from combining the operations of Dr. Fresh into Perrigo. The goodwill is attributable to our CSCA segment and is tax deductible for income tax purposes. The definite-lived intangible assets acquired consisted of trademarks and trade names, license agreements, and customer relationships, which are being amortized over a weighted average useful life of approximately 17.8 years. Customer relationships were valued using the multi-period excess earnings method. Trademarks and trade names and developed technology were valued using the relief from royalty method. Significant judgment was applied in estimating the fair value of the intangible assets acquired, which involved the use of significant estimates and assumptions with respect to the timing and amounts of cash flow projections, including revenue growth rates, projected profit margins, and discount rates. The opening balance sheet is final.

12

Perrigo Company plc - Item 1

Note 3

Pro Forma Impact of Business Combinations

The following table presents unaudited pro forma information as if the acquisitions of Dr. Fresh and the Eastern European Brands occurred on January 1, 2019, and had been combined with the results reported in our Condensed Consolidated Statements of Operations for all periods presented (in millions):

	Three Months Ended		Nine Months Ended
(Unaudited)	September 26, 2020		September 26, 2020
Net sales	$	1,009.2	$	3,083.2
Income from continuing operations	$	28.5	$	108.7

The unaudited pro forma information is presented for information purposes only and is not indicative of the results that would have been achieved if the acquisition had taken place at such time. The unaudited pro forma information presented above includes adjustments primarily for amortization charges for acquired intangible assets, depreciation of property, plant and equipment that have been revalued, certain acquisition-related charges, and related tax effects.

Acquisitions During the Nine Months Ended September 26, 2020

Dexsil®

On February 13, 2020, we acquired Dexsil®, a silicon supplement brand, from RXW Group Nv, for total cash consideration paid of approximately $8.0 million. The transaction was accounted for as an asset acquisition, in which we capitalized the consideration paid as a brand-named intangible asset. We began amortizing the brand intangible over a 25-year useful life. Operating results attributable to the product are included within our CSCI segment.

Steripod®

On January 3, 2020, we acquired Steripod®, a leading toothbrush accessory brand and innovator in the toothbrush protector market, from Bonfit America Inc. Total consideration paid was $26.0 million. The transaction was accounted for as an asset acquisition, in which we capitalized $25.1 million as a brand-named intangible asset. The remainder of the purchase price was allocated to working capital. We began amortizing the brand intangible asset over a 25-year useful life. Operating results attributable to Steripod® are included within our CSCA segment.     

Divestitures During the Nine Months Ended October 2, 2021

RX business

Refer to Note 8 - Discontinued Operations for details on the sale of the RX business.

Divestitures During the Nine Months Ended September 26, 2020

Rosemont Pharmaceuticals Business

On June 19, 2020, we completed the sale of our U.K.-based Rosemont Pharmaceuticals business, a generic prescription pharmaceuticals manufacturer focused on liquid medicines, to a U.K.-headquartered private equity firm for cash consideration of £155.6 million (approximately $195.0 million). The sale resulted in a pre-tax loss of $17.4 million during the three and six months ended June 27, 2020, $1.3 million during the three months ended September 26, 2020, and $2.4 million during the three months ended December 31, 2020. These losses were recorded in our CSCI segment in Other (income) expense, net on the Consolidated Statements of Operations. These losses included professional fees and a $46.4 million write-off of foreign currency translation adjustment from Accumulated other comprehensive income.

13

Perrigo Company plc - Item 1

Note 4

NOTE 4 – GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):

	December 31, 2020		Purchase accounting adjustments		Impairments		Currency translation adjustments		October 2, 2021
CSCA(1)	$	1,905.0	$	2.4	$	(6.1)	$	(0.7)	$	1,900.6
CSCI(2)	1,190.7		(2.4)		—		(57.5)		1,130.8
Total goodwill	$	3,095.7	$	—	$	(6.1)	$	(58.2)	$	3,031.4

(1) We had no accumulated goodwill impairments as of December 31, 2020 and $6.1 million as of October 2, 2021.

(2) We had accumulated goodwill impairments of $868.4 million as of December 31, 2020 and October 2, 2021.

CSCA Reporting Unit Goodwill

On May 18, 2021, we announced a definitive agreement to sell our Mexico and Brazil-based OTC businesses ("Latin American businesses"), both within our CSCA segment, to Advent International. As a result, we prepared a goodwill impairment test. We determined the carrying value of this business exceeded the fair value and recorded an impairment of $6.1 million within our CSCA segment during the three months ended July 3, 2021 (refer to Note 6 and Note 9).

Intangible Assets

Intangible assets and related accumulated amortization consisted of the following (in millions):

	October 2, 2021				December 31, 2020
	Gross		Accumulated Amortization		Gross		Accumulated Amortization
Indefinite-lived intangibles:
Trademarks, trade names, and brands	$	3.6	$	—	$	4.3	$	—
In-process research and development	1.9		—		2.7		—
Total indefinite-lived intangibles	$	5.5	$	—	$	7.0	$	—
Definite-lived intangibles:
Distribution and license agreements and supply agreements	$	72.8	$	56.1	$	74.8	$	55.4
Developed product technology, formulations, and product rights	300.7		187.6		303.3		177.3
Customer relationships and distribution networks	1,844.1		872.2		1,920.5		823.7
Trademarks, trade names, and brands	1,506.0		381.5		1,581.5		342.2
Non-compete agreements	2.1		2.1		2.9		2.9
Total definite-lived intangibles	$	3,725.7	$	1,499.5	$	3,883.0	$	1,401.5
Total intangible assets	$	3,731.2	$	1,499.5	$	3,890.0	$	1,401.5

We recorded amortization expense of $52.2 million and $159.0 million for the three and nine months ended October 2, 2021, respectively, and $53.3 million and $157.5 million for the three and nine months ended September 26, 2020, respectively.

14

Perrigo Company plc - Item 1

Note 5

NOTE 5 – INVENTORIES

Major components of inventory were as follows (in millions):

 

	October 2, 2021		December 31, 2020
Finished goods	$	617.1	$	574.1
Work in process	240.9		220.4
Raw materials	234.5		264.9
Total inventories	$	1,092.5	$	1,059.4

NOTE 6 – FAIR VALUE MEASUREMENTS

The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):

	October 2, 2021						December 31, 2020
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Measured at fair value on a recurring basis:
Assets:
Investment securities	$	1.5	$	—	$	—	$	2.5	$	—	$	—
Foreign currency forward contracts	—		5.8		—		—		9.8		—
Cross-currency swap	—		—		—		—		6.3		—
Foreign currency option contracts	—		13.3		—		—		—		—
Total assets	$	1.5	$	19.1	$	—	$	2.5	$	16.1	$	—
Liabilities:
Cross-currency swap	$	—	$	24.1	$	—	$	—	$	—	$	—
Foreign currency forward contracts	—		1.8		—		—		7.9		—
Total liabilities	$	—	$	25.9	$	—	$	—	$	7.9	$	—
Measured at fair value on a non-recurring basis:
Liabilities
Liabilities held for sale, net(1)	$	—	$	—	$	15.8	$	—	$	—	$	—
Total liabilities	$	—	$	—	$	15.8	$	—	$	—	$	—

(1)     We measured the net assets held for sale for impairment purposes and recorded a total impairment of $161.2 million, resulting in a net liability held for sale balance (refer to Note 9).

There were no transfers within Level 3 fair value measurements during the three and nine months ended October 2, 2021 or the year ended December 31, 2020.

Foreign Currency Option Contracts

We valued the foreign currency option contract derivatives using an extension of the Black-Scholes Option Pricing Model ("BSOPM") which uses the strike price and expiry as inputs obtained from the contractual agreement. Additionally, the model uses risk-free interest rates, forward currency quotes, and option volatility assumptions obtained from the observable market.

15

Perrigo Company plc - Item 1

Note 6

Royalty Pharma Contingent Milestone Receipts

During the year ended December 31, 2020, Royalty Pharma payments from Biogen for Tysabri® sales, as defined in the agreement between the parties, did not exceed the 2020 global net sales threshold. Therefore, we were not entitled to receive the remaining contingent milestone payment. As of December 31, 2020, there were no contingent milestone payments outstanding.

The table below summarizes the change in fair value of the Royalty Pharma contingent milestone (in millions):

	Three Months Ended		Nine Months Ended
	September 26, 2020		September 26, 2020
Beginning balance	$	99.0	$	95.3
Change in fair value	22.2		25.9
Ending balance	$	121.2	$	121.2

We valued our contingent milestone payment from Royalty Pharma using a modified BSOPM. Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri® that are received by Royalty Pharma until the contingent milestones are resolved. As of September 26, 2020, volatility and the estimated fair value of the milestones had a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. Rate of return and the estimated fair value of the milestones had an inverse relationship, such that a lower rate of return correlates with a higher estimated fair value of the contingent milestone payments. We assessed volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. The table below represents the volatility and rate of return:

	Three Months Ended
	September 26, 2020
Volatility	30.0	%
Rate of return	6.84	%

During the three and nine months ended September 26, 2020, the fair value of the Royalty Pharma contingent milestone payment related to 2020 increased by $22.2 million and $25.9 million, respectively, to $121.2 million, driven by higher projected global net sales of Tysabri® compared to the estimates in the prior period, and the estimated probability of achieving the earn-out. As of December 31, 2020, there were no contingent milestone payments outstanding and, accordingly, no asset recorded in the Condensed Consolidated Balance Sheet.

Non-recurring Fair Value Measurements

The non-recurring fair values represent only those assets whose carrying values were adjusted to fair value during the reporting period.

Goodwill

During the three months ended July 3, 2021 and nine months ended October 2, 2021, as a result of our definitive agreement to sell our Latin American businesses, we prepared a goodwill impairment test. We determined the carrying value of this business exceeded the fair value and recorded an impairment in the CSCA segment (refer to Note 4).

Assets (liabilities) held for sale, net

During the three months ended July 3, 2021 and nine months ended October 2, 2021, as a result of our definitive agreement to sell our Latin American businesses, we prepared an impairment test on the net assets held for sale related to this business. We determined the carrying value of the net assets held for sale exceed the fair

16

Perrigo Company plc - Item 1

Note 6

value less cost to sell and recorded an impairment in the CSCA segment (refer to Note 9).

Fixed Rate Long-term Debt    

Our fixed rate long-term debt consisted of the following (in millions):

	October 2, 2021				December 31, 2020
	Level 1		Level 2		Level 1		Level 2
Public Bonds
Carrying Value (excluding discount)	$	2,760.0	$	—	$	2,760.0	$	—
Fair value	$	2,906.0	$	—	$	3,031.1	$	—
Private placement note
Carrying value (excluding premium)	$	—	$	156.6	$	—	$	164.9
Fair value	$	—	$	166.9	$	—	$	177.5

The fair values of our public bonds for all periods were based on quoted market prices. The fair values of our private placement note for all periods were based on interest rates offered for borrowings of a similar nature and remaining maturities.

The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt, revolving credit agreements, promissory notes related to our equity method investment in Kazmira, and variable rate long-term debt, approximate their fair value.

NOTE 7 – INVESTMENTS

The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):

Measurement Category	Balance Sheet Location	October 2, 2021		December 31, 2020
Fair value method	Prepaid expenses and other current assets	$	1.5	$	2.5
Fair value method(1)	Other non-current assets	$	1.8	$	1.9
Equity method	Other non-current assets	$	69.0	$	69.8

(1)     Measured at fair value using the Net Asset Value practical expedient.

The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):

		Three Months Ended				Nine Months Ended
Measurement Category	Income Statement Location	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Fair value method	Other (income) expense, net	$	—	$	(0.4)	$	0.9	$	2.2
Equity method	Other (income) expense, net	$	—	$	(1.1)	$	0.8	$	(2.6)

NOTE 8 – DISCONTINUED OPERATIONS

Our discontinued operations primarily consist of our RX segment, which held our prescription pharmaceuticals business in the U.S. and our pharmaceuticals and diagnostic businesses in Israel (collectively, the “RX business”).

On March 1, 2021, we announced a definitive agreement to sell our RX business to Altaris. On July 6, 2021, we completed the sale of the RX business for aggregate consideration of $1.55 billion. The consideration includes a $53.3 million reimbursement related to an ANDA for a generic topical lotion which Altaris is required to deliver in

17

Perrigo Company plc - Item 1

Note 8

cash to Perrigo pursuant to the terms of the Agreement. The sale resulted in a pre-tax gain of $63.9 million recorded in Other (income) expense, net on the Statement of Operations for discontinued operations. The gain included a $160.0 million increase from the write-off of foreign currency translation adjustment from Accumulated other comprehensive income and a decrease from professional fees. The transaction gain is subject to final settlements under the Agreement, which we expect to finalize in the fourth quarter of 2021.

As of March 1, 2021, we determined that the RX business met the criteria to be classified as a discontinued operation and, as a result, its historical financial results have been reflected in our consolidated financial statements as a discontinued operation and its assets and liabilities have been classified as held for sale. We ceased recording depreciation and amortization on the RX business assets from March 1, 2021. We have not allocated any general corporate overhead to the discontinued operation.

Under the terms of the agreement, we will provide transition services for up to 24 months after the close of the transaction and we entered into a reciprocal supply agreement pursuant to which Perrigo will supply certain products to the RX business and the RX business will supply certain products to Perrigo. The supply agreements have a term of four years, extendable up to seven years by the party who is the purchaser of the products under such agreement. We also extended distribution rights to the RX business for certain OTC products owned and manufactured by Perrigo that may be fulfilled through pharmacy channels, in return for a share of the net profits.

During the three and nine months ended October 2, 2021, we recognized $3.6 million of income related to the transition services agreement ("TSA") in Other operating expense (income); $29.4 million of product sales and royalty income in Net sales related to the supply and distribution agreements with the RX business; and we purchased $9.5 million of inventories related to the supply arrangement with the RX business. No payments were made or received related to these agreements during the three and nine months ended October 2, 2021.

Additionally, under the TSA, we net settle any receipts received or payments made on behalf of the RX business’ customers or vendors. As of October 2, 2021, we recorded a receivable in the amount of $36.4 million in Prepaid expenses and other current assets for the reimbursement due to Perrigo.

In the transaction, Perrigo retained certain pre-closing liabilities arising out of antitrust (refer to Note 16 - Contingencies under the header "Price-Fixing Lawsuits") and opioid matters and the Company’s Albuterol recall, subject to, in each case, the buyer's obligation to indemnify the Company for fifty percent of these liabilities up to an aggregate cap on the buyer's obligation of $50.0 million. We have not requested payments from the buyer related to the indemnity of these liabilities during the three and nine months ended October 2, 2021.

18

Perrigo Company plc - Item 1

Note 8

Income from discontinued operations, net of tax was as follows (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Net sales	$	0.5	$	210.7	$	405.1	$	738.8
Cost of sales	0.1		149.8		258.4		496.2
Gross profit	0.4		60.9		146.7		242.6
Operating expenses
Distribution	—		3.6		6.1		11.4
Research and development	0.2		11.9		30.8		42.1
Selling	0.1		7.6		16.3		22.3
Administration	4.9		8.7		35.6		23.2
Impairment charges	—		202.4		—		202.4
Restructuring	—		—		—		0.4
Other operating expense (income)	—		0.6		(0.4)		0.8
Total operating expenses	5.2		234.8		88.4		302.6
Operating income (loss)	(4.8)		(173.9)		58.3		(60.0)
Interest expense, net	—		0.7		0.8		3.2
Other (income) expense, net	(63.7)		1.5		(65.5)		(0.7)
Income before income taxes	58.9		(176.1)		123.0		(62.5)
Income tax expense (benefit)	63.9		4.9		38.5		21.5
Income (loss) from discontinued operations, net of tax	$	(5.0)	$	(181.0)	$	84.5	$	(84.0)

During the three and nine months ended October 2, 2021, we incurred $29.1 million and $40.8 million, respectively, of separation costs related to the sale of the RX business. The costs incurred during the three months ended October 2, 2021 included selling costs, which were reported in other (income) expense, net as part of the gain on sale of the RX business. Separation costs incurred in prior periods were included in administration expenses.

Select cash flow information related to discontinued operations was as follows (in millions):

	Nine Months Ended
	October 2, 2021		September 26, 2020
Cash flows from discontinued operations operating activities:
Depreciation and amortization	$	15.3	$	72.4
Impairment charges	—		202.4
Loss (Gain) on sale of business	(63.9)		—
Cash flows from discontinued operations investing activities:
Asset acquisitions	$	(69.7)	$	(0.9)
Additions to property, plant and equipment	(6.6)		(10.0)
Net proceeds from sale of business	1,493.1		—

Asset acquisitions related to discontinued operations consisted of two Abbreviated New Drug Applications ("ANDAs") purchased under a contractual arrangement entered into on May 15, 2015 with a third party that specializes in research and development and obtaining approval for various drug candidates to develop specific products. On December 31, 2020, we purchased an ANDA for a generic topical gel for $16.4 million, which was subsequently paid during the three months ended April 3, 2021 and on March 8, 2021, we purchased an ANDA for a generic topical lotion for $53.3 million. These ANDAs were acquired by Altaris as part of the RX business sale.

19

Perrigo Company plc - Item 1

Note 8

The assets and liabilities classified as held for sale related to discontinued operations were as follows (in millions):

	December 31, 2020
Cash and cash equivalents	$	10.0
Accounts receivable, net of allowance for credit losses of $1.1	460.7
Inventories	140.8
Prepaid expenses and other current assets	55.4
Current assets held for sale	666.9
Property, plant and equipment, net	131.4
Operating lease assets	31.3
Goodwill and indefinite-lived intangible assets	681.2
Definite-lived intangible assets, net	492.8
Deferred income taxes	3.6
Other non-current assets	23.7
Non-current assets held for sale	1,364.0
Total assets held for sale	$	2,030.9
Accounts payable	$	92.2
Payroll and related taxes	22.3
Accrued customer programs	237.4
Other accrued liabilities	67.2
Current indebtedness	0.5
Current liabilities held for sale	419.6
Long-term debt, less current portion	0.7
Deferred income taxes	3.1
Other non-current liabilities	104.5
Non-current liabilities held for sale	108.3
Total liabilities held for sale	$	527.9

NOTE 9 – ASSETS HELD FOR SALE

We classify assets as "held for sale" when, among other factors, management approves and commits to a formal plan of sale with the expectation the sale will be completed within one year. The net assets of the business held for sale are then recorded at the lower of their current carrying value and the fair market value, less costs to sell.

During the three months ended July 3, 2021, management committed to a plan to sell our Latin American businesses; as a result, such assets were classified as held for sale. The assets associated with this business were reported within our CSCA segment. The sale is expected to close in the first half of 2022. At July 3, 2021, we determined the carrying value of the net assets held for sale of this business exceeded their fair value less cost to sell, resulting in an impairment charge of $152.5 million. At October 2, 2021 we recorded an additional impairment charge of $2.6 million resulting in a total impairment charge of $155.1 million. We also recorded a goodwill impairment charge of $6.1 million within our CSCA segment, related to the Latin American businesses (refer to Note 4), resulting in a total impairment charge of $161.2 million.

The assets and liabilities held for sale related to the Latin American businesses were reported within Current assets held for sale and Current liabilities held for sale on the Condensed Consolidated Balance Sheets. Net of impairment charges, the assets and liabilities of the Latin American businesses reported as held for sale as of October 2, 2021 totaled $13.4 million and $29.2 million, respectively.

20

Perrigo Company plc - Item 1

Note 10

NOTE 10 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES     

Foreign Currency Option Contracts

In September of 2021, to economically hedge the foreign currency exposure associated with the planned payment of the euro-denominated purchase price for HRA Pharma, we entered into two non-designated currency option contracts with a total notional amount of $1.1 billion that will mature in the third quarter of 2022. The company recorded a loss of $12.6 million for the change in fair value of the option contracts during the three months ended October 2, 2021 in Other (income) expense, net. Gains or losses on the derivatives due to changes in the EUR/USD exchange rate prior to the close of the acquisition will be economically offset at closing in the final settlement of the euro-denominated HRA Pharma purchase price. At the time of settlement, we are obligated to pay the deferred financing fee of $25.9 million.

Cross Currency Swaps

On August 15, 2019, we entered into a cross-currency swap designated as a net investment hedge to hedge the EUR currency exposure of our net investment in European operations. This agreement is a contract to exchange floating-rate Euro payments for floating-rate U.S. dollar payments through August 15, 2022. The payments are based on a notional basis of €450.0 million ($498.0 million) and settle quarterly.

Interest Rate Swaps

There were no active designated or non-designated interest rate swaps as of October 2, 2021 or December 31, 2020.

Foreign Currency Forwards

Net Investment Hedge

On June 19, 2020, we entered into a foreign currency forward contract designated as a net investment hedge of the GBP currency exposure of our net investment in certain of our U.K. operations. The hedge had a notional basis of £155.0 million ($194.5 million) and was settled during the three months ended September 26, 2020.

21

Perrigo Company plc - Item 1

Note 10

Foreign currency forward contracts were as follows (in millions):

	Notional Amount
	October 2, 2021		December 31, 2020
European Euro (EUR)	$	1,277.7	$	312.6
British Pound (GBP)	121.5		92.3
Israeli Shekel (ILS)	—		94.4
Danish Krone (DKK)	44.8		65.2
Swedish Krona (SEK)	41.9		41.2
Chinese Yuan (CNY)	36.2		49.1
United States Dollar (USD)	21.2		101.5
Polish Zloty (PLZ)	17.9		21.8
Canadian Dollar (CAD)	17.7		36.8
Norwegian Krone (NOK)	9.9		7.8
Switzerland Franc (CHF)	6.9		8.2
Turkish Lira (TRY)	4.7		4.0
Australian Dollar (AUD)	3.8		11.3
Romanian New Leu (RON)	3.7		3.6
Mexican Peso (MPX)	0.6		15.6
Other	2.2		2.3
Total	$	1,610.7	$	867.7

The maximum term of our forward currency exchange contracts is 60 months.

Effects of Derivatives on the Financial Statements

The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects.

The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions):

		Asset Derivatives
		Fair Value
	Balance Sheet Location	October 2, 2021		December 31, 2020
Designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	5.0	$	5.0
Foreign currency forward contracts	Other non-current assets	0.4		0.5
Cross-currency swap	Other non-current assets	—		6.3
Total designated derivatives		$	5.4	$	11.8
Non-designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	0.4	$	4.3
Foreign currency options	Prepaid expenses and other current assets	13.3		—
Total non-designated derivatives		$	13.7	$	4.3

22

Perrigo Company plc - Item 1

Note 10

		Liability Derivatives
		Fair Value
	Balance Sheet Location	October 2, 2021		December 31, 2020
Designated derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	0.4	$	5.5
Cross-currency swap	Other accrued liabilities	24.1		—
Total designated derivatives		$	24.5	$	5.5
Non-designated derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	1.4	$	2.4

The following tables summarize the effect of derivative instruments designated as hedging instruments in Accumulated Other Comprehensive Income ("AOCI") (in millions):

	Three Months Ended
	October 2, 2021
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Interest rate swap agreements	$	—	Interest expense, net	$	(0.4)	Interest expense, net	$	—
Foreign currency forward contracts	2.4		Net sales	(0.4)		Net sales	—
			Cost of sales	(0.5)		Cost of sales	—
						Other (income) expense, net	0.2
	$	2.4		$	(1.3)		$	0.2
Net investment hedges:
Cross-currency swap	$	(28.4)				Interest expense, net	$	(0.9)

23

Perrigo Company plc - Item 1

Note 10

	Nine Months Ended
	October 2, 2021
Instrument	Amount of Gain/(Loss) Recorded in OCI(1)		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Treasury locks	$	—	Interest expense, net	$	(0.1)	Interest expense, net	$	—
Interest rate swap agreements	—		Interest expense, net	(1.3)		Interest expense, net	—
Foreign currency forward contracts	2.0		Net sales	(2.3)		Net sales	—
			Cost of sales	1.4		Cost of sales	0.4
						Other (income) expense, net	0.6
	$	2.0		$	(2.3)		$	1.0
Net investment hedges:
Cross-currency swap	$	(30.5)				Interest expense, net	$	(2.9)

(1) Net loss of $7.9 million is expected to be reclassified out of AOCI into earnings during the next 12 months.

	Three Months Ended
	September 26, 2020
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Interest rate swap agreements	$	—	Interest expense, net	$	(0.4)	Interest expense, net	$	—
Foreign currency forward contracts	(1.5)		Net sales	(0.1)		Net sales	—
			Cost of sales	1.3		Cost of sales	0.2
	$	(1.5)		$	0.8		$	0.2
Net investment hedges:
Cross-currency swap	$	(0.3)				Interest expense, net	$	0.9
Foreign currency forward contract	(11.7)					Interest expense, net	(0.1)
	$	(12.0)					$	0.8

24

Perrigo Company plc - Item 1

Note 10

	Nine Months Ended
	September 26, 2020
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Treasury locks	$	—	Interest expense, net	$	(0.1)	Interest expense, net	$	—
Interest rate swap agreements	—		Interest expense, net	(1.3)		Interest expense, net	—
Foreign currency forward contracts	8.3		Net sales	(0.1)		Net sales	0.1
			Cost of sales	0.3		Cost of sales	0.8
	$	8.3		$	(1.2)		$	0.9
Net investment hedges:
Cross-currency swap	$	(18.6)				Interest expense, net	$	5.6
Foreign currency forward contract	(11.2)					Interest expense, net	(0.1)
	$	(29.8)					$	5.5

The amounts of (income)/expense recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):

		Three Months Ended				Nine Months Ended
Non-Designated Derivatives	Income Statement Location	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Foreign currency forward contracts	Other (income) expense, net	$	(0.1)	$	(0.3)	$	(6.1)	$	(1.3)
	Interest expense, net	0.2		0.9		1.2		2.8
		$	0.1	$	0.6	$	(4.9)	$	1.5
Foreign currency options	Other (income) expense, net	$	12.6	$	—	$	12.6	$	—

The classification and amount of gain/(loss) recognized in earnings on fair value and hedging relationships were as follows (in millions):

25

Perrigo Company plc - Item 1

Note 10

	Three Months Ended
	October 2, 2021
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	1,042.7	$	706.3	$	30.9	$	18.5
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(0.4)	$	(0.5)	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	—	$	—	$	0.2
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.4)	$	—

	Nine Months Ended
	October 2, 2021
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	3,033.8	$	1,980.0	$	94.5	$	20.4
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(2.3)	$	1.4	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	0.4	$	—	$	0.6
Treasury locks
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.1)	$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(1.3)	$	—

26

Perrigo Company plc - Item 1

Note 10

	Three Months Ended
	September 26, 2020
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	1,003.0	$	633.3	$	33.3	$	(1.0)
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(0.1)	$	1.3	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	0.2	$	—	$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.4)	$	—

	Nine Months Ended
	September 26, 2020
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	3,035.0	$	1,924.5	$	94.3	$	17.9
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(0.1)	$	0.3	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	0.1	$	0.8	$	—	$	—
Treasury locks
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.1)	$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(1.3)	$	—

27

Perrigo Company plc - Item 1

Note 11

NOTE 11 – LEASES

The balance sheet locations of our lease assets and liabilities were as follows (in millions):

Assets	Balance Sheet Location	October 2, 2021		December 31, 2020
Operating	Operating lease assets	$	170.6	$	154.7
Finance	Other non-current assets	29.5		29.8
Total		$	200.1	$	184.5

Liabilities	Balance Sheet Location	October 2, 2021		December 31, 2020
Current
Operating	Other accrued liabilities	$	27.2	$	28.3
Finance	Current indebtedness	5.1		6.7
Non-Current
Operating	Other non-current liabilities	148.9		132.5
Finance	Long-term debt, less current portion	22.1		20.2
Total		$	203.3	$	187.7

The below tables show our lease assets and liabilities by reporting segment (in millions):

	Assets
	Operating				Financing
	October 2, 2021		December 31, 2020		October 2, 2021		December 31, 2020
CSCA	$	100.8	$	75.9	$	15.7	$	16.7
CSCI	30.4		34.4		8.3		5.9
Unallocated	39.4		44.4		5.5		7.2
Total	$	170.6	$	154.7	$	29.5	$	29.8

	Liabilities
	Operating				Financing
	October 2, 2021		December 31, 2020		October 2, 2021		December 31, 2020
CSCA	$	101.3	$	75.8	$	16.4	$	17.0
CSCI	31.4		35.2		5.2		2.5
Unallocated	43.4		49.8		5.6		7.4
Total	$	176.1	$	160.8	$	27.2	$	26.9

Lease expense was as follows (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Operating leases(1)	$	10.0	$	8.5	$	29.9	$	26.6
Finance leases
Amortization	$	1.5	$	1.1	$	4.4	$	3.2
Interest	0.2		0.2		0.6		0.6
Total finance leases	$	1.7	$	1.3	$	5.0	$	3.8

28

Perrigo Company plc - Item 1

Note 11

            (1) Includes short-term leases and variable lease costs, which are immaterial.

The annual future maturities of our leases as of October 2, 2021 are as follows (in millions):

	Operating Leases		Finance Leases		Total
2021	$	8.2	$	1.5	$	9.7
2022	29.2		5.6		34.8
2023	21.8		3.9		25.7
2024	18.6		2.4		21.0
2025	16.5		2.2		18.7
After 2025	109.0		15.8		124.8
Total lease payments	203.3		31.4		234.7
Less: Interest	27.2		4.2		31.4
Present value of lease liabilities	$	176.1	$	27.2	$	203.3

Our weighted average lease terms and discount rates are as follows:

	October 2, 2021		September 26, 2020
Weighted-average remaining lease term (in years)
Operating leases	11.39		6.26
Finance leases	8.78		9.20
Weighted-average discount rate
Operating leases	2.60	%	3.64	%
Finance leases	2.64	%	3.20	%

Our lease cash flow classifications are as follows (in millions):

	Nine Months Ended
	October 2, 2021		September 26, 2020
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	26.3	$	25.4
Operating cash flows for finance leases	$	0.6	$	0.6
Financing cash flows for finance leases	$	3.9	$	2.9
Leased assets obtained in exchange for new finance lease liabilities	$	4.5	$	4.6
Leased assets obtained in exchange for new operating lease liabilities	$	42.5	$	24.5

29

Perrigo Company plc - Item 1

Note 12

NOTE 12 – INDEBTEDNESS

Total borrowings outstanding are summarized as follows (in millions):

			October 2, 2021		December 31, 2020
Term loan
	2019 Term loan due August 15, 2022		$	600.0	$	600.0
Notes and Bonds
	Coupon	Due
	5.105%	July 28, 2023(1)	$	156.6	$	164.9
	4.000%	November 15, 2023	215.6		215.6
	3.900%	December 15, 2024	700.0		700.0
	4.375%	March 15, 2026	700.0		700.0
	3.150%	June 15, 2030	750.0		750.0
	5.300%	November 15, 2043	90.5		90.5
	4.900%	December 15, 2044	303.9		303.9
	Total notes and bonds		2,916.6		2,924.9
Other financing			52.0		57.4
Unamortized premium (discount), net			(3.5)		(0.3)
Deferred financing fees			(14.8)		(17.1)
Total borrowings outstanding			3,550.3		3,564.9
	Current indebtedness		(629.4)		(37.3)
Total long-term debt less current portion			$	2,920.9	$	3,527.6

    (1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

Revolving Credit Agreements

On March 8, 2018, we entered into a $1.0 billion revolving credit agreement maturing on March 8, 2023 (the "2018 Revolver"). There were no borrowings outstanding under the 2018 Revolver as of October 2, 2021 or December 31, 2020.

Term Loan and Notes

In August 2019, we refinanced a prior term loan with the proceeds of a $600.0 million term loan, maturing on August 15, 2022 (the "2019 Term Loan"). We had $600.0 million outstanding under our 2019 Term Loan as of both October 2, 2021 and December 31, 2020.

Waiver and Amendment of Debt Covenants

We are subject to financial covenants in the 2018 Revolver and 2019 Term Loan, including a maximum leverage ratio covenant, which previously required us to maintain a ratio of Consolidated Net Indebtedness to Consolidated EBITDA (as such terms are defined in such credit agreements) of not more than 3.75 to 1.00 at the end of each fiscal quarter. During the nine months ended October 2, 2021, we received a waiver for non-compliance with such covenant as of July 3, 2021 from the lenders under both such credit facilities and entered into an amendment to each of the 2018 Revolver and 2019 Term Loan. Under such amendments, the maximum leverage ratio was increased to 5.75 to 1.00 for the third quarter of 2021, returning to 3.75 to 1.00 beginning with the fourth quarter of 2021. If we consummate certain qualifying acquisitions in the fourth quarter of 2021 or any subsequent quarter during the term of the loan, the maximum ratio would increase to 4.00 to 1.00 for such quarter. Due to the waiver and amendment described above, our leverage ratios at the end of the second and third quarters of 2021 do not prevent us from drawing under the 2018 Revolver. As of October 2, 2021, we are in compliance with all the covenants under our debt agreements.

30

Perrigo Company plc - Item 1

Note 12

2020 Notes and 2021 Notes Redemption

On June 19, 2020, Perrigo Finance Unlimited Company, an indirect wholly-owned finance subsidiary of Perrigo ("Perrigo Finance"), issued $750.0 million in aggregate principal amount of 3.150% Senior Notes due 2030 (the “2020 Notes") and received net proceeds of $737.1 million after the underwriting discount and offering expenses. Interest on the 2020 Notes is payable semi-annually in arrears on June 15 and December 15 of each year, beginning on December 15, 2020. Due to a credit ratings downgrade by S&P Global Ratings and Moody’s in the third quarter of 2021, the interest on the 2020 Notes will step up from 3.150% to 3.900%, starting after the interest payment due on December 15, 2021. The 2020 Notes will mature on June 15, 2030 and are governed by a base indenture and a third supplemental indenture (collectively, the "2020 Indenture"). The 2020 Notes are fully and unconditionally guaranteed on a senior unsecured basis by Perrigo. Perrigo Finance may redeem the 2020 Notes in whole or in part at any time for cash at the make-whole redemption prices described in the 2020 Indenture. On July 6, 2020, a portion of the proceeds of the 2020 Notes were used to fund the redemption of $280.4 million of Perrigo Finance's 3.500% Senior Notes due March 15, 2021 and $309.6 million of 3.500% Senior Notes due December 15, 2021 (collectively, the "2021 Notes").

As a result of the early redemption of the 2021 notes, during the three months ended September 26, 2020, we recorded a loss of $20.0 million in Loss on extinguishment of debt on the Condensed Consolidated Statements of Operations, consisting of the premium on debt repayments, the write-off of deferred financing fees, and the write-off of the remaining bond discounts.

Other Financing

We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under "Other financing". There were no borrowings outstanding under the facilities as of October 2, 2021 or December 31, 2020.

On June 17, 2020, we incurred debt of $34.3 million related to our equity method investment in Kazmira pursuant to two Promissory Notes, with $3.7 million, $5.8 million and $24.8 million to be settled in November 2020, May 2021 and November 2021, respectively. On December 8, 2020, we repaid the $3.7 million balance due on the November 2020 portion of the Promissory Notes. On June 7, 2021, we repaid the $5.8 million balance due on the May 2021 portion of the Promissory Notes.

We have financing leases that are reported in the above table under "Other financing" (refer to Note 11).

31

Perrigo Company plc - Item 1

Note 13

NOTE 13 – EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY

Earnings per Share

A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Numerator:
Income (loss) from continuing operations	$	(53.9)	$	26.4	$	(163.0)	$	96.4
Income (loss) from discontinued operations, net of tax	(5.0)		(181.0)		84.5		(84.0)
Net income (loss)	$	(58.9)	$	(154.6)	$	(78.5)	$	12.4
Denominator:
Weighted average shares outstanding for basic EPS	133.8		136.5		133.5		136.3
Dilutive effect of share-based awards*	—		1.1		—		1.2
Weighted average shares outstanding for diluted EPS	133.8		137.6		133.5		137.5
Anti-dilutive share-based awards excluded from computation of diluted EPS*	—		1.5		—		1.5
* In the period of a net loss, diluted shares equal basic shares.

Shareholders' Equity

Share Repurchases

In October 2018, our Board of Directors authorized up to $1.0 billion of share repurchases with no expiration date, subject to the Board of Directors’ approval of the pricing parameters and amount that may be repurchased under each specific share repurchase program (the "2018 Authorization"). We did not repurchase any shares during the three and nine months ended October 2, 2021 or September 26, 2020.

NOTE 14 – ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Changes in our AOCI balances, net of tax were as follows (in millions):

	Fair Value of Derivative Financial Instruments, net of tax		Foreign Currency Translation Adjustments		Post-Retirement and Pension Liability Adjustments, net of tax		Total AOCI
Balance at December 31, 2020	$	(0.7)	$	407.3	$	(11.6)	$	395.0
OCI before reclassifications	(33.4)		(147.5)		(2.2)		(183.1)
Amounts reclassified from AOCI(1)	2.3		(160.0)		—		(157.7)
Other comprehensive income (loss)	$	(31.1)	$	(307.5)	$	(2.2)	$	(340.8)
Balance at October 2, 2021	$	(31.8)	$	99.8	$	(13.8)	$	54.2

(1) Refer to Note 8, sale of RX business for information regarding amounts reclassified from AOCI related to foreign currency translation adjustments.

32

Perrigo Company plc - Item 1

Note 15

NOTE 15 – INCOME TAXES

The effective tax rates were as follows:

Three Months Ended				Nine Months Ended
October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
113.9	%	45.5	%	165.5	%	20.5	%

The effective tax rate for the three and nine months ended October 2, 2021 increased compared to the effective tax rate for the three and nine months ended September 26, 2020 primarily due to tax expense recorded in 2021 for settlement of the Irish Notice of Amended Assessment and intra-entity transfers of intellectual property, plus tax benefits recorded in the 2020 periods for reductions to the U.S. valuation allowance and the U.S. Coronavirus Aid, Relief and Economic Security ("CARES") Act, enacted in the first quarter of 2020.

In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes." It removes certain exceptions to the general principles in ASC Topic 740 and improves consistent application of and simplifies GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. This guidance was effective for interim and annual reporting periods beginning after December 15, 2020. We adopted this guidance as of January 1, 2021, and the impact on our Consolidated Financial Statements was immaterial.

Internal Revenue Service Audits of Perrigo Company, a U.S. Subsidiary

Perrigo Company, our U.S. subsidiary ("Perrigo U.S."), is engaged in a series of tax disputes in the U.S. relating primarily to transfer pricing adjustments including income in connection with the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States, including the heartburn medication omeprazole. On August 27, 2014, we received a statutory notice of deficiency from the IRS relating to our fiscal tax years ended June 27, 2009, and June 26, 2010 (the “2009 tax year” and “2010 tax year”, respectively). On April 20, 2017, we received a second statutory notice of deficiency from the IRS for the fiscal tax years ended June 25, 2011 and June 30, 2012 (the “2011 tax year” and “2012 tax year”, respectively). Specifically, both statutory notices proposed adjustments related to the offshore reporting of profits on sales of omeprazole in the United States resulting from the assignment of an omeprazole distribution contract to an affiliate. In addition to the transfer pricing adjustments, which applied to all four tax years, the statutory notice of deficiency for the 2011 and 2012 tax years included adjustments for the capitalization and amortization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits related to ANDAs.

We do not agree with the audit adjustments proposed by the IRS in either of the notices of deficiency. We paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and timely filed claims for refund on June 11, 2015 for the 2009 and 2010 tax years, and on June 7, 2017, for the 2011 and 2012 tax years. On August 15, 2017, following disallowance of such refund claims, we timely filed a complaint in the United States District Court for the Western District of Michigan seeking refunds of tax, interest, and penalties of $27.5 million for the 2009 tax year, $41.8 million for the 2010 tax year, $40.1 million for the 2011 tax year, and $24.7 million for the 2012 tax year, for a total of $134.1 million, plus statutory interest thereon from the dates of payment. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended July 1, 2017.

The previously rescheduled trial was held during the period May 25, 2021 to June 7, 2021 for the refund case in the United States District Court for the Western District of Michigan. The total amount of cumulative deferred charge that we are seeking to receive in this litigation is approximately $111.6 million, which reflects the impact of conceding that Perrigo U.S. should have received a 5.24% royalty on all omeprazole sales. That concession was previously paid and is the subject of the above refund claims. The issues outlined in the statutory notices of deficiency described above are continuing, and the IRS will likely carry forward the adjustments set forth therein as long as the drug is sold, in the case of the omeprazole issue, and for all post-2012 Paragraph IV filings that trigger patent infringement suits, in the case of the ANDA issue. On April 30, 2021, we filed a Notice of New Authority in our

33

Perrigo Company plc - Item 1

Note 15

refund case in the Western District of Michigan alerting the court to a Tax Court decision in Mylan v. Comm'r that ruled in favor of the taxpayer on the identical ANDA issues we have before the court. Post-trial briefings were completed on September 24, 2021 and the case is now fully submitted for the court's decision.

On January 13, 2021, the IRS issued a 30-day letter with respect to its audit of our fiscal tax years ended June 29, 2013 (the "2013 tax year"), June 28, 2014 (the "2014 tax year"), and June 27, 2015 (the "2015 tax year" and together with the 2013 tax year and the 2014 tax year, the "2013-2015 tax years"). The IRS letter proposed, among other modifications, carryforwards of the transfer pricing adjustments regarding our profits from the distribution of omeprazole in the aggregate amount of $141.6 million and ANDA adjustments in the aggregate amount of $21.9 million. The 30-day letter also set forth adjustments described in the next two paragraphs. We timely filed a protest to the 30-day letter for those additional adjustments, but noting that due to the pending litigation described above, IRS Appeals will not consider the merits of the omeprazole or ANDA matters. We believe that we should prevail on the merits on both carryforward issues and have reserved for taxes and interest payable on the 5.24% deemed royalty on omeprazole through the tax year ended December 31, 2018. Beginning with the tax year ended December 31, 2019, we began reporting income commensurate with the 5.24% deemed royalty. We have not reserved for the ANDA-related issue described above. While we believe we should prevail on the merits of this case, the outcome remains uncertain. If our litigation position on the omeprazole issue is not sustained, the outcome for the 2009–2012 tax years could range from a reduction in the refund amount to denial of any refund. In addition, we expect that the outcome of the refund litigation could effectively bind future tax years. In that event, an adverse ruling on the omeprazole issue could have a material impact on subsequent periods, with additional tax liability in the range of $24.0 million to $112.0 million, not including interest and any applicable penalties.

The 30-day letter for the 2013-2015 tax years also proposed to reduce Perrigo U.S.'s deductible interest expense for the 2014 tax year and the 2015 tax year on $7.5 billion in debts owed by it to Perrigo Company plc. The debts were incurred in connection with the Elan merger transaction in 2013. On May 7, 2020, the IRS issued a NOPA capping the interest rate on the debts for U.S. federal tax purposes at 130.0% of the Applicable Federal Rate ("AFR") (a blended rate reduction of 4.0% per annum), on the stated ground that the loans were not negotiated on an arms’-length basis. The NOPA proposes a reduction in gross interest expense of approximately $414.7 million for tax years 2014 and 2015. On January 13, 2021, we received a Revenue Agent Report ("RAR"), together with the 30-day letter, requiring our filing of a written Protest to request IRS Appeals consideration. The Protest was timely filed with the IRS on February 26, 2021. On May 3, 2021, the IRS notified us that it will no longer pursue the 130% of AFR position reflected in its NOPA due to a change in IRS policy. The IRS will provide a new proposed adjustment in its rebuttal to our Protest, which we have not yet received. Because the IRS' revised adjustment is currently unknown and cannot be quantified, we are unable to determine the amount of gross interest expense that the IRS proposes to disallow, and we cannot estimate any increase in tax expense attributable to any such disallowance for the period under audit. In addition, we expect the IRS to seek similar revised adjustments for the tax years ended December 31, 2015 through December 31, 2018 with potential section 163(j) carryover impacts beyond December 2018. We cannot determine the amount, if any, of the estimated increase in tax expense attributable to any such adjustments. No further interest adjustments are expected beyond this period. We strongly disagree with the IRS position and we will pursue all available administrative and judicial remedies necessary. At this stage, we are unable to estimate any additional liability associated with this matter.

In addition, the 30-day letter for the 2013-2015 tax years expanded on a NOPA issued on December 11, 2019 and proposed to disallow adjustments to gross sales income on the sale of prescription products to wholesalers for accrued wholesale customer pipeline chargebacks where the prescription products were not re-sold by such wholesalers to covered retailers by the end of the tax year for the 2013-2015 tax years. The IRS' NOPA asserts that the reduction of gross sales income of such chargebacks is an impermissible method of accounting. The IRS proposed a change in accounting method that would defer the reduction in gross sales income until the year the prescription products were re-sold to covered retailers. The NOPA proposes an increase in sales revenue of approximately $99.5 million for the 2013-2015 tax years. We filed a protest on February 26, 2021 to request IRS Appeals consideration. If the IRS were to prevail in its proposed adjustment, we estimate a payment of approximately $18.0 million, excluding interest and penalties for the 2013-2015 tax years. In addition, we expect the IRS to seek similar adjustments for future years. If those future adjustments were to be sustained, based on preliminary calculations and subject to further analysis, our current best estimate is a payment that will not exceed $7.0 million through tax year ended December 31, 2020, excluding interest and penalties. We have fully reserved for this issue. We strongly disagree with the IRS’s proposed adjustment and will pursue all available administrative and judicial remedies necessary.

34

Perrigo Company plc - Item 1

Note 15

Internal Revenue Service Audit of Athena Neurosciences, Inc., a U.S. Subsidiary    

On April 26, 2019, we received a revised NOPA from the IRS regarding transfer pricing positions related to the IRS audit of Athena Neurosciences, Inc. ("Athena") for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. The NOPA carries forward the IRS's theory from its 2017 draft NOPA that when Elan took over the future funding of Athena's in-process research and development after acquiring Athena in 1996, Elan should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation prepared by Elan's external tax advisors. The NOPA proposes a payment of $843.0 million, which represents additional tax and a 40.0% penalty. This amount excludes consideration of offsetting tax attributes and any potential interest that may be imposed. We strongly disagree with the IRS position. On December 22, 2016, we also received a NOPA for these years denying the deductibility of settlement costs related to illegal marketing of Zonegran in the United States raised in a Qui Tam action. We strongly disagree with the IRS' position on this issue as well. Because we believe that any concession on these issues in Appeals would be contrary to our evaluation of the issues, we pursued our remedies under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. On April 14, 2020, we filed a request for Competent Authority Assistance with the IRS on the royalty issue, and it was accepted. On October 20, 2020, we amended our request for Competent Authority Assistance to include the Zonegran issue and this amendment was also accepted. On May 6, 2021, we had our opening conference with the IRS and discussed our submission, which continues to be reviewed by the IRS. Our opening conference with Irish Revenue was held on July 23, 2021 and we discussed our submission, which continues to be reviewed by Irish Revenue.

No payment of the additional amounts is required until these two matters are resolved with finality under the treaty, or any additional administrative or judicial process if treaty negotiations are unsuccessful.

Irish Revenue Audit of Fiscal Years Ended December 31, 2012 and December 31, 2013

On October 30, 2018, we received an audit findings letter from the Irish Office of the Revenue Commissioners (“Irish Revenue”) for the tax years ended December 31, 2012 and December 31, 2013. The audit findings letter related to the tax treatment of the 2013 sale of the Tysabri® intellectual property and related assets to Biogen Idec by Elan Pharma. The consideration paid by Biogen Idec to Elan Pharma took the form of an upfront payment and future contingent royalty payments. Elan Pharma recognized such receipts as trading income in its tax returns filed with Irish Revenue, consistent with Elan Pharma's historical practice relating to its active management of intellectual property rights.

In its audit findings letter, Irish Revenue proposed to charge Elan Pharma tax on the net chargeable gain realized by Elan Pharma on the Tysabri® transaction in 2013 at a rate of 33%, rather than the 12.5% tax rate applied to trading income. On November 29, 2018, Irish Revenue issued a Notice of Amended Assessment (“NoA”) for the tax year ended December 31, 2013, in the amount of €1,643 million, and claiming tax payable in the amount of €1,636 million, not including any interest or applicable penalties.

Accordingly, we filed an appeal of the NoA on December 27, 2018 with the Irish Tax Appeals Commission ("TAC") which is the statutory body charged with considering whether the NoA was properly founded as a matter of Irish tax law. Separately, we were also granted leave by the Irish High Court on February 25, 2019 to seek judicial review of the issuance of the NoA by Irish Revenue.

On November 4, 2020, the High Court ruled that the Irish Revenue's decision to issue the NoA did not violate Elan Pharma's constitutional rights and legitimate expectations as a taxpayer. The Irish High Court did not rule on the merits of the NoA under Irish tax law.

We strongly believe that Elan Pharma’s tax position was correct and ultimately would have been confirmed through judicial process. However, in light of the risks and delays inherent in any litigation, on April 26, 2021, Perrigo, through its tax adviser, made a without prejudice written offer of settlement to Irish Revenue detailing a possible framework to resolve the dispute, which applied an alternative basis of taxation than the respective positions taken by Irish Revenue in the NoA and by Elan Pharma in its tax returns. On May 31, 2021, Irish Revenue issued a formal response to Perrigo's tax adviser indicating that the written settlement offer would not be accepted as presented. However, Irish Revenue did indicate that they would remain available for further discussion without prejudice and the Company's representatives continued to meet and correspond with Irish Revenue throughout the summer.

35

Perrigo Company plc - Item 1

Note 15

On July 9, 2021, Irish Revenue issued a letter acknowledging that not all relevant facts were known to them when they issued the NoA in 2018 and, accordingly, they would not object if the Appeal Commissioner were to make certain adjustments reducing Irish Revenue’s original assessment. Such adjustments would reflect contingent royalty payments that were never received by Elan Pharma, deductions for acquisition and development costs incurred, and allowable losses and reliefs, and would, if allowed, result in an aggregate reduction of more than €660.0 million from the income taxes claimed in the NoA as issued.

On September 29, 2021, Elan Pharma reached an agreement with Irish Revenue providing for full and final settlement of the NoA. Elan Pharma and Irish Revenue agreed to a settlement on the following terms: (i) on a 'without prejudice basis' and, for purposes of the settlement, an alternative basis of taxation was applied, (ii) Irish Revenue will take no further action in relation to the NoA or any Tysabri related income or transactions, (iii) no interest or penalties apply, (iv) a total tax of €297.0 million as full and final settlement of all liabilities arising from the sale of the Tysabri patents for the fiscal years 2013 to 2021, and (v) after Irish Revenue credited taxes already paid and certain unused R&D credits against the €297.0 million figure, the total cash payment due is €266.1 million. The payment of €266.1 million ($307.5 million) was made on October 5, 2021.

Israel Tax Authority Audit of Fiscal Year Ended June 27, 2015 and Calendar Years Ended December 31, 2015 through December 31, 2019

The Israel Tax Authority ("ITA") audited our income tax returns for the 2015 tax year, and calendar years ended December 31, 2015, December 31, 2016 and December 31, 2017. On December 29, 2020, we received a Stage A assessment from the ITA for the tax years ended December 31, 2015 through December 31, 2017 in the amount of $63.8 million relating to attribution of intangible income to Israel, income qualifying for a lower preferential rate of tax, exemption from capital gains tax, and deduction of certain settlement payments. Our protest was timely filed on March 11, 2021 to move the matter to Stage B of the assessment process.

Through negotiations with the ITA, we resolved the audit for the tax year ended June 27, 2015 through tax year ended December 31, 2019, by agreeing to add tax year ended December 31, 2018 and tax year ended December 31, 2019 to the audit period to reach an agreeable resolution to provide certainty for these additional periods. The agreement with the ITA required us to pay $19.0 million, after offset for refunds of $17.2 million, for the five taxable years. In addition, we paid $12.5 million to resolve a tax liability indemnity for the tax year ended December 31, 2017 relating to Perrigo API Ltd, which we disposed of in December 2017 (refer to Note 16).

As a result of the settlement with the ITA, we reduced our liability recorded for uncertain tax positions by $38.3 million including interest.

    Although we believe that our tax estimates are reasonable and that we prepare our tax filings in accordance with all applicable tax laws, the final determination with respect to any tax audit and any related litigation could be materially different from our estimates or from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on operating results and/or cash flows in the periods for which that determination is made. In addition, future period earnings may be adversely impacted by litigation costs, settlements, penalties, and/or interest assessments.

Based on the final resolution of tax examinations, judicial or administrative proceedings, changes in facts or law, expirations of statute of limitations in specific jurisdictions or other resolutions of, or changes in, tax positions - one or more of which may occur within the next twelve months - it is reasonably possible that unrecognized tax benefits for certain tax positions taken on previously filed tax returns may change materially from those recorded as of October 2, 2021. However, we are not able to estimate a reasonably possible range of how these events may impact our unrecognized tax benefits in the next twelve months.

36

Perrigo Company plc - Item 1

Note 16

NOTE 16 – CONTINGENCIES

    In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below. We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated. The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters. For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of October 2, 2021, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows. We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve. Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject to have, individually or in the aggregate, a material adverse effect on our financial condition, results of operations, or cash flows.

Price-Fixing Lawsuits

Perrigo is a defendant in several cases in the generic pricing multidistrict litigation MDL No. 2724 (United States District Court for Eastern District of Pennsylvania). This multidistrict litigation, which has many cases that do not include Perrigo, includes class action and opt-out cases for federal and state antitrust claims, as well as complaints filed by certain states alleging violations of state antitrust laws.

On July 14, 2020, the court issued an order designating the following cases to proceed on a more expedited basis (as a bellwether) than the other cases in MDL No. 2724: (a) the May 2019 state case alleging an overarching conspiracy involving more than 120 products (which does not name Perrigo a defendant) and (b) class actions alleging “single drug” conspiracies involving Clomipramine, Pravastatin, and Clobetasol. Perrigo is a defendant in the Clobetasol cases but not the others. On February 9, 2021, the Court entered an order provisionally deciding to remove the May 2019 state case and the pravastatin class cases from the bellwether proceedings. On May 7, 2021, the Court ruled that the clobetasol end payer and direct purchaser class cases will remain part of the bellwether. The Court also ruled that the June 10, 2020 state complaint against Perrigo and approximately 35 other manufacturers will move forward as a bellwether case. No schedule has been set for the bellwether cases.

Class Action Complaints

(a) Single Drug Conspiracy Class Actions

We have been named as a co-defendant with certain other generic pharmaceutical manufacturers in a number of class actions alleging single-product conspiracies to fix or raise the prices of certain drugs and/or allocate customers for those products starting, in some instances, as early as June 2013. The class actions were filed on behalf of putative classes of (a) direct purchasers, (b) end payors, and (c) indirect resellers. The products in question are Clobetasol gel, Desonide, and Econazole. The court denied motions to dismiss each of the complaints alleging “single drug” conspiracies involving Perrigo, and the cases are proceeding in discovery. As noted above, the Clobetasol cases have been designated to proceed on a more expedited schedule than the other cases. That schedule has not yet been set.

(b) “Overarching Conspiracy” Class Actions

The same three putative classes, including (a) direct purchasers, (b) end payors, and (c) indirect resellers, have filed two sets of class action complaints alleging that Perrigo and other manufacturers (and some individuals) entered into an “overarching conspiracy” that involved allocating customers, rigging bids and raising, maintaining, and fixing prices for various products. Each class brings claims for violations of Sections 1 and 3 of the Sherman Antitrust Act as well as several state antitrust and consumer protection statutes.

37

Perrigo Company plc - Item 1

Note 16

Filed in June 2018, and later amended in December 2018 (with respect to direct purchasers) and April 2019 (with respect to end payors and indirect resellers), the first set of “overarching conspiracy” class actions include allegations against Perrigo and approximately 27 other manufacturers involving 135 drugs with allegations dating back to March 2011. The allegations against Perrigo concern only two formulations (cream and ointment) of one of the products at issue, Nystatin. The court denied motions to dismiss the first set of “overarching conspiracy” class actions, and they are proceeding in discovery. None of these cases are included in the group of cases on a more expedited schedule pursuant to the court’s July 14, 2020 order.

In December 2019, both the end payor and indirect reseller class plaintiffs filed a second set of "overarching conspiracy” class actions against Perrigo, dozens of other manufacturers of generic prescription pharmaceuticals, and certain individuals dating back to July 2009 (end payors) or January 2010 (indirect resellers). The direct purchaser plaintiffs filed their second round overarching conspiracy complaint in February 2020 with claims dating back to July 2009. On March 11, 2020, the indirect reseller plaintiffs filed a motion to amend their second round December 2019 complaint, and that motion was granted. On September 4, 2020, and December 15, 2020, the end payor plaintiffs amended their second round complaint. On October 21, 2020, the direct purchaser plaintiffs amended their second round complaint. On December 15, 2020, the indirect reseller plaintiffs filed another complaint adding allegations for additional drugs that mirror the other class plaintiffs’ claims.

This second set of overarching complaints allege conspiracies relating to the sale of various products that are not at issue in the earlier-filed overarching conspiracy class actions, the majority of which Perrigo neither makes nor sells. The amended indirect reseller complaint alleges that Perrigo conspired in connection with its sales of Betamethasone Dipropionate lotion, Imiquimod cream, Desonide cream and ointment, and Hydrocortisone Valerate cream. The December 2020 indirect reseller complaint alleges that Perrigo conspired in connection with its sales of Adapalene, Ammonium Lactate, Bromocriptine Mesylate, Calcipotriene, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Methazolamide, Mometasone Furoate, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The amended end payor complaint alleges that Perrigo conspired in connection with its sale of the following drugs: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluocinonide, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone Furoate, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The amended direct purchaser complaint alleges that Perrigo conspired in connection with its sale of the following drugs: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Ciclopirox, Clindamycin Phosphate, Fenofibrate, Fluocinonide, Halobetasol Propionate, Hydrocortisone Valerate, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

Perrigo has not yet responded to the second set of overarching conspiracy complaints, and responses are currently stayed.

Opt-Out Complaints

On January 22, 2018, Perrigo was named a co-defendant along with 35 other manufacturers in a complaint filed by three supermarket chains alleging that defendants conspired to fix prices of 31 generic prescription pharmaceutical products starting in 2013. On December 21, 2018, an amended complaint was filed that adds additional products and allegations against a total of 39 manufacturers for 33 products. The only allegations specific to Perrigo relate to Clobetasol, Desonide, Econazole, Nystatin cream, and Nystatin ointment. Perrigo moved to dismiss this complaint on February 21, 2019. The motion was denied on August 15, 2019. The case is proceeding in discovery. On February 3, 2020, the plaintiffs requested leave to file a second amended complaint. The proposed amended complaint adds dozens of additional products and allegations to the original complaint. Perrigo is discussed in connection with allegations concerning an additional drug, Fenofibrate. Defendants opposed the motion for leave to file a second amended complaint and the court has yet to rule on the issue.

On August 3, 2018, a large managed care organization filed a complaint alleging price-fixing and customer allocation concerning 17 different products among 27 manufacturers including Perrigo. The only allegations specific to Perrigo concern Clobetasol. Perrigo moved to dismiss this complaint on February 21, 2019. Plaintiff filed a second amended complaint in April 2019 that adds additional products and allegations. The amended allegations

38

Perrigo Company plc - Item 1

Note 16

that concern Perrigo include: Clobetasol, Desonide, Econazole, and Nystatin. The motion to dismiss was denied on August 15, 2019. The case is proceeding in discovery.

The same organization amended a different complaint that it had filed in October 2019, which did not name Perrigo, on December 15, 2020, adding Perrigo as a defendant and asserting new allegations of alleged antitrust violations involving Perrigo and dozens of other generic pharmaceutical manufacturers. The allegations relating to Perrigo concern: Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Ciclopirox, Clindamycin Phosphate, Fenofibrate, Fluocinonide, Halobetasol Propionate, Hydrocortisone Valerate, Imiquimod, Permethrin, Prochlorperazine Maleate, and Triamcinolone Acetonide.

The same organization filed a third complaint on December 15, 2020, naming Perrigo and dozens of other manufacturers alleging antitrust violations concerning generic pharmaceutical drugs. The allegations relating to Perrigo concern: Ammonium Lactate, Calcipotriene Betamethasone Dipropionate, Erythromycin, Fluticasone Propionate, Hydrocortisone Acetate, Methazolamide, Promethazine HCL, and Tacrolimus.

On January 16, 2019, a health insurance carrier filed a complaint in the U.S. District Court for the District of Minnesota alleging a conspiracy to fix prices of 30 products among 30 defendants. The only allegations specific to Perrigo concerned Clobetasol gel, Desonide, Econazole, Nystatin cream, and Nystatin ointment. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations that concern Perrigo relate to Fluocinonide.

The same health insurance carrier filed a new complaint on December 15, 2020, naming Perrigo and dozens of other manufacturers alleging antitrust violations concerning generic pharmaceutical drugs. The allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

On July 18, 2019, 87 health plans filed a Praecipe to Issue Writ of Summons in Pennsylvania state court to commence an action against 53 generic pharmaceutical manufacturers and 17 individuals, alleging antitrust violations concerning generic pharmaceutical drugs. While Perrigo was named as a defendant, no complaint has been filed and the precise allegations and products at issue have not been identified. Proceedings in the case, including the filing of a complaint, have been stayed at the request of the plaintiffs.

On December 11, 2019, a health care service company filed a complaint against Perrigo and 38 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other multi-district litigation ("MDL") complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin cream/ointment. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluocinonide, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

On December 16, 2019, a Medicare Advantage claims recovery company filed a complaint against Perrigo and 39 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, and Econazole. The complaint was originally filed in the District of Connecticut but has been consolidated into the MDL. Perrigo has not yet had the opportunity to respond to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Desoximetasone, Erythromycin, Fenofibrate, Fluocinonide, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone

39

Perrigo Company plc - Item 1

Note 16

Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

On December 23, 2019, several counties in New York filed an amended complaint against Perrigo and 28 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. The complaint was originally filed in New York State court but was removed to federal court and has been consolidated into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone Furoate, Nystatin, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. On June 30, 2021, the counties filed a proposed revised second amended complaint. Perrigo has not yet responded to the complaint, and responses are currently stayed.

On December 27, 2019, a healthcare management organization filed a complaint against Perrigo and 25 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. The complaint was filed originally in the Northern District of California but has been consolidated into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

On March 1, 2020, Harris County of Texas filed a complaint against Perrigo and 29 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The products at issue that plaintiffs claim Perrigo manufacturers or sells include: Adapalene, Betamethasone Dipropionate, Ciclopirox, Clindamycin, Clobetasol, Desonide, Econazole, Ethinyl Estradiol/Levonorgestrel, Fenofibrate, Fluocinolone, Fluocinonide, Gentamicin, Glimepiride, Griseofulvin, Halobetasol Propionate, Hydrocortisone Valerate, Ketoconazole, Mupirocin, Nystatin, Olopatadine, Permethrin, Prednisone, Promethazine, Scopolamine, and Triamcinolone Acetonide. The complaint was originally filed in the Southern District of Texas but has been transferred to the MDL. Harris County amended its complaint in May 2020. Perrigo has not yet responded to the complaint, and responses are currently stayed.

In May 2020, seven health plans filed a writ of summons in the Pennsylvania Court of Common Pleas in Philadelphia concerning an as-yet unfiled complaint against Perrigo, three dozen other manufacturers, and seventeen individuals, concerning alleged antitrust violations in connection with the pricing and sale of generic prescription pharmaceutical products. No complaint has yet been filed, so the precise allegations and products at issue are not yet clear. Proceedings in the case have been stayed.

On June 9, 2020, a health insurance carrier filed a complaint against Perrigo and 25 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluocinonide, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

40

Perrigo Company plc - Item 1

Note 16

On July 9, 2020, a drugstore chain filed a complaint against Perrigo and 39 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. Perrigo is also listed in connection with Fenofibrate. The complaint was filed in the Eastern District of Pennsylvania and will be transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

On August 27, 2020, Suffolk County of New York filed a complaint against Perrigo and 35 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin cream and ointment. The other products at issue that plaintiffs claim Perrigo manufacturers or sells include: Adapalene gel, Albuterol, Benazepril HCTZ, Clotrimazole, Diclofenac Sodium, Fenofibrate, Fluocinonide, Glimepiride, Ketoconazole, Meprobamate, Imiquimod, Triamcinolone Acetonide, Erythromycin/Ethyl Solution, Betamethasone Valerate, Ciclopirox Olamine, Terconazole, Hydrocortisone Valerate, Fluticasone Propionate, Desoximetasone, Clindamycin Phosphate, Halobetasol Propionate, Hydrocortisone Acetate, Promethazine HCL, Mometasone Furoate, and Amiloride HCTZ. The complaint was filed in the Eastern District of New York and has been transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed.

On September 4, 2020, a drug wholesaler and distributor filed a complaint against Perrigo and 39 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin, Clobetasol, Desonide, Econazole, Erythromycin, Fenofibrate, Fluticasone, Halobetasol, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone furoate, Nystatin, Prochlorperazine, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed.

On December 11, 2020, a drugstore chain filed a complaint against Perrigo and 45 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Clobetasol, Desonide, Econazole, Erythromycin, Fenofibrate, Fluticasone Propionate, Halobetasol, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Nystatin, Permethrin, Prochlorperazine, Promethazine HCL, Tacrolimus, and Triamcinolone. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL.

On December 14, 2020, a supermarket chain filed a complaint against Perrigo and 45 other manufacturers (as well as certain individuals) alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on Betamethasone Dipropionate, Bromocriptine Mesylate, Ciclopirox, Clindamycin Phosphate, Clobetasol, Desonide, Econazole, Fenofibrate, Halobetasol, Hydrocortisone Valerate, Nystatin, Permethrin, and Triamcinolone Acetonide. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL.

On December 15, 2020, a drugstore chain filed a complaint against Perrigo and 45 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The complaint lists 63 drugs that the chain purchased from Perrigo, but the product conspiracies allegedly involving Perrigo focus on Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Desonide,

41

Perrigo Company plc - Item 1

Note 16

Econazole, Erythromycin, Fluocinonide, Fluticasone Propionate, Halobetasol, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Nystatin, Prochlorperazine, Promethazine HCL, Tacrolimus, and Triamcinolone. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL.

On December 15, 2020, several counties in New York filed a complaint against Perrigo and 45 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens products, most of which Perrigo neither makes nor sells. The allegations that concern Perrigo include: Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone Furoate, Nystatin, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The complaint was originally filed in New York State court but has been removed to federal court and consolidated into the MDL. The counties filed an amended complaint on June 30, 2021.

On August 30, 2021, the county of Westchester, NY filed a complaint in New York State court against Perrigo and 45 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens products, most of which Perrigo neither makes nor sells. The allegations that concern Perrigo include: Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Clobetasol, Desonide, Econazole, Erythromycin, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone Furoate, Nystatin, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. A motion to remove the case to federal court for consolidation into the MDL has been filed.

On October 8, 2021, approximately 20 health plans filed a Praecipe to Issue Writ of Summons in Pennsylvania state court to commence an action against 46 generic pharmaceutical manufacturers and 24 individuals, alleging antitrust violations concerning generic pharmaceutical drugs. While Perrigo was named as a defendant, no complaint has been filed and the precise allegations and products at issue have not been identified. Proceedings in the case, including the filing of a complaint, have not yet occurred.

State Attorney General Complaint

On June 10, 2020, the Connecticut Attorney General’s office filed a lawsuit on behalf of Connecticut and 50 other states and territories against Perrigo, 35 other generic pharmaceutical manufacturers, and certain individuals (including one former and one current Perrigo employee), alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of eighty products. The allegations against Perrigo focus on the following drugs: Adapalene Cream, Ammonium Lactate cream and lotion, Betamethasone dipropionate lotion, Bromocriptine tablets, Calcipotriene Betamethasone Dipropionate Ointment, Ciclopirox cream and solution, Clindamycin solution, Desonide cream and ointment, Econazole cream, Erythromycin base alcohol solution, Fluticasone cream and lotion, Halobetasol cream and ointment, Hydrocortisone Acetate suppositories, Hydrocortisone Valerate cream, Imiquimod cream, Methazolamide tablets, Nystatin ointment, Prochlorperazine suppositories, Promethazine HCL suppositories, Tacrolimus ointment, and Triamcinolone cream and ointment. The Complaint was filed in the District of Connecticut, but has been transferred into the MDL. On May 7, 2021, the Court ruled that this case will move forward as a bellwether case. On September 9, 2021, the States filed an amended complaint, although the substantive allegations against Perrigo did not change. Perrigo's motion to dismiss the complaint is due on November 12, 2021.

Canadian Class Action Complaint

In June 2020, an end payor filed a class action in Ontario, Canada against Perrigo and 29 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. In December 2020, Plaintiffs amended their complaint to add additional claims based on the State AG complaint of June 2020.

At this stage, we cannot reasonably estimate the outcome of the liability if any, associated with the claims listed above.

42

Perrigo Company plc - Item 1

Note 16

Securities Litigation

In the United States (cases related to events in 2015-2017)

On May 18, 2016, a shareholder filed a securities case against us and our former CEO, Joseph Papa, in the U.S. District Court for the District of New Jersey (Roofers’ Pension Fund v. Papa, et al.). The plaintiff purported to represent a class of shareholders for the period from April 21, 2015 through May 11, 2016, inclusive. The original complaint alleged violations of Securities Exchange Act sections 10(b) (and Rule 10b5) and 14(e) against both defendants and 20(a) control person liability against Mr. Papa. In general, the allegations concerned the actions taken by us and the former executive to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015. The plaintiff also alleged that the defendants provided inadequate disclosure concerning alleged integration problems related to the Omega acquisition in the period from April 21, 2015 through May 11, 2016. On July 19, 2016, a different shareholder filed a securities class action against us and our former CEO, Joseph Papa, also in the District of New Jersey (Wilson v. Papa, et al.). The plaintiff purported to represent a class of persons who sold put options on our shares between April 21, 2015 and May 11, 2016. In general, the allegations and the claims were the same as those made in the original complaint filed in the Roofers' Pension Fund case described above. On December 8, 2016, the court consolidated the Roofers' Pension Fund case and the Wilson case under the Roofers' Pension Fund case number. In February 2017, the court selected the lead plaintiffs for the consolidated case and the lead counsel to the putative class. In March 2017, the court entered a scheduling order.

On June 21, 2017, the court-appointed lead plaintiffs filed an amended complaint that superseded the original complaints in the Roofers’ Pension Fund case and the Wilson case. In the amended complaint, the lead plaintiffs seek to represent three classes of shareholders: (i) shareholders who purchased shares during the period from April 21, 2015 through May 3, 2017 on the U.S. exchanges; (ii) shareholders who purchased shares during the same period on the Tel Aviv exchange; and (iii) shareholders who owned shares on November 12, 2015 and held such stock through at least 8:00 a.m. on November 13, 2015 (the final day of the Mylan tender offer) regardless of whether the shareholders tendered their shares. The amended complaint names as defendants us and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The amended complaint alleges violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals. In general, the allegations concern the actions taken by us and the former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company and at Omega, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The amended complaint does not include an estimate of damages. During 2017, the defendants filed motions to dismiss, which the plaintiffs opposed. On July 27, 2018, the court issued an opinion and order granting the defendants’ motions to dismiss in part and denying the motions to dismiss in part. The court dismissed without prejudice defendants Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, Donal O’Connor, and Marc Coucke. The court also dismissed without prejudice claims arising from the Tysabri® accounting issue described above and claims alleging incorrect disclosure of organic growth described above. The defendants who were not dismissed are Perrigo Company plc, Joe Papa, and Judy Brown. The claims (described above) that were not dismissed relate to the integration issues regarding the Omega acquisition, the defense against the Mylan tender offer, and the alleged price fixing activities with respect to six generic prescription pharmaceuticals. The defendants who remain in the case (the Company, Mr. Papa, and Ms. Brown) have filed answers denying liability, and the discovery stage of litigation began in late 2018. Discovery in the class action ended on January 31, 2021. In early April 2021, the defendants filed various post-discovery motions, including summary judgment motions; the briefing of which was completed in early July 2021. The motions are now before the court. The court will hold oral argument in January 2022. We intend to defend the lawsuit vigorously.

On November 14, 2019, the court granted the lead plaintiffs’ motion and certified three classes for the case: (i) all those who purchased shares between April 21, 2015 through May 2, 2017 inclusive on a U.S. exchange and were damaged thereby; (ii) all those who purchased shares between April 21, 2015 through May 2, 2017 inclusive on the Tel Aviv exchange and were damaged thereby; and (iii) all those who owned shares as of November 12, 2015 and held such stock through at least 8:00 a.m. on November 13, 2015 (whether or not a person tendered shares in response to the Mylan tender offer) (the "tender offer class"). Defendants filed a petition for leave to appeal in the Third Circuit challenging the certification of the tender offer class. On April 30, 2020, the Third Circuit

43

Perrigo Company plc - Item 1

Note 16

denied leave to appeal. The District Court has approved the issuance of a notice of the pendency of the class action, and the notice has been sent to shareholders who are eligible to participate in the classes.

In early July 2021, the Court assigned the securities class action case (Roofer’s case) to a new judge within the U.S. District Court for the District of New Jersey. Unless otherwise noted, each of the lawsuits discussed in the following sections is pending in the U.S. District Court for the District of New Jersey and remains with the originally assigned judge. The allegations in the complaints relate to events during certain portions of the 2015 through 2017 calendar years, including the period of the Mylan tender offer. All but one of these lawsuits allege violations of federal securities laws, but none are class actions. One lawsuit (Highfields) alleges only state law claims. Discovery in all these cases, except Starboard Value and Highfields, is underway and currently scheduled to end in mid-November 2021. We intend to defend all these lawsuits vigorously.

Carmignac, First Manhattan and Similar Cases. The following seven cases were filed by the same law firm and generally make the same factual assertions but, at times, differ as to which securities laws violations they allege:

Case	Date Filed
Carmignac Gestion, S.A. v. Perrigo Company plc, et al.	11/1/2017
First Manhattan Co. v. Perrigo Company plc, et al.	2/16/2018; amended 4/20/2018
Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al.	10/29/2018
Schwab Capital Trust, et al. v. Perrigo Company plc, et al.	1/31/2019
Aberdeen Canada Funds -- Global Equity Fund, et al. v. Perrigo Company plc, et al.	2/22/2019
Principal Funds, Inc., et al. v. Perrigo Company plc, et al.	3/5/2020
Kuwait Investment Authority, et al. v. Perrigo Company plc, et al.	3/31/2020

The original complaints in the Carmignac case and the First Manhattan case named Perrigo, Mr. Papa, Ms. Brown, and Mr. Coucke as defendants. Mr. Coucke was dismissed as a defendant after the plaintiffs agreed to apply the July 2018 ruling in the Roofers' Pension Fund case to these two cases. The complaints in each of the other cases name only Perrigo, Mr. Papa, and Ms. Brown as defendants.

Each complaint asserts claims under Sections 10(b) (and Rule 10b-5 thereunder) and all cases except Aberdeen assert claims under Section 14(e) of the Securities Exchange Act against all defendants, as well as control person liability under Section 20(a) of the Securities Exchange Act against the individual defendants. The control person claims against the individual defendants are limited to the period from April 2015 through April 2016 in the Carmignac case. The complaints in the Carmignac and First Manhattan cases also assert claims under Section 18 of the Exchange Act.

Each complaint alleges inadequate disclosures concerning the valuation and integration of Omega, the financial guidance we provided, our reporting about the generic prescription pharmaceutical business and its prospects, and the activities surrounding the efforts to defeat the Mylan tender offer during 2015, and, in each of the cases other than Carmignac, alleged price fixing activities with respect to six generic prescription pharmaceuticals. The First Manhattan complaint also alleges improper accounting for the Tysabri® asset. With the exception of Carmignac, each of these cases relates to events during the period from April 2015 through May 2017. Many of the allegations in these cases overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case, though the Nationwide Mutual, Schwab Capital, Aberdeen, Principal Funds and Kuwait complaints do not include the factual allegations that the court dismissed in the July 2018 ruling in the Roofers' Pension Fund case.

After the court issued its July 2018 opinion in the Roofers’ Pension Fund case, the parties in Carmignac and First Manhattan conferred and agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in their cases. The later filed cases adopted a similar posture. The defendants in the Carmignac and other cases listed above filed motions to dismiss addressing the additional allegations in such cases. On July 31, 2019, the court granted such motions to dismiss in part and denied them in part. That ruling applies to each of the above cases. The defendants have filed answers in each case denying liability. Each case (except Highfields and Starboard Value) is currently in the discovery phase.

44

Perrigo Company plc - Item 1

Note 16

Mason Capital, Pentwater and Similar Cases. The following eight cases were filed by the same law firm and generally make the same factual allegations:

Case	Date Filed
Mason Capital L.P., et al. v. Perrigo Company plc, et al.	1/26/2018
Pentwater Equity Opportunities Master Fund Ltd., et al.  v. Perrigo Company plc, et al.	1/26/2018
WCM Alternatives: Event-Drive Fund, et al. v. Perrigo Co., plc, et al.	11/15/2018
Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al.	11/15/2018
Discovery Global Citizens Master Fund, Ltd., et al. v. Perrigo Co. plc, et al.	12/18/2019
York Capital Management, L.P., et al. v. Perrigo Co. plc, et al.	12/20/2019
Burlington Loan Management DAC v. Perrigo Co. plc, et al.	2/12/2020
Universities Superannuation Scheme Limited v. Perrigo Co. plc, et al.	3/2/2020

The complaints in the Mason Capital case and the Pentwater case originally named Perrigo and 11 current or former directors and officers of Perrigo as defendants. In the July 2018 Roofers’ Pension Fund ruling, the court dismissed without prejudice each of the defendants other than Perrigo, Mr. Papa and Ms. Brown from that case; these plaintiffs later agreed that this ruling would apply to their cases as well. The complaints in each of the other cases in the above table name only Perrigo, Mr. Papa, and Ms. Brown as defendants.

Each complaint asserts claims under Section 14(e) of the Securities Exchange Act against all defendants, as well as control person liability under Section 20(a) of the Securities Exchange Act against the individual defendants. The complaints in the WCM case and the Universities Superannuation Scheme case also assert claims under Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.

Each complaint alleges inadequate disclosure during the tender offer period in 2015 and at various times concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. The WCM complaint also makes these allegations for the period through May 2017 and the Universities Superannuation Scheme complaint also concerns certain times during 2016. Many of the factual allegations in these cases overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case, and the Mason Capital and Pentwater cases include factual allegations similar to those in the Carmignac case described above.

After the court issued its July 2018 opinion in the Roofers’ Pension Fund case, the parties in each of the above cases conferred and agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in their cases. The defendants in each of these cases have filed answers denying liability, and each of the cases is currently in the discovery phase.

Harel Insurance and TIAA-CREF Cases. The following two cases were filed by the same law firm and generally make the same factual allegations relating to the period from February 2014 through May 2017 (in the Harel case) and from August 2014 through May 2017 (in the TIAA-CREF case):

Case	Date Filed
Harel Insurance Company, Ltd., et al. v. Perrigo Company plc, et al.	2/13/2018
TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al.	4/20/2018

The complaints in the Harel and TIAA-CREF cases originally named Perrigo and 13 current or former directors and officers of Perrigo as defendants (adding two more individual defendants not sued in the other cases described in this section). In the July 2018 Roofers’ Pension Fund ruling, the court dismissed without prejudice 8 of the 11 defendants other than Perrigo, Mr. Papa and Ms. Brown from that case. These plaintiffs later agreed that that ruling would apply to these cases as well and also dismissed their claims against the two additional individuals that only these plaintiffs had named as defendants.

Each complaint asserts claims under Sections 10(b) and 14(e) of the Securities Exchange Act and Rule 10b-5 thereunder against all defendants, as well as control person liability under Section 20(a) of the Securities

45

Perrigo Company plc - Item 1

Note 16

Exchange Act against the individual defendants. The complaint in the Harel case also asserts claims based on Israeli securities laws.

Each of the complaints alleges inadequate disclosure around the tender offer events in 2015 and at various times during the relevant periods concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset from February 2014 until the withdrawal of past financial statements in April 2017.

After the court issued its July 2018 opinion in the Roofers’ Pension Fund case, the parties in the Harel and TIAA-CREF cases conferred and agreed that such ruling would apply equally to the common allegations in their cases. The defendants in each of these cases have filed answers denying liability, and each of the cases is currently in the discovery phase.

Other Cases Related to Events in 2015-2017. Certain allegations in the following three cases also overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case and with allegations in one or more of the other individual cases described in the sections above:

Case	Date Filed
Sculptor Master Fund (f/k/a OZ Master Fund, Ltd.), et al. v. Perrigo Company plc, et al.	2/6/2019
Highfields Capital I LP, et al. v. Perrigo Company plc, et al.	6/4/2020
BlackRock Global Allocation Fund, Inc., et al. v. Perrigo Co. plc, et al.	4/21/2020
Starboard Value and Opportunity C LP, et al. v. Perrigo Company plc, et al.	2/25/2021

Each of the above complaints names Perrigo, Mr. Papa, and Ms. Brown as defendants.

The Sculptor Master Fund (formerly OZ) complaint asserts claims under Sections 10(b) and 14(e) of the Securities Exchange Act and Rule 10b-5 thereunder against all defendants, as well as control person liability under Section 20(a) of the Securities Exchange Act against the individual defendants. The parties have agreed that the court's rulings in July 2018 in the Roofers' Pension Fund case and in July 2019 in the Carmignac and related cases will apply to this case as well. The defendants have filed answers denying liability. The plaintiffs are participating in the discovery proceedings in the Roofers' Pension Fund case and the various individual cases described above.

The BlackRock Global complaint also asserts claims under Securities Exchange Act section 10(b) (and Rule 10b-5) and section 14(e) against all defendants and section 20(a) control person claims against the individual defendants largely based on the same events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, alleged lower performance in the generic prescription drug business during 2015 and alleged improper accounting for the Tysabri® asset. The defendants have filed answers denying liability. The plaintiffs are participating in the discovery proceedings in the Roofers' Pension Fund case and the various individual cases described above.

The Starboard Value and Opportunity C LP complaint also asserts claims under Securities Exchange Act section 10(b) (and Rule 10b-5) against all defendants and section 20(a) control person claims against the individual defendants based on events related to alleged price fixing activities with respect to generic prescription drugs during periods that overlap to some extent with the period alleged in the various other cases described above. Plaintiffs contend that the defendants provided inadequate disclosure during 2016 about generic prescription drug business and those alleged matters. The lawsuit was filed on February 25, 2021; but by agreement the case was administratively terminated by the court in June 2021 pending a decision on the same defendants’ motions currently pending before the court in the Roofers' Pension Fund case described above.

The Highfields federal case complaint asserted claims under Sections 14(e) and 18 of the Securities Exchange Act against all defendants, as well as control person liability under Section 20(a) of the Securities Exchange Act against the individual defendants. As originally filed in the U.S. District Court for the District of Massachusetts, the Highfields complaint also alleged claims under the Massachusetts Unfair Business Methods

46

Perrigo Company plc - Item 1

Note 16

Law (chapter 93A) and Massachusetts common law claims of tortious interference with prospective economic advantage, common law fraud, negligent misrepresentation, and unjust enrichment. The factual allegations generally were similar to the factual allegations in the Amended Complaint in the Roofers' Pension Fund case described above, except that the Highfields plaintiffs did not include allegations about alleged collusive pricing of generic prescription drugs. In March 2020, the District of Massachusetts court granted defendants’ motion and transferred the case to the U.S. District Court for the District of New Jersey so that the activities in the case could proceed in tandem with the other cases in the District of New Jersey described above. After the transfer, in June 2020, the Highfields plaintiffs voluntarily dismissed their federal lawsuit. The same Highfields plaintiffs the same day then filed a new lawsuit in Massachusetts State Court asserting the same factual allegations as in their federal lawsuit and alleging only Massachusetts state law claims under the Massachusetts Unfair Business Methods Law (chapter 93A) and Massachusetts common law claims of tortious interference with prospective economic advantage, common law fraud, negligent misrepresentation, and unjust enrichment. Defendants’ motion to dismiss was fully briefed as of late November 2020, argument occurred in early May 2021, and the motion is pending before the court.

In Israel (cases related to events in 2015-2017)

Because our shares are traded on the Tel Aviv exchange under a dual trading arrangement, we are potentially subject to securities litigation in Israel. Three cases were filed; one was voluntarily dismissed in each of 2017 and 2018 and one was stayed in 2018. We are consulting with Israeli counsel about our response to these allegations and we intend to defend this case vigorously.

On June 28, 2017, a plaintiff filed a complaint in Tel Aviv District Court styled Israel Elec. Corp. Employees’ Educ. Fund v. Perrigo Company plc, et al. The lead plaintiff seeks to represent a class of shareholders who purchased Perrigo stock on the Tel Aviv exchange during the period from April 24, 2015 through May 3, 2017 and also a claim for those that owned shares on the final day of the Mylan tender offer (November 13, 2015). The amended complaint names as defendants the Company, Ernst & Young LLP (the Company’s auditor), and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The complaint alleges violations under U.S. securities laws of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals or, in the alternative, under Israeli securities laws. In general, the allegations concern the actions taken by us and our former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure concerning purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The plaintiff indicates an initial, preliminary class damages estimate of 2.7 billion NIS (approximately $760.0 million at 1 NIS = 0.28 cents). After the other two cases filed in Israel were voluntarily dismissed, the plaintiff in this case agreed to stay this case pending the outcome of the Roofers’ Pension Fund case in the U.S. (described above). The Israeli court approved the stay, and this case is now stayed. We intend to defend the lawsuit vigorously.

47

Perrigo Company plc - Item 1

Note 16

In the United States (cases related to Irish Tax events)

On January 3, 2019, a shareholder filed a complaint against the Company, our CEO Murray Kessler, and our former CFO Ronald Winowiecki in the U.S. District Court for the Southern District of New York (Masih v. Perrigo Company, et al.). Plaintiff purported to represent a class of shareholders for the period November 8, 2018 through December 20, 2018, inclusive. The complaint alleged violations of Securities Exchange Act section 10(b) (and Rule 10b‑5) against all defendants and section 20(a) control person liability against the individual defendants. In general the allegations contended that the Company, in its Form 10-Q filed November 8, 2018, disclosed information about an October 31, 2018 audit finding letter received from Irish tax authorities but failed to disclose enough material information about that letter until December 20, 2018, when we filed a current report on Form 8‑K about Irish tax matters. The plaintiff did not provide an estimate of class damages. The court selected lead plaintiffs and changed the name of the case to In re Perrigo Company plc Sec. Litig. The lead plaintiffs filed an amended complaint on April 12, 2019, which named the same defendants, asserted the same class period, and invoked the same Exchange Act sections. The amended complaint generally repeated the allegations of the original complaint with a few additional details and adds that the defendants also failed to timely disclose the Irish tax authorities’ Notice of Amended Assessment received on November 29, 2018. Defendants filed a motion to dismiss on May 3, 2019. On May 31, 2019, the plaintiffs filed a second amended complaint, which asserted a longer class period (March 1, 2018 through December 20, 2018) and added one additional individual defendant, former CEO Uwe Roehrhoff. In general, the second amended complaint contends that Perrigo’s disclosures about the Irish tax audit were inadequate beginning with Perrigo’s 10-K filed on March 1, 2018 through December 20, 2018 and repeats many of the allegations of the April 2019 amended complaint. The second amended complaint alleges violations of Securities Exchange Act section 10(b) (and Rule 10b-5) against all defendants and section 20(a) control person liability against the three individual defendants. All defendants filed a joint motion to dismiss, and the motion was fully briefed. On January 23, 2020, the court granted the motion to dismiss in part and denied it in part, dismissing Mr. Roehrhoff as a defendant and dismissing allegations of inadequate disclosures related to the audit by Irish Revenue during the period March 2018 through October 30, 2018. The court permitted the plaintiffs to pursue their claims against us, Mr. Kessler, and Mr. Winowiecki related to disclosures after Perrigo received the October 30, 2018 audit findings letter and later events through December 20, 2018. The defendants filed answers on February 13, 2020 denying liability, and the court issued a scheduling order on March 3, 2020 that has been subsequently modified. Discovery on the remaining issues ended in early March 2021. Plaintiffs filed a motion for class certification, which was granted in September 2020. In January 2021, class plaintiffs filed a motion for leave to file a third amended complaint in an effort to revive their claim that the disclosure of the audit during the period from March 1, 2018 to October 30, 2018 was also inadequate. The court denied the motion in February 2021. Defendants filed motions for summary judgement and other post discovery motions on March 31, 2021 and plaintiffs filed cross-motions of the same type on the same day. All motions were fully briefed by late May 2021. During the week of July 11, 2021, the Court issued various opinions and orders denying some of the motions by both parties, and granting in part certain motions by plaintiffs. Defendants filed a motion for reconsideration for some of the rulings in late July, which the court granted in part in August. The court also indicated that the parties should prepare for trial in mid-October 2021 (subject to COVID-19 developments), without setting an exact trial date.

The court simultaneously ordered mediation, which led to a settlement that the parties first publicly announced in a court filing on September 8, 2021. Trial was cancelled when a settlement was reached. Motion papers seeking approval of the class action settlement were filed on October 4, 2021. The court issued a preliminary approval order on October 29, 2021, which will lead to the issuance of notices to class members. The final approval hearing is set for February 16, 2022. The settlement will be funded by insurance.

In Israel (case related to Irish Tax events)

On December 31, 2018, a shareholder filed an action against the Company, our CEO Murray Kessler, and our former CFO Ronald Winowiecki in Tel Aviv District Court (Baton v. Perrigo Company plc, et. al.). The case is a securities class action brought in Israel making similar factual allegations for the same period as those asserted in the In re Perrigo Company plc Sec. Litig case in New York federal court. This case alleges that persons who invested through the Tel Aviv stock exchange can assert claims under Israeli securities law that will follow the liability principles of Sections 10(b) and 20(a) of the U.S. Securities Exchange Act. The plaintiff does not provide an estimate of class damages. In 2019, the court granted two requests by Perrigo to stay the proceedings pending the resolution of proceedings in the United States. Perrigo filed a further request for a stay in February 2020, and the court granted the stay indefinitely. The plaintiff filed a motion to lift the stay then later agreed that the case should remain stayed through February 2021. In late February 2021, Perrigo filed a motion to extend the stay to mid-May 2021, and plaintiff later agreed to the request. The case is currently stayed until December 15, 2021. We intend to defend the lawsuit vigorously.

48

Perrigo Company plc - Item 1

Note 16

Claim Arising from the Omega Acquisition

On December 16, 2016, we and Perrigo Ireland 2 brought an arbitral claim ("Claim") against Alychlo NV ("Alychlo") and Holdco I BE NV (together the "Sellers") in accordance with clause 26.2 of the Share Purchase Agreement dated November 6, 2014 ("SPA") and the rules of the Belgian Centre for Arbitration and Mediation ("CEPANI"). Our Claim relates to the accuracy and completeness of information about Omega provided by the Sellers as part of the sale process, the withholding of information by the Sellers during that process and breaches of Sellers’ warranties. We are seeking monetary damages from the Sellers. The Sellers served their respective responses to the Claim on February 20, 2017. In its response, Alychlo asserted a counterclaim for monetary damages contending that we breached a warranty in the SPA and breached the duty of good faith in performing the SPA. Alychlo subsequently filed papers seeking permission to introduce an additional counterclaim theory of recovery related to the Irish tax issues disclosed by the Company such that if the position of the Irish tax authorities prevails, Alychlo would have further basis for its counterclaim against Perrigo. In June 2019, the Tribunal denied permission for Alychlo to introduce the additional counterclaim and dismissed certain aspects of the original Alychlo counterclaim.

On August 27, 2021 the Tribunal issued its ruling. The panel found fraud by the Sellers of Omega and awarded Perrigo approximately €355.0 million ($417.6 million at the time of cash receipt) including fees and costs. The panel also ruled against the Sellers and in favor of Perrigo on all counterclaims. The Sellers have paid all amounts owed under the award which Perrigo publicly announced in a press release issued September 29, 2021. The Sellers have the right to challenge the Tribunal’s award for up to three months following the date of the award (until late November 2021). The arbitration proceedings are confidential as required by the SPA and the rules of CEPANI.

Other Matters

Talcum Powder

The Company has been named, together with other manufacturers, in product liability lawsuits in state courts in California, Florida, Missouri, New Jersey, Louisiana and Illinois alleging that the use of body powder products containing talcum powder causes mesothelioma and lung cancer due to the presence of asbestos. All but one of these cases involve legacy talcum powder products that have not been manufactured by the Company since 1999. One of the pending actions involves a current prescription product that contains talc as an excipient. As of October 2, 2021, the Company is currently named in 57 individual lawsuits seeking compensatory and punitive damages and has accepted a tender for a portion of the defense costs and liability from a retailer for one additional matter. The Company has several defenses and intends to aggressively defend these lawsuits. Trials for these lawsuits are currently scheduled throughout 2021, 2022 and 2023, with the earliest that began in September 2021.

Ranitidine

After regulatory bodies announced worldwide that ranitidine may potentially contain N-nitrosodimethylamine ("NDMA"), a known environmental contaminant, the Company promptly began testing its externally-sourced ranitidine API and ranitidine-based products. On October 8, 2019, the Company halted shipments of the product based upon preliminary results and on October 23, 2019, the Company made the decision to conduct a voluntary retail market withdrawal.

In February 2020, the resulting actions involving Zantac® and other ranitidine products were transferred for coordinated pretrial proceedings to a Multi-District Litigation (In re Zantac®/Ranitidine Products Liability Litigation MDL No. 2924) in the U.S. District Court for the Southern District of Florida. After the Company successfully moved to dismiss the first set of Master Complaints in the MDL, it now includes three: 1) an Amended Master Personal Injury Complaint; 2) a Consolidated Amended Consumer Economic Loss Class Action Complaint; and 3) a Consolidated Medical Monitoring Class Action Complaint. All three name the Company. Plaintiffs appealed one of the original Master Complaints, the Third-Party Payor Complaint, and two individual plaintiffs appealed their individual personal injury claims on limited grounds. The Company is not named in the appeals.

On June 30, 2021, the Court dismissed all claims against the retail and distributor defendants with prejudice, thereby reducing the Company’s potential for exposure and liability related to possible indemnification. On July 8, 2021, the Court dismissed all claims against the Company with prejudice. Appeals of these dismissal

49

Perrigo Company plc - Item 1

Note 16

orders to the U.S. Court of Appeals for the 11th Circuit have been filed, as well several state level claims related to the theories advanced in the MDL litigation. The Company will continue to vigorously defend each of these lawsuits.

As of November 5, 2021, the Company has been named in two hundred eighty (280) of the MDL’s consolidated personal injury lawsuits tied to various federal courts alleging that plaintiffs developed various types of cancers or are placed at higher risk of developing cancer as a result of ingesting products containing ranitidine. The Company is named in these lawsuits with manufacturers of the national brand Zantac® and other manufacturers of ranitidine products, as well as distributors, repackagers, and/or retailers. Plaintiffs seek compensatory and punitive damages, and in some instances seek applicable remedies under state consumer protection laws.

The Company has also been named in a Complaint brought by the New Mexico Attorney General based on the following theories: violation of a New Mexico public nuisance statute, NMSA 30-8-1 to -14; common law nuisance; and negligence and gross negligence. The Company is named in this lawsuit with manufacturers of the national brand Zantac® and other manufacturers of ranitidine products and/or retailers. Brand name manufactures named in the lawsuit also face claims under the state’s Unfair Practices & False Advertising acts. Likewise, the Company has also been named in a Complaint brought by the Mayor and City Council of Baltimore, along with manufacturers of the national brand Zantac® and other manufacturers of ranitidine products and/or retailers. This action brings claims under the Maryland Consumer Protection Act against the brand name defendants only, as well as public nuisance and negligence for the remaining defendants. The Company was originally able to consolidate the New Mexico and Baltimore Actions to the MDL, however both actions were recently remanded to state court. The Company filed motions to dismiss in both actions. The New Mexico District Court denied the Company’s Motion to Dismiss and litigation continues. The Maryland Circuit Court has not issued a ruling on the Company’s Motion. The Company will continue to vigorously defend each of these lawsuits.

Some of the Company’s retailer customers are seeking indemnity from the Company for a portion of their defense costs and liability relating to these cases.

Acetaminophen

The Company has received requests for indemnification and defense of several consumer fraud claims involving its store brand infants’ and children’s acetaminophen products. In September 2020, the Company was directly named as a defendant in one suit filed in the Central District of California. The Company was recently named in a cross complaint by a retailer for contractual indemnity in California Superior Court, Alameda County. The Company has also received 16 different claims for indemnification or defense from 10 different retailers for lawsuits filed in California, Illinois, Florida, Minnesota and Pennsylvania, with nationwide class action allegations.

The Plaintiffs generally allege that the children’s and infants’ acetaminophen products have identical drug concentration amounts, yet the infants’ product costs more than the children’s product and consumers have been misled into purchasing the more expensive product. The Company will aggressively defend the suits in which it is named and is continuing to assess whether, or to what extent, the Company may contribute in the lawsuits filed against its retail customers.

Guarantee Liability Related to The Israel API Sale

During the year ended December 31, 2017, we completed the sale of our Israel API business to SK Capital, resulting in a guarantee liability of $13.8 million, classified as a Level 3 liability within the fair value hierarchy. Pursuant to the agreement, we will be reimbursed for tax receivables for tax years prior to closing and will need to reimburse SK Capital for the settlement of any uncertain tax liability positions for tax years prior to closing. In addition, after closing and going forward, the Israel API business will be assessed by and liable to the ITA for any audit findings. We are no longer the primary obligor on the liabilities transferred to SK Capital, but we have provided a guarantee on certain obligations. During the three months ended July 3, 2021, we paid $12.5 million to resolve the tax liability indemnity for the tax year ended December 31, 2017 (refer to Note 15). At October 2, 2021 and December 31, 2020, the remaining guarantee liability was $0.6 million and $13.2 million, respectively.

50

Perrigo Company plc - Item 1

Note 16

Contingencies Accruals

As a result of the matters discussed in this Note, the Company has established a loss accrual for litigation contingencies where we believe a loss to be probable and for which an amount of loss can be reasonably estimated. However, we cannot determine a reasonable estimate of the maximum possible loss or range of loss for these matters given that they are at various stages of the litigation process and each case is subject to inherent uncertainties of litigation. At October 2, 2021, the loss accrual for litigation contingencies reflected on the balance sheet in Other accrued liabilities was approximately $96.9 million. The Company also recorded an insurance recovery receivable reflected on the balance sheet in Prepaid expenses and other current assets of approximately $83.4 million related to these litigation contingencies because it believes such amount is recoverable based on communications with its insurers to date; however, the Company may erode this insurance receivable as it incurs defense costs associated with defending the matters. The Company’s management believes these accruals for contingencies are reasonable and sufficient based upon information currently available to management; however, there can be no assurance that final costs related to these contingencies will not exceed current estimates or that all of the final costs related to these contingencies will be covered by insurance. (See "Insurance Coverage Litigation," below.) In addition, we have other litigation matters pending for which we have not recorded any accruals because our potential liability for those matters is not probable or cannot be reasonably estimated based on currently available information. For those matters where we have not recorded an accrual but a loss is reasonably possible, we cannot determine a reasonable estimate of the maximum possible loss or range of loss for these matters given that they are at various stages of the litigation process and each case is subject to the inherent uncertainties of litigation.

Insurance Coverage Litigation

In May 2021 insurers on multiple policies of D&O insurance filed an action in the High Court in Dublin against the Company and multiple current and former directors and officers of the Company seeking declaratory judgments on certain coverage issues. Those coverage issues include claims that policies for periods beginning in December 2015 and December 2016, respectively, do not have to provide coverage for the securities actions described above pending in the District of New Jersey or in Massachusetts state court concerning the events of 2015-2017. The policy for the period beginning December 2014 is currently providing coverage for those matters, and the litigation would not affect that existing coverage. However, if the plaintiffs are successful, the total amount of insurance coverage available to defend such lawsuits and to satisfy any judgment or settlement costs thereunder would be limited to one policy period. The insurers’ lawsuit also challenges coverage for Krueger derivatively on behalf of nominal defendant Perrigo Company plc v. Alford et al., a prior derivative action filed in the District of New Jersey that was dismissed in August 2020, and for the counterclaims brought in the Omega arbitration proceedings. Perrigo responded on November 1, 2021; Perrigo’s response includes its position that the policies for the periods beginning December 2015 and December 2016 provide coverage for the underlying litigation matters and seeks a ruling to that effect. We intend to defend the lawsuit vigorously.

NOTE 17 – RESTRUCTURING CHARGES

We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, lease exit costs, and related consulting fees. The following reflects our restructuring activity (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Beginning balance	$	10.2	$	9.4	$	9.1	$	19.5
Additional charges	1.0		0.8		11.8		1.5
Payments	(3.7)		(2.9)		(13.3)		(13.7)
Non-cash adjustments	(0.1)		0.2		(0.2)		0.2
Ending balance	$	7.4	$	7.5	$	7.4	$	7.5

The charges incurred during the three and nine months ended October 2, 2021 and September 26, 2020 were primarily associated with actions taken to streamline the organization.

51

Perrigo Company plc - Item 1

Note 17

There were no other material restructuring programs for the three and nine months ended October 2, 2021 and September 26, 2020. All charges are recorded in Restructuring expense on the Condensed Consolidated Statements of Operations. The remaining $7.4 million liability for employee severance benefits is expected to be paid within the next year.

NOTE 18 – SEGMENT INFORMATION

Our segments reflect the way in which our management makes operating decisions, allocates resources, and manages the growth and profitability of the Company. As discussed in Note 8, as of March 1, 2021, the financial results and assets and liabilities of the RX business are classified as discontinued operations in the Condensed Consolidated Statements of Operations and Condensed Consolidated Balance Sheets. As discussed in Note 9, as of July 3, 2021, the assets and liabilities of the Latin American businesses were classified as held for sale. The RX business and Latin American businesses assets held-for-sale are included below in the summary of total assets.

The tables below show select financial measures by reporting segment (in millions):

	Total Assets
	October 2, 2021		December 31, 2020
CSCA	$	6,290.6	$	4,585.1
CSCI	4,611.9		4,872.4
Held for sale	13.4		2,030.9
Total	$	10,915.9	$	11,488.4

	Three Months Ended
	October 2, 2021						September 26, 2020
	Net Sales		Operating Income (Loss)		Intangible Asset Amortization		Net Sales		Operating Income (Loss)		Intangible Asset Amortization
CSCA	$	694.2	$	90.4	$	12.7	$	664.0	$	121.7	$	13.0
CSCI	348.5		4.3		39.5		339.0		10.1		40.3
Unallocated	—		343.6		—		—		(53.3)		—
Continuing Operations Total	$	1,042.7	$	438.3	$	52.2	$	1,003.0	$	78.5	$	53.3

	Nine Months Ended
	October 2, 2021						September 26, 2020
	Net Sales		Operating Income (Loss)		Intangible Asset Amortization		Net Sales		Operating Income (Loss)		Intangible Asset Amortization
CSCA	$	1,957.0	$	113.9	$	38.7	$	1,992.2	$	348.4	$	40.6
CSCI	1,076.8		23.1		120.3		1,042.8		45.7		116.9
Unallocated	—		226.7		—		—		(166.5)		—
Continuing Operations Total	$	3,033.8	$	363.7	$	159.0	$	3,035.0	$	227.6	$	157.5

52

Perrigo Company plc - Item 2

Executive Overview

ITEM 2.        MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EXECUTIVE OVERVIEW

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements included in this Form 10-Q and our Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”). These historical financial statements may not be indicative of our future performance. This discussion contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks referred to under “Risk Factors” in Item 1A of our 2020 Form 10-K and Part II. Item 1A of this Form 10-Q.

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

Our vision is to make lives better by bringing Quality, Affordable Self-Care Products that consumers trust everywhere they are sold. We are a leading provider of over-the-counter ("OTC") health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

On March 1, 2021, we announced a definitive agreement to sell our RX business to Altaris. On July 6, 2021, we completed the sale of the RX business for aggregate consideration of $1.55 billion. The consideration includes a $53.3 million reimbursement which Altaris is required to deliver in cash to Perrigo pursuant to the terms of the Agreement. The sale resulted in a pre-tax gain of $63.9 million recorded in Other (income) expense, net on the Statement of Operations for discontinued operations. The gain included a $160.0 million increase from the write-off of foreign currency translation adjustment from Accumulated other comprehensive income and a decrease from professional fees. The transaction gain is subject to final settlements under the Agreement, which we expect to finalize in the fourth quarter of 2021.

The sale of the RX business establishes Perrigo as a pure-play consumer self-care company, and was an essential milestone in our transformation plan. The financial results of the RX business, which were previously reported as part of our RX segment, have been classified as discontinued operations in the Condensed Consolidated Statements of Operations, and its assets and liabilities have been classified as held for sale for all periods presented prior to the sale. Unless otherwise noted, amounts and disclosures throughout this Management’s Discussion and Analysis relate to our continuing operations. Refer to Item 1. Note 8 for additional information regarding discontinued operations.

Our Segments

Our reporting and operating segments are as follows:

•Consumer Self-Care Americas ("CSCA") comprises our consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the U.S., Mexico and Canada.

•Consumer Self-Care International ("CSCI") comprises our consumer self-care business primarily branded in Europe and Australia, our store brand business in the United Kingdom and parts of Europe and Asia, and our liquid licensed products business in the United Kingdom until it was disposed on June 19, 2020.

Our segments reflect the way in which our management makes operating decisions, allocates resources, and manages the growth and profitability of the Company. Financial information related to our business segments and geographic locations can be found in Item 1. Note 2 and Note 18. For results by segment, see "Segment Results" below.

53

Perrigo Company plc - Item 2

Executive Overview

Highlights and Recent Developments

Operating Trends

The self-care markets in which we compete have been negatively impacted over the past year by COVID-19 pandemic related factors including, a dramatic reduction in cough, cold, and flu illnesses in the first half of the year, higher input costs, and most recently supply chain disruptions. Starting in the second quarter of 2021, we were encouraged to see a sharp rebound in consumer takeaway in the US and Europe in almost all categories, as these countries began to remove restrictions and reopen and the incidences of cough and cold related illnesses begin to increase. Despite increased consumer purchases, net sales for the second quarter of 2021 significantly lagged this consumer takeaway, which we primarily attribute to year over year reductions in customer inventories. Consumer take-away remained strong in the third quarter and we saw a surge in orders however, due to supply chain disruptions, including the lack of truck drivers in the U.S. and record delays at global shipping ports, our net sales were negatively impacted because of the inability to ship products. These supply chain disruptions led to a large increase in unfulfilled customer orders compared to the prior year quarter. We have taken a series of actions to improve the current situation including, reconfiguring our distribution system for short term shipments, outsourcing highly complex product lines to a third party logistic provider, adding regional carriers for challenged shipping lanes, hiring additional distribution center personnel, and increasing the purchase cycle as it relates to the manufacturing process. Our actions have improved our ability to ship, however, we still do not think we will meet demand in the fourth quarter.

Higher input costs were somewhat offset by price increases initiated in the second quarter of 2021. We continue to take steps in order to mitigate the challenges of our current operating environment, including further pricing actions and a focus on reducing discretionary costs. While we believe these trends will continue in the near-term, we are expecting a gradual improvement heading into the middle of 2022. However, this will depend on the trajectory of the COVID-19 pandemic and worldwide supply chain challenges, as discussed below, and it is possible some of these factors may increase or decrease more than others, and could also negatively affect consumer purchases in the jurisdictions in which we operate.

Irish Revenue Notice of Amended Assessment

On October 30, 2018, we received an audit findings letter from the Irish Office of the Revenue Commissioners (“Irish Revenue”) for the tax years ended December 31, 2012 and December 31, 2013. The audit findings letter related to the tax treatment of the 2013 sale of the Tysabri® intellectual property and related assets to Biogen Idec by Elan Pharma. The consideration paid by Biogen Idec to Elan Pharma took the form of an upfront payment and future contingent royalty payments. Elan Pharma recognized such receipts as trading income in its tax returns filed with Irish Revenue, consistent with Elan Pharma's historical practice relating to its active management of intellectual property rights.

In its audit findings letter, Irish Revenue proposed to charge Elan Pharma tax on the net chargeable gain realized by Elan Pharma on the Tysabri® transaction in 2013 at a rate of 33%, rather than the 12.5% tax rate applied to trading income. On November 29, 2018, Irish Revenue issued a Notice of Amended Assessment (“NoA”) for the tax year ended December 31, 2013, in the amount of €1,643 million, and claiming tax payable in the amount of €1,636 million, not including any interest or applicable penalties.

Accordingly, we filed an appeal of the NoA on December 27, 2018 with the Irish Tax Appeals Commission ("TAC") which is the statutory body charged with considering whether the NoA was properly founded as a matter of Irish tax law. Separately, we were also granted leave by the Irish High Court on February 25, 2019 to seek judicial review of the issuance of the NoA by Irish Revenue.

On November 4, 2020, the High Court ruled that the Irish Revenue's decision to issue the NoA did not violate Elan Pharma's constitutional rights and legitimate expectations as a taxpayer. The Irish High Court did not rule on the merits of the NoA under Irish tax law.

We strongly believe that Elan Pharma’s tax position was correct and ultimately would have been confirmed through judicial process. However, in light of the risks and delays inherent in any litigation, on April 26, 2021, Perrigo, through its tax adviser, made a without prejudice written offer of settlement to Irish Revenue detailing a possible framework to resolve the dispute, which applied an alternative basis of taxation than the respective positions taken by Irish Revenue in the NoA and by Elan Pharma in its tax returns. On May 31, 2021, Irish Revenue

54

Perrigo Company plc - Item 2

Executive Overview

issued a formal response to Perrigo's tax adviser indicating that the written settlement offer would not be accepted as presented. However, Irish Revenue did indicate that they would remain available for further discussion without prejudice and the Company's representatives continued to meet and correspond with Irish Revenue throughout the summer.

On July 9, 2021, Irish Revenue issued a letter acknowledging that not all relevant facts were known to them when they issued the NoA in 2018 and, accordingly, they would not object if the Appeal Commissioner were to make certain adjustments reducing Irish Revenue’s original assessment. Such adjustments would reflect contingent royalty payments that were never received by Elan Pharma, deductions for acquisition and development costs incurred, and allowable losses and reliefs, and would, if allowed, result in an aggregate reduction of more than €660.0 million from the income taxes claimed in the NoA as issued.

On September 29, 2021, Elan Pharma reached an agreement with Irish Revenue providing for full and final settlement of the NoA. Elan Pharma and Irish Revenue agreed to a settlement on the following terms: (i) on a 'without prejudice basis' and, for purposes of the settlement, an alternative basis of taxation was applied, (ii) Irish Revenue will take no further action in relation to the NoA or any Tysabri related income or transactions, (iii) no interest or penalties apply, (iv) a total tax of €297.0 million as full and final settlement of all liabilities arising from the sale of the Tysabri patents for the fiscal years 2013 to 2021, and (v) after Irish Revenue credited taxes already paid and certain unused R&D credits against the €297.0 million figure, the total cash payment due is €266.1 million. The payment of €266.1 million ($307.5 million) was made on October 5, 2021 (refer to Item 1. Note 15).

Tribunal Ruling in Claim Arising from the Omega Acquisition

The Tribunal panel in the matter described under Claim Arising from the Omega Acquisition (as described in more detail in Item 1. Note 16) found fraud by the Sellers of Omega in a ruling on August 27, 2021 and awarded Perrigo approximately €355.0 million ($417.6 million at the time of cash receipt) including fees and costs. The panel also ruled against the Sellers and in favor of Perrigo on all the counterclaims. The Sellers have paid all amounts owed under the award which Perrigo publicly announced in a press release issued September 29, 2021. The Sellers have the right to challenge the Tribunal’s award for up to three months following the date of the award (until late November 2021). The arbitration proceedings remain confidential as required by the SPA and the rules of CEPANI.

Héra SAS (“HRA Pharma”) Acquisition Agreement

On September 8, 2021, we and our wholly-owned subsidiary Habsont Unlimited Company (the "Purchaser"), entered into a Put Option Agreement to acquire certain holding companies holding all of the outstanding equity interests of HRA Pharma from funds affiliated with private equity firms Astorg and Goldman Sachs Asset Management (collectively, the "Sellers"). Pursuant to the Put Option Agreement, following completion of the works council consultation process required under French law, the selling shareholders exercised their put option right under the Put Option Agreement and, on October 20, 2021, the Company, the Purchaser and the Sellers entered into a Securities Sale Agreement in the form previously agreed by the parties (the “Purchase Agreement”). Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, the Purchaser has agreed to acquire certain holding companies holding all of the outstanding equity interests of HRA from the Sellers for cash. The transaction values HRA at approximately €1.8 billion, or approximately $2.1 billion as of the date of the Put Option Agreement, on an enterprise value basis and using a lockbox mechanism set forth in the Purchase Agreement. The proposed final transaction is expected to close in the first half of 2022, subject to the satisfaction of customary closing conditions, including regulatory approvals. We intend to pay the purchase price using a combination of cash on hand and, depending upon market conditions, either funds available under our current credit facility or funds from new debt financing. HRA Pharma is one of the fastest growing OTC companies globally, with three category-leading self-care brands in blister care (Compeed®), women’s health (ellaOne®) and scar care (Mederma®), and brings expertise in prescription-to-OTC switches. This acquisition would strengthen our presence in Europe, improve our financial profile and margins, and will complete our transformation to a consumer self-care company. Operating results are expected to be reported within both our CSCA and CSCI segments.

Securities litigation settlement

A settlement was reached in the case, In re Perrigo Company plc Securities Litigation as described in more detail in Item 1. Note 16, that the parties first publicly announced in a court filing on September 8, 2021. Motion papers seeking approval of the class action settlement were filed on October 4, 2021. The Court issued a preliminary approval order on October 29, 2021, which will lead to notices being sent to class members. A final approval hearing before the Court is set for February 16, 2022. The settlement will be funded by insurance.

55

Perrigo Company plc - Item 2

Executive Overview

Consumer Self-Care Americas Leadership

Effective October 5, 2021, Jim Dillard was named Executive Vice President ("EVP") and President of our CSCA segment. Mr. Dillard's supply chain, manufacturing, R&D, innovation, and regulatory experience, along with his proven leadership skills, make him uniquely qualified to lead this segment. Before this role, Mr. Dillard served as Perrigo's EVP and Chief Scientific Officer.

Internal Revenue Service Audits of Perrigo Company, a U.S. Subsidiary

As described in more detail in Item 1. Note 15, Perrigo Company, our U.S. subsidiary ("Perrigo U.S."), is engaged in a series of tax disputes in the U.S. relating primarily to transfer pricing adjustments including income in connection with the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States, including the heartburn medication omeprazole. The previously re-scheduled trial of the refund case relating to the dispute of the amount of taxable income on Omeprazole sales was held during the period May 25, 2021 to June 7, 2021 in the United States District Court for the Western District of Michigan. Post-trial briefing is scheduled to be completed by late September 2021, when the case will be fully submitted for the court’s decision.

On May 7, 2020, we received final Notices of Proposed Adjustment ("NOPA") from the IRS regarding the deductibility of interest related to the IRS audit of Perrigo U.S. for the years ended June 28, 2014 and June 27, 2015. The NOPA capped the interest rate on the debts for U.S. federal tax purposes at 130.0% of the Applicable Federal Rate (a blended rate reduction of 4.0% per annum) on the stated ground that the loans were not negotiated on an arms’-length basis. On May 3, 2021, the IRS notified us that it will no longer pursue the 130% of AFR position as indicated in the NOPA due to a change in IRS policy. The new proposed adjustment, if any, will be provided by the IRS in its rebuttal to our Protest which we filed on February 26, 2021.

Internal Revenue Service Audit of Athena Neurosciences, Inc., a U.S. Subsidiary

On April 26, 2019, we received a revised NOPA from the IRS regarding transfer pricing positions related to the IRS audit of Athena for the years ended December 31, 2011, December 31, 2012 and December 31, 2013. Our request for Competent Authority Assistance with the IRS, which we made on April 14, 2020, was accepted. An opening conference with the IRS was held on May 6, 2021, and an opening conference with Irish Revenue was held on July 23, 2021 (refer to Item 1. Note 15).

Israeli Notice of Assessment

On December 29, 2020, we received a Stage A assessment from the Israeli Tax Authority for the tax years ended December 31, 2015 through December 31, 2017 in the amount of $63.8 million relating to attribution of intangible income to Israel, income qualifying for a lower preferential rate of tax, exemption from capital gains tax, and deduction of certain settlement payments. We timely filed our protest on March 11, 2021 to move the matter to Stage B of the assessment process. Through negotiations with the ITA, we resolved the audit for the tax year ended June 27, 2015 through tax year ended December 31, 2019, by agreeing to add tax year ended December 31, 2018 and tax year ended December 31, 2019 to the audit to reach an agreeable resolution to provide certainty for these additional periods. The agreement with the ITA required us to pay $19.0 million, after offset of refunds of $17.2 million, for the five taxable years. In addition, we paid $12.5 million to resolve a tax liability indemnity for the tax year ended December 31, 2017 relating to Perrigo API Ltd, which we disposed of in December 2017 (refer to Item 1. Note 15).

Impact of COVID-19 Pandemic

We have been impacted by the COVID-19 global pandemic and the responses by government entities to combat the virus. We currently continue to operate in all our jurisdictions and are complying with the rules and guidelines prescribed in each jurisdiction. We continue to closely monitor the impact of COVID-19 on all aspects of our business in all our global locations and have continued our COVID-19 safety protocols for employees. To date, these arrangements have not materially affected our ability to maintain our business operations, including the operation of financial reporting systems, internal control over financial reporting, and disclosure controls and procedures. However, the pandemic and actions to slow its spread have impacted our operations, including through increased absenteeism and increased costs of raw materials and finished goods, although most of our facilities have continued to produce at high levels despite these challenges. Moreover, our global operations have been negatively impacted by the worldwide supply chain challenges, which have increased costs and delays.

56

Perrigo Company plc - Item 2

Executive Overview

As many jurisdictions have relaxed COVID-19 related restrictions, a number of those jurisdictions have experienced increases in COVID-19 cases, including more contagious variants of the virus and in some cases have begun implementing new or renewed restrictions. In addition, as conditions worldwide continue to evolve, uncertainty remains about the timing of widespread availability and acceptance of vaccines and the efficacy of current vaccines against evolving strains or variants of the virus. As such, if the pandemic continues or intensifies, it is possible that these or other challenges may begin having a larger impact on our operations. Additionally, future volatility in financial and other capital markets may continue to adversely impact our stock price and our ability to access capital markets. The situation surrounding COVID-19 remains fluid, and we continue to actively manage our response and assess potential impacts to our financial condition, supply chains and other operations, employees, results of operations, consumer demand for our products, and our ability to access capital. The magnitude of any such adverse impact cannot currently be determined due to a number of uncertainties surrounding COVID-19.

During the first half of 2021, our segments experienced a sharp decline in net sales for cough and cold products in our upper respiratory and pain and sleep aid categories, due to the very low incidence of cough and cold related illness during that time. We believe the low incidence of cough and cold related illness was due to social distancing measures and mask mandates put in place. As many of these markets relaxed restrictions and reopen, we saw consumer behavior begin to return to normal, and the incidences of cough and cold related illnesses begin to increase. This resulted in rebounding consumer takeaway in the second quarter, including for cough and cold related products, although factory shipments lagged consumption. During the third quarter of 2021, consumer takeaway remained strong in both the US and Europe and further accelerated for cough and cold products. However, we also experienced supply chain disruptions, including a lack of truck drivers in the U.S. and record delays at global shipping ports, which lead to higher unfulfilled customer orders compared to the prior year. While we believe this will continue in the near-term, we are expecting a gradual improvement heading into the middle of 2022.

Moreover, we continue to incur additional operating costs related to COVID-19, due primarily to increased material costs and increased costs driven by pandemic-related global supply chain disruptions as well as costs related to our ongoing employee safety protocols. We expect these costs will continue into early calendar year 2022.

While the current trend of increased consumer takeaway suggests that the volatility in consumer behavior during the pandemic is improving, the emergence and spread of new disease variants or additional outbreaks in these or other jurisdictions could result in new restrictions or cause these trends to change, slow or reverse. Moving forward, it remains uncertain if the consumer and customer behavior surrounding COVID-19 that has impacted net sales will continue to normalize or change and if the increase in operating costs and supply chain disruptions will continue or change. Any change in these trends will likely depend on the duration and severity of the COVID-19 pandemic, including the emergence of new strains of the virus, including the Delta variant, that are more contagious or harmful, each individual country's evolving response to the pandemic, as well as the availability and efficacy of the COVID-19 vaccines. Given our financial strength, we expect to continue to maintain sufficient liquidity as we continue to operate through the pandemic.

57

Perrigo Company plc - Item 2

Consolidated

RESULTS OF OPERATIONS

CONSOLIDATED

Consolidated Financial Results

Three Month Comparison

	Three Months Ended
(in millions, except percentages)	October 2, 2021			September 26, 2020
Net sales	$	1,042.7		$	1,003.0
Gross profit	$	336.4		$	369.7
Gross profit %	32.3		%	36.9		%
Operating income	$	438.3		$	78.5
Operating income %	42.0		%	7.8		%

* Total net sales by geography is derived from the location of the entity that sells to a third party.

Three Months Ended October 2, 2021 vs. Three Months Ended September 26, 2020

Net sales increased $39.7 million, or 4.0%, due to:

•$25.9 million, or 2.6%, net increase in the base business driven by strong growth in e-commerce sales, primarily in the CSCA segment and the recognition of contract manufacturing sales to the now-divested RX business. Additional increases were driven by incremental new product sales and positive pricing. These increases were partially offset by discontinued products of $11.4 million, lost distribution within the healthy lifestyle category, lower net sales in the CSCI contract manufacturing business, and a decrease of $3.9 million for a product recall in the vitamin, minerals, and supplements ("VMS") category; and

•$13.8 million net increase due primarily to:

◦$8.8 million increase from favorable foreign currency translation; and

◦$5.0 million increase due to the acquisition of three Eastern European Brands in October 2020.

58

Perrigo Company plc - Item 2

Consolidated

Operating income increased $359.8 million, or 458.3%, due primarily to:

•$33.3 million decrease in gross profit due primarily to unfavorable plant overhead absorption due to lower production volumes resulting from the weak cough cold season in the first half of the year, higher input and freight costs, and product recalls initiated during the quarter. Gross profit as a percentage of net sales decreased 460 basis points due to the same factors as gross profit as well as unfavorable product mix; more than offset by

•$393.1 million decrease in operating expenses due primarily to:

◦$410.1 million decrease in other operating expenses due to:

▪$417.6 million award received for the Claim Arising from the Omega Acquisition, as described in Item 1. Note 16; partially offset by

▪$4.0 million increase for the absence of an insurance reimbursement received in the prior year period; and

▪$3.5 million impairment charge primarily on held for sale assets related to our Mexico and Brazil-based OTC businesses (the “Latin American businesses”).

◦$16.5 million increase in R&D and administration expenses due primarily to:

▪$19.3 million increase in administration expenses due primarily to an increase in legal and professional fees and a reduction in an insurance recovery receivable related to litigation contingencies, partially offset by a reduction in employee related expenses, Project Momentum savings and transition service agreement ("TSA") income from the RX business;

▪$2.8 million decrease in R&D expenses.

Nine Month Comparison

	Nine Months Ended
(in millions, except percentages)	October 2, 2021			September 26, 2020
Net sales	$	3,033.8		$	3,035.0
Gross profit	$	1,053.8		$	1,110.5
Gross profit %	34.7		%	36.6		%
Operating income	$	363.7		$	227.6
Operating income %	12.0		%	7.5		%

* Total net sales by geography is derived from the location of the entity that sells to a third party.

59

Perrigo Company plc - Item 2

Consolidated

Nine Months Ended October 2, 2021 vs. Nine Months Ended September 26, 2020

Net sales decreased $1.2 million, or 0.0% due to:

•$86.0 million, or 2.9%, net decrease in the base business due primarily to a decline of $102.3 million in sales of cough and cold products due to the low incidence of related illness in the first half of the year. Additional decreases were due primarily to a decrease in demand of certain products due primarily to COVID-19 restrictions, inventory reductions at our retail customers in the US compared to the prior year, and discontinued products. These decreases were partially offset by the incremental impact of new product sales, recognition of contract manufacturing sales to the now-divested RX business, and positive pricing; and

•$84.8 million increase due primarily to:

◦$69.4 million increase from favorable foreign currency translation; and

◦$44.1 million increase from our acquisitions of the three Eastern European Brands in October 2020 and Dr. Fresh in April 2020; partially offset by

◦$28.7 million decrease due to our now-divested Rosemont pharmaceuticals business previously included in our CSCI segment.

Operating income increased $136.1 million, or 59.8%, due primarily to:

•$56.7 million decrease in gross profit due primarily to unfavorable plant overhead absorption due to lower production volumes resulting from the weak cough cold season in the first half of the year, and by higher input and freight costs. Gross profit as a percentage of net sales decreased 190 basis points due to the same factors as gross profit as well as unfavorable product mix.

•$192.8 million decrease in operating expenses due primarily to:

◦$241.5 million decrease in other operating expenses due primarily to:

▪$417.6 million award received for the Claim Arising from the Omega Acquisition, as described in Item 1. Note 16; partially offset by

▪$162.1 million of impairment charges primarily on goodwill and held for sale assets related to the Latin American businesses;

▪$10.2 million increase in restructuring expenses primarily associated with actions taken to streamline the organization; and

▪$4.0 million increase for the absence of an insurance reimbursement received in the prior year period.

◦$48.6 million increase in selling, distribution, R&D, and administration expenses due primarily to:

▪$22.9 million increase in administration expenses due primarily to a reduction in an insurance recovery receivable related to litigation contingencies, and an increase in legal and professional fees, partially offset by Project Momentum savings and TSA income from the RX business;

▪$16.0 million increase in selling, advertising and promotion expenses due primarily to unfavorable foreign currency translation and the addition of expenses from acquired businesses;

▪$6.7 million increase in distribution expenses due primarily to increased warehouse costs; and

▪$3.0 million increase in R&D expenses.

60

Perrigo Company plc - Item 2

CSCA

CONSUMER SELF-CARE AMERICAS

Recent Trends and Developments

•During the first half of 2021, net sales of cough and cold products decreased as a result of the very low incidence of cough and cold related illness, which we believe is attributed to social distancing and mask mandates. However, increased consumer takeaway at our retail customers, starting in May, suggested normalizing consumer purchasing routines could be expected in the second half of 2021. In the third quarter, we experienced higher demand for cough, cold and pain products due primarily to the higher incidences of cough and cold illness as society returns to in-person activities. Further, consumer take away remained strong during the third quarter and, as such, we expect sales of cough, cold and pain products to continue to increase, depending on the trajectory of the COVID-19 pandemic (refer to "Impact of COVID-19 Pandemic" above).

•During the third quarter of 2021, supply chain disruptions, including a lack of truck drivers in the U.S. and record delays at global shipping ports, lead to higher unfulfilled customer orders and higher input costs compared to the prior year. While we believe this will continue in the near-term, we are expecting a gradual improvement heading into the middle of 2022. We have taken a series of actions to improve the current situation including, reconfiguring our distribution system for short term shipments, outsourcing highly complex product lines to a third party logistic provider, adding regional carriers for challenged shipping lanes, hiring additional distribution center personnel, and increasing the purchase cycle as it relates to the manufacturing process.

•On May 18, 2021, we announced a definitive agreement to sell our Latin American businesses to Advent International. This transaction is part of our margin improvement program and Project Momentum cost savings initiative and is expected to close in the first half of 2022. We determined that the carrying value of these businesses exceeded their fair value less cost to sell, resulting in an impairment charge of $161.2 million allocated to goodwill and assets held for sale (refer to Item 1. Note 9).

Segment Financial Results

Three Month Comparison

	Three Months Ended
(in millions, except percentages)	October 2, 2021			September 26, 2020
Net sales	$	694.2		$	664.0
Gross profit	$	187.6		$	215.6
Gross profit %	27.0		%	32.5		%
Operating income	$	90.4		$	121.7
Operating income %	13.0		%	18.3		%

Three Months Ended October 2, 2021 vs. Three Months Ended September 26, 2020

Net sales increased $30.2 million, or 4.5%, due to:

•$27.7 million, or 4.2%, net increase due primarily to:

◦$21.3 million increase in OTC due primarily to growth in e-commerce sales and the recognition of contract manufacturing sales to the now-divested RX business. Additional increases were due to higher demand for cough, cold and pain products, an increase in the branded OTC business, and positive pricing stemming from management actions taken earlier in the year. These gains were partially offset by lost distribution within the healthy lifestyle category, $9.9 million of discontinued products driven by the discontinuation of diabetes care products, and lower net sales in the allergy category.

◦Nutrition net sales increased $6.2 million due primarily to the incremental benefit of new product sales within infant formula and growth in the oral electrolytes business.

◦Net sales in our oral self-care category decreased $5.8 million due primarily to delayed receipt of products manufactured outside of the US, leading to unfulfilled customer orders.

61

Perrigo Company plc - Item 2

CSCA

•$2.5 million increase due to favorable Mexican peso foreign currency translation.

Operating income decreased $31.3 million, or 25.7%, due primarily to:

•$28.0 million decrease in gross profit due primarily to lower operating efficiencies driven by unfavorable plant overhead absorption from lower production volumes in OTC resulting from the weak cough cold season in the first half of the year, higher freight and input costs, and a product recall related to an allergy product, partially offset by the increase in net sales as described above. Gross profit as a percentage of net sales decreased 550 basis points due primarily to lower operating efficiencies discussed above and unfavorable product mix.

•$3.3 million increase in operating expenses due primarily to:

◦$6.5 million increase in other operating expenses due primarily to:

▪$2.6 million of additional impairment charges on held for sale assets related to the Latin American businesses; and

▪$4.0 million increase for the absence of an insurance reimbursement received in the prior year period.

◦$1.8 million decrease in distribution and administration expenses due primarily to:

▪$3.5 million decrease in administration expenses due primarily to a decrease in employee related expenses and legal and professional fees; partially offset by

▪$1.7 million increase in distribution costs due primarily to increased warehouse costs.

Nine Month Comparison

	Nine Months Ended
(in millions, except percentages)	October 2, 2021			September 26, 2020
Net sales	$	1,957.0		$	1,992.2
Gross profit	$	569.5		$	627.3
Gross profit %	29.1		%	31.5		%
Operating income	$	113.9		$	348.4
Operating income %	5.8		%	17.5		%

Nine Months Ended October 2, 2021 vs. Nine Months Ended September 26, 2020

Net sales decreased $35.2 million, or 1.8%, due to:

•$63.9 million, or 3.2%, net decrease due primarily to:

◦$82.5 million decrease in OTC due primarily to a decline of $63.1 million in sales of cough and cold products from the low incidence of related illness in the first half of the year. Additional decreases were due primarily to inventory reductions at our retail customers in the US compared to the prior year, and discontinued products driven by diabetes care products. These decreases were partially offset by the recognition of contract manufacturing sales to the now-divested RX business and incremental new product sales.

◦Nutrition net sales increased $6.6 million due primarily to growth in infant formula contract manufacturing, incremental new product sales, and higher net sales in oral electrolyte solutions. These factors were partially offset by inventory reductions at our retail customers compared to the prior year.

◦In the oral self-care category, net sales were flat compared to the prior period with incremental new product sales being offset by delayed receipt of products manufactured outside of the US, leading to unfulfilled customer orders.

•$28.7 million increase due to:

62

Perrigo Company plc - Item 2

CSCA

◦$23.8 million increase from our acquisition of Dr. Fresh in April 2020; and

◦$4.9 million increase from favorable Mexican peso foreign currency translation.

Operating income decreased $234.5 million, or 67.3%, due to:

•$57.8 million decrease in gross profit due primarily to unfavorable plant overhead absorption as a result of lower OTC production volumes resulting from the weak cough cold season in the first half of the year, higher freight and input costs, the decrease in net sales as described above, and a product recall related to an allergy product. Gross profit as a percentage of net sales decreased 240 basis points due primarily to unfavorable plant overhead absorption and the higher freight and input costs; and

•$176.7 million increase in operating expenses due primarily to:

◦$168.6 million increase in other operating expenses due primarily to:

▪$161.2 million of impairment charges on goodwill and held for sale assets related to the Latin American businesses;

▪$4.0 million increase for the absence of an insurance reimbursement received in the prior year period; and

▪$3.5 million increase in restructuring costs related primarily with actions taken to streamline the organization and business integrations.

◦$8.1 million increase in distribution, R&D, selling, and administration expenses due to:

▪$7.3 million increase in distribution costs related due primarily to increased warehouse costs;

▪$4.8 million increase in operating expenses due to the inclusion of Dr. Fresh expenses; and

▪$3.8 million increase in R&D expenses, partially for a new drug application filing fee and continued innovation; partially offset by

▪$7.8 million decrease in selling and administration expenses due primarily to a decrease in legal and professional fees, partially offset by an increase in selling expenses within the OTC business.

CONSUMER SELF-CARE INTERNATIONAL

Recent Trends and Developments

•During the first half of 2021, net sales of cough and cold products decreased as a result of the very low incidence of cough and cold related illness this year, which we believe is attributed to social distancing and mask mandates. However, increased consumer takeaway at our retail customers starting in May suggests normalizing consumer purchasing routines are expected through the remainder of 2021 depending on the trajectory of the COVID-19 pandemic (refer to "Impact of COVID-19 Pandemic" above).

•During the three months ended October 2, 2021, a number of EU regulators requested recalls, some at the consumer level, due to the detection of 2-chloroethanol (“2-CE”). 2-CE has been associated with the presence of ethylene oxide, a constituent in pesticides, which is not permitted for use in food products under food regulations in the EU. Due to the potential presence of ethylene oxide in certain of our VMS products, we initiated recalls. We have since secured alternate sourcing of the raw material. During the three months ended October 2, 2021, these recalls resulted in a decrease in net sales of $3.9 million and a decrease in gross profit of $5.5 million.

63

Perrigo Company plc - Item 2

CSCI

Segment Financial Results

Three Month Comparison

	Three Months Ended
(in millions, except percentages)	October 2, 2021			September 26, 2020
Net sales	$	348.5		$	339.0
Gross profit	$	148.8		$	154.1
Gross profit %	42.7		%	45.5		%
Operating income	$	4.3		$	10.1
Operating income %	1.2		%	3.0		%

Three Months Ended October 2, 2021 vs. Three Months Ended September 26, 2020

Net sales increased $9.5 million, or 2.8%, due to:

•$1.9 million, or 0.6%, net decrease due primarily to the lower than normal buy-in for cough and cold products by independent pharmacies, lower net sales in contract manufacturing, lower demand for weight loss products across Europe, which led to lower net sales for XLS Medical in the healthy lifestyle category, and a product recall that impacted the VMS category. These decreases were mostly offset by higher net sales in the U.K. store brand business, greater demand for NiQuitin smoking cessation products in the Healthy Lifestyle category, incremental new product sales, and positive pricing; more than offset by

•$11.4 million increase due primarily to:

◦$6.4 million increase from favorable foreign currency translation; and

◦$5.0 million increase from our acquisition of three Eastern European Brands in October 2020.

Operating income decreased $5.8 million, or 57.4%, due primarily to:

•$5.3 million decrease in gross profit due primarily to the VMS product recall. Gross profit as a percentage of net sales decreased 280 basis points due primarily to the VMS product recall and unfavorable product mix.

Nine Month Comparison

	Nine Months Ended
(in millions, except percentages)	October 2, 2021			September 26, 2020
Net sales	$	1,076.8		$	1,042.8
Gross profit	$	484.3		$	483.2
Gross profit %	45.0		%	46.3		%
Operating income	$	23.1		$	45.7
Operating income %	2.1		%	4.4		%

Nine Months Ended October 2, 2021 vs. Nine Months Ended September 26, 2020

Net sales increased $34.0 million, or 3.3%, due to:

•$22.1 million, or 2.2%, net decrease due primarily to a decline of $39.2 million in sales of cough and cold products due to the low incidence of related illness this year. Additional decreases were due primarily to lower demand for weight loss products across Europe, which led to lower net sales for XLS Medical in the healthy lifestyle category, lower consumer demand for anti-parasite products in the skincare and personal hygiene category due primarily to COVID-19 restrictions and a slow start to the mosquito summer season, lower net sales in contract manufacturing, and a product recall that impacted the VMS category. These decreases were partially offset by incremental new product sales including XLS Medical Forte 5 sticks in the healthy lifestyle category, the introduction of the Probify probiotics brand in the VMS category, and the

64

Perrigo Company plc - Item 2

CSCI

launch of Plackers® into new markets in the oral self-care category, positive pricing, and greater demand for NiQuitin smoking cessation products in the Healthy Lifestyle category. Such decreases were more than offset by

•$56.1 million increase due primarily to:

◦$64.5 million increase from favorable foreign currency translation; and

◦$20.3 million increase from our acquisitions of the three Eastern European Brands in October 2020 and Dr. Fresh in April 2020; partially offset by

◦$28.7 million decrease due to our now-divested Rosemont pharmaceuticals business.

Operating income decreased $22.6 million, or 49.5%, due to:

•$1.1 million increase in gross profit due primarily to greater operating efficiencies, positive pricing and foreign currency translation, partially offset by an increase in lower margin product sales, the now-divested Rosemont pharmaceuticals business, and the VMS product recall. Gross profit as a percentage of net sales decreased 130 basis points due primarily to unfavorable product mix and the VMS product recall, partially offset by greater operating efficiencies; and

•$23.7 million increase in operating expenses due primarily to:

◦$20.6 million increase in selling and administration expenses due primarily to:

▪$11.3 million increase in selling, advertising and promotion ("A&P") expenses due primarily to unfavorable foreign currency translation, more than offsetting the reduction in expenses from base business A&P and the divestiture of our Rosemont pharmaceuticals business; and

▪$9.3 million increase in administration expenses due primarily to an increase in employee expenses and unfavorable foreign currency translation, partially offset by the absence of expenses from the divestiture of our Rosemont pharmaceuticals business; and

◦$4.8 million increase in restructuring expenses associated with actions taken to streamline the organization.

Unallocated Expenses

Unallocated expenses are comprised of certain corporate services not allocated to our reporting segments and are recorded in Operating income on the Condensed Consolidated Statements of Operations. Unallocated expenses were as follows (in millions):

Three Months Ended				Nine Months Ended
October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
$	(343.6)	$	53.3	$	(226.7)	$	166.5

The decrease of $396.9 million in unallocated expenses during the three months ended October 2, 2021 compared to the prior year period was due primarily to the award in the Claim Arising from the Omega Acquisition, as described in Item 1. Note 16 for $417.6 million, TSA income from the RX business, and Project Momentum savings. This was partially offset by an increase in legal and professional fees and a reduction in an insurance recovery receivable related to litigation contingencies.

The decrease of $393.2 million in unallocated expenses during the nine months ended October 2, 2021 compared to the prior year period was due primarily to the award in the Claim Arising from the Omega Acquisition, as described in Item 1. Note 16 for $417.6 million, higher indirect costs in the prior year period relating to the RX business, TSA income from the RX business, and Project Momentum savings. These were partially offset by an increase in legal and professional fees, a reduction in an insurance recovery receivable related to litigation contingencies, and an increase in restructuring expenses.

65

Perrigo Company plc - Item 2

Unallocated, Interest, Other, and Taxes

Change in Financial Assets, Interest expense, net, and Other (income) expense, net and Loss on extinguishment of debt (Consolidated)

	Three Months Ended				Nine Months Ended
(in millions)	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Change in financial assets	$	—	$	(22.2)	$	—	$	(25.9)
Interest expense, net	$	30.9	$	33.3	$	94.5	$	94.3
Other (income) expense, net	$	18.5	$	(1.0)	$	20.4	$	17.9
Loss on extinguishment of debt	$	—	$	20.0	$	—	$	20.0

Change in Financial Assets

During the year ended December 31, 2020, Royalty Pharma payments from Biogen for Tysabri® sales, as defined in the agreement between the parties, did not exceed the 2020 global net sales threshold. Therefore, we were not entitled to receive the remaining contingent milestone payment. As of December 31, 2020, there are no contingent milestone payments outstanding.

During the three and nine months ended September 26, 2020, the fair value of the Royalty Pharma contingent milestone payment related to 2020 increased by $22.2 million and $25.9 million, respectively to $121.2 million, driven by higher projected global net sales of Tysabri® compared to the estimates in the prior period, and the estimated probability of achieving the earn-out (refer to Item 1. Note 6).

Interest Expense, Net

The $2.4 million decrease during the three months ended October 2, 2021, compared to the prior year period was due primarily to a reduction in interest expense due primarily to a reduction in interest rates.

The $0.2 million increase for the nine months ended October 2, 2021, compared to the prior year period was due primarily to a reduction in interest income received, partially offset by a reduction in interest expense.

Other (Income) Expense, Net

The $19.5 million increase in expense during the three months ended October 2, 2021 compared to the prior year period was due primarily to unfavorable changes in revaluation of monetary assets and liabilities held in foreign currencies.

The $2.5 million increase in expense during the nine months ended October 2, 2021 compared to the prior year period was due primarily to the absence of an $18.7 million pre-tax loss on the divestiture of our Rosemont Pharmaceuticals business partially offset by unfavorable changes in revaluation of monetary assets and liabilities held in foreign currencies.

Loss on Extinguishment of Debt

During the three months ended September 26, 2020, we recorded a loss of $20.0 million as a result of the early redemption of the 2021 Notes, consisting of the premium on debt repayments, the write-off of deferred financing fees, and the write-off of the remaining bond discounts (refer to Item 1. Note 12).

66

Perrigo Company plc - Item 2

Unallocated, Interest, Other, and Taxes

Income Taxes (Consolidated)

The effective tax rates were as follows:

Three Months Ended				Nine Months Ended
October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
113.9	%	45.5	%	165.5	%	20.5	%

The effective tax rate for the three and nine months ended October 2, 2021 increased compared to the effective tax rate for the three and nine months ended September 26, 2020 primarily due to tax expense recorded in 2021 for settlement of the Irish Notice of Amended Assessment and intra-entity transfers of intellectual property, plus tax benefits recorded in the 2020 periods for reductions to the U.S. valuation allowance and the U.S. Coronavirus Aid, Relief and Economic Security ("CARES") Act, enacted in the first quarter of 2020.

FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES

We finance our operations with internally generated funds, supplemented by credit arrangements with third parties and capital market financing. We routinely monitor current and expected operational requirements and financial market conditions to evaluate other available financing sources including term and revolving bank credit and securities offerings. In determining our future capital requirements, we regularly consider, among other factors, known trends and uncertainties, such as the Notices of Proposed Adjustment ("NOPAs") from the IRS, the current COVID-19 pandemic, and other contingencies. We note that no payment of the additional amounts proposed by the IRS in the NOPAs is currently required, and no such payment is expected to be required, unless and until a settlement or other final determination of the matter is reached that is adverse to us (refer to Item 1. Note 15 for additional information on the NOPAs). Based on the foregoing, management believes that our operations and borrowing resources are sufficient to provide for our short-term and long-term capital requirements, as described below. However, an adverse result with respect to our appeal of any material outstanding tax assessments or litigation, including securities or drug pricing matters and product liability cases, damages resulting from third-party claims, and related interest and/or penalties, could ultimately require the use of corporate assets to pay such assessments and any such use of corporate assets would limit the assets available for other corporate purposes. As such, we continue to evaluate the impact of the above factors on liquidity and may determine that modifications to our capital structure are appropriate if market conditions deteriorate, favorable capital market opportunities become available, or any change in conditions relating to the NOPAs, the COVID-19 pandemic or other contingencies have a material impact on our capital requirements. We received $1.5 billion in cash upon the completion of the RX business sale, on July 6, 2021. We intend to use a portion of these proceeds to fund the acquisition of HRA Pharma (refer to Item 1. Note 3). We also received $417.6 million relating to the Claim Arising from the Omega Acquisition in September 2021. A portion of these proceeds were used for the settlement of the NoA dispute with Irish Revenue.

67

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

Cash and Cash Equivalents

* Working capital represents current assets less current liabilities, excluding cash and cash equivalents, assets and liabilities held for sale, and excluding current indebtedness.

Cash, cash equivalents, cash flows from operations, and borrowings available under our credit facilities are expected to be sufficient to finance our liquidity and capital expenditures in both the short and long term. Although our lenders have made commitments to make funds available to us in a timely fashion under our revolving credit agreements and overdraft facilities, if economic conditions worsen, including due to the COVID-19 pandemic, or new information becomes publicly available impacting the institutions’ credit rating or capital ratios, these lenders may be unable or unwilling to lend money pursuant to our existing credit facilities. Should our outlook on liquidity requirements change substantially from current projections, we may seek additional sources of liquidity in the future.

68

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

Cash Generated by (Used in) Operating Activities

The $264.1 million decrease in operating cash inflow was due primarily to:

•$267.0 million decrease in cash flow from the change in net earnings after adjustments for items including impairment charges, deferred income taxes, restructuring charges, changes in our financial assets, share-based compensation, amortization of debt premium, loss (gain) on sale of businesses, loss on extinguishment of debt, and depreciation and amortization;

•$288.7 million decrease in cash flow from the change in accounts receivable, due primarily to timing of sales and receipt of payments;

•$58.4 million decrease in cash flow from the change in accrued payroll and related taxes, due primarily to the timing of payroll and the increase in annual management and employee bonus payments compared to the prior year period; and

•$50.7 million decrease in cash flow from the change in other assets and liabilities, due primarily to recording a receivable for the net settlement of receipts received and payments made on behalf of the RX business under the TSA arrangement; partially offset by

•$322.2 million increase in cash flow from the change in accrued income taxes, due primarily to the accruals recorded for the taxes related to the settlement of the Irish NoA and taxes related to the Omega Arbitration settlement;

•$48.9 million increase in cash flow from the change in accrued customer programs, due primarily to pricing dynamics and timing of rebate and chargeback payments related to our discontinued operations; and

•$22.0 million increase in cash flow from the change in prepaid expenses, due primarily to a decrease in our annual prepaid expenses compared to the prior year period and for a payment received in the current year related to a prior TSA agreement.

69

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

Cash Generated by (Used in) Investing Activities

The $1,378.0 million increase in cash from investing cash flow was due primarily to:

•$1,305.3 million increase in cash due to the proceeds from the RX business sale partially offset by the absence of the proceeds from the divestiture of our Rosemont Pharmaceuticals business (refer to Item 1. Note 3);

•$106.0 million increase in cash due to the absence of the payment for the acquisition of Dr. Fresh (refer to Item 1. Note 3); and

•$15.0 million increase in cash due to the absence of the payment for the purchase of our equity method investment in Kazmira LLC; partially offset by

•$36.5 million decrease in cash due to the increase in spending on asset acquisitions, primarily related to the payment for an ANDA for a generic topical gel for $16.4 million and the purchase of an ANDA for a generic topical lotion for $53.3 million, offset by prior year acquisitions for the Steripod® brand for $25.1 million and the Dexsil® brand for approximately $8.0 million (refer to Item 1. Note 3).

Cash Generated by (Used in) Financing Activities

The $141.0 million decrease in financing cash flow was due primarily to:

•$743.8 million decrease due to absence of the debt issuance completed in the prior year; and

•$5.9 million decrease due primarily to the payment made on the promissory notes related to our Kazmira investment; partially offset by

•$590.0 million increase due to the absence of the payment on long-term debt in the prior year; and

70

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

•$19.0 million increase due to the absence of the payment of premiums on the early redemption of the 2021 Notes in the prior year.

Dividends    

The declaration and payment of dividends, if any, is subject to the discretion of our Board of Directors and will depend on our earnings, financial condition, availability of distributable reserves, capital and surplus requirements, and other factors our Board of Directors may consider relevant.

Share Repurchases

In October 2018, our Board of Directors authorized up to $1.0 billion of share repurchases with no expiration date, subject to the Board of Directors’ approval of the pricing parameters and amount that may be repurchased under each specific share repurchase program. We did not repurchase any shares during the three and nine months ended October 2, 2021 or September 26, 2020.

Borrowings and Capital Resources

Revolving Credit Agreements

On March 8, 2018, we entered into a $1.0 billion revolving credit agreement maturing on March 8, 2023 (the "2018 Revolver"). There were no borrowings outstanding under the 2018 Revolver as of October 2, 2021 or December 31, 2020.

Term Loans and Notes

We had $2.9 billion outstanding under our notes and bonds as of both October 2, 2021 and December 31, 2020. In August 2019, we refinanced a prior term loan with the proceeds of a $600.0 million term loan, maturing on August 15, 2022 (the "2019 Term Loan"). We had $600.0 million outstanding under our 2019 Term Loan as of both October 2, 2021 and December 31, 2020.

Waiver and Amendment of Debt Covenants

We are subject to financial covenants in the 2018 Revolver and 2019 Term Loan, including a maximum leverage ratio covenant, which previously required us to maintain a ratio of Consolidated Net Indebtedness to Consolidated EBITDA (as such terms are defined in the respective credit agreements) of not more than 3.75 to 1.00 at the end of each fiscal quarter. During the nine months ended October 2, 2021, we received a waiver for non-compliance with such covenant as of July 3, 2021 from the lenders under both credit facilities and entered into an amendment to each of the 2018 Revolver and 2019 Term Loan. Under such amendments, the maximum leverage ratio was increased to 5.75 to 1.00 for the third quarter of 2021, returning to 3.75 to 1.00 beginning with the fourth quarter of 2021. If we consummate certain qualifying acquisitions in the fourth quarter of 2021 or any subsequent quarter during the term of the loan, the maximum ratio would increase to 4.00 to 1.00 for such quarter. Due to the waiver and amendment described above, our leverage ratios at the end of the second and third quarters of 2021 do

71

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

not prevent us from drawing under the 2018 Revolver. As of October 2, 2021, we are in compliance with all the covenants under our debt agreements. No assurance can be given that the Company will meet the leverage covenant under such credit agreements. However, given the Company’s strong cash position, we do not believe that any failure to comply with such leverage covenant would have a material adverse effect on the Company or its liquidity. The 2019 Term Loan currently matures in the third quarter of 2022, and the amount outstanding thereunder has been classified as current indebtedness on our balance sheet as of July 3, 2021. The Company is currently evaluating various options relating to the 2018 Revolver and the 2019 Term Loan, which may include further amendments, repayment of the 2019 Term Loan, and/or refinancing.

Other Financing

On June 17, 2020, we incurred debt of $34.3 million related to our equity method investment in Kazmira pursuant to two Promissory Notes, with $3.7 million, $5.8 million and $24.8 million to be settled in November 2020, May 2021 and November 2021, respectively. On December 8, 2020, we repaid the $3.7 million balance due on the November 2020 portion of the Promissory Notes. On June 7, 2021, we repaid the $5.8 million balance due on the May 2021 portion of the Promissory Notes.

Overdraft Facilities

We have overdraft facilities available that we use to support our cash management operations. There were no borrowings outstanding under the facilities as of October 2, 2021 or December 31, 2020.

Leases

We had $203.3 million and $187.7 million of lease liabilities and $200.1 million and $184.5 million of lease assets as of October 2, 2021 and December 31, 2020, respectively.

Accounts Receivable Factoring

The total amount factored on a non-recourse basis and excluded from accounts receivable was zero and $6.9 million at October 2, 2021 and December 31, 2020, respectively.

Refer to Item 1. Note 11 and Note 12 for more information on all of the above lease activity and debt facilities, respectively.

Credit Ratings

During the third quarter of 2021, our credit ratings were downgraded by Moody’s and S&P Global Ratings to Ba1 (negative) and BB (stable), respectively, which are not investment grade ratings. On October 2, 2021, our credit rating was BBB- (negative) by Fitch Ratings Inc., which is an investment grade rating.

Credit rating agencies review their ratings periodically and, therefore, the credit rating assigned to us by each agency may be subject to revision at any time. Accordingly, we are not able to predict whether current credit ratings will remain as disclosed above. Factors that can affect our credit ratings include changes in operating performance, the economic environment, our financial position, and changes in business strategy. If changes in our credit ratings were to occur, they could impact, among other things, future borrowing costs, access to capital markets, and vendor financing terms. A security rating is not a recommendation to buy, sell or hold securities.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, net sales or expenses, results of operations, liquidity, capital expenditures, or capital resources. We acquire and collaborate on potential products still in development and enter into R&D arrangements with third parties that often require milestone payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required contingent upon the successful achievement of an important point in the development life cycle of the product. Because of the contingent nature of these payments, they are not included in our table of contractual obligations.

72

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

Contractual Obligations and Commitments

There were no material changes in contractual obligations as of October 2, 2021 from those provided in our 2020 Form 10-K.

Significant Accounting Policies

Other than the adoption of ASU 2019-12: Income taxes (refer to Item 1. Note 15), there have been no material changes to the significant accounting policies as disclosed in our 2020 Form 10-K.

Critical Accounting Estimates

The determination of certain amounts in our financial statements requires the use of estimates. These estimates are based upon our historical experiences combined with management’s understanding of current facts and circumstances. Although the estimates are considered reasonable based on the currently available information, actual results could differ from the estimates we have used. There have been no material changes to the critical accounting estimates as disclosed in our 2020 Form 10-K.

ITEM 3.        QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to our quantitative or qualitative disclosures found in Item 7A, "Quantitative and Qualitative Disclosures about Market Risk," of our 2020 Form 10-K.

ITEM 4.        CONTROLS AND PROCEDURES

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act) as of October 2, 2021. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective in ensuring that all material information relating to us and our consolidated subsidiaries required to be included in our periodic SEC filings would be made known to them by others within those entities in a timely manner and that no changes are required at this time.

Evaluation of the Effectiveness of Internal Control over Financial Reporting

Our management assessed the effectiveness of our internal control over financial reporting as of October 2, 2021. The framework used in carrying out our evaluation was the 2013 Internal Control - Integrated Framework published by the Committee of Sponsoring Organizations ("COSO") of the Treadway Commission. In evaluating our information technology controls, we also used components of the framework contained in the Control Objectives for Information and related Technology, which was developed by the Information Systems Audit and Control Association’s IT Governance Institute, as a complement to the COSO internal control framework. Management has concluded that our internal control over financial reporting was effective as of October 2, 2021. The results of management’s assessment have been reviewed with our Audit Committee.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended October 2, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

73

Perrigo Company plc - Part II - Other Information

PART II.     OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS

Refer to Item 1. Note 15 and Item 1. Note 16 of the Notes to the Condensed Consolidated Financial Statements.

ITEM 1A.    RISK FACTORS

Our Annual Report on Form 10-K for the year ended December 31, 2020 includes a detailed discussion of our risk factors. At the time of this filing, there have been no material changes to the risk factors that were included in the Form 10-K, other than as described below.

Management transition creates uncertainties, and any difficulties we experience in managing such transitions may negatively impact our business.

Effective October 4, 2021, Jim Dillard was named EVP and President of our CSCA segment, following the mutual separation of Rich Sorota. Changes in executive management create uncertainty. Moreover, changes in our company as a result of management transition could have a disruptive impact on our ability to implement, or result in changes to, our strategy and could negatively impact our business, financial condition and results of operations.

74

Perrigo Company plc - Item 6

Exhibits

ITEM 6.    EXHIBITS

Exhibit Number	Description
2.1	Put Option Agreement, dated as of September 8, 2021, by and among Perrigo Company plc, Habsont Unlimited Company and certain other parties set forth therein (incorporated by reference from Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on September 9, 2021).
3.1	Certificate of Incorporation of Perrigo Company plc (formerly known as Perrigo Company Limited) (incorporated by reference from Exhibit 4.1 to the Company’s Registration Statement on Form S-8 filed on December 19, 2013).
3.2	Memorandum and Articles of Association of Perrigo Company plc, as amended and restated (incorporated by reference from Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed on August 10, 2017).
10.1	Amendment to Stock and Asset Purchase Agreement, by and between Perrigo Company plc and Padagis LLC, dated as of July 6, 2021 (incorporated by reference from Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on July 12, 2021).
10.2	Amendment No. 1 and Waiver to 2019 Term Loan, dated as of August 10, 2021, by and among Perrigo Finance Unlimited Company, Perrigo Company plc, JPMorgan Chase Bank, N.A., and the other lenders party thereto, dated as of August 15, 2019 (incorporated by reference from Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on August 11, 2021).
10.3	Amendment No. 2 and Waiver to 2018 Revolver, dated as of August 10, 2021, by and among Perrigo Finance Unlimited Company, Perrigo Company plc, JPMorgan Chase Bank, N.A., and the other lenders party thereto, dated as of August 15, 2019 (incorporated by reference from Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed August 11, 2021).
10.4	Supplement to Letter Agreement, dated as of August 11, 2021, by and between the Company and Raymond Silcock (filed herewith).
31.1	Rule 13a-14(a) Certification by Murray S. Kessler, Chief Executive Officer (filed herewith).
31.2	Rule 13a-14(a) Certification by Raymond P. Silcock, Chief Financial Officer (filed herewith).
32	Certification Pursuant to 18 United States Code 1350 and Rule 13a-14(b) of the Securities Exchange Act of 1934 (furnished herewith).
101. INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Date File, formatted in Inline XBRL (contained in Exhibit 101).

*Denotes Management contract or compensatory plan or arrangement.

75

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		PERRIGO COMPANY PLC
		(Registrant)
Date:	November 12, 2021	/s/ Murray S. Kessler
		Murray S. Kessler
		Chief Executive Officer and President
		(Principal Executive Officer)
Date:	November 12, 2021	/s/ Raymond P. Silcock
		Raymond P. Silcock
		Chief Financial Officer
		(Principal Accounting and Financial Officer)

76

EX-10.4

August 11, 2021                                        Exhibit 10.4

Raymond Silcock

Dear Ray,

I would like to update your March 17, 2019 Offer Letter to reflect that your primary work location and residency have changed.

The last two bullet points in your offer letter are replaced in their entirety as follows:

•Your primary work location will be West Palm Beach, Florida. You will be eligible for payment of, or reimbursement for, all business related travel expenses to Grand Rapids, Michigan or any other Perrigo location consistent with the terms of the Perrigo Corporate Travel Policy. You will be responsible for any personal travel or commuting costs to and from the West Palm Beach offices.

•We understand you have changed your state residency to Florida. Perrigo is required to withhold state taxes from the portion of the compensation earned in Michigan even if you are not a resident.  Should you begin to work from the Michigan offices again in the future you must let us know. In that event, we advise you to seek counsel from your personal tax advisor on how to manage your state income tax withholdings and reconcile between Florida and Michigan.  

All other terms and conditions contained in your March 17, 2019 offer letter remain unchanged.

Perrigo is an at-will employer, meaning that either you or Perrigo are free to end the employment relationship at any time, with or without notice or cause. Nothing in this amendment to your March 17, 2019 offer letter or in Perrigo’s policies or procedures, either now or in the future, are intended to change the at-will nature of our relationship.

Sincerely,                    

PERRIGO COMPANY                    ACKNOWLEDGEMENT    

Date     8/11/2021

/s/ Raymond P. Silcock

Raymond P. Silcock

Chief Financial Officer

/s/ Murray S. Kessler

Murray S. Kessler

Chief Executive Officer

515 Eastern Ave

Allegan, Michigan, 49010 • U.S.A.

(269) 673-8451

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Murray S. Kessler, certify that:

1.I have reviewed this report on Form 10-Q of Perrigo Company plc;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 12, 2021

/s/ Murray S. Kessler

Murray S. Kessler

Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Raymond P. Silcock, certify that:

1.I have reviewed this report on Form 10-Q of Perrigo Company plc;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 12, 2021

/s/ Raymond P. Silcock

Raymond P. Silcock

Chief Financial Officer

EX-32

Exhibit 32

The following statement is being made to the Securities and Exchange Commission solely for the purposes of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), which carries with it certain criminal penalties in the event of a knowing or willful misrepresentation.

Securities and Exchange Commission

450 100 F Street NE

Washington, D.C. 20549

Re: Perrigo Company plc

Ladies and Gentlemen:

In accordance with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), each of the undersigned hereby certifies that:

(i)this Quarterly Report on Form 10-Q for the period ended October 2, 2021 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(ii)the information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of Perrigo Company plc.

Date:	November 12, 2021	/s/ Murray S. Kessler
		Murray S. Kessler
		Chief Executive Officer and President
Date:	November 12, 2021	/s/ Raymond P. Silcock
		Raymond P. Silcock
		Chief Financial Officer

XML

Cover Page - shares	9 Months Ended
	Oct. 02, 2021	Nov. 05, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document period end date	Oct. 02, 2021
Document Transition Report	false
Entity File Number	001-36353
Entity registrant name	Perrigo Company plc
Entity Incorporation, State or Country Code	L2
Entity Address, Address Line One	The Sharp Building,
Entity Address, Address Line Two	Hogan Place,
Entity Address, City or Town	Dublin 2,
Entity Address, Country	IE
Entity Address, Postal Zip Code	D02 TY74
Country Region	353
City Area Code	1
Local Phone Number	7094000
Title of 12(b) Security	Ordinary shares
Trading Symbol	PRGO
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity small business	false
Entity emerging growth company	false
Entity Shell Company	false
Entity common stock, shares outstanding		133,773,881
Entity central index key	0001585364
Current calendar year end date	--12-31
Document calendar year focus	2021
Document calendar period focus	Q3
Amendment flag	false

XML

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Income Statement [Abstract]
Net sales	$ 1,042.7	$ 1,003.0	$ 3,033.8	$ 3,035.0
Cost of sales	706.3	633.3	1,980.0	1,924.5
Gross profit	336.4	369.7	1,053.8	1,110.5
Operating expenses
Distribution	23.3	22.5	69.0	62.4
Research and development	27.6	30.4	91.7	88.7
Selling	129.7	130.1	405.0	389.0
Administration	130.6	111.3	368.1	345.2
Impairment charges	3.5	0.0	162.1	0.0
Restructuring	1.0	0.8	11.8	1.5
Other operating expense (income)	(417.6)	(3.9)	(417.6)	(3.9)
Total operating expenses	(101.9)	291.2	690.1	882.9
Operating income	438.3	78.5	363.7	227.6
Change in financial assets	0.0	(22.2)	0.0	(25.9)
Interest expense, net	30.9	33.3	94.5	94.3
Other (income) expense, net	18.5	(1.0)	20.4	17.9
Loss on extinguishment of debt	0.0	20.0	0.0	20.0
Income (loss) from continuing operations before income taxes	388.9	48.4	248.8	121.3
Income tax expense (benefit)	442.8	22.0	411.8	24.9
Income (loss) from continuing operations	(53.9)	26.4	(163.0)	96.4
Income (loss) from discontinued operations, net of tax	(5.0)	(181.0)	84.5	(84.0)
Net income (loss)	$ (58.9)	$ (154.6)	$ (78.5)	$ 12.4
Basic
Continuing operations (in dollars per share)	$ (0.40)	$ 0.19	$ (1.22)	$ 0.71
Discontinued operations (in dollars per share)	(0.04)	(1.32)	0.63	(0.62)
Basic earnings per share (in dollars per share)	(0.44)	(1.13)	(0.59)	0.09
Diluted
Continuing operations (in dollars per share)	(0.40)	0.19	(1.22)	0.70
Discontinued operations (in dollars per share)	(0.04)	(1.31)	0.63	(0.61)
Diluted earnings per share (in dollars per share)	$ (0.44)	$ (1.12)	$ (0.59)	$ 0.09
Weighted-average shares outstanding
Basic (in shares)	133.8	136.5	133.5	136.3
Diluted (in shares)	133.8	137.6	133.5	137.5

XML

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (58.9)	$ (154.6)	$ (78.5)	$ 12.4
Other comprehensive income (loss):
Foreign currency translation adjustments	(228.3)	86.5	(307.5)	81.0
Change in fair value of derivative financial instruments, net of tax	(23.8)	(2.3)	(31.1)	(12.4)
Change in post-retirement and pension liability, net of tax	(0.8)	(1.2)	(2.2)	(4.3)
Other comprehensive income (loss), net of tax	(252.9)	83.0	(340.8)	64.3
Comprehensive income (loss)	$ (311.8)	$ (71.6)	$ (419.3)	$ 76.7

XML

Condensed Consolidated Balance Sheets - USD ($) shares in Millions, $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents	$ 2,078.1	$ 631.5
Accounts receivable, net of allowance for credit losses of $7.6 and $6.5, respectively	686.2	593.5
Inventories	1,092.5	1,059.4
Prepaid expenses and other current assets	355.7	182.2
Current assets held for sale	13.4	666.9
Total current assets	4,225.9	3,133.5
Property, plant and equipment, net	842.8	864.6
Operating lease assets	170.6	154.7
Goodwill and indefinite-lived intangible assets	3,036.9	3,102.7
Definite-lived intangible assets, net	2,226.2	2,481.5
Deferred income taxes	40.2	40.6
Non-current assets held for sale	0.0	1,364.0
Other non-current assets	373.3	346.8
Total non-current assets	6,690.0	8,354.9
Total assets	10,915.9	11,488.4
Liabilities and Shareholders’ Equity
Accounts payable	405.6	451.6
Payroll and related taxes	106.6	152.9
Accrued customer programs	140.1	128.5
Other accrued liabilities	339.9	183.1
Accrued income taxes	353.0	9.0
Current indebtedness	629.4	37.3
Current liabilities held for sale	29.2	419.6
Total current liabilities	2,003.8	1,382.0
Long-term debt, less current portion	2,920.9	3,527.6
Deferred income taxes	243.0	276.2
Non-current liabilities held for sale	0.0	108.3
Other non-current liabilities	565.8	539.2
Total non-current liabilities	3,729.7	4,451.3
Total liabilities	5,733.5	5,833.3
Commitments and contingencies - Refer to Note 16
Controlling interests:
Preferred shares, $0.0001 par value per share, 10 shares authorized	0.0	0.0
Ordinary shares, €0.001 par value per share, 10,000 shares authorized	7,064.8	7,118.2
Accumulated other comprehensive income	54.2	395.0
Retained earnings (accumulated deficit)	(1,936.6)	(1,858.1)
Total shareholders’ equity	5,182.4	5,655.1
Total liabilities and shareholders' equity	$ 10,915.9	$ 11,488.4
Supplemental Disclosures of Balance Sheet Information
Preferred shares, issued and outstanding (in shares)	0.0	0.0
Ordinary shares, issued and outstanding (in shares)	133.7	133.1

XML

Condensed Consolidated Balance Sheets (Parenthetical) $ in Millions	Oct. 02, 2021 USD ($) $ / shares shares	Oct. 02, 2021 € / shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2020 € / shares
Statement of Financial Position [Abstract]
Allowance for credit losses | $	$ 7.6		$ 6.5
Stockholders' Equity:
Preferred shares, par value (in dollars per share) | $ / shares	$ 0.0001		$ 0.0001
Preferred shares, authorized (shares)	10,000,000		10,000,000
Ordinary shares, par value (in EUR per share) | € / shares		€ 0.001		€ 0.001
Ordinary shares, authorized (shares)	10,000,000,000		10,000,000,000

XML

Condensed Consolidated Statements of Shareholders' Equity Statement - USD ($) $ in Millions	Total	Ordinary Shares Issued	Accumulated Other Comprehensive Income	Retained Earnings (Accumulated Deficit)
Beginning balance (shares) at Dec. 31, 2019		136,100,000
Balance, beginning at Dec. 31, 2019	$ 5,803.8	$ 7,359.9	$ 139.4	$ (1,695.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	106.4			106.4
Other comprehensive loss	(103.5)		(103.5)
Restricted stock plan (shares)		300,000
Compensation for stock options	0.8	$ 0.8
Compensation for restricted stock	15.4	15.4
Cash dividends	(30.9)	$ (30.9)
Shares withheld for payment of employees' withholding tax liability (shares)		(100,000)
Shares withheld for payment of employees' withholding tax liability	(5.6)	$ (5.6)
Ending balance (shares) at Mar. 28, 2020		136,300,000
Balance, ending at Mar. 28, 2020	5,786.4	$ 7,339.6	35.9	(1,589.1)
Beginning balance (shares) at Dec. 31, 2019		136,100,000
Balance, beginning at Dec. 31, 2019	5,803.8	$ 7,359.9	139.4	(1,695.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	12.4
Other comprehensive loss	$ 64.3
Minority share purchase (shares)	0
Ending balance (shares) at Sep. 26, 2020		136,500,000
Balance, ending at Sep. 26, 2020	$ 5,820.3	$ 7,299.7	203.7	(1,683.1)
Beginning balance (shares) at Mar. 28, 2020		136,300,000
Balance, beginning at Mar. 28, 2020	5,786.4	$ 7,339.6	35.9	(1,589.1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	60.6			60.6
Other comprehensive loss	84.8		84.8
Restricted stock plan (shares)		300,000
Compensation for stock options	0.4	$ 0.4
Compensation for restricted stock	13.1	13.1
Cash dividends	(31.0)	$ (31.0)
Shares withheld for payment of employees' withholding tax liability (shares)		(100,000)
Shares withheld for payment of employees' withholding tax liability	(3.9)	$ (3.9)
Ending balance (shares) at Jun. 27, 2020		136,500,000
Balance, ending at Jun. 27, 2020	5,910.4	$ 7,318.2	120.7	(1,528.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(154.6)			(154.6)
Other comprehensive loss	83.0		83.0
Compensation for stock options	0.4	0.4
Compensation for restricted stock	13.8	13.8
Cash dividends	(31.1)	(31.1)
Shares withheld for payment of employees' withholding tax liability	$ (0.5)	$ (0.5)
Minority share purchase (shares)	0	0
Minority share purchase	$ (1.1)	$ (1.1)
Ending balance (shares) at Sep. 26, 2020		136,500,000
Balance, ending at Sep. 26, 2020	5,820.3	$ 7,299.7	203.7	(1,683.1)
Beginning balance (shares) at Dec. 31, 2020		133,100,000
Balance, beginning at Dec. 31, 2020	5,655.1	$ 7,118.2	395.0	(1,858.1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	38.1			38.1
Other comprehensive loss	(118.3)		(118.3)
Restricted stock plan (shares)		600,000
Compensation for stock options	0.4	$ 0.4
Compensation for restricted stock	24.6	24.6
Cash dividends	(32.6)	$ (32.6)
Shares withheld for payment of employees' withholding tax liability (shares)		(200,000)
Shares withheld for payment of employees' withholding tax liability	(9.3)	$ (9.3)
Ending balance (shares) at Apr. 03, 2021		133,500,000
Balance, ending at Apr. 03, 2021	5,558.0	$ 7,101.3	276.7	(1,820.0)
Beginning balance (shares) at Dec. 31, 2020		133,100,000
Balance, beginning at Dec. 31, 2020	5,655.1	$ 7,118.2	395.0	(1,858.1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(78.5)
Other comprehensive loss	$ (340.8)
Minority share purchase (shares)	0
Ending balance (shares) at Oct. 02, 2021		133,700,000
Balance, ending at Oct. 02, 2021	$ 5,182.4	$ 7,064.8	54.2	(1,936.6)
Beginning balance (shares) at Apr. 03, 2021		133,500,000
Balance, beginning at Apr. 03, 2021	5,558.0	$ 7,101.3	276.7	(1,820.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(57.7)			(57.7)
Other comprehensive loss	30.4		30.4
Restricted stock plan (shares)		100,000
Compensation for stock options	0.2	$ 0.2
Compensation for restricted stock	13.9	13.9
Cash dividends	(32.5)	$ (32.5)
Shares withheld for payment of employees' withholding tax liability (shares)		0
Shares withheld for payment of employees' withholding tax liability	(1.2)	$ (1.2)
Ending balance (shares) at Jul. 03, 2021		133,600,000
Balance, ending at Jul. 03, 2021	5,511.1	$ 7,081.7	307.1	(1,877.7)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(58.9)			(58.9)
Other comprehensive loss	(252.9)		(252.9)
Restricted stock plan (shares)		200,000
Compensation for stock options	0.2	$ 0.2
Compensation for restricted stock	18.5	18.5
Cash dividends	(32.7)	$ (32.7)
Shares withheld for payment of employees' withholding tax liability (shares)		(100,000)
Shares withheld for payment of employees' withholding tax liability	$ (2.9)	$ (2.9)
Minority share purchase (shares)	0
Ending balance (shares) at Oct. 02, 2021		133,700,000
Balance, ending at Oct. 02, 2021	$ 5,182.4	$ 7,064.8	$ 54.2	$ (1,936.6)

XML

Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares	3 Months Ended
	Oct. 02, 2021	Jul. 03, 2021	Apr. 03, 2021	Sep. 26, 2020	Jun. 27, 2020	Mar. 28, 2020
Statement of Stockholders' Equity [Abstract]
Dividends paid (in dollars per share)	$ 0.24	$ 0.24	$ 0.24	$ 0.23	$ 0.23	$ 0.23

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020
Cash Flows From (For) Operating Activities
Net income (loss)	$ (78,500)	$ 12,400
Adjustments to derive cash flows:
Depreciation and amortization	238,800	284,700
Loss (Gain) on sale of business	(63,900)	18,600
Share-based compensation	50,200	43,900
Impairment charges	162,100	202,400
Change in financial assets	0	(25,900)
Loss on extinguishment of debt	0	20,000
Restructuring charges	11,800	1,900
Deferred income taxes	(24,000)	25,700
Amortization of debt premium	(2,700)	(1,700)
Other non-cash adjustments, net	9,200	(12,000)
Subtotal	303,000	570,000
Increase (decrease) in cash due to:
Accounts receivable	(182,300)	106,400
Inventories	(70,200)	(93,200)
Prepaid expenses	(1,800)	(23,800)
Accounts payable	(10,400)	15,200
Payroll and related taxes	(60,600)	(2,200)
Accrued customer programs	13,400	(35,500)
Accrued liabilities	(5,800)	(16,000)
Accrued income taxes	313,200	(9,000)
Other, net	(36,800)	13,900
Subtotal	(41,300)	(44,200)
Net cash from (for) operating activities	261,700	525,800
Cash Flows From (For) Investing Activities
Proceeds from royalty rights	2,800	3,200
Purchase of equity method investment	0	(15,000)
Acquisitions of businesses, net of cash acquired	0	(106,000)
Asset acquisitions	(70,600)	(34,100)
Additions to property, plant and equipment	(110,400)	(104,300)
Net proceeds from sale of business	1,493,100	187,800
Other investing, net	2,800	8,100
Net cash from (for) investing activities	1,317,700	(60,300)
Cash Flows From (For) Financing Activities
Issuances of long-term debt	0	743,800
Payments on long-term debt	0	(590,000)
Borrowings (repayments) of revolving credit agreements and other financing, net	(5,800)	100
Deferred financing fees	0	(6,700)
Premiums on early debt retirement	0	(19,000)
Cash dividends	(97,800)	(93,000)
Other financing, net	(17,100)	(14,900)
Net cash from (for) financing activities	(120,700)	20,300
Effect of exchange rate changes on cash and cash equivalents	(12,000)	9,300
Net increase (decrease) in cash and cash equivalents	1,446,700	495,100
Cash and cash equivalents of continuing operations, beginning of period	631,500	344,500
Cash and cash equivalents held for sale, beginning of period	10,000	9,800
Less cash and cash equivalents held for sale, end of period	(10,100)	(9,200)
Cash and cash equivalents of continuing operations, end of period	$ 2,078,100	$ 840,200

XML

Summary of Significant Accounting Policies

9 Months Ended

Oct. 02, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General Information

The Company

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

Our vision is to make lives better by bringing Quality, Affordable Self-Care Products that consumers trust everywhere they are sold. We are a leading provider of over-the-counter ("OTC") health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

On March 1, 2021, we announced a definitive agreement to sell our generic RX Pharmaceuticals business ("RX business") to Altaris Capital Partners, LLC ("Altaris"). On July 6, 2021, we completed the sale of the RX business. The financial results of our RX business, which were previously reported in our Prescription Pharmaceuticals ("RX") segment, have been classified as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented. The assets and liabilities of our RX business are reflected as assets and liabilities held for sale in the Condensed Consolidated Balance Sheets for all periods presented prior to the sale. Refer to Note 8 for additional information regarding discontinued operations. Unless otherwise noted, amounts and disclosures throughout the Notes to the unaudited Condensed Consolidated Financial Statements relate to our continuing operations.

Segment Reporting

Our reporting and operating segments are as follows:

•Consumer Self-Care Americas ("CSCA") comprises our consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the U.S., Mexico and Canada.

•Consumer Self-Care International ("CSCI") comprises our consumer self-care business primarily branded in Europe and Australia, our store brand business in the United Kingdom and parts of Europe and Asia, and our liquid licensed products business in the United Kingdom until it was disposed on June 19, 2020.

Allowance for Credit Losses

Expected credit losses on trade receivables and contract assets are measured collectively by geographic location. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and for reasonable and supportable forecasts. Historical credit loss experience provides the primary basis for estimation of expected credit losses. Adjustments to historical loss information may be made for

significant changes in a geographic location’s economic conditions. Receivables that do not share risk characteristics are evaluated on an individual basis. These receivables are not included in the collective evaluation.

The allowance for credit losses is a valuation account that is deducted from the instruments’ cost basis to present the net amount expected to be collected. Trade receivables and contract assets are charged off against the allowance when the balance is no longer deemed collectible.

The following table presents the allowance for credit losses activity (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Beginning balance	$	7.7	$	5.5	$	6.5	$	6.0
Provision for credit losses, net	0.1		0.6		3.7		1.1
Receivables written-off	—		(0.4)		(0.7)		(1.5)
Transfer to held for sale	—		—		(1.4)		—
Currency translation adjustment	(0.2)		0.1		(0.5)		0.2
Ending balance	$	7.6	$	5.8	$	7.6	$	5.8

XML

Revenue Recognition

9 Months Ended

Oct. 02, 2021

Revenue from Contract with Customer [Abstract]

Revenue Recognition

REVENUE RECOGNITION

Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.

Disaggregation of Revenue

We generated net sales in the following geographic locations(1) (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
U.S.	$	657.4	$	638.7	$	1,859.0	$	1,913.4
Europe(2)	334.5		326.6		1,037.6		1,011.0
All other countries(3)	50.8		37.7		137.2		110.6
Total net sales	$	1,042.7	$	1,003.0	$	3,033.8	$	3,035.0

(1) Derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $7.6 million and $17.4 million for the three and nine months ended October 2, 2021 respectively, and $10.8 million and $22.3 million for the three and nine months ended September 26, 2020, respectively.

(3) Includes net sales generated primarily in Mexico, Australia and Canada.

Product Category

The following is a summary of our net sales by category (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
CSCA(1)
Upper respiratory	$	121.9	$	117.1	$	345.8	$	397.2
Digestive health	110.6		111.8		344.0		339.9
Pain and sleep-aids	108.4		102.6		292.9		325.7
Nutrition	105.3		100.3		293.3		291.5
Oral self-care	76.7		81.9		227.4		202.5
Healthy lifestyle	72.9		86.9		214.9		256.2
Skincare and personal hygiene	56.0		51.4		165.9		145.4
Vitamins, minerals, and supplements	8.1		6.3		24.3		19.1
Other CSCA(2)	34.3		5.7		48.5		14.7
Total CSCA	694.2		664.0		1,957.0		1,992.2
CSCI
Skincare and personal hygiene	88.5		83.1		307.9		275.4
Upper respiratory	58.7		62.3		144.2		191.9
Vitamins, minerals, and supplements	54.7		52.9		162.8		139.9
Pain and sleep-aids	52.1		49.0		148.4		136.0
Healthy lifestyle	42.2		40.6		140.5		124.7
Oral self-care	24.4		25.2		72.4		68.8
Digestive health	10.1		6.8		28.3		17.9
Other CSCI(3)	17.8		19.1		72.3		88.2
Total CSCI	348.5		339.0		1,076.8		1,042.8
Total net sales	$	1,042.7	$	1,003.0	$	3,033.8	$	3,035.0

(1) Includes net sales from our OTC contract manufacturing business.

(2) Consists primarily of diagnostic and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

(3) Consists primarily of our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $80.8 million and $213.7 million for the three and nine months ended October 2, 2021, respectively and $76.3 million and $190.0 million for the three and nine months ended September 26, 2020, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):

	Balance Sheet Location	October 2, 2021		December 31, 2020
Short-term contract assets	Prepaid expenses and other current assets	$	42.2	$	19.7

XML

Acquisitions and Divestitures

9 Months Ended

Oct. 02, 2021

Business Combination and Asset Acquisition [Abstract]

Acquisitions and Divestitures

ACQUISITIONS AND DIVESTITURES

Acquisitions During the Nine Months Ended October 2, 2021

Héra SAS (“HRA Pharma”) Acquisition Agreement

On September 8, 2021, we and our wholly-owned subsidiary Habsont Unlimited Company (the "Purchaser"), entered into a Put Option Agreement to acquire certain holding companies holding all of the outstanding equity interests of HRA Pharma from funds affiliated with private equity firms Astorg and Goldman Sachs Asset Management (collectively, the "Sellers"). Pursuant to the Put Option Agreement, following completion of the works council consultation process required under French law, the selling shareholders exercised their put option right under the Put Option Agreement and, on October 20, 2021, the Company, the Purchaser and the Sellers entered into a Securities Sale Agreement in the form previously agreed by the parties (the “Purchase Agreement”). Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, the Purchaser has agreed to acquire certain holding companies holding all of the outstanding equity interests of HRA from the Sellers for cash. The transaction values HRA at approximately €1.8 billion, or approximately $2.1 billion as of the date of the Put Option Agreement, on an enterprise value basis and using a lockbox mechanism set forth in the Purchase Agreement. The proposed final transaction is expected to close in the first half of 2022, subject to the satisfaction of customary closing conditions, including regulatory approvals. We intend to pay the purchase price using a combination of cash on hand and, depending upon market conditions, either funds available under our current credit facility or funds from new debt financing. HRA Pharma is one of the fastest growing OTC companies globally, with three category-leading self-care brands in blister care (Compeed®), women’s health (ellaOne®) and scar care (Mederma®), and brings expertise in prescription-to-OTC switches. This acquisition would strengthen our presence in Europe, improve our financial profile and margins, and will complete our transformation to a consumer self-care company. Operating results are expected to be reported within both our CSCA and CSCI segments.

Acquisitions Accounted for as a Business Combination During the Year Ended December 31, 2020

Eastern European OTC Dermatological Brands Acquisition

On October 30, 2020, we acquired three Eastern European OTC dermatological brands ("Eastern European Brands"), skincare brands Emolium® and Iwostin® and hair loss treatment brand Loxon®, from Sanofi. The transaction closed for €53.3 million ($62.3 million). We capitalized $52.5 million as brand-named intangible assets and allocated the remainder of the purchase price to goodwill, inventory, customer relationships and deferred tax assets.

The addition of these market-leading OTC brands complements our already robust skincare portfolio and adds scale to our Eastern European business. The acquisition also serves as another step for Perrigo’s CSCI growth plans and provides new opportunities for self-care revenue synergy in the European markets. The operating results of the brands are reported within our CSCI segment. The acquisition of the Eastern European Brands was accounted for as a business combination and has been reported in our Consolidated Statements of Operations as of the acquisition date.

The goodwill arising from the acquisition consists largely of the assembled workforce, and the cost and revenue synergies expected from integrating the business into the CSCI segment. The goodwill was allocated to our CSCI segment, none of which is deductible for income tax purposes. The definite-lived intangible assets acquired consisted of brands and customer relationships which are being amortized over a weighted average useful life of approximately 18.8 years. Both the brands and customer relationships were valued using the multi-period excess earnings method. Significant judgment was applied in estimating the fair value of the intangible assets acquired, which involved the use of significant estimates and assumptions with respect to the timing and amounts of cash flow projections, including revenue growth rates, projected profit margins, and discount rates. The opening balance sheet is final.

Oral Care Assets of High Ridge Brands

On April 1, 2020, we acquired the oral care assets of High Ridge Brands ("Dr. Fresh") for total purchase consideration of $113.0 million, subject to customary adjustments, including a working capital settlement. After such adjustments as of December 31, 2020, total cash consideration paid was $106.2 million net of $2.0 million that we allocated as prepayment of contract consideration for transitional services to be received related to the transaction.

This acquisition includes the children’s oral care value brand, Firefly®, in addition to the REACH® and Dr. Fresh® brands, and a licensing portfolio. The U.S. operations, which represent a significant portion of the business, are reported in our CSCA segment and the non-U.S. operations are reported in our CSCI segment.

The following table summarizes the consideration paid for Dr. Fresh and the amounts of the assets acquired and liabilities assumed (in millions):

	Oral Care Assets of High Ridge Brands (Dr. Fresh)
Purchase price paid	$	106.2
Assets acquired:
Accounts receivable	13.1
Inventories	22.2
Prepaid expenses and other current assets	0.4
Property, plant and equipment, net	0.7
Operating lease assets	2.6
Goodwill	17.2
Distribution and license agreements and supply agreements	$	2.2
Developed product technology, formulations, and product rights	0.1
Customer relationships and distribution networks	20.6
Trademarks, trade names, and brands	43.2
Total intangible assets	$	66.1
Total assets	$	122.3
Liabilities assumed:
Accounts payable	$	6.1
Other accrued liabilities	3.8
Payroll and related taxes	0.7
Accrued customer programs	3.0
Other non-current liabilities	2.5
Total liabilities	$	16.1
Net assets acquired	$	106.2

The goodwill of $17.2 million arising from the acquisition consists largely of the anticipated growth from new product sales, sales to new customers, the assembled workforce, and the synergies expected from combining the operations of Dr. Fresh into Perrigo. The goodwill is attributable to our CSCA segment and is tax deductible for income tax purposes. The definite-lived intangible assets acquired consisted of trademarks and trade names, license agreements, and customer relationships, which are being amortized over a weighted average useful life of approximately 17.8 years. Customer relationships were valued using the multi-period excess earnings method. Trademarks and trade names and developed technology were valued using the relief from royalty method. Significant judgment was applied in estimating the fair value of the intangible assets acquired, which involved the use of significant estimates and assumptions with respect to the timing and amounts of cash flow projections, including revenue growth rates, projected profit margins, and discount rates. The opening balance sheet is final.

Pro Forma Impact of Business Combinations

The following table presents unaudited pro forma information as if the acquisitions of Dr. Fresh and the Eastern European Brands occurred on January 1, 2019, and had been combined with the results reported in our Condensed Consolidated Statements of Operations for all periods presented (in millions):

	Three Months Ended		Nine Months Ended
(Unaudited)	September 26, 2020		September 26, 2020
Net sales	$	1,009.2	$	3,083.2
Income from continuing operations	$	28.5	$	108.7

The unaudited pro forma information is presented for information purposes only and is not indicative of the results that would have been achieved if the acquisition had taken place at such time. The unaudited pro forma information presented above includes adjustments primarily for amortization charges for acquired intangible assets, depreciation of property, plant and equipment that have been revalued, certain acquisition-related charges, and related tax effects.

Acquisitions During the Nine Months Ended September 26, 2020

Dexsil®

On February 13, 2020, we acquired Dexsil®, a silicon supplement brand, from RXW Group Nv, for total cash consideration paid of approximately $8.0 million. The transaction was accounted for as an asset acquisition, in which we capitalized the consideration paid as a brand-named intangible asset. We began amortizing the brand intangible over a 25-year useful life. Operating results attributable to the product are included within our CSCI segment.

Steripod®

On January 3, 2020, we acquired Steripod®, a leading toothbrush accessory brand and innovator in the toothbrush protector market, from Bonfit America Inc. Total consideration paid was $26.0 million. The transaction was accounted for as an asset acquisition, in which we capitalized $25.1 million as a brand-named intangible asset. The remainder of the purchase price was allocated to working capital. We began amortizing the brand intangible asset over a 25-year useful life. Operating results attributable to Steripod® are included within our CSCA segment.     

Divestitures During the Nine Months Ended October 2, 2021

RX business

Refer to Note 8 - Discontinued Operations for details on the sale of the RX business.

Divestitures During the Nine Months Ended September 26, 2020

Rosemont Pharmaceuticals Business

On June 19, 2020, we completed the sale of our U.K.-based Rosemont Pharmaceuticals business, a generic prescription pharmaceuticals manufacturer focused on liquid medicines, to a U.K.-headquartered private equity firm for cash consideration of £155.6 million (approximately $195.0 million). The sale resulted in a pre-tax loss of $17.4 million during the three and six months ended June 27, 2020, $1.3 million during the three months ended September 26, 2020, and $2.4 million during the three months ended December 31, 2020. These losses were recorded in our CSCI segment in Other (income) expense, net on the Consolidated Statements of Operations. These losses included professional fees and a $46.4 million write-off of foreign currency translation adjustment from Accumulated other comprehensive income.

XML

Goodwill and Intangible Assets

9 Months Ended

Oct. 02, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):

	December 31, 2020		Purchase accounting adjustments		Impairments		Currency translation adjustments		October 2, 2021
CSCA(1)	$	1,905.0	$	2.4	$	(6.1)	$	(0.7)	$	1,900.6
CSCI(2)	1,190.7		(2.4)		—		(57.5)		1,130.8
Total goodwill	$	3,095.7	$	—	$	(6.1)	$	(58.2)	$	3,031.4

(1) We had no accumulated goodwill impairments as of December 31, 2020 and $6.1 million as of October 2, 2021.

(2) We had accumulated goodwill impairments of $868.4 million as of December 31, 2020 and October 2, 2021.

CSCA Reporting Unit Goodwill

On May 18, 2021, we announced a definitive agreement to sell our Mexico and Brazil-based OTC businesses ("Latin American businesses"), both within our CSCA segment, to Advent International. As a result, we prepared a goodwill impairment test. We determined the carrying value of this business exceeded the fair value and recorded an impairment of $6.1 million within our CSCA segment during the three months ended July 3, 2021 (refer to Note 6 and Note 9).

Intangible Assets

Intangible assets and related accumulated amortization consisted of the following (in millions):

	October 2, 2021				December 31, 2020
	Gross		Accumulated Amortization		Gross		Accumulated Amortization
Indefinite-lived intangibles:
Trademarks, trade names, and brands	$	3.6	$	—	$	4.3	$	—
In-process research and development	1.9		—		2.7		—
Total indefinite-lived intangibles	$	5.5	$	—	$	7.0	$	—
Definite-lived intangibles:
Distribution and license agreements and supply agreements	$	72.8	$	56.1	$	74.8	$	55.4
Developed product technology, formulations, and product rights	300.7		187.6		303.3		177.3
Customer relationships and distribution networks	1,844.1		872.2		1,920.5		823.7
Trademarks, trade names, and brands	1,506.0		381.5		1,581.5		342.2
Non-compete agreements	2.1		2.1		2.9		2.9
Total definite-lived intangibles	$	3,725.7	$	1,499.5	$	3,883.0	$	1,401.5
Total intangible assets	$	3,731.2	$	1,499.5	$	3,890.0	$	1,401.5

We recorded amortization expense of $52.2 million and $159.0 million for the three and nine months ended October 2, 2021, respectively, and $53.3 million and $157.5 million for the three and nine months ended September 26, 2020, respectively.

XML

Inventories

9 Months Ended

Oct. 02, 2021

Inventory Disclosure [Abstract]

Inventories

INVENTORIES

Major components of inventory were as follows (in millions):

 

	October 2, 2021		December 31, 2020
Finished goods	$	617.1	$	574.1
Work in process	240.9		220.4
Raw materials	234.5		264.9
Total inventories	$	1,092.5	$	1,059.4

XML

Fair Value Measurements

9 Months Ended

Oct. 02, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS

The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):

	October 2, 2021						December 31, 2020
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Measured at fair value on a recurring basis:
Assets:
Investment securities	$	1.5	$	—	$	—	$	2.5	$	—	$	—
Foreign currency forward contracts	—		5.8		—		—		9.8		—
Cross-currency swap	—		—		—		—		6.3		—
Foreign currency option contracts	—		13.3		—		—		—		—
Total assets	$	1.5	$	19.1	$	—	$	2.5	$	16.1	$	—
Liabilities:
Cross-currency swap	$	—	$	24.1	$	—	$	—	$	—	$	—
Foreign currency forward contracts	—		1.8		—		—		7.9		—
Total liabilities	$	—	$	25.9	$	—	$	—	$	7.9	$	—
Measured at fair value on a non-recurring basis:
Liabilities
Liabilities held for sale, net(1)	$	—	$	—	$	15.8	$	—	$	—	$	—
Total liabilities	$	—	$	—	$	15.8	$	—	$	—	$	—

(1)     We measured the net assets held for sale for impairment purposes and recorded a total impairment of $161.2 million, resulting in a net liability held for sale balance (refer to Note 9).

There were no transfers within Level 3 fair value measurements during the three and nine months ended October 2, 2021 or the year ended December 31, 2020.

Foreign Currency Option Contracts

We valued the foreign currency option contract derivatives using an extension of the Black-Scholes Option Pricing Model ("BSOPM") which uses the strike price and expiry as inputs obtained from the contractual agreement. Additionally, the model uses risk-free interest rates, forward currency quotes, and option volatility assumptions obtained from the observable market.

Royalty Pharma Contingent Milestone Receipts

During the year ended December 31, 2020, Royalty Pharma payments from Biogen for Tysabri® sales, as defined in the agreement between the parties, did not exceed the 2020 global net sales threshold. Therefore, we were not entitled to receive the remaining contingent milestone payment. As of December 31, 2020, there were no contingent milestone payments outstanding.

The table below summarizes the change in fair value of the Royalty Pharma contingent milestone (in millions):

	Three Months Ended		Nine Months Ended
	September 26, 2020		September 26, 2020
Beginning balance	$	99.0	$	95.3
Change in fair value	22.2		25.9
Ending balance	$	121.2	$	121.2

We valued our contingent milestone payment from Royalty Pharma using a modified BSOPM. Key inputs in the BSOPM are the estimated volatility and rate of return of royalties on global net sales of Tysabri® that are received by Royalty Pharma until the contingent milestones are resolved. As of September 26, 2020, volatility and the estimated fair value of the milestones had a positive relationship such that higher volatility translates to a higher estimated fair value of the contingent milestone payments. Rate of return and the estimated fair value of the milestones had an inverse relationship, such that a lower rate of return correlates with a higher estimated fair value of the contingent milestone payments. We assessed volatility and rate of return inputs quarterly by analyzing certain market volatility benchmarks and the risk associated with Royalty Pharma achieving the underlying projected royalties. The table below represents the volatility and rate of return:

	Three Months Ended
	September 26, 2020
Volatility	30.0	%
Rate of return	6.84	%

During the three and nine months ended September 26, 2020, the fair value of the Royalty Pharma contingent milestone payment related to 2020 increased by $22.2 million and $25.9 million, respectively, to $121.2 million, driven by higher projected global net sales of Tysabri® compared to the estimates in the prior period, and the estimated probability of achieving the earn-out. As of December 31, 2020, there were no contingent milestone payments outstanding and, accordingly, no asset recorded in the Condensed Consolidated Balance Sheet.

Non-recurring Fair Value Measurements

The non-recurring fair values represent only those assets whose carrying values were adjusted to fair value during the reporting period.

Goodwill

During the three months ended July 3, 2021 and nine months ended October 2, 2021, as a result of our definitive agreement to sell our Latin American businesses, we prepared a goodwill impairment test. We determined the carrying value of this business exceeded the fair value and recorded an impairment in the CSCA segment (refer to Note 4).

Assets (liabilities) held for sale, net

During the three months ended July 3, 2021 and nine months ended October 2, 2021, as a result of our definitive agreement to sell our Latin American businesses, we prepared an impairment test on the net assets held for sale related to this business. We determined the carrying value of the net assets held for sale exceed the fair

value less cost to sell and recorded an impairment in the CSCA segment (refer to Note 9).

Fixed Rate Long-term Debt    

Our fixed rate long-term debt consisted of the following (in millions):

	October 2, 2021				December 31, 2020
	Level 1		Level 2		Level 1		Level 2
Public Bonds
Carrying Value (excluding discount)	$	2,760.0	$	—	$	2,760.0	$	—
Fair value	$	2,906.0	$	—	$	3,031.1	$	—
Private placement note
Carrying value (excluding premium)	$	—	$	156.6	$	—	$	164.9
Fair value	$	—	$	166.9	$	—	$	177.5

The fair values of our public bonds for all periods were based on quoted market prices. The fair values of our private placement note for all periods were based on interest rates offered for borrowings of a similar nature and remaining maturities.

The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt, revolving credit agreements, promissory notes related to our equity method investment in Kazmira, and variable rate long-term debt, approximate their fair value.

XML

Investments

9 Months Ended

Oct. 02, 2021

Investments [Abstract]

Investments

INVESTMENTS

The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):

Measurement Category	Balance Sheet Location	October 2, 2021		December 31, 2020
Fair value method	Prepaid expenses and other current assets	$	1.5	$	2.5
Fair value method(1)	Other non-current assets	$	1.8	$	1.9
Equity method	Other non-current assets	$	69.0	$	69.8

(1)     Measured at fair value using the Net Asset Value practical expedient.

The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):

		Three Months Ended				Nine Months Ended
Measurement Category	Income Statement Location	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Fair value method	Other (income) expense, net	$	—	$	(0.4)	$	0.9	$	2.2
Equity method	Other (income) expense, net	$	—	$	(1.1)	$	0.8	$	(2.6)

XML

Discontinued Operations

9 Months Ended

Oct. 02, 2021

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

DISCONTINUED OPERATIONS

Our discontinued operations primarily consist of our RX segment, which held our prescription pharmaceuticals business in the U.S. and our pharmaceuticals and diagnostic businesses in Israel (collectively, the “RX business”).

On March 1, 2021, we announced a definitive agreement to sell our RX business to Altaris. On July 6, 2021, we completed the sale of the RX business for aggregate consideration of $1.55 billion. The consideration includes a $53.3 million reimbursement related to an ANDA for a generic topical lotion which Altaris is required to deliver in

cash to Perrigo pursuant to the terms of the Agreement. The sale resulted in a pre-tax gain of $63.9 million recorded in Other (income) expense, net on the Statement of Operations for discontinued operations. The gain included a $160.0 million increase from the write-off of foreign currency translation adjustment from Accumulated other comprehensive income and a decrease from professional fees. The transaction gain is subject to final settlements under the Agreement, which we expect to finalize in the fourth quarter of 2021.

As of March 1, 2021, we determined that the RX business met the criteria to be classified as a discontinued operation and, as a result, its historical financial results have been reflected in our consolidated financial statements as a discontinued operation and its assets and liabilities have been classified as held for sale. We ceased recording depreciation and amortization on the RX business assets from March 1, 2021. We have not allocated any general corporate overhead to the discontinued operation.

Under the terms of the agreement, we will provide transition services for up to 24 months after the close of the transaction and we entered into a reciprocal supply agreement pursuant to which Perrigo will supply certain products to the RX business and the RX business will supply certain products to Perrigo. The supply agreements have a term of four years, extendable up to seven years by the party who is the purchaser of the products under such agreement. We also extended distribution rights to the RX business for certain OTC products owned and manufactured by Perrigo that may be fulfilled through pharmacy channels, in return for a share of the net profits.

During the three and nine months ended October 2, 2021, we recognized $3.6 million of income related to the transition services agreement ("TSA") in Other operating expense (income); $29.4 million of product sales and royalty income in Net sales related to the supply and distribution agreements with the RX business; and we purchased $9.5 million of inventories related to the supply arrangement with the RX business. No payments were made or received related to these agreements during the three and nine months ended October 2, 2021.

Additionally, under the TSA, we net settle any receipts received or payments made on behalf of the RX business’ customers or vendors. As of October 2, 2021, we recorded a receivable in the amount of $36.4 million in Prepaid expenses and other current assets for the reimbursement due to Perrigo.

In the transaction, Perrigo retained certain pre-closing liabilities arising out of antitrust (refer to Note 16 - Contingencies under the header "Price-Fixing Lawsuits") and opioid matters and the Company’s Albuterol recall, subject to, in each case, the buyer's obligation to indemnify the Company for fifty percent of these liabilities up to an aggregate cap on the buyer's obligation of $50.0 million. We have not requested payments from the buyer related to the indemnity of these liabilities during the three and nine months ended October 2, 2021.

Income from discontinued operations, net of tax was as follows (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Net sales	$	0.5	$	210.7	$	405.1	$	738.8
Cost of sales	0.1		149.8		258.4		496.2
Gross profit	0.4		60.9		146.7		242.6
Operating expenses
Distribution	—		3.6		6.1		11.4
Research and development	0.2		11.9		30.8		42.1
Selling	0.1		7.6		16.3		22.3
Administration	4.9		8.7		35.6		23.2
Impairment charges	—		202.4		—		202.4
Restructuring	—		—		—		0.4
Other operating expense (income)	—		0.6		(0.4)		0.8
Total operating expenses	5.2		234.8		88.4		302.6
Operating income (loss)	(4.8)		(173.9)		58.3		(60.0)
Interest expense, net	—		0.7		0.8		3.2
Other (income) expense, net	(63.7)		1.5		(65.5)		(0.7)
Income before income taxes	58.9		(176.1)		123.0		(62.5)
Income tax expense (benefit)	63.9		4.9		38.5		21.5
Income (loss) from discontinued operations, net of tax	$	(5.0)	$	(181.0)	$	84.5	$	(84.0)

During the three and nine months ended October 2, 2021, we incurred $29.1 million and $40.8 million, respectively, of separation costs related to the sale of the RX business. The costs incurred during the three months ended October 2, 2021 included selling costs, which were reported in other (income) expense, net as part of the gain on sale of the RX business. Separation costs incurred in prior periods were included in administration expenses.

Select cash flow information related to discontinued operations was as follows (in millions):

	Nine Months Ended
	October 2, 2021		September 26, 2020
Cash flows from discontinued operations operating activities:
Depreciation and amortization	$	15.3	$	72.4
Impairment charges	—		202.4
Loss (Gain) on sale of business	(63.9)		—
Cash flows from discontinued operations investing activities:
Asset acquisitions	$	(69.7)	$	(0.9)
Additions to property, plant and equipment	(6.6)		(10.0)
Net proceeds from sale of business	1,493.1		—

Asset acquisitions related to discontinued operations consisted of two Abbreviated New Drug Applications ("ANDAs") purchased under a contractual arrangement entered into on May 15, 2015 with a third party that specializes in research and development and obtaining approval for various drug candidates to develop specific products. On December 31, 2020, we purchased an ANDA for a generic topical gel for $16.4 million, which was subsequently paid during the three months ended April 3, 2021 and on March 8, 2021, we purchased an ANDA for a generic topical lotion for $53.3 million. These ANDAs were acquired by Altaris as part of the RX business sale.

The assets and liabilities classified as held for sale related to discontinued operations were as follows (in millions):

	December 31, 2020
Cash and cash equivalents	$	10.0
Accounts receivable, net of allowance for credit losses of $1.1	460.7
Inventories	140.8
Prepaid expenses and other current assets	55.4
Current assets held for sale	666.9
Property, plant and equipment, net	131.4
Operating lease assets	31.3
Goodwill and indefinite-lived intangible assets	681.2
Definite-lived intangible assets, net	492.8
Deferred income taxes	3.6
Other non-current assets	23.7
Non-current assets held for sale	1,364.0
Total assets held for sale	$	2,030.9
Accounts payable	$	92.2
Payroll and related taxes	22.3
Accrued customer programs	237.4
Other accrued liabilities	67.2
Current indebtedness	0.5
Current liabilities held for sale	419.6
Long-term debt, less current portion	0.7
Deferred income taxes	3.1
Other non-current liabilities	104.5
Non-current liabilities held for sale	108.3
Total liabilities held for sale	$	527.9

ASSETS HELD FOR SALE

We classify assets as "held for sale" when, among other factors, management approves and commits to a formal plan of sale with the expectation the sale will be completed within one year. The net assets of the business held for sale are then recorded at the lower of their current carrying value and the fair market value, less costs to sell.

During the three months ended July 3, 2021, management committed to a plan to sell our Latin American businesses; as a result, such assets were classified as held for sale. The assets associated with this business were reported within our CSCA segment. The sale is expected to close in the first half of 2022. At July 3, 2021, we determined the carrying value of the net assets held for sale of this business exceeded their fair value less cost to sell, resulting in an impairment charge of $152.5 million. At October 2, 2021 we recorded an additional impairment charge of $2.6 million resulting in a total impairment charge of $155.1 million. We also recorded a goodwill impairment charge of $6.1 million within our CSCA segment, related to the Latin American businesses (refer to Note 4), resulting in a total impairment charge of $161.2 million.

The assets and liabilities held for sale related to the Latin American businesses were reported within Current assets held for sale and Current liabilities held for sale on the Condensed Consolidated Balance Sheets. Net of impairment charges, the assets and liabilities of the Latin American businesses reported as held for sale as of October 2, 2021 totaled $13.4 million and $29.2 million, respectively.

XML

Discontinued Operations and Disposal Groups

9 Months Ended

Oct. 02, 2021

Discontinued Operations and Disposal Groups [Abstract]

Assets Held for Sale

DISCONTINUED OPERATIONS

Our discontinued operations primarily consist of our RX segment, which held our prescription pharmaceuticals business in the U.S. and our pharmaceuticals and diagnostic businesses in Israel (collectively, the “RX business”).

On March 1, 2021, we announced a definitive agreement to sell our RX business to Altaris. On July 6, 2021, we completed the sale of the RX business for aggregate consideration of $1.55 billion. The consideration includes a $53.3 million reimbursement related to an ANDA for a generic topical lotion which Altaris is required to deliver in

cash to Perrigo pursuant to the terms of the Agreement. The sale resulted in a pre-tax gain of $63.9 million recorded in Other (income) expense, net on the Statement of Operations for discontinued operations. The gain included a $160.0 million increase from the write-off of foreign currency translation adjustment from Accumulated other comprehensive income and a decrease from professional fees. The transaction gain is subject to final settlements under the Agreement, which we expect to finalize in the fourth quarter of 2021.

As of March 1, 2021, we determined that the RX business met the criteria to be classified as a discontinued operation and, as a result, its historical financial results have been reflected in our consolidated financial statements as a discontinued operation and its assets and liabilities have been classified as held for sale. We ceased recording depreciation and amortization on the RX business assets from March 1, 2021. We have not allocated any general corporate overhead to the discontinued operation.

Under the terms of the agreement, we will provide transition services for up to 24 months after the close of the transaction and we entered into a reciprocal supply agreement pursuant to which Perrigo will supply certain products to the RX business and the RX business will supply certain products to Perrigo. The supply agreements have a term of four years, extendable up to seven years by the party who is the purchaser of the products under such agreement. We also extended distribution rights to the RX business for certain OTC products owned and manufactured by Perrigo that may be fulfilled through pharmacy channels, in return for a share of the net profits.

During the three and nine months ended October 2, 2021, we recognized $3.6 million of income related to the transition services agreement ("TSA") in Other operating expense (income); $29.4 million of product sales and royalty income in Net sales related to the supply and distribution agreements with the RX business; and we purchased $9.5 million of inventories related to the supply arrangement with the RX business. No payments were made or received related to these agreements during the three and nine months ended October 2, 2021.

Additionally, under the TSA, we net settle any receipts received or payments made on behalf of the RX business’ customers or vendors. As of October 2, 2021, we recorded a receivable in the amount of $36.4 million in Prepaid expenses and other current assets for the reimbursement due to Perrigo.

In the transaction, Perrigo retained certain pre-closing liabilities arising out of antitrust (refer to Note 16 - Contingencies under the header "Price-Fixing Lawsuits") and opioid matters and the Company’s Albuterol recall, subject to, in each case, the buyer's obligation to indemnify the Company for fifty percent of these liabilities up to an aggregate cap on the buyer's obligation of $50.0 million. We have not requested payments from the buyer related to the indemnity of these liabilities during the three and nine months ended October 2, 2021.

Income from discontinued operations, net of tax was as follows (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Net sales	$	0.5	$	210.7	$	405.1	$	738.8
Cost of sales	0.1		149.8		258.4		496.2
Gross profit	0.4		60.9		146.7		242.6
Operating expenses
Distribution	—		3.6		6.1		11.4
Research and development	0.2		11.9		30.8		42.1
Selling	0.1		7.6		16.3		22.3
Administration	4.9		8.7		35.6		23.2
Impairment charges	—		202.4		—		202.4
Restructuring	—		—		—		0.4
Other operating expense (income)	—		0.6		(0.4)		0.8
Total operating expenses	5.2		234.8		88.4		302.6
Operating income (loss)	(4.8)		(173.9)		58.3		(60.0)
Interest expense, net	—		0.7		0.8		3.2
Other (income) expense, net	(63.7)		1.5		(65.5)		(0.7)
Income before income taxes	58.9		(176.1)		123.0		(62.5)
Income tax expense (benefit)	63.9		4.9		38.5		21.5
Income (loss) from discontinued operations, net of tax	$	(5.0)	$	(181.0)	$	84.5	$	(84.0)

During the three and nine months ended October 2, 2021, we incurred $29.1 million and $40.8 million, respectively, of separation costs related to the sale of the RX business. The costs incurred during the three months ended October 2, 2021 included selling costs, which were reported in other (income) expense, net as part of the gain on sale of the RX business. Separation costs incurred in prior periods were included in administration expenses.

Select cash flow information related to discontinued operations was as follows (in millions):

	Nine Months Ended
	October 2, 2021		September 26, 2020
Cash flows from discontinued operations operating activities:
Depreciation and amortization	$	15.3	$	72.4
Impairment charges	—		202.4
Loss (Gain) on sale of business	(63.9)		—
Cash flows from discontinued operations investing activities:
Asset acquisitions	$	(69.7)	$	(0.9)
Additions to property, plant and equipment	(6.6)		(10.0)
Net proceeds from sale of business	1,493.1		—

Asset acquisitions related to discontinued operations consisted of two Abbreviated New Drug Applications ("ANDAs") purchased under a contractual arrangement entered into on May 15, 2015 with a third party that specializes in research and development and obtaining approval for various drug candidates to develop specific products. On December 31, 2020, we purchased an ANDA for a generic topical gel for $16.4 million, which was subsequently paid during the three months ended April 3, 2021 and on March 8, 2021, we purchased an ANDA for a generic topical lotion for $53.3 million. These ANDAs were acquired by Altaris as part of the RX business sale.

The assets and liabilities classified as held for sale related to discontinued operations were as follows (in millions):

	December 31, 2020
Cash and cash equivalents	$	10.0
Accounts receivable, net of allowance for credit losses of $1.1	460.7
Inventories	140.8
Prepaid expenses and other current assets	55.4
Current assets held for sale	666.9
Property, plant and equipment, net	131.4
Operating lease assets	31.3
Goodwill and indefinite-lived intangible assets	681.2
Definite-lived intangible assets, net	492.8
Deferred income taxes	3.6
Other non-current assets	23.7
Non-current assets held for sale	1,364.0
Total assets held for sale	$	2,030.9
Accounts payable	$	92.2
Payroll and related taxes	22.3
Accrued customer programs	237.4
Other accrued liabilities	67.2
Current indebtedness	0.5
Current liabilities held for sale	419.6
Long-term debt, less current portion	0.7
Deferred income taxes	3.1
Other non-current liabilities	104.5
Non-current liabilities held for sale	108.3
Total liabilities held for sale	$	527.9

ASSETS HELD FOR SALE

We classify assets as "held for sale" when, among other factors, management approves and commits to a formal plan of sale with the expectation the sale will be completed within one year. The net assets of the business held for sale are then recorded at the lower of their current carrying value and the fair market value, less costs to sell.

During the three months ended July 3, 2021, management committed to a plan to sell our Latin American businesses; as a result, such assets were classified as held for sale. The assets associated with this business were reported within our CSCA segment. The sale is expected to close in the first half of 2022. At July 3, 2021, we determined the carrying value of the net assets held for sale of this business exceeded their fair value less cost to sell, resulting in an impairment charge of $152.5 million. At October 2, 2021 we recorded an additional impairment charge of $2.6 million resulting in a total impairment charge of $155.1 million. We also recorded a goodwill impairment charge of $6.1 million within our CSCA segment, related to the Latin American businesses (refer to Note 4), resulting in a total impairment charge of $161.2 million.

The assets and liabilities held for sale related to the Latin American businesses were reported within Current assets held for sale and Current liabilities held for sale on the Condensed Consolidated Balance Sheets. Net of impairment charges, the assets and liabilities of the Latin American businesses reported as held for sale as of October 2, 2021 totaled $13.4 million and $29.2 million, respectively.

XML

Derivative Instruments and Hedging Activities

9 Months Ended

Oct. 02, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES     

Foreign Currency Option Contracts

In September of 2021, to economically hedge the foreign currency exposure associated with the planned payment of the euro-denominated purchase price for HRA Pharma, we entered into two non-designated currency option contracts with a total notional amount of $1.1 billion that will mature in the third quarter of 2022. The company recorded a loss of $12.6 million for the change in fair value of the option contracts during the three months ended October 2, 2021 in Other (income) expense, net. Gains or losses on the derivatives due to changes in the EUR/USD exchange rate prior to the close of the acquisition will be economically offset at closing in the final settlement of the euro-denominated HRA Pharma purchase price. At the time of settlement, we are obligated to pay the deferred financing fee of $25.9 million.

Cross Currency Swaps

On August 15, 2019, we entered into a cross-currency swap designated as a net investment hedge to hedge the EUR currency exposure of our net investment in European operations. This agreement is a contract to exchange floating-rate Euro payments for floating-rate U.S. dollar payments through August 15, 2022. The payments are based on a notional basis of €450.0 million ($498.0 million) and settle quarterly.

Interest Rate Swaps

There were no active designated or non-designated interest rate swaps as of October 2, 2021 or December 31, 2020.

Foreign Currency Forwards

Net Investment Hedge

On June 19, 2020, we entered into a foreign currency forward contract designated as a net investment hedge of the GBP currency exposure of our net investment in certain of our U.K. operations. The hedge had a notional basis of £155.0 million ($194.5 million) and was settled during the three months ended September 26, 2020.

Foreign currency forward contracts were as follows (in millions):

	Notional Amount
	October 2, 2021		December 31, 2020
European Euro (EUR)	$	1,277.7	$	312.6
British Pound (GBP)	121.5		92.3
Israeli Shekel (ILS)	—		94.4
Danish Krone (DKK)	44.8		65.2
Swedish Krona (SEK)	41.9		41.2
Chinese Yuan (CNY)	36.2		49.1
United States Dollar (USD)	21.2		101.5
Polish Zloty (PLZ)	17.9		21.8
Canadian Dollar (CAD)	17.7		36.8
Norwegian Krone (NOK)	9.9		7.8
Switzerland Franc (CHF)	6.9		8.2
Turkish Lira (TRY)	4.7		4.0
Australian Dollar (AUD)	3.8		11.3
Romanian New Leu (RON)	3.7		3.6
Mexican Peso (MPX)	0.6		15.6
Other	2.2		2.3
Total	$	1,610.7	$	867.7

The maximum term of our forward currency exchange contracts is 60 months.

Effects of Derivatives on the Financial Statements

The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects.

The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions):

		Asset Derivatives
		Fair Value
	Balance Sheet Location	October 2, 2021		December 31, 2020
Designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	5.0	$	5.0
Foreign currency forward contracts	Other non-current assets	0.4		0.5
Cross-currency swap	Other non-current assets	—		6.3
Total designated derivatives		$	5.4	$	11.8
Non-designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	0.4	$	4.3
Foreign currency options	Prepaid expenses and other current assets	13.3		—
Total non-designated derivatives		$	13.7	$	4.3

		Liability Derivatives
		Fair Value
	Balance Sheet Location	October 2, 2021		December 31, 2020
Designated derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	0.4	$	5.5
Cross-currency swap	Other accrued liabilities	24.1		—
Total designated derivatives		$	24.5	$	5.5
Non-designated derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	1.4	$	2.4

The following tables summarize the effect of derivative instruments designated as hedging instruments in Accumulated Other Comprehensive Income ("AOCI") (in millions):

	Three Months Ended
	October 2, 2021
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Interest rate swap agreements	$	—	Interest expense, net	$	(0.4)	Interest expense, net	$	—
Foreign currency forward contracts	2.4		Net sales	(0.4)		Net sales	—
			Cost of sales	(0.5)		Cost of sales	—
						Other (income) expense, net	0.2
	$	2.4		$	(1.3)		$	0.2
Net investment hedges:
Cross-currency swap	$	(28.4)				Interest expense, net	$	(0.9)

	Nine Months Ended
	October 2, 2021
Instrument	Amount of Gain/(Loss) Recorded in OCI(1)		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Treasury locks	$	—	Interest expense, net	$	(0.1)	Interest expense, net	$	—
Interest rate swap agreements	—		Interest expense, net	(1.3)		Interest expense, net	—
Foreign currency forward contracts	2.0		Net sales	(2.3)		Net sales	—
			Cost of sales	1.4		Cost of sales	0.4
						Other (income) expense, net	0.6
	$	2.0		$	(2.3)		$	1.0
Net investment hedges:
Cross-currency swap	$	(30.5)				Interest expense, net	$	(2.9)

(1) Net loss of $7.9 million is expected to be reclassified out of AOCI into earnings during the next 12 months.

	Three Months Ended
	September 26, 2020
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Interest rate swap agreements	$	—	Interest expense, net	$	(0.4)	Interest expense, net	$	—
Foreign currency forward contracts	(1.5)		Net sales	(0.1)		Net sales	—
			Cost of sales	1.3		Cost of sales	0.2
	$	(1.5)		$	0.8		$	0.2
Net investment hedges:
Cross-currency swap	$	(0.3)				Interest expense, net	$	0.9
Foreign currency forward contract	(11.7)					Interest expense, net	(0.1)
	$	(12.0)					$	0.8

	Nine Months Ended
	September 26, 2020
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Treasury locks	$	—	Interest expense, net	$	(0.1)	Interest expense, net	$	—
Interest rate swap agreements	—		Interest expense, net	(1.3)		Interest expense, net	—
Foreign currency forward contracts	8.3		Net sales	(0.1)		Net sales	0.1
			Cost of sales	0.3		Cost of sales	0.8
	$	8.3		$	(1.2)		$	0.9
Net investment hedges:
Cross-currency swap	$	(18.6)				Interest expense, net	$	5.6
Foreign currency forward contract	(11.2)					Interest expense, net	(0.1)
	$	(29.8)					$	5.5

The amounts of (income)/expense recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):

		Three Months Ended				Nine Months Ended
Non-Designated Derivatives	Income Statement Location	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Foreign currency forward contracts	Other (income) expense, net	$	(0.1)	$	(0.3)	$	(6.1)	$	(1.3)
	Interest expense, net	0.2		0.9		1.2		2.8
		$	0.1	$	0.6	$	(4.9)	$	1.5
Foreign currency options	Other (income) expense, net	$	12.6	$	—	$	12.6	$	—

The classification and amount of gain/(loss) recognized in earnings on fair value and hedging relationships were as follows (in millions):

	Three Months Ended
	October 2, 2021
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	1,042.7	$	706.3	$	30.9	$	18.5
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(0.4)	$	(0.5)	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	—	$	—	$	0.2
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.4)	$	—

	Nine Months Ended
	October 2, 2021
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	3,033.8	$	1,980.0	$	94.5	$	20.4
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(2.3)	$	1.4	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	0.4	$	—	$	0.6
Treasury locks
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.1)	$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(1.3)	$	—

	Three Months Ended
	September 26, 2020
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	1,003.0	$	633.3	$	33.3	$	(1.0)
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(0.1)	$	1.3	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	0.2	$	—	$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.4)	$	—

	Nine Months Ended
	September 26, 2020
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	3,035.0	$	1,924.5	$	94.3	$	17.9
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(0.1)	$	0.3	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	0.1	$	0.8	$	—	$	—
Treasury locks
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.1)	$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(1.3)	$	—

XML

Leases

9 Months Ended

Oct. 02, 2021

Leases [Abstract]

Leases

LEASES

The balance sheet locations of our lease assets and liabilities were as follows (in millions):

Assets	Balance Sheet Location	October 2, 2021		December 31, 2020
Operating	Operating lease assets	$	170.6	$	154.7
Finance	Other non-current assets	29.5		29.8
Total		$	200.1	$	184.5

Liabilities	Balance Sheet Location	October 2, 2021		December 31, 2020
Current
Operating	Other accrued liabilities	$	27.2	$	28.3
Finance	Current indebtedness	5.1		6.7
Non-Current
Operating	Other non-current liabilities	148.9		132.5
Finance	Long-term debt, less current portion	22.1		20.2
Total		$	203.3	$	187.7

The below tables show our lease assets and liabilities by reporting segment (in millions):

	Assets
	Operating				Financing
	October 2, 2021		December 31, 2020		October 2, 2021		December 31, 2020
CSCA	$	100.8	$	75.9	$	15.7	$	16.7
CSCI	30.4		34.4		8.3		5.9
Unallocated	39.4		44.4		5.5		7.2
Total	$	170.6	$	154.7	$	29.5	$	29.8

	Liabilities
	Operating				Financing
	October 2, 2021		December 31, 2020		October 2, 2021		December 31, 2020
CSCA	$	101.3	$	75.8	$	16.4	$	17.0
CSCI	31.4		35.2		5.2		2.5
Unallocated	43.4		49.8		5.6		7.4
Total	$	176.1	$	160.8	$	27.2	$	26.9

Lease expense was as follows (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Operating leases(1)	$	10.0	$	8.5	$	29.9	$	26.6
Finance leases
Amortization	$	1.5	$	1.1	$	4.4	$	3.2
Interest	0.2		0.2		0.6		0.6
Total finance leases	$	1.7	$	1.3	$	5.0	$	3.8

            (1) Includes short-term leases and variable lease costs, which are immaterial.

The annual future maturities of our leases as of October 2, 2021 are as follows (in millions):

	Operating Leases		Finance Leases		Total
2021	$	8.2	$	1.5	$	9.7
2022	29.2		5.6		34.8
2023	21.8		3.9		25.7
2024	18.6		2.4		21.0
2025	16.5		2.2		18.7
After 2025	109.0		15.8		124.8
Total lease payments	203.3		31.4		234.7
Less: Interest	27.2		4.2		31.4
Present value of lease liabilities	$	176.1	$	27.2	$	203.3

Our weighted average lease terms and discount rates are as follows:

	October 2, 2021		September 26, 2020
Weighted-average remaining lease term (in years)
Operating leases	11.39		6.26
Finance leases	8.78		9.20
Weighted-average discount rate
Operating leases	2.60	%	3.64	%
Finance leases	2.64	%	3.20	%

Our lease cash flow classifications are as follows (in millions):

	Nine Months Ended
	October 2, 2021		September 26, 2020
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	26.3	$	25.4
Operating cash flows for finance leases	$	0.6	$	0.6
Financing cash flows for finance leases	$	3.9	$	2.9
Leased assets obtained in exchange for new finance lease liabilities	$	4.5	$	4.6
Leased assets obtained in exchange for new operating lease liabilities	$	42.5	$	24.5

Leases

LEASES

The balance sheet locations of our lease assets and liabilities were as follows (in millions):

Assets	Balance Sheet Location	October 2, 2021		December 31, 2020
Operating	Operating lease assets	$	170.6	$	154.7
Finance	Other non-current assets	29.5		29.8
Total		$	200.1	$	184.5

Liabilities	Balance Sheet Location	October 2, 2021		December 31, 2020
Current
Operating	Other accrued liabilities	$	27.2	$	28.3
Finance	Current indebtedness	5.1		6.7
Non-Current
Operating	Other non-current liabilities	148.9		132.5
Finance	Long-term debt, less current portion	22.1		20.2
Total		$	203.3	$	187.7

The below tables show our lease assets and liabilities by reporting segment (in millions):

	Assets
	Operating				Financing
	October 2, 2021		December 31, 2020		October 2, 2021		December 31, 2020
CSCA	$	100.8	$	75.9	$	15.7	$	16.7
CSCI	30.4		34.4		8.3		5.9
Unallocated	39.4		44.4		5.5		7.2
Total	$	170.6	$	154.7	$	29.5	$	29.8

	Liabilities
	Operating				Financing
	October 2, 2021		December 31, 2020		October 2, 2021		December 31, 2020
CSCA	$	101.3	$	75.8	$	16.4	$	17.0
CSCI	31.4		35.2		5.2		2.5
Unallocated	43.4		49.8		5.6		7.4
Total	$	176.1	$	160.8	$	27.2	$	26.9

Lease expense was as follows (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Operating leases(1)	$	10.0	$	8.5	$	29.9	$	26.6
Finance leases
Amortization	$	1.5	$	1.1	$	4.4	$	3.2
Interest	0.2		0.2		0.6		0.6
Total finance leases	$	1.7	$	1.3	$	5.0	$	3.8

            (1) Includes short-term leases and variable lease costs, which are immaterial.

The annual future maturities of our leases as of October 2, 2021 are as follows (in millions):

	Operating Leases		Finance Leases		Total
2021	$	8.2	$	1.5	$	9.7
2022	29.2		5.6		34.8
2023	21.8		3.9		25.7
2024	18.6		2.4		21.0
2025	16.5		2.2		18.7
After 2025	109.0		15.8		124.8
Total lease payments	203.3		31.4		234.7
Less: Interest	27.2		4.2		31.4
Present value of lease liabilities	$	176.1	$	27.2	$	203.3

Our weighted average lease terms and discount rates are as follows:

	October 2, 2021		September 26, 2020
Weighted-average remaining lease term (in years)
Operating leases	11.39		6.26
Finance leases	8.78		9.20
Weighted-average discount rate
Operating leases	2.60	%	3.64	%
Finance leases	2.64	%	3.20	%

Our lease cash flow classifications are as follows (in millions):

	Nine Months Ended
	October 2, 2021		September 26, 2020
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	26.3	$	25.4
Operating cash flows for finance leases	$	0.6	$	0.6
Financing cash flows for finance leases	$	3.9	$	2.9
Leased assets obtained in exchange for new finance lease liabilities	$	4.5	$	4.6
Leased assets obtained in exchange for new operating lease liabilities	$	42.5	$	24.5

XML

Indebtedness

9 Months Ended

Oct. 02, 2021

Debt Disclosure [Abstract]

Indebtedness

INDEBTEDNESS

Total borrowings outstanding are summarized as follows (in millions):

			October 2, 2021		December 31, 2020
Term loan
	2019 Term loan due August 15, 2022		$	600.0	$	600.0
Notes and Bonds
	Coupon	Due
	5.105%	July 28, 2023(1)	$	156.6	$	164.9
	4.000%	November 15, 2023	215.6		215.6
	3.900%	December 15, 2024	700.0		700.0
	4.375%	March 15, 2026	700.0		700.0
	3.150%	June 15, 2030	750.0		750.0
	5.300%	November 15, 2043	90.5		90.5
	4.900%	December 15, 2044	303.9		303.9
	Total notes and bonds		2,916.6		2,924.9
Other financing			52.0		57.4
Unamortized premium (discount), net			(3.5)		(0.3)
Deferred financing fees			(14.8)		(17.1)
Total borrowings outstanding			3,550.3		3,564.9
	Current indebtedness		(629.4)		(37.3)
Total long-term debt less current portion			$	2,920.9	$	3,527.6

    (1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

Revolving Credit Agreements

On March 8, 2018, we entered into a $1.0 billion revolving credit agreement maturing on March 8, 2023 (the "2018 Revolver"). There were no borrowings outstanding under the 2018 Revolver as of October 2, 2021 or December 31, 2020.

Term Loan and Notes

In August 2019, we refinanced a prior term loan with the proceeds of a $600.0 million term loan, maturing on August 15, 2022 (the "2019 Term Loan"). We had $600.0 million outstanding under our 2019 Term Loan as of both October 2, 2021 and December 31, 2020.

Waiver and Amendment of Debt Covenants

We are subject to financial covenants in the 2018 Revolver and 2019 Term Loan, including a maximum leverage ratio covenant, which previously required us to maintain a ratio of Consolidated Net Indebtedness to Consolidated EBITDA (as such terms are defined in such credit agreements) of not more than 3.75 to 1.00 at the end of each fiscal quarter. During the nine months ended October 2, 2021, we received a waiver for non-compliance with such covenant as of July 3, 2021 from the lenders under both such credit facilities and entered into an amendment to each of the 2018 Revolver and 2019 Term Loan. Under such amendments, the maximum leverage ratio was increased to 5.75 to 1.00 for the third quarter of 2021, returning to 3.75 to 1.00 beginning with the fourth quarter of 2021. If we consummate certain qualifying acquisitions in the fourth quarter of 2021 or any subsequent quarter during the term of the loan, the maximum ratio would increase to 4.00 to 1.00 for such quarter. Due to the waiver and amendment described above, our leverage ratios at the end of the second and third quarters of 2021 do not prevent us from drawing under the 2018 Revolver. As of October 2, 2021, we are in compliance with all the covenants under our debt agreements.

2020 Notes and 2021 Notes Redemption

On June 19, 2020, Perrigo Finance Unlimited Company, an indirect wholly-owned finance subsidiary of Perrigo ("Perrigo Finance"), issued $750.0 million in aggregate principal amount of 3.150% Senior Notes due 2030 (the “2020 Notes") and received net proceeds of $737.1 million after the underwriting discount and offering expenses. Interest on the 2020 Notes is payable semi-annually in arrears on June 15 and December 15 of each year, beginning on December 15, 2020. Due to a credit ratings downgrade by S&P Global Ratings and Moody’s in the third quarter of 2021, the interest on the 2020 Notes will step up from 3.150% to 3.900%, starting after the interest payment due on December 15, 2021. The 2020 Notes will mature on June 15, 2030 and are governed by a base indenture and a third supplemental indenture (collectively, the "2020 Indenture"). The 2020 Notes are fully and unconditionally guaranteed on a senior unsecured basis by Perrigo. Perrigo Finance may redeem the 2020 Notes in whole or in part at any time for cash at the make-whole redemption prices described in the 2020 Indenture. On July 6, 2020, a portion of the proceeds of the 2020 Notes were used to fund the redemption of $280.4 million of Perrigo Finance's 3.500% Senior Notes due March 15, 2021 and $309.6 million of 3.500% Senior Notes due December 15, 2021 (collectively, the "2021 Notes").

As a result of the early redemption of the 2021 notes, during the three months ended September 26, 2020, we recorded a loss of $20.0 million in Loss on extinguishment of debt on the Condensed Consolidated Statements of Operations, consisting of the premium on debt repayments, the write-off of deferred financing fees, and the write-off of the remaining bond discounts.

Other Financing

We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under "Other financing". There were no borrowings outstanding under the facilities as of October 2, 2021 or December 31, 2020.

On June 17, 2020, we incurred debt of $34.3 million related to our equity method investment in Kazmira pursuant to two Promissory Notes, with $3.7 million, $5.8 million and $24.8 million to be settled in November 2020, May 2021 and November 2021, respectively. On December 8, 2020, we repaid the $3.7 million balance due on the November 2020 portion of the Promissory Notes. On June 7, 2021, we repaid the $5.8 million balance due on the May 2021 portion of the Promissory Notes.

We have financing leases that are reported in the above table under "Other financing" (refer to Note 11).

XML

Earnings Per Share and Shareholders' Equity

9 Months Ended

Oct. 02, 2021

Earnings Per Share [Abstract]

Earnings Per Share and Shareholders' Equity

EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY

Earnings per Share

A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Numerator:
Income (loss) from continuing operations	$	(53.9)	$	26.4	$	(163.0)	$	96.4
Income (loss) from discontinued operations, net of tax	(5.0)		(181.0)		84.5		(84.0)
Net income (loss)	$	(58.9)	$	(154.6)	$	(78.5)	$	12.4
Denominator:
Weighted average shares outstanding for basic EPS	133.8		136.5		133.5		136.3
Dilutive effect of share-based awards*	—		1.1		—		1.2
Weighted average shares outstanding for diluted EPS	133.8		137.6		133.5		137.5
Anti-dilutive share-based awards excluded from computation of diluted EPS*	—		1.5		—		1.5
* In the period of a net loss, diluted shares equal basic shares.

Shareholders' Equity

Share Repurchases

In October 2018, our Board of Directors authorized up to $1.0 billion of share repurchases with no expiration date, subject to the Board of Directors’ approval of the pricing parameters and amount that may be repurchased under each specific share repurchase program (the "2018 Authorization"). We did not repurchase any shares during the three and nine months ended October 2, 2021 or September 26, 2020.

XML

Accumulated Other Comprehensive Income (Loss)

9 Months Ended

Oct. 02, 2021

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Accumulated Other Comprehensive Income (Loss)

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Changes in our AOCI balances, net of tax were as follows (in millions):

	Fair Value of Derivative Financial Instruments, net of tax		Foreign Currency Translation Adjustments		Post-Retirement and Pension Liability Adjustments, net of tax		Total AOCI
Balance at December 31, 2020	$	(0.7)	$	407.3	$	(11.6)	$	395.0
OCI before reclassifications	(33.4)		(147.5)		(2.2)		(183.1)
Amounts reclassified from AOCI(1)	2.3		(160.0)		—		(157.7)
Other comprehensive income (loss)	$	(31.1)	$	(307.5)	$	(2.2)	$	(340.8)
Balance at October 2, 2021	$	(31.8)	$	99.8	$	(13.8)	$	54.2

(1) Refer to Note 8, sale of RX business for information regarding amounts reclassified from AOCI related to foreign currency translation adjustments.

XML

Income Taxes

9 Months Ended

Oct. 02, 2021

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

The effective tax rates were as follows:

Three Months Ended				Nine Months Ended
October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
113.9	%	45.5	%	165.5	%	20.5	%

The effective tax rate for the three and nine months ended October 2, 2021 increased compared to the effective tax rate for the three and nine months ended September 26, 2020 primarily due to tax expense recorded in 2021 for settlement of the Irish Notice of Amended Assessment and intra-entity transfers of intellectual property, plus tax benefits recorded in the 2020 periods for reductions to the U.S. valuation allowance and the U.S. Coronavirus Aid, Relief and Economic Security ("CARES") Act, enacted in the first quarter of 2020.

In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes." It removes certain exceptions to the general principles in ASC Topic 740 and improves consistent application of and simplifies GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. This guidance was effective for interim and annual reporting periods beginning after December 15, 2020. We adopted this guidance as of January 1, 2021, and the impact on our Consolidated Financial Statements was immaterial.

Internal Revenue Service Audits of Perrigo Company, a U.S. Subsidiary

Perrigo Company, our U.S. subsidiary ("Perrigo U.S."), is engaged in a series of tax disputes in the U.S. relating primarily to transfer pricing adjustments including income in connection with the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States, including the heartburn medication omeprazole. On August 27, 2014, we received a statutory notice of deficiency from the IRS relating to our fiscal tax years ended June 27, 2009, and June 26, 2010 (the “2009 tax year” and “2010 tax year”, respectively). On April 20, 2017, we received a second statutory notice of deficiency from the IRS for the fiscal tax years ended June 25, 2011 and June 30, 2012 (the “2011 tax year” and “2012 tax year”, respectively). Specifically, both statutory notices proposed adjustments related to the offshore reporting of profits on sales of omeprazole in the United States resulting from the assignment of an omeprazole distribution contract to an affiliate. In addition to the transfer pricing adjustments, which applied to all four tax years, the statutory notice of deficiency for the 2011 and 2012 tax years included adjustments for the capitalization and amortization of certain expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits related to ANDAs.

We do not agree with the audit adjustments proposed by the IRS in either of the notices of deficiency. We paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and timely filed claims for refund on June 11, 2015 for the 2009 and 2010 tax years, and on June 7, 2017, for the 2011 and 2012 tax years. On August 15, 2017, following disallowance of such refund claims, we timely filed a complaint in the United States District Court for the Western District of Michigan seeking refunds of tax, interest, and penalties of $27.5 million for the 2009 tax year, $41.8 million for the 2010 tax year, $40.1 million for the 2011 tax year, and $24.7 million for the 2012 tax year, for a total of $134.1 million, plus statutory interest thereon from the dates of payment. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended July 1, 2017.

The previously rescheduled trial was held during the period May 25, 2021 to June 7, 2021 for the refund case in the United States District Court for the Western District of Michigan. The total amount of cumulative deferred charge that we are seeking to receive in this litigation is approximately $111.6 million, which reflects the impact of conceding that Perrigo U.S. should have received a 5.24% royalty on all omeprazole sales. That concession was previously paid and is the subject of the above refund claims. The issues outlined in the statutory notices of deficiency described above are continuing, and the IRS will likely carry forward the adjustments set forth therein as long as the drug is sold, in the case of the omeprazole issue, and for all post-2012 Paragraph IV filings that trigger patent infringement suits, in the case of the ANDA issue. On April 30, 2021, we filed a Notice of New Authority in our

refund case in the Western District of Michigan alerting the court to a Tax Court decision in Mylan v. Comm'r that ruled in favor of the taxpayer on the identical ANDA issues we have before the court. Post-trial briefings were completed on September 24, 2021 and the case is now fully submitted for the court's decision.

On January 13, 2021, the IRS issued a 30-day letter with respect to its audit of our fiscal tax years ended June 29, 2013 (the "2013 tax year"), June 28, 2014 (the "2014 tax year"), and June 27, 2015 (the "2015 tax year" and together with the 2013 tax year and the 2014 tax year, the "2013-2015 tax years"). The IRS letter proposed, among other modifications, carryforwards of the transfer pricing adjustments regarding our profits from the distribution of omeprazole in the aggregate amount of $141.6 million and ANDA adjustments in the aggregate amount of $21.9 million. The 30-day letter also set forth adjustments described in the next two paragraphs. We timely filed a protest to the 30-day letter for those additional adjustments, but noting that due to the pending litigation described above, IRS Appeals will not consider the merits of the omeprazole or ANDA matters. We believe that we should prevail on the merits on both carryforward issues and have reserved for taxes and interest payable on the 5.24% deemed royalty on omeprazole through the tax year ended December 31, 2018. Beginning with the tax year ended December 31, 2019, we began reporting income commensurate with the 5.24% deemed royalty. We have not reserved for the ANDA-related issue described above. While we believe we should prevail on the merits of this case, the outcome remains uncertain. If our litigation position on the omeprazole issue is not sustained, the outcome for the 2009–2012 tax years could range from a reduction in the refund amount to denial of any refund. In addition, we expect that the outcome of the refund litigation could effectively bind future tax years. In that event, an adverse ruling on the omeprazole issue could have a material impact on subsequent periods, with additional tax liability in the range of $24.0 million to $112.0 million, not including interest and any applicable penalties.

The 30-day letter for the 2013-2015 tax years also proposed to reduce Perrigo U.S.'s deductible interest expense for the 2014 tax year and the 2015 tax year on $7.5 billion in debts owed by it to Perrigo Company plc. The debts were incurred in connection with the Elan merger transaction in 2013. On May 7, 2020, the IRS issued a NOPA capping the interest rate on the debts for U.S. federal tax purposes at 130.0% of the Applicable Federal Rate ("AFR") (a blended rate reduction of 4.0% per annum), on the stated ground that the loans were not negotiated on an arms’-length basis. The NOPA proposes a reduction in gross interest expense of approximately $414.7 million for tax years 2014 and 2015. On January 13, 2021, we received a Revenue Agent Report ("RAR"), together with the 30-day letter, requiring our filing of a written Protest to request IRS Appeals consideration. The Protest was timely filed with the IRS on February 26, 2021. On May 3, 2021, the IRS notified us that it will no longer pursue the 130% of AFR position reflected in its NOPA due to a change in IRS policy. The IRS will provide a new proposed adjustment in its rebuttal to our Protest, which we have not yet received. Because the IRS' revised adjustment is currently unknown and cannot be quantified, we are unable to determine the amount of gross interest expense that the IRS proposes to disallow, and we cannot estimate any increase in tax expense attributable to any such disallowance for the period under audit. In addition, we expect the IRS to seek similar revised adjustments for the tax years ended December 31, 2015 through December 31, 2018 with potential section 163(j) carryover impacts beyond December 2018. We cannot determine the amount, if any, of the estimated increase in tax expense attributable to any such adjustments. No further interest adjustments are expected beyond this period. We strongly disagree with the IRS position and we will pursue all available administrative and judicial remedies necessary. At this stage, we are unable to estimate any additional liability associated with this matter.

In addition, the 30-day letter for the 2013-2015 tax years expanded on a NOPA issued on December 11, 2019 and proposed to disallow adjustments to gross sales income on the sale of prescription products to wholesalers for accrued wholesale customer pipeline chargebacks where the prescription products were not re-sold by such wholesalers to covered retailers by the end of the tax year for the 2013-2015 tax years. The IRS' NOPA asserts that the reduction of gross sales income of such chargebacks is an impermissible method of accounting. The IRS proposed a change in accounting method that would defer the reduction in gross sales income until the year the prescription products were re-sold to covered retailers. The NOPA proposes an increase in sales revenue of approximately $99.5 million for the 2013-2015 tax years. We filed a protest on February 26, 2021 to request IRS Appeals consideration. If the IRS were to prevail in its proposed adjustment, we estimate a payment of approximately $18.0 million, excluding interest and penalties for the 2013-2015 tax years. In addition, we expect the IRS to seek similar adjustments for future years. If those future adjustments were to be sustained, based on preliminary calculations and subject to further analysis, our current best estimate is a payment that will not exceed $7.0 million through tax year ended December 31, 2020, excluding interest and penalties. We have fully reserved for this issue. We strongly disagree with the IRS’s proposed adjustment and will pursue all available administrative and judicial remedies necessary.

Internal Revenue Service Audit of Athena Neurosciences, Inc., a U.S. Subsidiary    

On April 26, 2019, we received a revised NOPA from the IRS regarding transfer pricing positions related to the IRS audit of Athena Neurosciences, Inc. ("Athena") for the years ended December 31, 2011, December 31, 2012, and December 31, 2013. The NOPA carries forward the IRS's theory from its 2017 draft NOPA that when Elan took over the future funding of Athena's in-process research and development after acquiring Athena in 1996, Elan should have paid a substantially higher royalty rate for the right to exploit Athena’s intellectual property, rather than rates based on transfer pricing documentation prepared by Elan's external tax advisors. The NOPA proposes a payment of $843.0 million, which represents additional tax and a 40.0% penalty. This amount excludes consideration of offsetting tax attributes and any potential interest that may be imposed. We strongly disagree with the IRS position. On December 22, 2016, we also received a NOPA for these years denying the deductibility of settlement costs related to illegal marketing of Zonegran in the United States raised in a Qui Tam action. We strongly disagree with the IRS' position on this issue as well. Because we believe that any concession on these issues in Appeals would be contrary to our evaluation of the issues, we pursued our remedies under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. On April 14, 2020, we filed a request for Competent Authority Assistance with the IRS on the royalty issue, and it was accepted. On October 20, 2020, we amended our request for Competent Authority Assistance to include the Zonegran issue and this amendment was also accepted. On May 6, 2021, we had our opening conference with the IRS and discussed our submission, which continues to be reviewed by the IRS. Our opening conference with Irish Revenue was held on July 23, 2021 and we discussed our submission, which continues to be reviewed by Irish Revenue.

No payment of the additional amounts is required until these two matters are resolved with finality under the treaty, or any additional administrative or judicial process if treaty negotiations are unsuccessful.

Irish Revenue Audit of Fiscal Years Ended December 31, 2012 and December 31, 2013

On October 30, 2018, we received an audit findings letter from the Irish Office of the Revenue Commissioners (“Irish Revenue”) for the tax years ended December 31, 2012 and December 31, 2013. The audit findings letter related to the tax treatment of the 2013 sale of the Tysabri® intellectual property and related assets to Biogen Idec by Elan Pharma. The consideration paid by Biogen Idec to Elan Pharma took the form of an upfront payment and future contingent royalty payments. Elan Pharma recognized such receipts as trading income in its tax returns filed with Irish Revenue, consistent with Elan Pharma's historical practice relating to its active management of intellectual property rights.

In its audit findings letter, Irish Revenue proposed to charge Elan Pharma tax on the net chargeable gain realized by Elan Pharma on the Tysabri® transaction in 2013 at a rate of 33%, rather than the 12.5% tax rate applied to trading income. On November 29, 2018, Irish Revenue issued a Notice of Amended Assessment (“NoA”) for the tax year ended December 31, 2013, in the amount of €1,643 million, and claiming tax payable in the amount of €1,636 million, not including any interest or applicable penalties.

Accordingly, we filed an appeal of the NoA on December 27, 2018 with the Irish Tax Appeals Commission ("TAC") which is the statutory body charged with considering whether the NoA was properly founded as a matter of Irish tax law. Separately, we were also granted leave by the Irish High Court on February 25, 2019 to seek judicial review of the issuance of the NoA by Irish Revenue.

On November 4, 2020, the High Court ruled that the Irish Revenue's decision to issue the NoA did not violate Elan Pharma's constitutional rights and legitimate expectations as a taxpayer. The Irish High Court did not rule on the merits of the NoA under Irish tax law.

We strongly believe that Elan Pharma’s tax position was correct and ultimately would have been confirmed through judicial process. However, in light of the risks and delays inherent in any litigation, on April 26, 2021, Perrigo, through its tax adviser, made a without prejudice written offer of settlement to Irish Revenue detailing a possible framework to resolve the dispute, which applied an alternative basis of taxation than the respective positions taken by Irish Revenue in the NoA and by Elan Pharma in its tax returns. On May 31, 2021, Irish Revenue issued a formal response to Perrigo's tax adviser indicating that the written settlement offer would not be accepted as presented. However, Irish Revenue did indicate that they would remain available for further discussion without prejudice and the Company's representatives continued to meet and correspond with Irish Revenue throughout the summer.

On July 9, 2021, Irish Revenue issued a letter acknowledging that not all relevant facts were known to them when they issued the NoA in 2018 and, accordingly, they would not object if the Appeal Commissioner were to make certain adjustments reducing Irish Revenue’s original assessment. Such adjustments would reflect contingent royalty payments that were never received by Elan Pharma, deductions for acquisition and development costs incurred, and allowable losses and reliefs, and would, if allowed, result in an aggregate reduction of more than €660.0 million from the income taxes claimed in the NoA as issued.

On September 29, 2021, Elan Pharma reached an agreement with Irish Revenue providing for full and final settlement of the NoA. Elan Pharma and Irish Revenue agreed to a settlement on the following terms: (i) on a 'without prejudice basis' and, for purposes of the settlement, an alternative basis of taxation was applied, (ii) Irish Revenue will take no further action in relation to the NoA or any Tysabri related income or transactions, (iii) no interest or penalties apply, (iv) a total tax of €297.0 million as full and final settlement of all liabilities arising from the sale of the Tysabri patents for the fiscal years 2013 to 2021, and (v) after Irish Revenue credited taxes already paid and certain unused R&D credits against the €297.0 million figure, the total cash payment due is €266.1 million. The payment of €266.1 million ($307.5 million) was made on October 5, 2021.

Israel Tax Authority Audit of Fiscal Year Ended June 27, 2015 and Calendar Years Ended December 31, 2015 through December 31, 2019

The Israel Tax Authority ("ITA") audited our income tax returns for the 2015 tax year, and calendar years ended December 31, 2015, December 31, 2016 and December 31, 2017. On December 29, 2020, we received a Stage A assessment from the ITA for the tax years ended December 31, 2015 through December 31, 2017 in the amount of $63.8 million relating to attribution of intangible income to Israel, income qualifying for a lower preferential rate of tax, exemption from capital gains tax, and deduction of certain settlement payments. Our protest was timely filed on March 11, 2021 to move the matter to Stage B of the assessment process.

Through negotiations with the ITA, we resolved the audit for the tax year ended June 27, 2015 through tax year ended December 31, 2019, by agreeing to add tax year ended December 31, 2018 and tax year ended December 31, 2019 to the audit period to reach an agreeable resolution to provide certainty for these additional periods. The agreement with the ITA required us to pay $19.0 million, after offset for refunds of $17.2 million, for the five taxable years. In addition, we paid $12.5 million to resolve a tax liability indemnity for the tax year ended December 31, 2017 relating to Perrigo API Ltd, which we disposed of in December 2017 (refer to Note 16).

As a result of the settlement with the ITA, we reduced our liability recorded for uncertain tax positions by $38.3 million including interest.

    Although we believe that our tax estimates are reasonable and that we prepare our tax filings in accordance with all applicable tax laws, the final determination with respect to any tax audit and any related litigation could be materially different from our estimates or from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on operating results and/or cash flows in the periods for which that determination is made. In addition, future period earnings may be adversely impacted by litigation costs, settlements, penalties, and/or interest assessments.

Based on the final resolution of tax examinations, judicial or administrative proceedings, changes in facts or law, expirations of statute of limitations in specific jurisdictions or other resolutions of, or changes in, tax positions - one or more of which may occur within the next twelve months - it is reasonably possible that unrecognized tax benefits for certain tax positions taken on previously filed tax returns may change materially from those recorded as of October 2, 2021. However, we are not able to estimate a reasonably possible range of how these events may impact our unrecognized tax benefits in the next twelve months.

XML

Contingencies

9 Months Ended

Oct. 02, 2021

Commitments and Contingencies Disclosure [Abstract]

Contingencies

CONTINGENCIES

    In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below. We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated. The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters. For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of October 2, 2021, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows. We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve. Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject to have, individually or in the aggregate, a material adverse effect on our financial condition, results of operations, or cash flows.

Price-Fixing Lawsuits

Perrigo is a defendant in several cases in the generic pricing multidistrict litigation MDL No. 2724 (United States District Court for Eastern District of Pennsylvania). This multidistrict litigation, which has many cases that do not include Perrigo, includes class action and opt-out cases for federal and state antitrust claims, as well as complaints filed by certain states alleging violations of state antitrust laws.

On July 14, 2020, the court issued an order designating the following cases to proceed on a more expedited basis (as a bellwether) than the other cases in MDL No. 2724: (a) the May 2019 state case alleging an overarching conspiracy involving more than 120 products (which does not name Perrigo a defendant) and (b) class actions alleging “single drug” conspiracies involving Clomipramine, Pravastatin, and Clobetasol. Perrigo is a defendant in the Clobetasol cases but not the others. On February 9, 2021, the Court entered an order provisionally deciding to remove the May 2019 state case and the pravastatin class cases from the bellwether proceedings. On May 7, 2021, the Court ruled that the clobetasol end payer and direct purchaser class cases will remain part of the bellwether. The Court also ruled that the June 10, 2020 state complaint against Perrigo and approximately 35 other manufacturers will move forward as a bellwether case. No schedule has been set for the bellwether cases.

Class Action Complaints

(a) Single Drug Conspiracy Class Actions

We have been named as a co-defendant with certain other generic pharmaceutical manufacturers in a number of class actions alleging single-product conspiracies to fix or raise the prices of certain drugs and/or allocate customers for those products starting, in some instances, as early as June 2013. The class actions were filed on behalf of putative classes of (a) direct purchasers, (b) end payors, and (c) indirect resellers. The products in question are Clobetasol gel, Desonide, and Econazole. The court denied motions to dismiss each of the complaints alleging “single drug” conspiracies involving Perrigo, and the cases are proceeding in discovery. As noted above, the Clobetasol cases have been designated to proceed on a more expedited schedule than the other cases. That schedule has not yet been set.

(b) “Overarching Conspiracy” Class Actions

The same three putative classes, including (a) direct purchasers, (b) end payors, and (c) indirect resellers, have filed two sets of class action complaints alleging that Perrigo and other manufacturers (and some individuals) entered into an “overarching conspiracy” that involved allocating customers, rigging bids and raising, maintaining, and fixing prices for various products. Each class brings claims for violations of Sections 1 and 3 of the Sherman Antitrust Act as well as several state antitrust and consumer protection statutes.

Filed in June 2018, and later amended in December 2018 (with respect to direct purchasers) and April 2019 (with respect to end payors and indirect resellers), the first set of “overarching conspiracy” class actions include allegations against Perrigo and approximately 27 other manufacturers involving 135 drugs with allegations dating back to March 2011. The allegations against Perrigo concern only two formulations (cream and ointment) of one of the products at issue, Nystatin. The court denied motions to dismiss the first set of “overarching conspiracy” class actions, and they are proceeding in discovery. None of these cases are included in the group of cases on a more expedited schedule pursuant to the court’s July 14, 2020 order.

In December 2019, both the end payor and indirect reseller class plaintiffs filed a second set of "overarching conspiracy” class actions against Perrigo, dozens of other manufacturers of generic prescription pharmaceuticals, and certain individuals dating back to July 2009 (end payors) or January 2010 (indirect resellers). The direct purchaser plaintiffs filed their second round overarching conspiracy complaint in February 2020 with claims dating back to July 2009. On March 11, 2020, the indirect reseller plaintiffs filed a motion to amend their second round December 2019 complaint, and that motion was granted. On September 4, 2020, and December 15, 2020, the end payor plaintiffs amended their second round complaint. On October 21, 2020, the direct purchaser plaintiffs amended their second round complaint. On December 15, 2020, the indirect reseller plaintiffs filed another complaint adding allegations for additional drugs that mirror the other class plaintiffs’ claims.

This second set of overarching complaints allege conspiracies relating to the sale of various products that are not at issue in the earlier-filed overarching conspiracy class actions, the majority of which Perrigo neither makes nor sells. The amended indirect reseller complaint alleges that Perrigo conspired in connection with its sales of Betamethasone Dipropionate lotion, Imiquimod cream, Desonide cream and ointment, and Hydrocortisone Valerate cream. The December 2020 indirect reseller complaint alleges that Perrigo conspired in connection with its sales of Adapalene, Ammonium Lactate, Bromocriptine Mesylate, Calcipotriene, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Methazolamide, Mometasone Furoate, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The amended end payor complaint alleges that Perrigo conspired in connection with its sale of the following drugs: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluocinonide, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone Furoate, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The amended direct purchaser complaint alleges that Perrigo conspired in connection with its sale of the following drugs: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Ciclopirox, Clindamycin Phosphate, Fenofibrate, Fluocinonide, Halobetasol Propionate, Hydrocortisone Valerate, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

Perrigo has not yet responded to the second set of overarching conspiracy complaints, and responses are currently stayed.

Opt-Out Complaints

On January 22, 2018, Perrigo was named a co-defendant along with 35 other manufacturers in a complaint filed by three supermarket chains alleging that defendants conspired to fix prices of 31 generic prescription pharmaceutical products starting in 2013. On December 21, 2018, an amended complaint was filed that adds additional products and allegations against a total of 39 manufacturers for 33 products. The only allegations specific to Perrigo relate to Clobetasol, Desonide, Econazole, Nystatin cream, and Nystatin ointment. Perrigo moved to dismiss this complaint on February 21, 2019. The motion was denied on August 15, 2019. The case is proceeding in discovery. On February 3, 2020, the plaintiffs requested leave to file a second amended complaint. The proposed amended complaint adds dozens of additional products and allegations to the original complaint. Perrigo is discussed in connection with allegations concerning an additional drug, Fenofibrate. Defendants opposed the motion for leave to file a second amended complaint and the court has yet to rule on the issue.

On August 3, 2018, a large managed care organization filed a complaint alleging price-fixing and customer allocation concerning 17 different products among 27 manufacturers including Perrigo. The only allegations specific to Perrigo concern Clobetasol. Perrigo moved to dismiss this complaint on February 21, 2019. Plaintiff filed a second amended complaint in April 2019 that adds additional products and allegations. The amended allegations

that concern Perrigo include: Clobetasol, Desonide, Econazole, and Nystatin. The motion to dismiss was denied on August 15, 2019. The case is proceeding in discovery.

The same organization amended a different complaint that it had filed in October 2019, which did not name Perrigo, on December 15, 2020, adding Perrigo as a defendant and asserting new allegations of alleged antitrust violations involving Perrigo and dozens of other generic pharmaceutical manufacturers. The allegations relating to Perrigo concern: Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Ciclopirox, Clindamycin Phosphate, Fenofibrate, Fluocinonide, Halobetasol Propionate, Hydrocortisone Valerate, Imiquimod, Permethrin, Prochlorperazine Maleate, and Triamcinolone Acetonide.

The same organization filed a third complaint on December 15, 2020, naming Perrigo and dozens of other manufacturers alleging antitrust violations concerning generic pharmaceutical drugs. The allegations relating to Perrigo concern: Ammonium Lactate, Calcipotriene Betamethasone Dipropionate, Erythromycin, Fluticasone Propionate, Hydrocortisone Acetate, Methazolamide, Promethazine HCL, and Tacrolimus.

On January 16, 2019, a health insurance carrier filed a complaint in the U.S. District Court for the District of Minnesota alleging a conspiracy to fix prices of 30 products among 30 defendants. The only allegations specific to Perrigo concerned Clobetasol gel, Desonide, Econazole, Nystatin cream, and Nystatin ointment. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations that concern Perrigo relate to Fluocinonide.

The same health insurance carrier filed a new complaint on December 15, 2020, naming Perrigo and dozens of other manufacturers alleging antitrust violations concerning generic pharmaceutical drugs. The allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

On July 18, 2019, 87 health plans filed a Praecipe to Issue Writ of Summons in Pennsylvania state court to commence an action against 53 generic pharmaceutical manufacturers and 17 individuals, alleging antitrust violations concerning generic pharmaceutical drugs. While Perrigo was named as a defendant, no complaint has been filed and the precise allegations and products at issue have not been identified. Proceedings in the case, including the filing of a complaint, have been stayed at the request of the plaintiffs.

On December 11, 2019, a health care service company filed a complaint against Perrigo and 38 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other multi-district litigation ("MDL") complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin cream/ointment. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluocinonide, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

On December 16, 2019, a Medicare Advantage claims recovery company filed a complaint against Perrigo and 39 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, and Econazole. The complaint was originally filed in the District of Connecticut but has been consolidated into the MDL. Perrigo has not yet had the opportunity to respond to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Desoximetasone, Erythromycin, Fenofibrate, Fluocinonide, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone

Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

On December 23, 2019, several counties in New York filed an amended complaint against Perrigo and 28 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. The complaint was originally filed in New York State court but was removed to federal court and has been consolidated into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone Furoate, Nystatin, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. On June 30, 2021, the counties filed a proposed revised second amended complaint. Perrigo has not yet responded to the complaint, and responses are currently stayed.

On December 27, 2019, a healthcare management organization filed a complaint against Perrigo and 25 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. The complaint was filed originally in the Northern District of California but has been consolidated into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

On March 1, 2020, Harris County of Texas filed a complaint against Perrigo and 29 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The products at issue that plaintiffs claim Perrigo manufacturers or sells include: Adapalene, Betamethasone Dipropionate, Ciclopirox, Clindamycin, Clobetasol, Desonide, Econazole, Ethinyl Estradiol/Levonorgestrel, Fenofibrate, Fluocinolone, Fluocinonide, Gentamicin, Glimepiride, Griseofulvin, Halobetasol Propionate, Hydrocortisone Valerate, Ketoconazole, Mupirocin, Nystatin, Olopatadine, Permethrin, Prednisone, Promethazine, Scopolamine, and Triamcinolone Acetonide. The complaint was originally filed in the Southern District of Texas but has been transferred to the MDL. Harris County amended its complaint in May 2020. Perrigo has not yet responded to the complaint, and responses are currently stayed.

In May 2020, seven health plans filed a writ of summons in the Pennsylvania Court of Common Pleas in Philadelphia concerning an as-yet unfiled complaint against Perrigo, three dozen other manufacturers, and seventeen individuals, concerning alleged antitrust violations in connection with the pricing and sale of generic prescription pharmaceutical products. No complaint has yet been filed, so the precise allegations and products at issue are not yet clear. Proceedings in the case have been stayed.

On June 9, 2020, a health insurance carrier filed a complaint against Perrigo and 25 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluocinonide, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

On July 9, 2020, a drugstore chain filed a complaint against Perrigo and 39 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. Perrigo is also listed in connection with Fenofibrate. The complaint was filed in the Eastern District of Pennsylvania and will be transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed. On December 15, 2020, the complaint was amended to add additional defendants and claims. The new allegations relating to Perrigo concern: Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fenofibrate, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide.

On August 27, 2020, Suffolk County of New York filed a complaint against Perrigo and 35 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin cream and ointment. The other products at issue that plaintiffs claim Perrigo manufacturers or sells include: Adapalene gel, Albuterol, Benazepril HCTZ, Clotrimazole, Diclofenac Sodium, Fenofibrate, Fluocinonide, Glimepiride, Ketoconazole, Meprobamate, Imiquimod, Triamcinolone Acetonide, Erythromycin/Ethyl Solution, Betamethasone Valerate, Ciclopirox Olamine, Terconazole, Hydrocortisone Valerate, Fluticasone Propionate, Desoximetasone, Clindamycin Phosphate, Halobetasol Propionate, Hydrocortisone Acetate, Promethazine HCL, Mometasone Furoate, and Amiloride HCTZ. The complaint was filed in the Eastern District of New York and has been transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed.

On September 4, 2020, a drug wholesaler and distributor filed a complaint against Perrigo and 39 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin, Clobetasol, Desonide, Econazole, Erythromycin, Fenofibrate, Fluticasone, Halobetasol, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone furoate, Nystatin, Prochlorperazine, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL. Perrigo has not yet responded to the complaint, and responses are currently stayed.

On December 11, 2020, a drugstore chain filed a complaint against Perrigo and 45 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on Adapalene, Ammonium Lactate, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Clobetasol, Desonide, Econazole, Erythromycin, Fenofibrate, Fluticasone Propionate, Halobetasol, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Nystatin, Permethrin, Prochlorperazine, Promethazine HCL, Tacrolimus, and Triamcinolone. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL.

On December 14, 2020, a supermarket chain filed a complaint against Perrigo and 45 other manufacturers (as well as certain individuals) alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on Betamethasone Dipropionate, Bromocriptine Mesylate, Ciclopirox, Clindamycin Phosphate, Clobetasol, Desonide, Econazole, Fenofibrate, Halobetasol, Hydrocortisone Valerate, Nystatin, Permethrin, and Triamcinolone Acetonide. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL.

On December 15, 2020, a drugstore chain filed a complaint against Perrigo and 45 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The complaint lists 63 drugs that the chain purchased from Perrigo, but the product conspiracies allegedly involving Perrigo focus on Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Desonide,

Econazole, Erythromycin, Fluocinonide, Fluticasone Propionate, Halobetasol, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Nystatin, Prochlorperazine, Promethazine HCL, Tacrolimus, and Triamcinolone. The complaint was filed in the Eastern District of Pennsylvania and has been transferred into the MDL.

On December 15, 2020, several counties in New York filed a complaint against Perrigo and 45 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens products, most of which Perrigo neither makes nor sells. The allegations that concern Perrigo include: Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Erythromycin, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone Furoate, Nystatin, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. The complaint was originally filed in New York State court but has been removed to federal court and consolidated into the MDL. The counties filed an amended complaint on June 30, 2021.

On August 30, 2021, the county of Westchester, NY filed a complaint in New York State court against Perrigo and 45 other pharmaceutical companies alleging an overarching conspiracy to fix, raise or stabilize prices of dozens products, most of which Perrigo neither makes nor sells. The allegations that concern Perrigo include: Adapalene, Betamethasone Dipropionate, Bromocriptine Mesylate, Calcipotriene Betamethasone Dipropionate, Ciclopirox, Clindamycin Phosphate, Clobetasol, Desonide, Econazole, Erythromycin, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone Acetate, Hydrocortisone Valerate, Imiquimod, Methazolamide, Mometasone Furoate, Nystatin, Permethrin, Prochlorperazine Maleate, Promethazine HCL, Tacrolimus, and Triamcinolone Acetonide. A motion to remove the case to federal court for consolidation into the MDL has been filed.

On October 8, 2021, approximately 20 health plans filed a Praecipe to Issue Writ of Summons in Pennsylvania state court to commence an action against 46 generic pharmaceutical manufacturers and 24 individuals, alleging antitrust violations concerning generic pharmaceutical drugs. While Perrigo was named as a defendant, no complaint has been filed and the precise allegations and products at issue have not been identified. Proceedings in the case, including the filing of a complaint, have not yet occurred.

State Attorney General Complaint

On June 10, 2020, the Connecticut Attorney General’s office filed a lawsuit on behalf of Connecticut and 50 other states and territories against Perrigo, 35 other generic pharmaceutical manufacturers, and certain individuals (including one former and one current Perrigo employee), alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of eighty products. The allegations against Perrigo focus on the following drugs: Adapalene Cream, Ammonium Lactate cream and lotion, Betamethasone dipropionate lotion, Bromocriptine tablets, Calcipotriene Betamethasone Dipropionate Ointment, Ciclopirox cream and solution, Clindamycin solution, Desonide cream and ointment, Econazole cream, Erythromycin base alcohol solution, Fluticasone cream and lotion, Halobetasol cream and ointment, Hydrocortisone Acetate suppositories, Hydrocortisone Valerate cream, Imiquimod cream, Methazolamide tablets, Nystatin ointment, Prochlorperazine suppositories, Promethazine HCL suppositories, Tacrolimus ointment, and Triamcinolone cream and ointment. The Complaint was filed in the District of Connecticut, but has been transferred into the MDL. On May 7, 2021, the Court ruled that this case will move forward as a bellwether case. On September 9, 2021, the States filed an amended complaint, although the substantive allegations against Perrigo did not change. Perrigo's motion to dismiss the complaint is due on November 12, 2021.

Canadian Class Action Complaint

In June 2020, an end payor filed a class action in Ontario, Canada against Perrigo and 29 other manufacturers alleging an overarching conspiracy to allocate customers and/or fix, raise or stabilize prices of dozens of products, most of which Perrigo neither makes nor sells. The product conspiracies allegedly involving Perrigo focus on the same products as those involved in other MDL complaints naming Perrigo: Clobetasol, Desonide, Econazole, and Nystatin. In December 2020, Plaintiffs amended their complaint to add additional claims based on the State AG complaint of June 2020.

At this stage, we cannot reasonably estimate the outcome of the liability if any, associated with the claims listed above.

Securities Litigation

In the United States (cases related to events in 2015-2017)

On May 18, 2016, a shareholder filed a securities case against us and our former CEO, Joseph Papa, in the U.S. District Court for the District of New Jersey (Roofers’ Pension Fund v. Papa, et al.). The plaintiff purported to represent a class of shareholders for the period from April 21, 2015 through May 11, 2016, inclusive. The original complaint alleged violations of Securities Exchange Act sections 10(b) (and Rule 10b5) and 14(e) against both defendants and 20(a) control person liability against Mr. Papa. In general, the allegations concerned the actions taken by us and the former executive to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015. The plaintiff also alleged that the defendants provided inadequate disclosure concerning alleged integration problems related to the Omega acquisition in the period from April 21, 2015 through May 11, 2016. On July 19, 2016, a different shareholder filed a securities class action against us and our former CEO, Joseph Papa, also in the District of New Jersey (Wilson v. Papa, et al.). The plaintiff purported to represent a class of persons who sold put options on our shares between April 21, 2015 and May 11, 2016. In general, the allegations and the claims were the same as those made in the original complaint filed in the Roofers' Pension Fund case described above. On December 8, 2016, the court consolidated the Roofers' Pension Fund case and the Wilson case under the Roofers' Pension Fund case number. In February 2017, the court selected the lead plaintiffs for the consolidated case and the lead counsel to the putative class. In March 2017, the court entered a scheduling order.

On June 21, 2017, the court-appointed lead plaintiffs filed an amended complaint that superseded the original complaints in the Roofers’ Pension Fund case and the Wilson case. In the amended complaint, the lead plaintiffs seek to represent three classes of shareholders: (i) shareholders who purchased shares during the period from April 21, 2015 through May 3, 2017 on the U.S. exchanges; (ii) shareholders who purchased shares during the same period on the Tel Aviv exchange; and (iii) shareholders who owned shares on November 12, 2015 and held such stock through at least 8:00 a.m. on November 13, 2015 (the final day of the Mylan tender offer) regardless of whether the shareholders tendered their shares. The amended complaint names as defendants us and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The amended complaint alleges violations of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals. In general, the allegations concern the actions taken by us and the former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company and at Omega, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The amended complaint does not include an estimate of damages. During 2017, the defendants filed motions to dismiss, which the plaintiffs opposed. On July 27, 2018, the court issued an opinion and order granting the defendants’ motions to dismiss in part and denying the motions to dismiss in part. The court dismissed without prejudice defendants Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, Donal O’Connor, and Marc Coucke. The court also dismissed without prejudice claims arising from the Tysabri® accounting issue described above and claims alleging incorrect disclosure of organic growth described above. The defendants who were not dismissed are Perrigo Company plc, Joe Papa, and Judy Brown. The claims (described above) that were not dismissed relate to the integration issues regarding the Omega acquisition, the defense against the Mylan tender offer, and the alleged price fixing activities with respect to six generic prescription pharmaceuticals. The defendants who remain in the case (the Company, Mr. Papa, and Ms. Brown) have filed answers denying liability, and the discovery stage of litigation began in late 2018. Discovery in the class action ended on January 31, 2021. In early April 2021, the defendants filed various post-discovery motions, including summary judgment motions; the briefing of which was completed in early July 2021. The motions are now before the court. The court will hold oral argument in January 2022. We intend to defend the lawsuit vigorously.

On November 14, 2019, the court granted the lead plaintiffs’ motion and certified three classes for the case: (i) all those who purchased shares between April 21, 2015 through May 2, 2017 inclusive on a U.S. exchange and were damaged thereby; (ii) all those who purchased shares between April 21, 2015 through May 2, 2017 inclusive on the Tel Aviv exchange and were damaged thereby; and (iii) all those who owned shares as of November 12, 2015 and held such stock through at least 8:00 a.m. on November 13, 2015 (whether or not a person tendered shares in response to the Mylan tender offer) (the "tender offer class"). Defendants filed a petition for leave to appeal in the Third Circuit challenging the certification of the tender offer class. On April 30, 2020, the Third Circuit

denied leave to appeal. The District Court has approved the issuance of a notice of the pendency of the class action, and the notice has been sent to shareholders who are eligible to participate in the classes.

In early July 2021, the Court assigned the securities class action case (Roofer’s case) to a new judge within the U.S. District Court for the District of New Jersey. Unless otherwise noted, each of the lawsuits discussed in the following sections is pending in the U.S. District Court for the District of New Jersey and remains with the originally assigned judge. The allegations in the complaints relate to events during certain portions of the 2015 through 2017 calendar years, including the period of the Mylan tender offer. All but one of these lawsuits allege violations of federal securities laws, but none are class actions. One lawsuit (Highfields) alleges only state law claims. Discovery in all these cases, except Starboard Value and Highfields, is underway and currently scheduled to end in mid-November 2021. We intend to defend all these lawsuits vigorously.

Carmignac, First Manhattan and Similar Cases. The following seven cases were filed by the same law firm and generally make the same factual assertions but, at times, differ as to which securities laws violations they allege:

Case	Date Filed
Carmignac Gestion, S.A. v. Perrigo Company plc, et al.	11/1/2017
First Manhattan Co. v. Perrigo Company plc, et al.	2/16/2018; amended 4/20/2018
Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al.	10/29/2018
Schwab Capital Trust, et al. v. Perrigo Company plc, et al.	1/31/2019
Aberdeen Canada Funds -- Global Equity Fund, et al. v. Perrigo Company plc, et al.	2/22/2019
Principal Funds, Inc., et al. v. Perrigo Company plc, et al.	3/5/2020
Kuwait Investment Authority, et al. v. Perrigo Company plc, et al.	3/31/2020

The original complaints in the Carmignac case and the First Manhattan case named Perrigo, Mr. Papa, Ms. Brown, and Mr. Coucke as defendants. Mr. Coucke was dismissed as a defendant after the plaintiffs agreed to apply the July 2018 ruling in the Roofers' Pension Fund case to these two cases. The complaints in each of the other cases name only Perrigo, Mr. Papa, and Ms. Brown as defendants.

Each complaint asserts claims under Sections 10(b) (and Rule 10b-5 thereunder) and all cases except Aberdeen assert claims under Section 14(e) of the Securities Exchange Act against all defendants, as well as control person liability under Section 20(a) of the Securities Exchange Act against the individual defendants. The control person claims against the individual defendants are limited to the period from April 2015 through April 2016 in the Carmignac case. The complaints in the Carmignac and First Manhattan cases also assert claims under Section 18 of the Exchange Act.

Each complaint alleges inadequate disclosures concerning the valuation and integration of Omega, the financial guidance we provided, our reporting about the generic prescription pharmaceutical business and its prospects, and the activities surrounding the efforts to defeat the Mylan tender offer during 2015, and, in each of the cases other than Carmignac, alleged price fixing activities with respect to six generic prescription pharmaceuticals. The First Manhattan complaint also alleges improper accounting for the Tysabri® asset. With the exception of Carmignac, each of these cases relates to events during the period from April 2015 through May 2017. Many of the allegations in these cases overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case, though the Nationwide Mutual, Schwab Capital, Aberdeen, Principal Funds and Kuwait complaints do not include the factual allegations that the court dismissed in the July 2018 ruling in the Roofers' Pension Fund case.

After the court issued its July 2018 opinion in the Roofers’ Pension Fund case, the parties in Carmignac and First Manhattan conferred and agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in their cases. The later filed cases adopted a similar posture. The defendants in the Carmignac and other cases listed above filed motions to dismiss addressing the additional allegations in such cases. On July 31, 2019, the court granted such motions to dismiss in part and denied them in part. That ruling applies to each of the above cases. The defendants have filed answers in each case denying liability. Each case (except Highfields and Starboard Value) is currently in the discovery phase.

Mason Capital, Pentwater and Similar Cases. The following eight cases were filed by the same law firm and generally make the same factual allegations:

Case	Date Filed
Mason Capital L.P., et al. v. Perrigo Company plc, et al.	1/26/2018
Pentwater Equity Opportunities Master Fund Ltd., et al.  v. Perrigo Company plc, et al.	1/26/2018
WCM Alternatives: Event-Drive Fund, et al. v. Perrigo Co., plc, et al.	11/15/2018
Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al.	11/15/2018
Discovery Global Citizens Master Fund, Ltd., et al. v. Perrigo Co. plc, et al.	12/18/2019
York Capital Management, L.P., et al. v. Perrigo Co. plc, et al.	12/20/2019
Burlington Loan Management DAC v. Perrigo Co. plc, et al.	2/12/2020
Universities Superannuation Scheme Limited v. Perrigo Co. plc, et al.	3/2/2020

The complaints in the Mason Capital case and the Pentwater case originally named Perrigo and 11 current or former directors and officers of Perrigo as defendants. In the July 2018 Roofers’ Pension Fund ruling, the court dismissed without prejudice each of the defendants other than Perrigo, Mr. Papa and Ms. Brown from that case; these plaintiffs later agreed that this ruling would apply to their cases as well. The complaints in each of the other cases in the above table name only Perrigo, Mr. Papa, and Ms. Brown as defendants.

Each complaint asserts claims under Section 14(e) of the Securities Exchange Act against all defendants, as well as control person liability under Section 20(a) of the Securities Exchange Act against the individual defendants. The complaints in the WCM case and the Universities Superannuation Scheme case also assert claims under Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.

Each complaint alleges inadequate disclosure during the tender offer period in 2015 and at various times concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset. The WCM complaint also makes these allegations for the period through May 2017 and the Universities Superannuation Scheme complaint also concerns certain times during 2016. Many of the factual allegations in these cases overlap with the allegations of the June 2017 amended complaint in the Roofers’ Pension Fund case, and the Mason Capital and Pentwater cases include factual allegations similar to those in the Carmignac case described above.

After the court issued its July 2018 opinion in the Roofers’ Pension Fund case, the parties in each of the above cases conferred and agreed that the ruling in the Roofers’ Pension Fund case would apply equally to the common allegations in their cases. The defendants in each of these cases have filed answers denying liability, and each of the cases is currently in the discovery phase.

Harel Insurance and TIAA-CREF Cases. The following two cases were filed by the same law firm and generally make the same factual allegations relating to the period from February 2014 through May 2017 (in the Harel case) and from August 2014 through May 2017 (in the TIAA-CREF case):

Case	Date Filed
Harel Insurance Company, Ltd., et al. v. Perrigo Company plc, et al.	2/13/2018
TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al.	4/20/2018

The complaints in the Harel and TIAA-CREF cases originally named Perrigo and 13 current or former directors and officers of Perrigo as defendants (adding two more individual defendants not sued in the other cases described in this section). In the July 2018 Roofers’ Pension Fund ruling, the court dismissed without prejudice 8 of the 11 defendants other than Perrigo, Mr. Papa and Ms. Brown from that case. These plaintiffs later agreed that that ruling would apply to these cases as well and also dismissed their claims against the two additional individuals that only these plaintiffs had named as defendants.

Each complaint asserts claims under Sections 10(b) and 14(e) of the Securities Exchange Act and Rule 10b-5 thereunder against all defendants, as well as control person liability under Section 20(a) of the Securities

Exchange Act against the individual defendants. The complaint in the Harel case also asserts claims based on Israeli securities laws.

Each of the complaints alleges inadequate disclosure around the tender offer events in 2015 and at various times during the relevant periods concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® asset from February 2014 until the withdrawal of past financial statements in April 2017.

After the court issued its July 2018 opinion in the Roofers’ Pension Fund case, the parties in the Harel and TIAA-CREF cases conferred and agreed that such ruling would apply equally to the common allegations in their cases. The defendants in each of these cases have filed answers denying liability, and each of the cases is currently in the discovery phase.

Other Cases Related to Events in 2015-2017. Certain allegations in the following three cases also overlap with the allegations of the June 2017 amended complaint in the Roofers' Pension Fund case and with allegations in one or more of the other individual cases described in the sections above:

Case	Date Filed
Sculptor Master Fund (f/k/a OZ Master Fund, Ltd.), et al. v. Perrigo Company plc, et al.	2/6/2019
Highfields Capital I LP, et al. v. Perrigo Company plc, et al.	6/4/2020
BlackRock Global Allocation Fund, Inc., et al. v. Perrigo Co. plc, et al.	4/21/2020
Starboard Value and Opportunity C LP, et al. v. Perrigo Company plc, et al.	2/25/2021

Each of the above complaints names Perrigo, Mr. Papa, and Ms. Brown as defendants.

The Sculptor Master Fund (formerly OZ) complaint asserts claims under Sections 10(b) and 14(e) of the Securities Exchange Act and Rule 10b-5 thereunder against all defendants, as well as control person liability under Section 20(a) of the Securities Exchange Act against the individual defendants. The parties have agreed that the court's rulings in July 2018 in the Roofers' Pension Fund case and in July 2019 in the Carmignac and related cases will apply to this case as well. The defendants have filed answers denying liability. The plaintiffs are participating in the discovery proceedings in the Roofers' Pension Fund case and the various individual cases described above.

The BlackRock Global complaint also asserts claims under Securities Exchange Act section 10(b) (and Rule 10b-5) and section 14(e) against all defendants and section 20(a) control person claims against the individual defendants largely based on the same events during the period from April 2015 through May 2017. Plaintiffs contend that the defendants provided inadequate disclosure during the tender offer period in 2015 and point to disclosures at various times during the period concerning valuation and integration of Omega, the financial guidance provided by us during that period, alleged price fixing activities with respect to six generic prescription pharmaceuticals, alleged lower performance in the generic prescription drug business during 2015 and alleged improper accounting for the Tysabri® asset. The defendants have filed answers denying liability. The plaintiffs are participating in the discovery proceedings in the Roofers' Pension Fund case and the various individual cases described above.

The Starboard Value and Opportunity C LP complaint also asserts claims under Securities Exchange Act section 10(b) (and Rule 10b-5) against all defendants and section 20(a) control person claims against the individual defendants based on events related to alleged price fixing activities with respect to generic prescription drugs during periods that overlap to some extent with the period alleged in the various other cases described above. Plaintiffs contend that the defendants provided inadequate disclosure during 2016 about generic prescription drug business and those alleged matters. The lawsuit was filed on February 25, 2021; but by agreement the case was administratively terminated by the court in June 2021 pending a decision on the same defendants’ motions currently pending before the court in the Roofers' Pension Fund case described above.

The Highfields federal case complaint asserted claims under Sections 14(e) and 18 of the Securities Exchange Act against all defendants, as well as control person liability under Section 20(a) of the Securities Exchange Act against the individual defendants. As originally filed in the U.S. District Court for the District of Massachusetts, the Highfields complaint also alleged claims under the Massachusetts Unfair Business Methods

Law (chapter 93A) and Massachusetts common law claims of tortious interference with prospective economic advantage, common law fraud, negligent misrepresentation, and unjust enrichment. The factual allegations generally were similar to the factual allegations in the Amended Complaint in the Roofers' Pension Fund case described above, except that the Highfields plaintiffs did not include allegations about alleged collusive pricing of generic prescription drugs. In March 2020, the District of Massachusetts court granted defendants’ motion and transferred the case to the U.S. District Court for the District of New Jersey so that the activities in the case could proceed in tandem with the other cases in the District of New Jersey described above. After the transfer, in June 2020, the Highfields plaintiffs voluntarily dismissed their federal lawsuit. The same Highfields plaintiffs the same day then filed a new lawsuit in Massachusetts State Court asserting the same factual allegations as in their federal lawsuit and alleging only Massachusetts state law claims under the Massachusetts Unfair Business Methods Law (chapter 93A) and Massachusetts common law claims of tortious interference with prospective economic advantage, common law fraud, negligent misrepresentation, and unjust enrichment. Defendants’ motion to dismiss was fully briefed as of late November 2020, argument occurred in early May 2021, and the motion is pending before the court.

In Israel (cases related to events in 2015-2017)

Because our shares are traded on the Tel Aviv exchange under a dual trading arrangement, we are potentially subject to securities litigation in Israel. Three cases were filed; one was voluntarily dismissed in each of 2017 and 2018 and one was stayed in 2018. We are consulting with Israeli counsel about our response to these allegations and we intend to defend this case vigorously.

On June 28, 2017, a plaintiff filed a complaint in Tel Aviv District Court styled Israel Elec. Corp. Employees’ Educ. Fund v. Perrigo Company plc, et al. The lead plaintiff seeks to represent a class of shareholders who purchased Perrigo stock on the Tel Aviv exchange during the period from April 24, 2015 through May 3, 2017 and also a claim for those that owned shares on the final day of the Mylan tender offer (November 13, 2015). The amended complaint names as defendants the Company, Ernst & Young LLP (the Company’s auditor), and 11 current or former directors and officers of Perrigo (Mses. Judy Brown, Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, and Messrs. Joe Papa, Marc Coucke, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, and Donal O’Connor). The complaint alleges violations under U.S. securities laws of Securities Exchange Act sections 10(b) (and Rule 10b‑5) and 14(e) against all defendants and 20(a) control person liability against the 11 individuals or, in the alternative, under Israeli securities laws. In general, the allegations concern the actions taken by us and our former executives to defend against the unsolicited takeover bid by Mylan in the period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure concerning purported integration problems related to the Omega acquisition, alleges incorrect reporting of organic growth at the Company, alleges price fixing activities with respect to six generic prescription pharmaceuticals, and alleges improper accounting for the Tysabri® royalty stream. The plaintiff indicates an initial, preliminary class damages estimate of 2.7 billion NIS (approximately $760.0 million at 1 NIS = 0.28 cents). After the other two cases filed in Israel were voluntarily dismissed, the plaintiff in this case agreed to stay this case pending the outcome of the Roofers’ Pension Fund case in the U.S. (described above). The Israeli court approved the stay, and this case is now stayed. We intend to defend the lawsuit vigorously.

In the United States (cases related to Irish Tax events)

On January 3, 2019, a shareholder filed a complaint against the Company, our CEO Murray Kessler, and our former CFO Ronald Winowiecki in the U.S. District Court for the Southern District of New York (Masih v. Perrigo Company, et al.). Plaintiff purported to represent a class of shareholders for the period November 8, 2018 through December 20, 2018, inclusive. The complaint alleged violations of Securities Exchange Act section 10(b) (and Rule 10b‑5) against all defendants and section 20(a) control person liability against the individual defendants. In general the allegations contended that the Company, in its Form 10-Q filed November 8, 2018, disclosed information about an October 31, 2018 audit finding letter received from Irish tax authorities but failed to disclose enough material information about that letter until December 20, 2018, when we filed a current report on Form 8‑K about Irish tax matters. The plaintiff did not provide an estimate of class damages. The court selected lead plaintiffs and changed the name of the case to In re Perrigo Company plc Sec. Litig. The lead plaintiffs filed an amended complaint on April 12, 2019, which named the same defendants, asserted the same class period, and invoked the same Exchange Act sections. The amended complaint generally repeated the allegations of the original complaint with a few additional details and adds that the defendants also failed to timely disclose the Irish tax authorities’ Notice of Amended Assessment received on November 29, 2018. Defendants filed a motion to dismiss on May 3, 2019. On May 31, 2019, the plaintiffs filed a second amended complaint, which asserted a longer class period (March 1, 2018 through December 20, 2018) and added one additional individual defendant, former CEO Uwe Roehrhoff. In general, the second amended complaint contends that Perrigo’s disclosures about the Irish tax audit were inadequate beginning with Perrigo’s 10-K filed on March 1, 2018 through December 20, 2018 and repeats many of the allegations of the April 2019 amended complaint. The second amended complaint alleges violations of Securities Exchange Act section 10(b) (and Rule 10b-5) against all defendants and section 20(a) control person liability against the three individual defendants. All defendants filed a joint motion to dismiss, and the motion was fully briefed. On January 23, 2020, the court granted the motion to dismiss in part and denied it in part, dismissing Mr. Roehrhoff as a defendant and dismissing allegations of inadequate disclosures related to the audit by Irish Revenue during the period March 2018 through October 30, 2018. The court permitted the plaintiffs to pursue their claims against us, Mr. Kessler, and Mr. Winowiecki related to disclosures after Perrigo received the October 30, 2018 audit findings letter and later events through December 20, 2018. The defendants filed answers on February 13, 2020 denying liability, and the court issued a scheduling order on March 3, 2020 that has been subsequently modified. Discovery on the remaining issues ended in early March 2021. Plaintiffs filed a motion for class certification, which was granted in September 2020. In January 2021, class plaintiffs filed a motion for leave to file a third amended complaint in an effort to revive their claim that the disclosure of the audit during the period from March 1, 2018 to October 30, 2018 was also inadequate. The court denied the motion in February 2021. Defendants filed motions for summary judgement and other post discovery motions on March 31, 2021 and plaintiffs filed cross-motions of the same type on the same day. All motions were fully briefed by late May 2021. During the week of July 11, 2021, the Court issued various opinions and orders denying some of the motions by both parties, and granting in part certain motions by plaintiffs. Defendants filed a motion for reconsideration for some of the rulings in late July, which the court granted in part in August. The court also indicated that the parties should prepare for trial in mid-October 2021 (subject to COVID-19 developments), without setting an exact trial date.

The court simultaneously ordered mediation, which led to a settlement that the parties first publicly announced in a court filing on September 8, 2021. Trial was cancelled when a settlement was reached. Motion papers seeking approval of the class action settlement were filed on October 4, 2021. The court issued a preliminary approval order on October 29, 2021, which will lead to the issuance of notices to class members. The final approval hearing is set for February 16, 2022. The settlement will be funded by insurance.

In Israel (case related to Irish Tax events)

On December 31, 2018, a shareholder filed an action against the Company, our CEO Murray Kessler, and our former CFO Ronald Winowiecki in Tel Aviv District Court (Baton v. Perrigo Company plc, et. al.). The case is a securities class action brought in Israel making similar factual allegations for the same period as those asserted in the In re Perrigo Company plc Sec. Litig case in New York federal court. This case alleges that persons who invested through the Tel Aviv stock exchange can assert claims under Israeli securities law that will follow the liability principles of Sections 10(b) and 20(a) of the U.S. Securities Exchange Act. The plaintiff does not provide an estimate of class damages. In 2019, the court granted two requests by Perrigo to stay the proceedings pending the resolution of proceedings in the United States. Perrigo filed a further request for a stay in February 2020, and the court granted the stay indefinitely. The plaintiff filed a motion to lift the stay then later agreed that the case should remain stayed through February 2021. In late February 2021, Perrigo filed a motion to extend the stay to mid-May 2021, and plaintiff later agreed to the request. The case is currently stayed until December 15, 2021. We intend to defend the lawsuit vigorously.

Claim Arising from the Omega Acquisition

On December 16, 2016, we and Perrigo Ireland 2 brought an arbitral claim ("Claim") against Alychlo NV ("Alychlo") and Holdco I BE NV (together the "Sellers") in accordance with clause 26.2 of the Share Purchase Agreement dated November 6, 2014 ("SPA") and the rules of the Belgian Centre for Arbitration and Mediation ("CEPANI"). Our Claim relates to the accuracy and completeness of information about Omega provided by the Sellers as part of the sale process, the withholding of information by the Sellers during that process and breaches of Sellers’ warranties. We are seeking monetary damages from the Sellers. The Sellers served their respective responses to the Claim on February 20, 2017. In its response, Alychlo asserted a counterclaim for monetary damages contending that we breached a warranty in the SPA and breached the duty of good faith in performing the SPA. Alychlo subsequently filed papers seeking permission to introduce an additional counterclaim theory of recovery related to the Irish tax issues disclosed by the Company such that if the position of the Irish tax authorities prevails, Alychlo would have further basis for its counterclaim against Perrigo. In June 2019, the Tribunal denied permission for Alychlo to introduce the additional counterclaim and dismissed certain aspects of the original Alychlo counterclaim.

On August 27, 2021 the Tribunal issued its ruling. The panel found fraud by the Sellers of Omega and awarded Perrigo approximately €355.0 million ($417.6 million at the time of cash receipt) including fees and costs. The panel also ruled against the Sellers and in favor of Perrigo on all counterclaims. The Sellers have paid all amounts owed under the award which Perrigo publicly announced in a press release issued September 29, 2021. The Sellers have the right to challenge the Tribunal’s award for up to three months following the date of the award (until late November 2021). The arbitration proceedings are confidential as required by the SPA and the rules of CEPANI.

Other Matters

Talcum Powder

The Company has been named, together with other manufacturers, in product liability lawsuits in state courts in California, Florida, Missouri, New Jersey, Louisiana and Illinois alleging that the use of body powder products containing talcum powder causes mesothelioma and lung cancer due to the presence of asbestos. All but one of these cases involve legacy talcum powder products that have not been manufactured by the Company since 1999. One of the pending actions involves a current prescription product that contains talc as an excipient. As of October 2, 2021, the Company is currently named in 57 individual lawsuits seeking compensatory and punitive damages and has accepted a tender for a portion of the defense costs and liability from a retailer for one additional matter. The Company has several defenses and intends to aggressively defend these lawsuits. Trials for these lawsuits are currently scheduled throughout 2021, 2022 and 2023, with the earliest that began in September 2021.

Ranitidine

After regulatory bodies announced worldwide that ranitidine may potentially contain N-nitrosodimethylamine ("NDMA"), a known environmental contaminant, the Company promptly began testing its externally-sourced ranitidine API and ranitidine-based products. On October 8, 2019, the Company halted shipments of the product based upon preliminary results and on October 23, 2019, the Company made the decision to conduct a voluntary retail market withdrawal.

In February 2020, the resulting actions involving Zantac® and other ranitidine products were transferred for coordinated pretrial proceedings to a Multi-District Litigation (In re Zantac®/Ranitidine Products Liability Litigation MDL No. 2924) in the U.S. District Court for the Southern District of Florida. After the Company successfully moved to dismiss the first set of Master Complaints in the MDL, it now includes three: 1) an Amended Master Personal Injury Complaint; 2) a Consolidated Amended Consumer Economic Loss Class Action Complaint; and 3) a Consolidated Medical Monitoring Class Action Complaint. All three name the Company. Plaintiffs appealed one of the original Master Complaints, the Third-Party Payor Complaint, and two individual plaintiffs appealed their individual personal injury claims on limited grounds. The Company is not named in the appeals.

On June 30, 2021, the Court dismissed all claims against the retail and distributor defendants with prejudice, thereby reducing the Company’s potential for exposure and liability related to possible indemnification. On July 8, 2021, the Court dismissed all claims against the Company with prejudice. Appeals of these dismissal

orders to the U.S. Court of Appeals for the 11th Circuit have been filed, as well several state level claims related to the theories advanced in the MDL litigation. The Company will continue to vigorously defend each of these lawsuits.

As of November 5, 2021, the Company has been named in two hundred eighty (280) of the MDL’s consolidated personal injury lawsuits tied to various federal courts alleging that plaintiffs developed various types of cancers or are placed at higher risk of developing cancer as a result of ingesting products containing ranitidine. The Company is named in these lawsuits with manufacturers of the national brand Zantac® and other manufacturers of ranitidine products, as well as distributors, repackagers, and/or retailers. Plaintiffs seek compensatory and punitive damages, and in some instances seek applicable remedies under state consumer protection laws.

The Company has also been named in a Complaint brought by the New Mexico Attorney General based on the following theories: violation of a New Mexico public nuisance statute, NMSA 30-8-1 to -14; common law nuisance; and negligence and gross negligence. The Company is named in this lawsuit with manufacturers of the national brand Zantac® and other manufacturers of ranitidine products and/or retailers. Brand name manufactures named in the lawsuit also face claims under the state’s Unfair Practices & False Advertising acts. Likewise, the Company has also been named in a Complaint brought by the Mayor and City Council of Baltimore, along with manufacturers of the national brand Zantac® and other manufacturers of ranitidine products and/or retailers. This action brings claims under the Maryland Consumer Protection Act against the brand name defendants only, as well as public nuisance and negligence for the remaining defendants. The Company was originally able to consolidate the New Mexico and Baltimore Actions to the MDL, however both actions were recently remanded to state court. The Company filed motions to dismiss in both actions. The New Mexico District Court denied the Company’s Motion to Dismiss and litigation continues. The Maryland Circuit Court has not issued a ruling on the Company’s Motion. The Company will continue to vigorously defend each of these lawsuits.

Some of the Company’s retailer customers are seeking indemnity from the Company for a portion of their defense costs and liability relating to these cases.

Acetaminophen

The Company has received requests for indemnification and defense of several consumer fraud claims involving its store brand infants’ and children’s acetaminophen products. In September 2020, the Company was directly named as a defendant in one suit filed in the Central District of California. The Company was recently named in a cross complaint by a retailer for contractual indemnity in California Superior Court, Alameda County. The Company has also received 16 different claims for indemnification or defense from 10 different retailers for lawsuits filed in California, Illinois, Florida, Minnesota and Pennsylvania, with nationwide class action allegations.

The Plaintiffs generally allege that the children’s and infants’ acetaminophen products have identical drug concentration amounts, yet the infants’ product costs more than the children’s product and consumers have been misled into purchasing the more expensive product. The Company will aggressively defend the suits in which it is named and is continuing to assess whether, or to what extent, the Company may contribute in the lawsuits filed against its retail customers.

Guarantee Liability Related to The Israel API Sale

During the year ended December 31, 2017, we completed the sale of our Israel API business to SK Capital, resulting in a guarantee liability of $13.8 million, classified as a Level 3 liability within the fair value hierarchy. Pursuant to the agreement, we will be reimbursed for tax receivables for tax years prior to closing and will need to reimburse SK Capital for the settlement of any uncertain tax liability positions for tax years prior to closing. In addition, after closing and going forward, the Israel API business will be assessed by and liable to the ITA for any audit findings. We are no longer the primary obligor on the liabilities transferred to SK Capital, but we have provided a guarantee on certain obligations. During the three months ended July 3, 2021, we paid $12.5 million to resolve the tax liability indemnity for the tax year ended December 31, 2017 (refer to Note 15). At October 2, 2021 and December 31, 2020, the remaining guarantee liability was $0.6 million and $13.2 million, respectively.

Contingencies Accruals

As a result of the matters discussed in this Note, the Company has established a loss accrual for litigation contingencies where we believe a loss to be probable and for which an amount of loss can be reasonably estimated. However, we cannot determine a reasonable estimate of the maximum possible loss or range of loss for these matters given that they are at various stages of the litigation process and each case is subject to inherent uncertainties of litigation. At October 2, 2021, the loss accrual for litigation contingencies reflected on the balance sheet in Other accrued liabilities was approximately $96.9 million. The Company also recorded an insurance recovery receivable reflected on the balance sheet in Prepaid expenses and other current assets of approximately $83.4 million related to these litigation contingencies because it believes such amount is recoverable based on communications with its insurers to date; however, the Company may erode this insurance receivable as it incurs defense costs associated with defending the matters. The Company’s management believes these accruals for contingencies are reasonable and sufficient based upon information currently available to management; however, there can be no assurance that final costs related to these contingencies will not exceed current estimates or that all of the final costs related to these contingencies will be covered by insurance. (See "Insurance Coverage Litigation," below.) In addition, we have other litigation matters pending for which we have not recorded any accruals because our potential liability for those matters is not probable or cannot be reasonably estimated based on currently available information. For those matters where we have not recorded an accrual but a loss is reasonably possible, we cannot determine a reasonable estimate of the maximum possible loss or range of loss for these matters given that they are at various stages of the litigation process and each case is subject to the inherent uncertainties of litigation.

Insurance Coverage Litigation

In May 2021 insurers on multiple policies of D&O insurance filed an action in the High Court in Dublin against the Company and multiple current and former directors and officers of the Company seeking declaratory judgments on certain coverage issues. Those coverage issues include claims that policies for periods beginning in December 2015 and December 2016, respectively, do not have to provide coverage for the securities actions described above pending in the District of New Jersey or in Massachusetts state court concerning the events of 2015-2017. The policy for the period beginning December 2014 is currently providing coverage for those matters, and the litigation would not affect that existing coverage. However, if the plaintiffs are successful, the total amount of insurance coverage available to defend such lawsuits and to satisfy any judgment or settlement costs thereunder would be limited to one policy period. The insurers’ lawsuit also challenges coverage for Krueger derivatively on behalf of nominal defendant Perrigo Company plc v. Alford et al., a prior derivative action filed in the District of New Jersey that was dismissed in August 2020, and for the counterclaims brought in the Omega arbitration proceedings. Perrigo responded on November 1, 2021; Perrigo’s response includes its position that the policies for the periods beginning December 2015 and December 2016 provide coverage for the underlying litigation matters and seeks a ruling to that effect. We intend to defend the lawsuit vigorously.

XML

Restructuring Charges

9 Months Ended

Oct. 02, 2021

Restructuring Charges [Abstract]

Restructuring Charges

RESTRUCTURING CHARGES

We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, lease exit costs, and related consulting fees. The following reflects our restructuring activity (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Beginning balance	$	10.2	$	9.4	$	9.1	$	19.5
Additional charges	1.0		0.8		11.8		1.5
Payments	(3.7)		(2.9)		(13.3)		(13.7)
Non-cash adjustments	(0.1)		0.2		(0.2)		0.2
Ending balance	$	7.4	$	7.5	$	7.4	$	7.5

The charges incurred during the three and nine months ended October 2, 2021 and September 26, 2020 were primarily associated with actions taken to streamline the organization.

There were no other material restructuring programs for the three and nine months ended October 2, 2021 and September 26, 2020. All charges are recorded in Restructuring expense on the Condensed Consolidated Statements of Operations. The remaining $7.4 million liability for employee severance benefits is expected to be paid within the next year.

XML

Segment Information

9 Months Ended

Oct. 02, 2021

Segment Reporting [Abstract]

Segment Information

SEGMENT INFORMATION

Our segments reflect the way in which our management makes operating decisions, allocates resources, and manages the growth and profitability of the Company. As discussed in Note 8, as of March 1, 2021, the financial results and assets and liabilities of the RX business are classified as discontinued operations in the Condensed Consolidated Statements of Operations and Condensed Consolidated Balance Sheets. As discussed in Note 9, as of July 3, 2021, the assets and liabilities of the Latin American businesses were classified as held for sale. The RX business and Latin American businesses assets held-for-sale are included below in the summary of total assets.

The tables below show select financial measures by reporting segment (in millions):

	Total Assets
	October 2, 2021		December 31, 2020
CSCA	$	6,290.6	$	4,585.1
CSCI	4,611.9		4,872.4
Held for sale	13.4		2,030.9
Total	$	10,915.9	$	11,488.4

	Three Months Ended
	October 2, 2021						September 26, 2020
	Net Sales		Operating Income (Loss)		Intangible Asset Amortization		Net Sales		Operating Income (Loss)		Intangible Asset Amortization
CSCA	$	694.2	$	90.4	$	12.7	$	664.0	$	121.7	$	13.0
CSCI	348.5		4.3		39.5		339.0		10.1		40.3
Unallocated	—		343.6		—		—		(53.3)		—
Continuing Operations Total	$	1,042.7	$	438.3	$	52.2	$	1,003.0	$	78.5	$	53.3

	Nine Months Ended
	October 2, 2021						September 26, 2020
	Net Sales		Operating Income (Loss)		Intangible Asset Amortization		Net Sales		Operating Income (Loss)		Intangible Asset Amortization
CSCA	$	1,957.0	$	113.9	$	38.7	$	1,992.2	$	348.4	$	40.6
CSCI	1,076.8		23.1		120.3		1,042.8		45.7		116.9
Unallocated	—		226.7		—		—		(166.5)		—
Continuing Operations Total	$	3,033.8	$	363.7	$	159.0	$	3,035.0	$	227.6	$	157.5

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Oct. 02, 2021

Accounting Policies [Abstract]

Basis of Presentation

Basis of PresentationThe accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2020.

Principles of consolidation

In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.On March 1, 2021, we announced a definitive agreement to sell our generic RX Pharmaceuticals business ("RX business") to Altaris Capital Partners, LLC ("Altaris"). On July 6, 2021, we completed the sale of the RX business. The financial results of our RX business, which were previously reported in our Prescription Pharmaceuticals ("RX") segment, have been classified as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented. The assets and liabilities of our RX business are reflected as assets and liabilities held for sale in the Condensed Consolidated Balance Sheets for all periods presented prior to the sale. Refer to Note 8 for additional information regarding discontinued operations. Unless otherwise noted, amounts and disclosures throughout the Notes to the unaudited Condensed Consolidated Financial Statements relate to our continuing operations.

Segment Reporting

Segment Reporting

Our reporting and operating segments are as follows:

•Consumer Self-Care Americas ("CSCA") comprises our consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the U.S., Mexico and Canada.

•Consumer Self-Care International ("CSCI") comprises our consumer self-care business primarily branded in Europe and Australia, our store brand business in the United Kingdom and parts of Europe and Asia, and our liquid licensed products business in the United Kingdom until it was disposed on June 19, 2020.

Allowance for Credit Losses

Allowance for Credit Losses

Expected credit losses on trade receivables and contract assets are measured collectively by geographic location. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and for reasonable and supportable forecasts. Historical credit loss experience provides the primary basis for estimation of expected credit losses. Adjustments to historical loss information may be made for

significant changes in a geographic location’s economic conditions. Receivables that do not share risk characteristics are evaluated on an individual basis. These receivables are not included in the collective evaluation.The allowance for credit losses is a valuation account that is deducted from the instruments’ cost basis to present the net amount expected to be collected. Trade receivables and contract assets are charged off against the allowance when the balance is no longer deemed collectible.

XML

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Oct. 02, 2021

Accounting Policies [Abstract]

Allowance for Credit Losses

The following table presents the allowance for credit losses activity (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Beginning balance	$	7.7	$	5.5	$	6.5	$	6.0
Provision for credit losses, net	0.1		0.6		3.7		1.1
Receivables written-off	—		(0.4)		(0.7)		(1.5)
Transfer to held for sale	—		—		(1.4)		—
Currency translation adjustment	(0.2)		0.1		(0.5)		0.2
Ending balance	$	7.6	$	5.8	$	7.6	$	5.8

XML

Revenue Recognition (Tables)

9 Months Ended

Oct. 02, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

We generated net sales in the following geographic locations(1) (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
U.S.	$	657.4	$	638.7	$	1,859.0	$	1,913.4
Europe(2)	334.5		326.6		1,037.6		1,011.0
All other countries(3)	50.8		37.7		137.2		110.6
Total net sales	$	1,042.7	$	1,003.0	$	3,033.8	$	3,035.0

(1) Derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $7.6 million and $17.4 million for the three and nine months ended October 2, 2021 respectively, and $10.8 million and $22.3 million for the three and nine months ended September 26, 2020, respectively.

(3) Includes net sales generated primarily in Mexico, Australia and Canada.

Product Category

The following is a summary of our net sales by category (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
CSCA(1)
Upper respiratory	$	121.9	$	117.1	$	345.8	$	397.2
Digestive health	110.6		111.8		344.0		339.9
Pain and sleep-aids	108.4		102.6		292.9		325.7
Nutrition	105.3		100.3		293.3		291.5
Oral self-care	76.7		81.9		227.4		202.5
Healthy lifestyle	72.9		86.9		214.9		256.2
Skincare and personal hygiene	56.0		51.4		165.9		145.4
Vitamins, minerals, and supplements	8.1		6.3		24.3		19.1
Other CSCA(2)	34.3		5.7		48.5		14.7
Total CSCA	694.2		664.0		1,957.0		1,992.2
CSCI
Skincare and personal hygiene	88.5		83.1		307.9		275.4
Upper respiratory	58.7		62.3		144.2		191.9
Vitamins, minerals, and supplements	54.7		52.9		162.8		139.9
Pain and sleep-aids	52.1		49.0		148.4		136.0
Healthy lifestyle	42.2		40.6		140.5		124.7
Oral self-care	24.4		25.2		72.4		68.8
Digestive health	10.1		6.8		28.3		17.9
Other CSCI(3)	17.8		19.1		72.3		88.2
Total CSCI	348.5		339.0		1,076.8		1,042.8
Total net sales	$	1,042.7	$	1,003.0	$	3,033.8	$	3,035.0

(1) Includes net sales from our OTC contract manufacturing business.

(2) Consists primarily of diagnostic and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

(3) Consists primarily of our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

Contract with Customer Balances

The following table provides information about contract assets from contracts with customers (in millions):

	Balance Sheet Location	October 2, 2021		December 31, 2020
Short-term contract assets	Prepaid expenses and other current assets	$	42.2	$	19.7

XML

Acquisitions and Divestitures (Tables)

9 Months Ended

Oct. 02, 2021

Business Combination and Asset Acquisition [Abstract]

Schedule of Assets Acquired and Liabilities Assumed

The following table summarizes the consideration paid for Dr. Fresh and the amounts of the assets acquired and liabilities assumed (in millions):

	Oral Care Assets of High Ridge Brands (Dr. Fresh)
Purchase price paid	$	106.2
Assets acquired:
Accounts receivable	13.1
Inventories	22.2
Prepaid expenses and other current assets	0.4
Property, plant and equipment, net	0.7
Operating lease assets	2.6
Goodwill	17.2
Distribution and license agreements and supply agreements	$	2.2
Developed product technology, formulations, and product rights	0.1
Customer relationships and distribution networks	20.6
Trademarks, trade names, and brands	43.2
Total intangible assets	$	66.1
Total assets	$	122.3
Liabilities assumed:
Accounts payable	$	6.1
Other accrued liabilities	3.8
Payroll and related taxes	0.7
Accrued customer programs	3.0
Other non-current liabilities	2.5
Total liabilities	$	16.1
Net assets acquired	$	106.2

Business Acquisition, Pro Forma Information

The following table presents unaudited pro forma information as if the acquisitions of Dr. Fresh and the Eastern European Brands occurred on January 1, 2019, and had been combined with the results reported in our Condensed Consolidated Statements of Operations for all periods presented (in millions):

	Three Months Ended		Nine Months Ended
(Unaudited)	September 26, 2020		September 26, 2020
Net sales	$	1,009.2	$	3,083.2
Income from continuing operations	$	28.5	$	108.7

XML

Goodwill and Intangible Assets (Tables)

9 Months Ended

Oct. 02, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):

	December 31, 2020		Purchase accounting adjustments		Impairments		Currency translation adjustments		October 2, 2021
CSCA(1)	$	1,905.0	$	2.4	$	(6.1)	$	(0.7)	$	1,900.6
CSCI(2)	1,190.7		(2.4)		—		(57.5)		1,130.8
Total goodwill	$	3,095.7	$	—	$	(6.1)	$	(58.2)	$	3,031.4

(1) We had no accumulated goodwill impairments as of December 31, 2020 and $6.1 million as of October 2, 2021.

(2) We had accumulated goodwill impairments of $868.4 million as of December 31, 2020 and October 2, 2021.

Schedule of Finite and Indefinite-lived Intangible Assets

Intangible assets and related accumulated amortization consisted of the following (in millions):

	October 2, 2021				December 31, 2020
	Gross		Accumulated Amortization		Gross		Accumulated Amortization
Indefinite-lived intangibles:
Trademarks, trade names, and brands	$	3.6	$	—	$	4.3	$	—
In-process research and development	1.9		—		2.7		—
Total indefinite-lived intangibles	$	5.5	$	—	$	7.0	$	—
Definite-lived intangibles:
Distribution and license agreements and supply agreements	$	72.8	$	56.1	$	74.8	$	55.4
Developed product technology, formulations, and product rights	300.7		187.6		303.3		177.3
Customer relationships and distribution networks	1,844.1		872.2		1,920.5		823.7
Trademarks, trade names, and brands	1,506.0		381.5		1,581.5		342.2
Non-compete agreements	2.1		2.1		2.9		2.9
Total definite-lived intangibles	$	3,725.7	$	1,499.5	$	3,883.0	$	1,401.5
Total intangible assets	$	3,731.2	$	1,499.5	$	3,890.0	$	1,401.5

XML

Inventories (Tables)

9 Months Ended

Oct. 02, 2021

Inventory Disclosure [Abstract]

Major Components of Inventory

Major components of inventory were as follows (in millions):

 

	October 2, 2021		December 31, 2020
Finished goods	$	617.1	$	574.1
Work in process	240.9		220.4
Raw materials	234.5		264.9
Total inventories	$	1,092.5	$	1,059.4

XML

Fair Value Measurements (Tables)

9 Months Ended

Oct. 02, 2021

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring and Nonrecurring Basis

The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):

	October 2, 2021						December 31, 2020
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Measured at fair value on a recurring basis:
Assets:
Investment securities	$	1.5	$	—	$	—	$	2.5	$	—	$	—
Foreign currency forward contracts	—		5.8		—		—		9.8		—
Cross-currency swap	—		—		—		—		6.3		—
Foreign currency option contracts	—		13.3		—		—		—		—
Total assets	$	1.5	$	19.1	$	—	$	2.5	$	16.1	$	—
Liabilities:
Cross-currency swap	$	—	$	24.1	$	—	$	—	$	—	$	—
Foreign currency forward contracts	—		1.8		—		—		7.9		—
Total liabilities	$	—	$	25.9	$	—	$	—	$	7.9	$	—
Measured at fair value on a non-recurring basis:
Liabilities
Liabilities held for sale, net(1)	$	—	$	—	$	15.8	$	—	$	—	$	—
Total liabilities	$	—	$	—	$	15.8	$	—	$	—	$	—

(1)     We measured the net assets held for sale for impairment purposes and recorded a total impairment of $161.2 million, resulting in a net liability held for sale balance (refer to Note 9).

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

The table below summarizes the change in fair value of the Royalty Pharma contingent milestone (in millions):

	Three Months Ended		Nine Months Ended
	September 26, 2020		September 26, 2020
Beginning balance	$	99.0	$	95.3
Change in fair value	22.2		25.9
Ending balance	$	121.2	$	121.2

Schedule of Fair Value Assumptions

The table below represents the volatility and rate of return:

	Three Months Ended
	September 26, 2020
Volatility	30.0	%
Rate of return	6.84	%

Schedule of Carrying Values and Estimated Fair Values of Debt Instruments

Our fixed rate long-term debt consisted of the following (in millions):

	October 2, 2021				December 31, 2020
	Level 1		Level 2		Level 1		Level 2
Public Bonds
Carrying Value (excluding discount)	$	2,760.0	$	—	$	2,760.0	$	—
Fair value	$	2,906.0	$	—	$	3,031.1	$	—
Private placement note
Carrying value (excluding premium)	$	—	$	156.6	$	—	$	164.9
Fair value	$	—	$	166.9	$	—	$	177.5

XML

Investments (Tables)

9 Months Ended

Oct. 02, 2021

Investments [Abstract]

Equity Securities

The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):

Measurement Category	Balance Sheet Location	October 2, 2021		December 31, 2020
Fair value method	Prepaid expenses and other current assets	$	1.5	$	2.5
Fair value method(1)	Other non-current assets	$	1.8	$	1.9
Equity method	Other non-current assets	$	69.0	$	69.8

(1)     Measured at fair value using the Net Asset Value practical expedient.

Equity Security Expense (Income)

The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):

		Three Months Ended				Nine Months Ended
Measurement Category	Income Statement Location	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Fair value method	Other (income) expense, net	$	—	$	(0.4)	$	0.9	$	2.2
Equity method	Other (income) expense, net	$	—	$	(1.1)	$	0.8	$	(2.6)

XML

Discontinued Operations (Tables)

9 Months Ended

Oct. 02, 2021

Discontinued Operations, Disposed of by Sale | RX

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Discontined Operations - Financial Statement Information

Income from discontinued operations, net of tax was as follows (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Net sales	$	0.5	$	210.7	$	405.1	$	738.8
Cost of sales	0.1		149.8		258.4		496.2
Gross profit	0.4		60.9		146.7		242.6
Operating expenses
Distribution	—		3.6		6.1		11.4
Research and development	0.2		11.9		30.8		42.1
Selling	0.1		7.6		16.3		22.3
Administration	4.9		8.7		35.6		23.2
Impairment charges	—		202.4		—		202.4
Restructuring	—		—		—		0.4
Other operating expense (income)	—		0.6		(0.4)		0.8
Total operating expenses	5.2		234.8		88.4		302.6
Operating income (loss)	(4.8)		(173.9)		58.3		(60.0)
Interest expense, net	—		0.7		0.8		3.2
Other (income) expense, net	(63.7)		1.5		(65.5)		(0.7)
Income before income taxes	58.9		(176.1)		123.0		(62.5)
Income tax expense (benefit)	63.9		4.9		38.5		21.5
Income (loss) from discontinued operations, net of tax	$	(5.0)	$	(181.0)	$	84.5	$	(84.0)

During the three and nine months ended October 2, 2021, we incurred $29.1 million and $40.8 million, respectively, of separation costs related to the sale of the RX business. The costs incurred during the three months ended October 2, 2021 included selling costs, which were reported in other (income) expense, net as part of the gain on sale of the RX business. Separation costs incurred in prior periods were included in administration expenses.

Select cash flow information related to discontinued operations was as follows (in millions):

	Nine Months Ended
	October 2, 2021		September 26, 2020
Cash flows from discontinued operations operating activities:
Depreciation and amortization	$	15.3	$	72.4
Impairment charges	—		202.4
Loss (Gain) on sale of business	(63.9)		—
Cash flows from discontinued operations investing activities:
Asset acquisitions	$	(69.7)	$	(0.9)
Additions to property, plant and equipment	(6.6)		(10.0)
Net proceeds from sale of business	1,493.1		—

The assets and liabilities classified as held for sale related to discontinued operations were as follows (in millions):

	December 31, 2020
Cash and cash equivalents	$	10.0
Accounts receivable, net of allowance for credit losses of $1.1	460.7
Inventories	140.8
Prepaid expenses and other current assets	55.4
Current assets held for sale	666.9
Property, plant and equipment, net	131.4
Operating lease assets	31.3
Goodwill and indefinite-lived intangible assets	681.2
Definite-lived intangible assets, net	492.8
Deferred income taxes	3.6
Other non-current assets	23.7
Non-current assets held for sale	1,364.0
Total assets held for sale	$	2,030.9
Accounts payable	$	92.2
Payroll and related taxes	22.3
Accrued customer programs	237.4
Other accrued liabilities	67.2
Current indebtedness	0.5
Current liabilities held for sale	419.6
Long-term debt, less current portion	0.7
Deferred income taxes	3.1
Other non-current liabilities	104.5
Non-current liabilities held for sale	108.3
Total liabilities held for sale	$	527.9

XML

Derivative Instruments and Hedging Activities (Tables)

9 Months Ended

Oct. 02, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Foreign Currency Forward Contracts

Foreign currency forward contracts were as follows (in millions):

	Notional Amount
	October 2, 2021		December 31, 2020
European Euro (EUR)	$	1,277.7	$	312.6
British Pound (GBP)	121.5		92.3
Israeli Shekel (ILS)	—		94.4
Danish Krone (DKK)	44.8		65.2
Swedish Krona (SEK)	41.9		41.2
Chinese Yuan (CNY)	36.2		49.1
United States Dollar (USD)	21.2		101.5
Polish Zloty (PLZ)	17.9		21.8
Canadian Dollar (CAD)	17.7		36.8
Norwegian Krone (NOK)	9.9		7.8
Switzerland Franc (CHF)	6.9		8.2
Turkish Lira (TRY)	4.7		4.0
Australian Dollar (AUD)	3.8		11.3
Romanian New Leu (RON)	3.7		3.6
Mexican Peso (MPX)	0.6		15.6
Other	2.2		2.3
Total	$	1,610.7	$	867.7

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The balance sheet location and gross fair value of our outstanding derivative instruments were as follows (in millions):

		Asset Derivatives
		Fair Value
	Balance Sheet Location	October 2, 2021		December 31, 2020
Designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	5.0	$	5.0
Foreign currency forward contracts	Other non-current assets	0.4		0.5
Cross-currency swap	Other non-current assets	—		6.3
Total designated derivatives		$	5.4	$	11.8
Non-designated derivatives:
Foreign currency forward contracts	Prepaid expenses and other current assets	$	0.4	$	4.3
Foreign currency options	Prepaid expenses and other current assets	13.3		—
Total non-designated derivatives		$	13.7	$	4.3

		Liability Derivatives
		Fair Value
	Balance Sheet Location	October 2, 2021		December 31, 2020
Designated derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	0.4	$	5.5
Cross-currency swap	Other accrued liabilities	24.1		—
Total designated derivatives		$	24.5	$	5.5
Non-designated derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	1.4	$	2.4

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)

The following tables summarize the effect of derivative instruments designated as hedging instruments in Accumulated Other Comprehensive Income ("AOCI") (in millions):

	Three Months Ended
	October 2, 2021
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Interest rate swap agreements	$	—	Interest expense, net	$	(0.4)	Interest expense, net	$	—
Foreign currency forward contracts	2.4		Net sales	(0.4)		Net sales	—
			Cost of sales	(0.5)		Cost of sales	—
						Other (income) expense, net	0.2
	$	2.4		$	(1.3)		$	0.2
Net investment hedges:
Cross-currency swap	$	(28.4)				Interest expense, net	$	(0.9)

	Nine Months Ended
	October 2, 2021
Instrument	Amount of Gain/(Loss) Recorded in OCI(1)		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Treasury locks	$	—	Interest expense, net	$	(0.1)	Interest expense, net	$	—
Interest rate swap agreements	—		Interest expense, net	(1.3)		Interest expense, net	—
Foreign currency forward contracts	2.0		Net sales	(2.3)		Net sales	—
			Cost of sales	1.4		Cost of sales	0.4
						Other (income) expense, net	0.6
	$	2.0		$	(2.3)		$	1.0
Net investment hedges:
Cross-currency swap	$	(30.5)				Interest expense, net	$	(2.9)

(1) Net loss of $7.9 million is expected to be reclassified out of AOCI into earnings during the next 12 months.

	Three Months Ended
	September 26, 2020
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Interest rate swap agreements	$	—	Interest expense, net	$	(0.4)	Interest expense, net	$	—
Foreign currency forward contracts	(1.5)		Net sales	(0.1)		Net sales	—
			Cost of sales	1.3		Cost of sales	0.2
	$	(1.5)		$	0.8		$	0.2
Net investment hedges:
Cross-currency swap	$	(0.3)				Interest expense, net	$	0.9
Foreign currency forward contract	(11.7)					Interest expense, net	(0.1)
	$	(12.0)					$	0.8

	Nine Months Ended
	September 26, 2020
Instrument	Amount of Gain/(Loss) Recorded in OCI		Classification of Gain/(Loss) Reclassified from AOCI into Earnings	Amount of Gain/(Loss) Reclassified from AOCI into Earnings		Classification of Gain/(Loss) Recognized into Earnings Related to Amounts Excluded from Effectiveness Testing	Amount of Gain/(Loss) Recognized in Earnings on Derivatives Related to Amounts Excluded from Effectiveness Testing
Cash flow hedges:
Treasury locks	$	—	Interest expense, net	$	(0.1)	Interest expense, net	$	—
Interest rate swap agreements	—		Interest expense, net	(1.3)		Interest expense, net	—
Foreign currency forward contracts	8.3		Net sales	(0.1)		Net sales	0.1
			Cost of sales	0.3		Cost of sales	0.8
	$	8.3		$	(1.2)		$	0.9
Net investment hedges:
Cross-currency swap	$	(18.6)				Interest expense, net	$	5.6
Foreign currency forward contract	(11.2)					Interest expense, net	(0.1)
	$	(29.8)					$	5.5

Amount of Gain/(Loss) Recognized against Earnings

The amounts of (income)/expense recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):

		Three Months Ended				Nine Months Ended
Non-Designated Derivatives	Income Statement Location	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Foreign currency forward contracts	Other (income) expense, net	$	(0.1)	$	(0.3)	$	(6.1)	$	(1.3)
	Interest expense, net	0.2		0.9		1.2		2.8
		$	0.1	$	0.6	$	(4.9)	$	1.5
Foreign currency options	Other (income) expense, net	$	12.6	$	—	$	12.6	$	—

Classification of Gain (Loss) Recognized in Earnings on Fair Value and Cash Flow Hedging Relationships

The classification and amount of gain/(loss) recognized in earnings on fair value and hedging relationships were as follows (in millions):

	Three Months Ended
	October 2, 2021
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	1,042.7	$	706.3	$	30.9	$	18.5
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(0.4)	$	(0.5)	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	—	$	—	$	0.2
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.4)	$	—

	Nine Months Ended
	October 2, 2021
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	3,033.8	$	1,980.0	$	94.5	$	20.4
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(2.3)	$	1.4	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	0.4	$	—	$	0.6
Treasury locks
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.1)	$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(1.3)	$	—

	Three Months Ended
	September 26, 2020
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	1,003.0	$	633.3	$	33.3	$	(1.0)
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(0.1)	$	1.3	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	—	$	0.2	$	—	$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.4)	$	—

	Nine Months Ended
	September 26, 2020
	Net Sales		Cost of Sales		Interest Expense, net		Other (Income) Expense, net
Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded	$	3,035.0	$	1,924.5	$	94.3	$	17.9
The effects of cash flow hedging:
Gain (loss) on cash flow hedging relationships
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	$	(0.1)	$	0.3	$	—	$	—
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$	0.1	$	0.8	$	—	$	—
Treasury locks
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(0.1)	$	—
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$	—	$	—	$	(1.3)	$	—

XML

Leases (Tables)

9 Months Ended

Oct. 02, 2021

Leases [Abstract]

Balance Sheet Location of Lease Assets and Liabilities

The balance sheet locations of our lease assets and liabilities were as follows (in millions):

Assets	Balance Sheet Location	October 2, 2021		December 31, 2020
Operating	Operating lease assets	$	170.6	$	154.7
Finance	Other non-current assets	29.5		29.8
Total		$	200.1	$	184.5

Liabilities	Balance Sheet Location	October 2, 2021		December 31, 2020
Current
Operating	Other accrued liabilities	$	27.2	$	28.3
Finance	Current indebtedness	5.1		6.7
Non-Current
Operating	Other non-current liabilities	148.9		132.5
Finance	Long-term debt, less current portion	22.1		20.2
Total		$	203.3	$	187.7

The below tables show our lease assets and liabilities by reporting segment (in millions):

	Assets
	Operating				Financing
	October 2, 2021		December 31, 2020		October 2, 2021		December 31, 2020
CSCA	$	100.8	$	75.9	$	15.7	$	16.7
CSCI	30.4		34.4		8.3		5.9
Unallocated	39.4		44.4		5.5		7.2
Total	$	170.6	$	154.7	$	29.5	$	29.8

	Liabilities
	Operating				Financing
	October 2, 2021		December 31, 2020		October 2, 2021		December 31, 2020
CSCA	$	101.3	$	75.8	$	16.4	$	17.0
CSCI	31.4		35.2		5.2		2.5
Unallocated	43.4		49.8		5.6		7.4
Total	$	176.1	$	160.8	$	27.2	$	26.9

Lease Expense

Lease expense was as follows (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Operating leases(1)	$	10.0	$	8.5	$	29.9	$	26.6
Finance leases
Amortization	$	1.5	$	1.1	$	4.4	$	3.2
Interest	0.2		0.2		0.6		0.6
Total finance leases	$	1.7	$	1.3	$	5.0	$	3.8

            (1) Includes short-term leases and variable lease costs, which are immaterial.

Finance Lease Maturity

The annual future maturities of our leases as of October 2, 2021 are as follows (in millions):

	Operating Leases		Finance Leases		Total
2021	$	8.2	$	1.5	$	9.7
2022	29.2		5.6		34.8
2023	21.8		3.9		25.7
2024	18.6		2.4		21.0
2025	16.5		2.2		18.7
After 2025	109.0		15.8		124.8
Total lease payments	203.3		31.4		234.7
Less: Interest	27.2		4.2		31.4
Present value of lease liabilities	$	176.1	$	27.2	$	203.3

Operating Lease Liability Maturity

The annual future maturities of our leases as of October 2, 2021 are as follows (in millions):

	Operating Leases		Finance Leases		Total
2021	$	8.2	$	1.5	$	9.7
2022	29.2		5.6		34.8
2023	21.8		3.9		25.7
2024	18.6		2.4		21.0
2025	16.5		2.2		18.7
After 2025	109.0		15.8		124.8
Total lease payments	203.3		31.4		234.7
Less: Interest	27.2		4.2		31.4
Present value of lease liabilities	$	176.1	$	27.2	$	203.3

Weighted Average Lease Terms and Discount Rates

Our weighted average lease terms and discount rates are as follows:

	October 2, 2021		September 26, 2020
Weighted-average remaining lease term (in years)
Operating leases	11.39		6.26
Finance leases	8.78		9.20
Weighted-average discount rate
Operating leases	2.60	%	3.64	%
Finance leases	2.64	%	3.20	%

Lease Cash Flow Classifications

Our lease cash flow classifications are as follows (in millions):

	Nine Months Ended
	October 2, 2021		September 26, 2020
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	26.3	$	25.4
Operating cash flows for finance leases	$	0.6	$	0.6
Financing cash flows for finance leases	$	3.9	$	2.9
Leased assets obtained in exchange for new finance lease liabilities	$	4.5	$	4.6
Leased assets obtained in exchange for new operating lease liabilities	$	42.5	$	24.5

XML

Indebtedness (Tables)

9 Months Ended

Oct. 02, 2021

Debt Disclosure [Abstract]

Schedule of Debt

Total borrowings outstanding are summarized as follows (in millions):

			October 2, 2021		December 31, 2020
Term loan
	2019 Term loan due August 15, 2022		$	600.0	$	600.0
Notes and Bonds
	Coupon	Due
	5.105%	July 28, 2023(1)	$	156.6	$	164.9
	4.000%	November 15, 2023	215.6		215.6
	3.900%	December 15, 2024	700.0		700.0
	4.375%	March 15, 2026	700.0		700.0
	3.150%	June 15, 2030	750.0		750.0
	5.300%	November 15, 2043	90.5		90.5
	4.900%	December 15, 2044	303.9		303.9
	Total notes and bonds		2,916.6		2,924.9
Other financing			52.0		57.4
Unamortized premium (discount), net			(3.5)		(0.3)
Deferred financing fees			(14.8)		(17.1)
Total borrowings outstanding			3,550.3		3,564.9
	Current indebtedness		(629.4)		(37.3)
Total long-term debt less current portion			$	2,920.9	$	3,527.6

    (1) Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

XML

Earnings Per Share and Shareholders' Equity (Tables)

9 Months Ended

Oct. 02, 2021

Earnings Per Share [Abstract]

Schedule of Earnings per Share, Basic and Diluted

A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Numerator:
Income (loss) from continuing operations	$	(53.9)	$	26.4	$	(163.0)	$	96.4
Income (loss) from discontinued operations, net of tax	(5.0)		(181.0)		84.5		(84.0)
Net income (loss)	$	(58.9)	$	(154.6)	$	(78.5)	$	12.4
Denominator:
Weighted average shares outstanding for basic EPS	133.8		136.5		133.5		136.3
Dilutive effect of share-based awards*	—		1.1		—		1.2
Weighted average shares outstanding for diluted EPS	133.8		137.6		133.5		137.5
Anti-dilutive share-based awards excluded from computation of diluted EPS*	—		1.5		—		1.5
* In the period of a net loss, diluted shares equal basic shares.

XML

Accumulated Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Oct. 02, 2021

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in our AOCI balances, net of tax were as follows (in millions):

	Fair Value of Derivative Financial Instruments, net of tax		Foreign Currency Translation Adjustments		Post-Retirement and Pension Liability Adjustments, net of tax		Total AOCI
Balance at December 31, 2020	$	(0.7)	$	407.3	$	(11.6)	$	395.0
OCI before reclassifications	(33.4)		(147.5)		(2.2)		(183.1)
Amounts reclassified from AOCI(1)	2.3		(160.0)		—		(157.7)
Other comprehensive income (loss)	$	(31.1)	$	(307.5)	$	(2.2)	$	(340.8)
Balance at October 2, 2021	$	(31.8)	$	99.8	$	(13.8)	$	54.2

(1) Refer to Note 8, sale of RX business for information regarding amounts reclassified from AOCI related to foreign currency translation adjustments.

XML

Income Taxes (Tables)

9 Months Ended

Oct. 02, 2021

Income Tax Disclosure [Abstract]

Schedule of effective income tax rate reconciliation

The effective tax rates were as follows:

Three Months Ended				Nine Months Ended
October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
113.9	%	45.5	%	165.5	%	20.5	%

XML

Restructuring Charges (Tables)

9 Months Ended

Oct. 02, 2021

Restructuring Charges [Abstract]

Restructuring and Related Costs

The following reflects our restructuring activity (in millions):

	Three Months Ended				Nine Months Ended
	October 2, 2021		September 26, 2020		October 2, 2021		September 26, 2020
Beginning balance	$	10.2	$	9.4	$	9.1	$	19.5
Additional charges	1.0		0.8		11.8		1.5
Payments	(3.7)		(2.9)		(13.3)		(13.7)
Non-cash adjustments	(0.1)		0.2		(0.2)		0.2
Ending balance	$	7.4	$	7.5	$	7.4	$	7.5

XML

Segment Information (Tables)

9 Months Ended

Oct. 02, 2021

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The tables below show select financial measures by reporting segment (in millions):

	Total Assets
	October 2, 2021		December 31, 2020
CSCA	$	6,290.6	$	4,585.1
CSCI	4,611.9		4,872.4
Held for sale	13.4		2,030.9
Total	$	10,915.9	$	11,488.4

	Three Months Ended
	October 2, 2021						September 26, 2020
	Net Sales		Operating Income (Loss)		Intangible Asset Amortization		Net Sales		Operating Income (Loss)		Intangible Asset Amortization
CSCA	$	694.2	$	90.4	$	12.7	$	664.0	$	121.7	$	13.0
CSCI	348.5		4.3		39.5		339.0		10.1		40.3
Unallocated	—		343.6		—		—		(53.3)		—
Continuing Operations Total	$	1,042.7	$	438.3	$	52.2	$	1,003.0	$	78.5	$	53.3

	Nine Months Ended
	October 2, 2021						September 26, 2020
	Net Sales		Operating Income (Loss)		Intangible Asset Amortization		Net Sales		Operating Income (Loss)		Intangible Asset Amortization
CSCA	$	1,957.0	$	113.9	$	38.7	$	1,992.2	$	348.4	$	40.6
CSCI	1,076.8		23.1		120.3		1,042.8		45.7		116.9
Unallocated	—		226.7		—		—		(166.5)		—
Continuing Operations Total	$	3,033.8	$	363.7	$	159.0	$	3,035.0	$	227.6	$	157.5

XML

Summary of Significant Accounting Policies - Allowance for Credit Losses (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 7.7	$ 5.5	$ 6.5	$ 6.0
Provision for credit losses, net	0.1	0.6	3.7	1.1
Receivables written-off	0.0	(0.4)	(0.7)	(1.5)
Transfer to held for sale	0.0	0.0	(1.4)	0.0
Currency translation adjustment	(0.2)	0.1	(0.5)	0.2
Ending balance	$ 7.6	$ 5.8	$ 7.6	$ 5.8

XML

Revenue Recognition - Schedule of Revenue by Geographic Location (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Disaggregation of Revenue [Line Items]
Net sales	$ 1,042.7	$ 1,003.0	$ 3,033.8	$ 3,035.0
U.S.
Disaggregation of Revenue [Line Items]
Net sales	657.4	638.7	1,859.0	1,913.4
Europe
Disaggregation of Revenue [Line Items]
Net sales	334.5	326.6	1,037.6	1,011.0
All other countries
Disaggregation of Revenue [Line Items]
Net sales	50.8	37.7	137.2	110.6
Ireland
Disaggregation of Revenue [Line Items]
Net sales	$ 7.6	$ 10.8	$ 17.4	$ 22.3

XML

Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Disaggregation of Revenue [Line Items]
Net sales	$ 1,042.7	$ 1,003.0	$ 3,033.8	$ 3,035.0
CSCA
Disaggregation of Revenue [Line Items]
Net sales	694.2	664.0	1,957.0	1,992.2
CSCA | Upper respiratory
Disaggregation of Revenue [Line Items]
Net sales	121.9	117.1	345.8	397.2
CSCA | Digestive health
Disaggregation of Revenue [Line Items]
Net sales	110.6	111.8	344.0	339.9
CSCA | Pain and sleep-aids
Disaggregation of Revenue [Line Items]
Net sales	108.4	102.6	292.9	325.7
CSCA | Nutrition
Disaggregation of Revenue [Line Items]
Net sales	105.3	100.3	293.3	291.5
CSCA | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales	76.7	81.9	227.4	202.5
CSCA | Healthy lifestyle
Disaggregation of Revenue [Line Items]
Net sales	72.9	86.9	214.9	256.2
CSCA | Skincare and personal hygiene
Disaggregation of Revenue [Line Items]
Net sales	56.0	51.4	165.9	145.4
CSCA | Vitamins, minerals, and supplements
Disaggregation of Revenue [Line Items]
Net sales	8.1	6.3	24.3	19.1
CSCA | Other CSCA
Disaggregation of Revenue [Line Items]
Net sales	34.3	5.7	48.5	14.7
CSCI
Disaggregation of Revenue [Line Items]
Net sales	348.5	339.0	1,076.8	1,042.8
CSCI | Upper respiratory
Disaggregation of Revenue [Line Items]
Net sales	58.7	62.3	144.2	191.9
CSCI | Digestive health
Disaggregation of Revenue [Line Items]
Net sales	10.1	6.8	28.3	17.9
CSCI | Pain and sleep-aids
Disaggregation of Revenue [Line Items]
Net sales	52.1	49.0	148.4	136.0
CSCI | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales	24.4	25.2	72.4	68.8
CSCI | Healthy lifestyle
Disaggregation of Revenue [Line Items]
Net sales	42.2	40.6	140.5	124.7
CSCI | Skincare and personal hygiene
Disaggregation of Revenue [Line Items]
Net sales	88.5	83.1	307.9	275.4
CSCI | Vitamins, minerals, and supplements
Disaggregation of Revenue [Line Items]
Net sales	54.7	52.9	162.8	139.9
CSCI | Other CSCI
Disaggregation of Revenue [Line Items]
Net sales	$ 17.8	$ 19.1	$ 72.3	$ 88.2

XML

Revenue Recognition - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Disaggregation of Revenue [Line Items]
Net sales	$ 1,042.7	$ 1,003.0	$ 3,033.8	$ 3,035.0
Contract manufacturing
Disaggregation of Revenue [Line Items]
Net sales	$ 80.8	$ 76.3	$ 213.7	$ 190.0

XML

Revenue Recognition - Schedule of Contract Balances (Details) - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Short-term contract assets	$ 42.2	$ 19.7

XML

Acquisitions and Divestitures - Acquisitions (Details) € in Millions, $ in Millions					6 Months Ended
	Oct. 30, 2020 EUR (€) brand	Oct. 30, 2020 USD ($) brand	Feb. 13, 2020 USD ($)	Jan. 03, 2020 USD ($)	Jul. 02, 2022 EUR (€)	Jul. 02, 2022 USD ($)
HRA Pharma | Forecast
Business Acquisition [Line Items]
Binding offer for acquisition					€ 1,800.0	$ 2,100.0
Sanofi Brands
Business Acquisition [Line Items]
Number of brands acquired | brand	3	3
Purchase price paid	€ 53.3	$ 62.3
Useful life of intangible assets	18 years 9 months 18 days	18 years 9 months 18 days
Sanofi Brands | Brand
Business Acquisition [Line Items]
Intangible assets acquired		$ 52.5
Dexsil | Brand
Business Acquisition [Line Items]
Intangible assets acquired			$ 8.0
Useful life of intangible assets			25 years
Steripod
Business Acquisition [Line Items]
Purchase price paid				$ 26.0
Steripod | Brand
Business Acquisition [Line Items]
Intangible assets acquired				$ 25.1
Useful life of intangible assets				25 years

XML

Acquisitions and Divestitures - Oral Care Assets of High Ridge Brands and Ranir Global Holdings,LLC Acquisitions (Details) - USD ($) $ in Millions	Dec. 31, 2020	Apr. 01, 2020	Oct. 02, 2021
Estimated fair value of assets acquired and liabilities assumed:
Goodwill	$ 3,095.7		$ 3,031.4
Oral Care Assets of High Ridge Brands (Dr. Fresh)
Business Acquisition [Line Items]
Purchase price paid	106.2	$ 113.0
Prepayment of contract consideration for transitional services	2.0
Estimated fair value of assets acquired and liabilities assumed:
Accounts receivable	13.1
Inventories	22.2
Prepaid expenses and other current assets	0.4
Property, plant and equipment, net	0.7
Operating lease assets	2.6
Goodwill	17.2
Total intangible assets	66.1
Total assets	122.3
Accounts payable	6.1
Other accrued liabilities	3.8
Payroll and related taxes	0.7
Accrued customer programs	3.0
Other non-current liabilities	2.5
Total liabilities	16.1
Net assets acquired	106.2
Useful life of intangible assets		17 years 9 months 18 days
Oral Care Assets of High Ridge Brands (Dr. Fresh) | Distribution and license agreements and supply agreements
Estimated fair value of assets acquired and liabilities assumed:
Total intangible assets	2.2
Oral Care Assets of High Ridge Brands (Dr. Fresh) | Developed product technology, formulations, and product rights
Estimated fair value of assets acquired and liabilities assumed:
Total intangible assets	0.1
Oral Care Assets of High Ridge Brands (Dr. Fresh) | Customer relationships and distribution networks
Estimated fair value of assets acquired and liabilities assumed:
Total intangible assets	20.6
Oral Care Assets of High Ridge Brands (Dr. Fresh) | Trademarks, trade names, and brands
Estimated fair value of assets acquired and liabilities assumed:
Total intangible assets	$ 43.2

XML

Acquisitions and Divestitures - Pro Forma Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 26, 2020	Sep. 26, 2020
Business Combination and Asset Acquisition [Abstract]
Net sales	$ 1,009.2	$ 3,083.2
Income from continuing operations	$ 28.5	$ 108.7

XML

Acquisitions and Divestitures - Divestiture (Details) £ in Millions, $ in Millions			3 Months Ended			6 Months Ended	9 Months Ended
	Jun. 19, 2020 USD ($)	Jun. 19, 2020 GBP (£)	Dec. 31, 2020 USD ($)	Sep. 26, 2020 USD ($)	Jun. 27, 2020 USD ($)	Jun. 27, 2020 USD ($)	Oct. 02, 2021 USD ($)	Sep. 26, 2020 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net proceeds from sale of business							$ 1,493.1	$ 187.8
Loss on sale of business							$ (63.9)	$ 18.6
Rosemont Pharmaceuticals
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net proceeds from sale of business	$ 195.0	£ 155.6
Loss on sale of business			$ 2.4	$ 1.3	$ 17.4	$ 17.4
Foreign currency translation adjustment	$ (46.4)

XML

Goodwill and Intangible Assets - Goodwill (Details) - USD ($) $ in Millions	9 Months Ended
	Oct. 02, 2021	Jul. 03, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Goodwill, Beginning Balance	$ 3,095.7
Purchase accounting adjustments	0.0
Impairments	(6.1)
Currency translation adjustments	(58.2)
Goodwill, Ending Balance	3,031.4
CSCA
Goodwill [Roll Forward]
Goodwill, Beginning Balance	1,905.0
Purchase accounting adjustments	2.4
Impairments	(6.1)
Currency translation adjustments	(0.7)
Goodwill, Ending Balance	1,900.6
Accumulated impairments	6.1	$ 6.1	$ 0.0
CSCI
Goodwill [Roll Forward]
Goodwill, Beginning Balance	1,190.7
Purchase accounting adjustments	(2.4)
Impairments	0.0
Currency translation adjustments	(57.5)
Goodwill, Ending Balance	1,130.8
Accumulated impairments	$ 868.4		$ 868.4

XML

Goodwill and Intangible Assets - Intangible categories (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020	Dec. 31, 2020
Finite And Indefinite Lived Assets By Major Class [Line Items]
Indefinite-lived intangibles:	$ 5.5		$ 5.5		$ 7.0
Gross	3,725.7		3,725.7		3,883.0
Accumulated Amortization	1,499.5		1,499.5		1,401.5
Total other intangible assets	3,731.2		3,731.2		3,890.0
Intangible assets amortization expense	52.2	$ 53.3	159.0	$ 157.5
Distribution and license agreements and supply agreements
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	72.8		72.8		74.8
Accumulated Amortization	56.1		56.1		55.4
Developed product technology, formulations, and product rights
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	300.7		300.7		303.3
Accumulated Amortization	187.6		187.6		177.3
Customer relationships and distribution networks
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	1,844.1		1,844.1		1,920.5
Accumulated Amortization	872.2		872.2		823.7
Trademarks, trade names, and brands
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	1,506.0		1,506.0		1,581.5
Accumulated Amortization	381.5		381.5		342.2
Non-compete agreements
Finite And Indefinite Lived Assets By Major Class [Line Items]
Gross	2.1		2.1		2.9
Accumulated Amortization	2.1		2.1		2.9
Trademarks, trade names, and brands
Finite And Indefinite Lived Assets By Major Class [Line Items]
Indefinite-lived intangibles:	3.6		3.6		4.3
In-process research and development
Finite And Indefinite Lived Assets By Major Class [Line Items]
Indefinite-lived intangibles:	$ 1.9		$ 1.9		$ 2.7

XML

Inventories (Details) - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Finished goods	$ 617.1	$ 574.1
Work in process	240.9	220.4
Raw materials	234.5	264.9
Total inventories	$ 1,092.5	$ 1,059.4

XML

Fair Value Measurements - Financial Instruments at Fair Value (Details) - USD ($) $ in Millions	3 Months Ended
	Oct. 02, 2021	Dec. 31, 2020
Liabilities Held for Sale | Latin America Business
Liabilities:
Total impairment charge	$ 161.2
Measured at fair value on a recurring basis | Level 1
Assets:
Investment securities	1.5	$ 2.5
Foreign currency forward contracts	0.0	0.0
Cross-currency swap	0.0	0.0
Foreign currency option contracts	0.0	0.0
Total assets	1.5	2.5
Liabilities:
Cross-currency swap	0.0	0.0
Foreign currency forward contracts	0.0	0.0
Total liabilities	0.0	0.0
Measured at fair value on a recurring basis | Level 2
Assets:
Investment securities	0.0	0.0
Foreign currency forward contracts	5.8	9.8
Cross-currency swap	0.0	6.3
Foreign currency option contracts		0.0
Total assets	19.1	16.1
Liabilities:
Cross-currency swap	24.1	0.0
Foreign currency forward contracts	1.8	7.9
Total liabilities	25.9	7.9
Measured at fair value on a recurring basis | Level 3
Assets:
Investment securities	0.0	0.0
Foreign currency forward contracts	0.0	0.0
Cross-currency swap	0.0	0.0
Foreign currency option contracts	0.0	0.0
Total assets	0.0	0.0
Liabilities:
Cross-currency swap	0.0	0.0
Foreign currency forward contracts	0.0	0.0
Total liabilities	0.0	0.0
Measured at fair value on a non-recurring basis | Level 1
Liabilities:
Liabilities held for sale, net	0.0	0.0
Total liabilities	0.0	0.0
Measured at fair value on a non-recurring basis | Level 2
Liabilities:
Liabilities held for sale, net	0.0	0.0
Total liabilities	0.0	0.0
Measured at fair value on a non-recurring basis | Level 3
Liabilities:
Liabilities held for sale, net	15.8	0.0
Total liabilities	$ 15.8	$ 0.0

XML

Fair Value Measurements - Reconciliation of Level 3 Assets and Liabilities (Details) - Royalty Pharma Contingent Milestone Payments - Measured on a recurring basis - Level 3 - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 26, 2020	Sep. 26, 2020
Royalty Pharma Contingent Milestone Payments
Beginning balance	$ 99.0	$ 95.3
Change in fair value	22.2	25.9
Ending balance	$ 121.2	$ 121.2

XML

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 26, 2020	Sep. 26, 2020	Dec. 31, 2020	Jun. 27, 2020	Dec. 31, 2019
Royalty Pharma Contingent Milestone Payments | Measured on a recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase (decrease) in fair value of milestone payment	$ 22.2	$ 25.9
Estimated fair valued contingent milestone payment	$ 121.2	$ 121.2	$ 0.0	$ 99.0	$ 95.3
Royalty Pharma
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Volatility	30.00%
Rate of return	6.84%

XML

Fair Value Measurements - Schedule of Fixed Rate Long-term Debt (Details) - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Public bonds	$ 2,916.6	$ 2,924.9
Public Bonds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Public bonds	2,906.0	3,031.1
Private placement note | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Private placement note	166.9	177.5
Reported Value Measurement | Public Bonds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Public bonds	2,760.0	2,760.0
Reported Value Measurement | Private placement note | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Private placement note	$ 156.6	$ 164.9

XML

Investments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020	Dec. 31, 2020
Other (income) expense, net
Schedule of Equity Method Investments [Line Items]
Equity securities, fair value method, other expense (income)	$ 0.0	$ (0.4)	$ 0.9	$ 2.2
Equity securities, equity method, other expense (income)	0.0	$ (1.1)	0.8	$ (2.6)
Prepaid expenses and other current assets
Schedule of Equity Method Investments [Line Items]
Equity securities, fair value method	1.5		1.5		$ 2.5
Other non-current assets
Schedule of Equity Method Investments [Line Items]
Equity securities, fair value method	1.8		1.8		1.9
Equity securities, equity method, other non-current assets	$ 69.0		$ 69.0		$ 69.8

XML

Discontinued Operations (Details) - USD ($)		3 Months Ended	9 Months Ended
	Jul. 06, 2021	Oct. 02, 2021	Oct. 02, 2021	Sep. 26, 2020
Discontinued Operations
Gain on sale of business			$ 63,900,000	$ (18,600,000)
Write-off of foreign currency translation adjustment	$ (160,000,000)
Purchase of inventory			70,200,000	$ 93,200,000
Prepaid expenses and other current assets
Discontinued Operations
Receivable from transition services agreement		$ 36,400,000	36,400,000
Other Operating Expense (Income)
Discontinued Operations
Income from transition services agreement		3,600,000	3,600,000
Net Sales
Discontinued Operations
Product sales and royalty income from transition services agreement		29,400,000	29,400,000
RX Business
Discontinued Operations
Purchase of inventory		9,500,000	9,500,000
RX | Discontinued Operations, Disposed of by Sale
Discontinued Operations
Total consideration	1,550,000,000
Potential R&D milestone payments and contingent purchase obligations assumed by purchaser	53,300,000
Gain on sale of business	$ 63,900,000
Transition service period	24 months
Supply agreement term	4 years
Supply agreement, extension period	7 years
Aggregate cap on buyer's obligation for certain pre-closing liabilities (percent)	50.00%
Aggregate cap on buyer's obligation for certain pre-closing liabilities	$ 50,000,000
Separation costs		$ 29,100,000	$ 40,800,000

XML

Discontinued Operations - Results of Discontinued Operations (Details) - Discontinued Operations, Disposed of by Sale - RX - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	$ 500	$ 210,700	$ 405,100	$ 738,800
Cost of sales	100	149,800	258,400	496,200
Gross profit	400	60,900	146,700	242,600
Distribution	0	3,600	6,100	11,400
Research and development	200	11,900	30,800	42,100
Selling	100	7,600	16,300	22,300
Administration	4,900	8,700	35,600	23,200
Impairment charges	0	202,400	0	202,400
Total operating expenses	5,200	234,800	88,400	302,600
Restructuring	0	0	0	400
Other operating expense (income)	0	600	(400)	800
Total operating expenses	5,200	234,800	88,400	302,600
Operating income	(4,800)	(173,900)	58,300	(60,000)
Interest expense, net	0	700	800	3,200
Other (income) expense, net	(63,700)	1,500	(65,500)	(700)
Income before income taxes	58,900	(176,100)	123,000	(62,500)
Income tax expense (benefit)	63,900	4,900	38,500	21,500
Income (loss) from discontinued operations, net of tax	$ (5,000)	$ (181,000)	$ 84,500	$ (84,000)

XML

Discontinued Operations - Cash Flow Information (Details) - USD ($) $ in Thousands			3 Months Ended		9 Months Ended
	Mar. 08, 2021	Dec. 31, 2020	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Cash flows from discontinued operations investing activities:
Net proceeds from sale of business					$ 1,493,100	$ 187,800
Discontinued Operations, Disposed of by Sale | RX
Cash flows from discontinued operations operating activities:
Depreciation and amortization					15,300	72,400
Impairment charges			$ 0	$ 202,400	0	202,400
Loss (Gain) on sale of business					(63,900)	0
Cash flows from discontinued operations investing activities:
Asset acquisitions	$ (53,300)	$ (16,400)			(69,700)	(900)
Additions to property, plant and equipment					(6,600)	(10,000)
Net proceeds from sale of business					$ 1,493,100	$ 0

XML

Discontinued Operations - Additional Cash Flow Information (Details) $ in Millions				9 Months Ended
	Mar. 08, 2021 USD ($)	Dec. 31, 2020 USD ($)	May 15, 2015 brand	Oct. 02, 2021 USD ($)	Sep. 26, 2020 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of ANDAs acquired | brand			2
Discontinued Operations, Disposed of by Sale | RX
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset acquisitions | $	$ 53.3	$ 16.4		$ 69.7	$ 0.9

XML

Discontinued Operations - Assets and Liabilities (Details) - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020	Sep. 26, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	$ 10.1	$ 10.0	$ 9.2	$ 9.8
Current assets held for sale	13.4	666.9
Non-current assets held for sale	0.0	1,364.0
Current liabilities held for sale	29.2	419.6
Non-current liabilities held for sale	$ 0.0	108.3
Discontinued Operations, Disposed of by Sale | RX
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents		10.0
Accounts receivable, net of allowance for credit losses of $1.1		460.7
Inventories		140.8
Prepaid expenses and other current assets		55.4
Current assets held for sale		666.9
Property, plant and equipment, net		131.4
Operating lease assets		31.3
Goodwill and indefinite-lived intangible assets		681.2
Definite-lived intangible assets, net		492.8
Deferred income taxes		3.6
Other non-current assets		23.7
Non-current assets held for sale		1,364.0
Total assets held for sale		2,030.9
Accounts payable		92.2
Payroll and related taxes		22.3
Accrued customer programs		237.4
Other accrued liabilities		67.2
Current indebtedness		0.5
Current liabilities held for sale		419.6
Long-term debt, less current portion		0.7
Deferred income taxes		3.1
Other non-current liabilities		104.5
Non-current liabilities held for sale		108.3
Total liabilities held for sale		527.9
Allowance for credit losses		$ 1.1

XML

Discontinued Operations and Disposal Groups (Details) - USD ($) $ in Millions			3 Months Ended
	Oct. 02, 2021	Jul. 03, 2021	Oct. 02, 2021	Dec. 31, 2020
CSCA
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accumulated impairments	$ 6.1	$ 6.1	$ 6.1	$ 0.0
Assets Held for Sale | Mexico and Brazil-based Over-the-counter Businesses
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Fair value impairment charge	2.6	$ 152.5	155.1
Total impairment charge			161.2
Assets Held for Sale | Mexico and Brazil-based Over-the-counter Businesses | Current Assets Held for Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets held for sale	13.4		13.4
Assets Held for Sale | Mexico and Brazil-based Over-the-counter Businesses | Current Liabilities Held for Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Liabilities held for sale	$ 29.2		$ 29.2

XML

Derivative Instruments and Hedging Activities - Foreign Currency Forward Contracts (Details) € in Millions, £ in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021 USD ($)	Sep. 26, 2020 USD ($)	Oct. 02, 2021 USD ($)	Sep. 26, 2020 USD ($)	Oct. 02, 2021 EUR (€)	Sep. 30, 2021 USD ($) derivative	Dec. 31, 2020 USD ($)	Jun. 19, 2020 USD ($)	Jun. 19, 2020 GBP (£)
Cross-currency swap
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	$ 498.0		$ 498.0		€ 450.0
Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	1,610.7		$ 1,610.7				$ 867.7	$ 194.5	£ 155.0
Maximum remaining maturity of foreign currency derivatives			60 months
Foreign currency forward contracts | European Euro (EUR)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	1,277.7		$ 1,277.7				312.6
Foreign currency forward contracts | British Pound (GBP)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	121.5		121.5				92.3
Foreign currency forward contracts | Israeli Shekel (ILS)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	0.0		0.0				94.4
Foreign currency forward contracts | Danish Krone (DKK)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	44.8		44.8				65.2
Foreign currency forward contracts | Swedish Krona (SEK)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	41.9		41.9				41.2
Foreign currency forward contracts | Chinese Yuan (CNY)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	36.2		36.2				49.1
Foreign currency forward contracts | United States Dollar (USD)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	21.2		21.2				101.5
Foreign currency forward contracts | Polish Zloty (PLZ)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	17.9		17.9				21.8
Foreign currency forward contracts | Canadian Dollar (CAD)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	17.7		17.7				36.8
Foreign currency forward contracts | Norwegian Krone (NOK)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	9.9		9.9				7.8
Foreign currency forward contracts | Switzerland Franc (CHF)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	6.9		6.9				8.2
Foreign currency forward contracts | Turkish Lira (TRY)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	4.7		4.7				4.0
Foreign currency forward contracts | Australian Dollar (AUD)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	3.8		3.8				11.3
Foreign currency forward contracts | Romanian New Leu (RON)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	3.7		3.7				3.6
Foreign currency forward contracts | Mexican Peso (MPX)
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	0.6		0.6				15.6
Foreign currency forward contracts | Other
Foreign Currency Fair Value Hedge Derivative [Line Items]
Notional amount of derivatives	2.2		2.2				$ 2.3
Non-designated derivatives: | Foreign currency options
Foreign Currency Fair Value Hedge Derivative [Line Items]
Number of non-designated currency option contracts | derivative						2
Notional amount of derivatives						$ 1,100.0
Deferred financing fee	25.9		25.9
Non-designated derivatives: | Foreign currency forward contracts
Foreign Currency Fair Value Hedge Derivative [Line Items]
Loss on change in fair value of option contract	$ (0.1)	$ (0.6)	$ 4.9	$ (1.5)

XML

Derivative Instruments and Hedging Activities - Balance Sheet Location (Details) - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Designated derivatives:
Derivatives, Fair Value [Line Items]
Asset Derivatives	$ 5.4	$ 11.8
Liability Derivatives	24.5	5.5
Designated derivatives: | Prepaid expenses and other current assets | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives	5.0	5.0
Designated derivatives: | Other non-current assets | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives	0.4	0.5
Designated derivatives: | Other non-current assets | Cross-currency swap
Derivatives, Fair Value [Line Items]
Asset Derivatives	0.0	6.3
Designated derivatives: | Other accrued liabilities | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Liability Derivatives	0.4	5.5
Designated derivatives: | Other accrued liabilities | Cross-currency swap
Derivatives, Fair Value [Line Items]
Liability Derivatives	24.1	0.0
Non-designated derivatives:
Derivatives, Fair Value [Line Items]
Asset Derivatives	13.7	4.3
Non-designated derivatives: | Prepaid expenses and other current assets | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives	0.4	4.3
Non-designated derivatives: | Prepaid expenses and other current assets | Foreign currency options
Derivatives, Fair Value [Line Items]
Asset Derivatives	13.3	0.0
Non-designated derivatives: | Other accrued liabilities | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Liability Derivatives	$ 1.4	$ 2.4

XML

Derivative Instruments and Hedging Activities - Effect of Cash Flow Hedges Included in AOCI (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Recorded in OCI, Cash flow hedges	$ 2.4	$ (1.5)	$ 2.0	$ 8.3
Amount of Gain/(Loss) Recorded in OCI, Net investment hedges		(12.0)		(29.8)
Amount of Gain/(Loss) Reclassified from AOCI into Earnings	(1.3)	0.8	(2.3)	(1.2)
Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net	0.2	0.2	1.0	0.9
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach		0.8		5.5
Foreign currency cash flow hedge loss to be reclassified during next 12 months	7.9		7.9
Interest expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts	0.0	0.0	0.0	0.0
Gain (loss) recognized in earnings on derivatives related to amounts excluded from effectiveness testing	0.0	0.0	0.0	0.0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0.0	0.0	0.0	0.0
Net Sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts	(0.4)	(0.1)	(2.3)	(0.1)
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0.0	0.0	0.0	0.1
Cost of sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Foreign currency forward contracts	(0.5)	1.3	1.4	0.3
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0.0	0.2	0.4	0.8
Treasury Locks | Interest expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Recorded in OCI, Cash flow hedges			0.0	0.0
Amount of gain or (loss) reclassified from AOCI into earnings			(0.1)	(0.1)
Gain (loss) recognized in earnings on derivatives related to amounts excluded from effectiveness testing			0.0	0.0
Treasury Locks | Net Sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings			0.0	0.0
Treasury Locks | Cost of sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings			0.0	0.0
Interest Rate Swap | Interest expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Recorded in OCI, Cash flow hedges	0.0	0.0	0.0	0.0
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements	(0.4)	(0.4)	(1.3)	(1.3)
Interest Rate Swap | Net Sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements	0.0	0.0	0.0	0.0
Interest Rate Swap | Cost of sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings - Interest rate swap agreements	0.0	0.0	0.0	0.0
Foreign currency forward contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Recorded in OCI, Cash flow hedges	2.4	(1.5)	2.0	8.3
Amount of Gain/(Loss) Recorded in OCI, Net investment hedges		(11.7)		(11.2)
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach		(0.1)		(0.1)
Cross-currency swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain/(Loss) Recorded in OCI, Net investment hedges	(28.4)	(0.3)	(30.5)	(18.6)
Cross-currency swap | Interest expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	$ (0.9)	$ 0.9	$ (2.9)	$ 5.6

XML

Derivative Instruments and Hedging Activities - Non-designated Derivatives (Details) - Non-designated derivatives: - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Change in fair value of option contract	$ 0.1	$ 0.6	$ (4.9)	$ 1.5
Foreign currency forward contracts | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Change in fair value of option contract	(0.1)	(0.3)	(6.1)	(1.3)
Foreign currency forward contracts | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Change in fair value of option contract	0.2	0.9	1.2	2.8
Foreign currency options | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Change in fair value of option contract	$ 12.6	$ 0.0	$ 12.6	$ 0.0

XML

Derivative Instruments and Hedging Activities - Classification of Gain (Loss) of Cash Flow And Fair Value Hedging Relationships (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Net sales	$ 1,042.7	$ 1,003.0	$ 3,033.8	$ 3,035.0
Cost of sales	706.3	633.3	1,980.0	1,924.5
Interest expense, net	30.9	33.3	94.5	94.3
Other (income) expense, net	18.5	(1.0)	20.4	17.9
Net Sales
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	(0.4)	(0.1)	(2.3)	(0.1)
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0.0	0.0	0.0	0.1
Cost of sales
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	(0.5)	1.3	1.4	0.3
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0.0	0.2	0.4	0.8
Interest expense, net
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	0.0	0.0	0.0	0.0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0.0	0.0	0.0	0.0
Other (income) expense, net
Foreign currency forward contracts
Amount of gain or (loss) reclassified from AOCI into earnings	0.0	0.0	0.0	0.0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach	0.2	0.0	0.6	0.0
Treasury Locks | Net Sales
Treasury locks
Amount of gain or (loss) reclassified from AOCI into earnings			0.0	0.0
Treasury Locks | Cost of sales
Treasury locks
Amount of gain or (loss) reclassified from AOCI into earnings			0.0	0.0
Treasury Locks | Interest expense, net
Treasury locks
Amount of gain or (loss) reclassified from AOCI into earnings			(0.1)	(0.1)
Treasury Locks | Other (income) expense, net
Treasury locks
Amount of gain or (loss) reclassified from AOCI into earnings		0.0	0.0
Interest Rate Swap | Net Sales
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	0.0	0.0	0.0	0.0
Interest Rate Swap | Cost of sales
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	0.0	0.0	0.0	0.0
Interest Rate Swap | Interest expense, net
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	(0.4)	(0.4)	(1.3)	(1.3)
Interest Rate Swap | Other (income) expense, net
Interest rate swap agreements
Amount of gain or (loss) reclassified from AOCI into earnings	$ 0.0	$ 0.0	$ 0.0	$ 0.0

XML

Leases - Balance Sheet Location of Assets and Liabilities (Details) - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Operating lease assets	$ 170.6	$ 154.7
Finance leases	29.5	29.8
Right-of-Use Asset	200.1	184.5
Operating lease liability, current	27.2	28.3
Finance lease liability, current	5.1	6.7
Operating lease liability, noncurrent	148.9	132.5
Finance lease liability, noncurrent	22.1	20.2
Present value of lease liabilities	203.3	187.7
Total operating lease liabilities	176.1	160.8
Total finance lease liabilities	$ 27.2	$ 26.9
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other non-current assets	Other non-current assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other accrued liabilities	Other accrued liabilities
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Current indebtedness	Current indebtedness
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other non-current liabilities	Other non-current liabilities
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term debt, less current portion	Long-term debt, less current portion
Unallocated
Lessee, Lease, Description [Line Items]
Operating lease assets	$ 39.4	$ 44.4
Finance leases	5.5	7.2
Total operating lease liabilities	43.4	49.8
Total finance lease liabilities	5.6	7.4
CSCA | Operating Segments
Lessee, Lease, Description [Line Items]
Operating lease assets	100.8	75.9
Finance leases	15.7	16.7
Total operating lease liabilities	101.3	75.8
Total finance lease liabilities	16.4	17.0
CSCI | Operating Segments
Lessee, Lease, Description [Line Items]
Operating lease assets	30.4	34.4
Finance leases	8.3	5.9
Total operating lease liabilities	31.4	35.2
Total finance lease liabilities	$ 5.2	$ 2.5

XML

Leases - Lease Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Leases [Abstract]
Operating leases	$ 10.0	$ 8.5	$ 29.9	$ 26.6
Finance leases
Amortization	1.5	1.1	4.4	3.2
Interest	0.2	0.2	0.6	0.6
Total finance leases	$ 1.7	$ 1.3	$ 5.0	$ 3.8

XML

Leases - Annual Future Maturities of Leases (Details) - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Operating Leases
2021	$ 8.2
2022	29.2
2023	21.8
2024	18.6
2025	16.5
After 2025	109.0
Total lease payments	203.3
Less: Interest	27.2
Present value of lease liabilities	176.1	$ 160.8
Finance Leases
2021	1.5
2022	5.6
2023	3.9
2024	2.4
2025	2.2
After 2025	15.8
Total lease payments	31.4
Less: Interest	4.2
Present value of lease liabilities	27.2	26.9
Total
2021	9.7
2022	34.8
2023	25.7
2024	21.0
2025	18.7
After 2025	124.8
Total lease payments	234.7
Less: Interest	31.4
Present value of lease liabilities	$ 203.3	$ 187.7

XML

Leases - Weighted Average Lease Terms and Discount Rates (Details)	Oct. 02, 2021	Sep. 26, 2020
Leases [Abstract]
Weighted-average remaining lease term - Operating leases	11 years 4 months 20 days	6 years 3 months 3 days
Weighted-average lease term - Finance leases	8 years 9 months 10 days	9 years 2 months 12 days
Weighted-average discount rate - Operating lease (percent)	2.60%	3.64%
Weighted-average discount rate - Finance lease (percent)	2.64%	3.20%

XML

Leases - Lease Cash Flow Classifications (Details) - USD ($) $ in Millions	9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020
Leases [Abstract]
Operating cash flows for operating leases	$ 26.3	$ 25.4
Operating cash flows for finance leases	0.6	0.6
Financing cash flows for finance leases	3.9	2.9
Leased assets obtained in exchange for new finance lease liabilities	4.5	4.6
Leased assets obtained in exchange for new operating lease liabilities	$ 42.5	$ 24.5

XML

Indebtedness - Schedule of Borrowings Outstanding (Details) - USD ($) $ in Millions		9 Months Ended
		Oct. 02, 2021	Dec. 31, 2020	Jun. 19, 2020
Debt Instrument [Line Items]
Notes and Bonds		$ 2,916.6	$ 2,924.9
Other financing		52.0	57.4
Unamortized premium (discount), net		(3.5)	(0.3)
Deferred financing fees		(14.8)	(17.1)
Total borrowings outstanding		3,550.3	3,564.9
Current indebtedness		(629.4)	(37.3)
Long-term debt, less current portion		2,920.9	3,527.6
2019 Term loan due August 15, 2022
Debt Instrument [Line Items]
Term loans		$ 600.0	600.0
5.105% Senior note due July 28, 2023
Debt Instrument [Line Items]
Interest rate, stated percentage		5.105%
Series	[1]	July 28, 2023(1)
Notes and Bonds		$ 156.6	164.9
4.00% unsecured senior notes due November 15, 2023
Debt Instrument [Line Items]
Interest rate, stated percentage		4.00%
Series		November 15, 2023
Notes and Bonds		$ 215.6	215.6
3.9% senior note due December 15, 2024
Debt Instrument [Line Items]
Interest rate, stated percentage		3.90%
Series		December 15, 2024
Notes and Bonds		$ 700.0	700.0
4.375% senior note due March 15, 2026
Debt Instrument [Line Items]
Interest rate, stated percentage		4.375%
Series		March 15, 2026
Notes and Bonds		$ 700.0	700.0
3.150% Senior Notes due June 15, 2030
Debt Instrument [Line Items]
Interest rate, stated percentage		3.15%		3.15%
Series		June 15, 2030
Notes and Bonds		$ 750.0	750.0
5.30% unsecured senior notes due November 15, 2043
Debt Instrument [Line Items]
Interest rate, stated percentage		5.30%
Series		November 15, 2043
Notes and Bonds		$ 90.5	90.5
4.9% senior notes due December 15, 2044
Debt Instrument [Line Items]
Interest rate, stated percentage		4.90%
Series		December 15, 2044
Notes and Bonds		$ 303.9	$ 303.9

[1] Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

XML

Indebtedness - Additional Information (Details)					3 Months Ended				9 Months Ended
	Jun. 19, 2021 USD ($)	Jun. 07, 2021 USD ($)	Dec. 08, 2020 USD ($)	Jul. 06, 2020 USD ($)	Apr. 02, 2022	Dec. 31, 2021	Oct. 02, 2021 USD ($)	Sep. 26, 2020 USD ($)	Oct. 02, 2021 USD ($)	Sep. 26, 2020 USD ($)	Dec. 15, 2021	Dec. 31, 2020 USD ($)	Jun. 19, 2020 USD ($)	Jun. 17, 2020 USD ($) promissoryNote	Aug. 15, 2019 USD ($)	Mar. 08, 2018 USD ($)
Debt Instrument [Line Items]
Loss on extinguishment of debt							$ 0	$ 20,000,000.0	$ 0	$ 20,000,000.0
Outstanding balance							0		0			$ 0
Kazmira, LLC
Debt Instrument [Line Items]
Promissory notes														$ 34,300,000
Number of promissory notes | promissoryNote														2
2018 Revolver due March 8, 2023
Debt Instrument [Line Items]
Face amount of debt																$ 1,000,000,000
Borrowings on line of credit							0		0			0
2019 Term loan due August 15, 2022
Debt Instrument [Line Items]
Face amount of debt															$ 600,000,000
Term loans							$ 600,000,000		$ 600,000,000			$ 600,000,000.0
Maximum leverage ratio							575.00%		375.00%
2019 Term loan due August 15, 2022 | Forecast
Debt Instrument [Line Items]
Maximum leverage ratio						375.00%
Maximum leverage ratio, subject to consummation of qualifying acquisitions					4.00
3.150% Senior Notes due June 15, 2030
Debt Instrument [Line Items]
Face amount of debt													$ 750,000,000
Interest rate, stated percentage							3.15%		3.15%				3.15%
Net proceeds from issuance of senior notes	$ 737,100,000
3.150% Senior Notes due June 15, 2030 | Forecast
Debt Instrument [Line Items]
Interest rate, stated percentage											3.90%
3.500% Unsecured Senior notes due March 15, 2021
Debt Instrument [Line Items]
Interest rate, stated percentage				3.50%
Debt repaid				$ 280,400,000
3.500% Senior note due December 15, 2021
Debt Instrument [Line Items]
Interest rate, stated percentage				3.50%
Debt repaid				$ 309,600,000
2018 Term loan due March 8, 2020
Debt Instrument [Line Items]
Loss on extinguishment of debt								$ 20,000,000
Note due November 2020 | Kazmira, LLC
Debt Instrument [Line Items]
Debt repaid			$ 3,700,000
Promissory notes														$ 3,700,000
Note due May 2021 | Kazmira, LLC
Debt Instrument [Line Items]
Debt repaid		$ 5,800,000
Promissory notes														5,800,000
Note due November 2021 | Kazmira, LLC
Debt Instrument [Line Items]
Promissory notes														$ 24,800,000

XML

Earnings Per Share and Shareholders' Equity (Details) - USD ($)	3 Months Ended						9 Months Ended
	Oct. 02, 2021	Jul. 03, 2021	Apr. 03, 2021	Sep. 26, 2020	Jun. 27, 2020	Mar. 28, 2020	Oct. 02, 2021	Sep. 26, 2020	Oct. 31, 2018
Numerator:
Income (loss) from continuing operations	$ (53,900,000)			$ 26,400,000			$ (163,000,000.0)	$ 96,400,000
Income (loss) from discontinued operations, net of tax	(5,000,000.0)			(181,000,000.0)			84,500,000	(84,000,000.0)
Net income (loss)	$ (58,900,000)	$ (57,700,000)	$ 38,100,000	$ (154,600,000)	$ 60,600,000	$ 106,400,000	$ (78,500,000)	$ 12,400,000
Denominator:
Weighted average shares outstanding for basic EPS (in shares)	133,800,000			136,500,000			133,500,000	136,300,000
Dilutive effect of share-based awards (in shares)	0			1,100,000			0	1,200,000
Weighted average shares outstanding for diluted EPS (in shares)	133,800,000			137,600,000			133,500,000	137,500,000
Anti-dilutive share-based awards excluded from computation of diluted EPS (shares)	0			1,500,000			0	1,500,000
Stock repurchase program, authorized amount									$ 1,000,000,000
Repurchases of ordinary shares (shares)	0			0			0	0

XML

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Oct. 02, 2021	Jul. 03, 2021	Apr. 03, 2021	Sep. 26, 2020	Jun. 27, 2020	Mar. 28, 2020	Oct. 02, 2021	Sep. 26, 2020
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	$ 5,511.1	$ 5,558.0	$ 5,655.1	$ 5,910.4	$ 5,786.4	$ 5,803.8	$ 5,655.1	$ 5,803.8
OCI before reclassifications							(183.1)
Amounts reclassified from AOCI							(157.7)
Other comprehensive income (loss), net of tax	(252.9)	30.4	(118.3)	83.0	84.8	(103.5)	(340.8)	64.3
Balance, ending	5,182.4	5,511.1	5,558.0	5,820.3	5,910.4	5,786.4	5,182.4	5,820.3
Total AOCI
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	307.1	276.7	395.0	120.7	35.9	139.4	395.0	139.4
Other comprehensive income (loss), net of tax	(252.9)	30.4	(118.3)	83.0	84.8	(103.5)
Balance, ending	54.2	$ 307.1	276.7	$ 203.7	$ 120.7	$ 35.9	54.2	$ 203.7
Fair Value of Derivative Financial Instruments, net of tax
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning			(0.7)				(0.7)
OCI before reclassifications							(33.4)
Amounts reclassified from AOCI							2.3
Other comprehensive income (loss), net of tax							(31.1)
Balance, ending	(31.8)						(31.8)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning			407.3				407.3
OCI before reclassifications							(147.5)
Amounts reclassified from AOCI							(160.0)
Other comprehensive income (loss), net of tax							(307.5)
Balance, ending	99.8						99.8
Post-Retirement and Pension Liability Adjustments, net of tax
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning			$ (11.6)				(11.6)
OCI before reclassifications							(2.2)
Amounts reclassified from AOCI							0.0
Other comprehensive income (loss), net of tax							(2.2)
Balance, ending	$ (13.8)						$ (13.8)

XML

Income Taxes (Details) € in Millions, $ in Millions										3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 05, 2021 USD ($)	Oct. 05, 2021 EUR (€)	Sep. 29, 2021 EUR (€)	May 03, 2021	Feb. 26, 2021 USD ($)	Jan. 13, 2021 USD ($)	Dec. 19, 2020 USD ($)	May 07, 2020 USD ($)	Aug. 15, 2017 USD ($)	Oct. 02, 2021 USD ($)	Sep. 26, 2020	Oct. 02, 2021 USD ($) year	Sep. 26, 2020	Dec. 31, 2013	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)	Jul. 09, 2021 EUR (€)	Dec. 29, 2020 USD ($)	Apr. 26, 2019 USD ($)	Nov. 29, 2018 EUR (€)
Income Tax Contingency [Line Items]
Effective income tax rate reconciliation, percent										113.90%	45.50%	165.50%	20.50%
Income tax examination, penalties and interest expense									$ 134.1						$ 24.7	$ 40.1	$ 41.8	$ 27.5
Cumulative deferred charge related to tax litigation										$ 111.6		$ 111.6
Royalty conceded on all omeprazole sales as a percent of refund claims (percent)												5.24%
IRS Notice of Proposed Audit Adjustment from 2013, 2014 and 2015						$ 141.6
IRS Notice of Proposed Audit Adjustment for ANDA from 2013, 2014 and 2015						21.9
Income tax examination, debts subject to limit of deductibility of interest expense						7,500.0
Interest rate cap on debts for U.S. Federal tax purposes, as percent of Applicable Federal Rate								130.00%
Income tax examination, reduction in blended interest rate due to cap for U.S. Federal tax purposes								4.00%
IRS notice of proposed audit adjustment to reduce deductible interest expense for fiscal years 2014 and 2015								$ 414.7
Interest rate cap on debts for U.S. Federal tax purposes, as percent of Applicable Federal Rate, no longer pursued				130.00%
IRS notice of proposed audit adjustment, increase to gross sales revenue for the 2013, 2014 and 2015 tax years							$ 99.5
IRS notice of proposed adjustment amount from 2011,2012 and 2013 audit of Athena, including penalty																					$ 843.0
IRS notice of proposed adjustment, penalty (percent)																					40.00%
Tax Years 2013 - 2015
Income Tax Contingency [Line Items]
Income tax examination, estimate of additional tax expense, excluding interest and penalties					$ 18.0
Tax Year 2020
Income Tax Contingency [Line Items]
Income tax examination, estimate of additional tax expense, excluding interest and penalties												$ 7.0
Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Income tax examination, number of taxable years | year												4
Revenue Commissioners, Ireland
Income Tax Contingency [Line Items]
Irish Revenue proposed tax rate on net chargeable gain realized (percent)														33.00%
Irish Revenue tax rate applied to trading income (percent)														12.50%
Irish Revenue notice of amended assessment unsettled assessed audit liability | €																						€ 1,643.0
Irish Revenue, potential reduction in tax assessment | €																			€ 660.0
Income tax examination, full and final settlement amount | €			€ 297.0
Unsettled audit assessment from income tax examination | €																						€ 1,636.0
Revenue Commissioners, Ireland | Subsequent Event
Income Tax Contingency [Line Items]
Income tax examination, taxes paid	$ 307.5	€ 266.1
Israel Tax Authority
Income Tax Contingency [Line Items]
Income tax examination, number of taxable years | year												5
Income tax examination, taxes paid												$ 19.0
Unsettled audit assessment from income tax examination																				$ 63.8
Income tax examination, offset for tax refunds												17.2
Payment to resolve tax liability indemnity												12.5
Reduction in liability recorded for uncertain tax positions										$ 38.3		$ 38.3
Minimum
Income Tax Contingency [Line Items]
Income tax examination, estimate of additional tax expense, excluding interest and penalties						24.0
Maximum
Income Tax Contingency [Line Items]
Income tax examination, estimate of additional tax expense, excluding interest and penalties						$ 112.0

XML

Contingencies (Details) € in Millions, $ in Millions, ₪ in Billions									3 Months Ended		6 Months Ended	9 Months Ended
	Nov. 05, 2021 lawsuit	Oct. 15, 2021 tender lawsuit	Sep. 30, 2021 complaint claim	Sep. 26, 2020 retailer lawsuit claim	May 31, 2019 individual	Jan. 16, 2019 genericPrescriptionPharmaceutical defendant	Jun. 28, 2017 USD ($) individual case genericPrescriptionPharmaceutical $ / ₪	Jun. 28, 2017 ILS (₪) individual case genericPrescriptionPharmaceutical $ / ₪	Mar. 30, 2019 brand case	Mar. 31, 2018 case	Jun. 27, 2020 case	Oct. 02, 2021 USD ($) defendant genericPrescriptionPharmaceutical lawsuit case individual complaint class	Oct. 08, 2021 individual manufacturer healthPlan	Aug. 30, 2021 pharmaceuticalCompany	Aug. 27, 2021 USD ($)	Aug. 27, 2021 EUR (€)	May 31, 2021 policyPeriod	Dec. 31, 2020 USD ($) manufacturer	Dec. 15, 2020 brand pharmaceuticalCompany manufacturer	Dec. 14, 2020 manufacturer	Dec. 11, 2020 manufacturer	Sep. 04, 2020 manufacturer	Aug. 27, 2020 manufacturer	Jul. 14, 2020 brand manufacturer case	Jul. 09, 2020 pharmaceuticalCompany	Jun. 10, 2020 employee pharmaceuticalProduct manufacturer plaintiffGroup	Jun. 09, 2020 manufacturer	May 31, 2020 individual manufacturer healthPlan	Mar. 01, 2020 defendant	Dec. 27, 2019 defendant	Dec. 23, 2019 defendant	Dec. 16, 2019 defendant	Dec. 11, 2019 defendant	Nov. 14, 2019 class	Jul. 18, 2019 healthPlan individual manufacturer	Apr. 30, 2019 genericPrescriptionPharmaceutical pharmaceuticalProduct manufacturer	Dec. 31, 2018 case	Dec. 21, 2018 genericPrescriptionPharmaceutical manufacturer	Aug. 03, 2018 genericPrescriptionPharmaceutical manufacturer	Jul. 31, 2018 individual	Jan. 22, 2018 supermarket manufacturer genericPrescriptionPharmaceutical	Dec. 31, 2017 USD ($)	Jun. 30, 2017 case	Jun. 21, 2017 individual genericPrescriptionPharmaceutical class
Loss Contingencies [Line Items]
Number of putative classes | class												3																						3										3
Number of sets of class action complaints | complaint												2
Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical																																												6
Number of individuals | individual																																												11
Number of current or former directors and officers | individual																																												11
Loss accrual for litigation contingencies | $												$ 96.9
Insurance recovery receivable | $												83.4
Insurance coverage available to defend and satisfy judgments, number of policy periods | policyPeriod																	1
Israel Tax Authority
Loss Contingencies [Line Items]
Payment to resolve tax liability indemnity | $												12.5
Level 3
Loss Contingencies [Line Items]
Guaranty liability | $												$ 0.6						$ 13.2																								$ 13.8
States' May 2019 Case Alleging Conspiracy (which does not Name Perrigo a Defendant)
Loss Contingencies [Line Items]
Number of products included in expedited cases | brand																								120
Number of manufacturers																								35
Overarching Conspiracy Class Actions
Loss Contingencies [Line Items]
Number of manufacturers																																				27
Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical																																				135
Number of formulations of products manufactured by the Company | genericPrescriptionPharmaceutical																																				2
Number of products manufactured by the Company | pharmaceuticalProduct																																				1
Number of cases included in expedited schedule | case																								0
Price-Fixing Lawsuit, Supermarket Chains
Loss Contingencies [Line Items]
Number of manufacturers																				45																					35
Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical																																									31
Number of supermarket chains | supermarket																																									3
Price-Fixing Lawsuit, Supermarket Chains, Amended Complaint
Loss Contingencies [Line Items]
Number of manufacturers																																						39
Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical																																						33
Price-fixing Lawsuit, Managed Care Organization
Loss Contingencies [Line Items]
Number of manufacturers																																							27
Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical																																							17
Price-fixing Lawsuit, Health Insurance Carrier
Loss Contingencies [Line Items]
Number of manufacturers																											25
Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical						30
Number of defendants | defendant						30
Price-fixing Lawsuit, Healthcare Service Company
Loss Contingencies [Line Items]
Number of co-defendants | defendant																																	38
Price-Fixing Lawsuit, Suffolk County of New York
Loss Contingencies [Line Items]
Number of manufacturers																							35
Price-Fixing Lawsuit, Drug Wholesaler and Distributor
Loss Contingencies [Line Items]
Number of manufacturers																						39
Price-fixing Lawsuit, Medicare Advantage Claims Recovery Company
Loss Contingencies [Line Items]
Number of co-defendants | defendant																																39
Price-Fixing Lawsuit, Drugstore Chain
Loss Contingencies [Line Items]
Number of manufacturers																			45		45
Number of products manufactured by the Company | brand																			63
Number of other pharmaceutical companies | pharmaceuticalCompany																									39
Price-fixing Lawsuit, Healthcare Management Organization
Loss Contingencies [Line Items]
Number of co-defendants | defendant																														25
Price-fixing Lawsuit, Several Counties in New York
Loss Contingencies [Line Items]
Number of other pharmaceutical companies | pharmaceuticalCompany																			45
Number of co-defendants | defendant																															28
Price-fixing Lawsuit, Westchester County, NY
Loss Contingencies [Line Items]
Number of other pharmaceutical companies | pharmaceuticalCompany														45
Price-fixing Lawsuit, Pennsylvania State Court | Subsequent Event
Loss Contingencies [Line Items]
Number of manufacturers													46
Number of health plans | healthPlan													20
Number of individuals | individual													24
Price-fixing Lawsuit, Harris County of Texas
Loss Contingencies [Line Items]
Number of co-defendants | defendant																													29
Price-fixing Lawsuit, Health Plans
Loss Contingencies [Line Items]
Number of manufacturers																																			53
Number of health plans | healthPlan																												7							87
Number of individuals | individual																												17							17
Number of dozens of manufacturers																												3
State Attorney General Complaint
Loss Contingencies [Line Items]
Number of manufacturers																										35
Number of generic prescription pharmaceuticals | pharmaceuticalProduct																										80
Number of additional states and territories | plaintiffGroup																										50
Number of former employees | employee																										1
Number of current employees | employee																										1
Canadian Class Action Complaint
Loss Contingencies [Line Items]
Number of manufacturers																		29
Highfields Capital I LP, et al. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of cases alleging only state law claims | lawsuit												1
Carmignac, First Manhattan and Similar Cases
Loss Contingencies [Line Items]
Number of cases with similar factual allegations | case												7
First Manhattan and Similar Cases
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | case												6
Mason Capital, Pentwater and Similar Cases
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical												6
Number of cases with similar factual allegations | case												8
Number of current or former directors and officers | case												11
Harel Insurance and TIAA-CREF Cases
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical												6
Number of individuals | individual																																								11
Number of cases with similar factual allegations | case												2
Number of current or former directors and officers | individual												13
Number of defendants added | defendant												2
Number of defendants dismissed without prejudice | individual																																								8
Blackrock Global Complaint
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical												6
Other Cases Related to Events in 2015-2017
Loss Contingencies [Line Items]
Number of cases with similar factual allegations | case																																											1
Number of overlapped cases | case																																											3
Israel Elec. Corp. Employees' Educ. Fund v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | genericPrescriptionPharmaceutical							6	6
Number of cases voluntarily dismissed | case							2	2
Number of current or former directors and officers | individual							11	11
Damages sought by plaintiff							$ 760.0	₪ 2.7
Foreign currency exchange rate, remeasurement | $ / ₪							0.28	0.28
Claim Arising from the Omega Acquisition | Judicial Ruling | Damages Awarded
Loss Contingencies [Line Items]
Estimated litigation settlement receivable															$ 417.6	€ 355.0
Talcum Powder Litigation | Subsequent Event
Loss Contingencies [Line Items]
Number of lawsuits | lawsuit		57
Number of tenders accepted for a portion of the defense costs and liability from a retailer | tender		1
Ranitidine Litigation
Loss Contingencies [Line Items]
Number of master complaints | complaint			3
Number of master complaints naming the company | complaint			3
Number of appeals of master complaints | complaint			1
Number of appeals of personal injury claims | claim			2
Ranitidine Litigation | Subsequent Event
Loss Contingencies [Line Items]
Number of personal injury lawsuits | lawsuit	280
In Israel (Cases Related to Events in 2015-2017)
Loss Contingencies [Line Items]
Number of cases | case																																					3
Number of cases voluntarily dismissed | case									1	1
Number of cases stayed | brand									1
In the United States (Cases Related to Irish Tax Events)
Loss Contingencies [Line Items]
Number of defendants | individual					3
Number of defendants added | individual					1
In Israel (Cases Related to Irish Tax Events)
Loss Contingencies [Line Items]
Number of cases stayed | case											2
Acetaminophen Litigation
Loss Contingencies [Line Items]
Number of lawsuits | lawsuit				1
Number of claims for indemnification or defense | claim				16
Number of retailers | retailer				10

XML

Restructuring Charges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Restructuring Reserve [Roll Forward]
Beginning balance	$ 10.2	$ 9.4	$ 9.1	$ 19.5
Additional charges	1.0	0.8	11.8	1.5
Payments	(3.7)	(2.9)	(13.3)	(13.7)
Non-cash adjustments	(0.1)	0.2	(0.2)	0.2
Ending balance	$ 7.4	$ 7.5	$ 7.4	$ 7.5

XML

Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020	Dec. 31, 2020
Segment Reporting Information [Line Items]
Assets	$ 10,915.9		$ 10,915.9		$ 11,488.4
Net sales	1,042.7	$ 1,003.0	3,033.8	$ 3,035.0
Operating Income (Loss)	438.3	78.5	363.7	227.6
Intangible Asset Amortization	52.2	53.3	159.0	157.5
Unallocated
Segment Reporting Information [Line Items]
Net sales	0.0	0.0	0.0	0.0
Operating Income (Loss)	343.6	(53.3)	226.7	(166.5)
Intangible Asset Amortization	0.0	0.0	0.0	0.0
Held-for-sale
Segment Reporting Information [Line Items]
Assets	13.4		13.4		2,030.9
CSCA
Segment Reporting Information [Line Items]
Assets	6,290.6		6,290.6		4,585.1
Net sales	694.2	664.0	1,957.0	1,992.2
CSCA | Operating Segments
Segment Reporting Information [Line Items]
Net sales	694.2	664.0	1,957.0	1,992.2
Operating Income (Loss)	90.4	121.7	113.9	348.4
Intangible Asset Amortization	12.7	13.0	38.7	40.6
CSCI
Segment Reporting Information [Line Items]
Assets	4,611.9		4,611.9		$ 4,872.4
Net sales	348.5	339.0	1,076.8	1,042.8
CSCI | Operating Segments
Segment Reporting Information [Line Items]
Net sales	348.5	339.0	1,076.8	1,042.8
Operating Income (Loss)	4.3	10.1	23.1	45.7
Intangible Asset Amortization	$ 39.5	$ 40.3	$ 120.3	$ 116.9